

chain nodes :

13 14 15 16 17 18 103 105

ring nodes :

1	2	3	4	5	6	7	8	9	10	11	12	29	30	31	32	33	34	35	36	37	38	39	40	41
42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64		
65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	88	89	90	91	92		
93	94	95	96	97	98	99																		

chain bonds :

5-35 8-105 13-14 13-17 15-16 15-18 29-45 51-53 63-65 71-81 93-95 103-105

ring bonds :

1-2	1-6	2-3	3-4	4-5	5-6	7-8	7-12	8-9	9-10	10-11	11-12	29-30	29-34	30-31
31-32	32-33	33-34	35-36	35-40	36-37	37-38	38-39	39-40	41-42	41-46	42-43	43-44		
44-45	45-46	47-48	47-52	48-49	49-50	50-51	51-52	53-54	53-58	54-55	55-56	56-57		
57-58	59-60	59-64	60-61	61-62	62-63	63-64	65-66	65-70	66-67	67-68	68-69	69-70		
71-72	71-76	72-73	73-74	74-75	75-76	77-78	77-82	78-79	79-80	80-81	81-82	88-89		
88-93	89-90	90-91	91-92	92-93	94-95	94-99	95-96	96-97	97-98	98-99				

exact/norm bonds :

8-105 103-105

exact bonds :

5-35 13-14 13-17 15-16 15-18 29-45 51-53 63-65 71-81 93-95

normalized bonds :

1-2	1-6	2-3	3-4	4-5	5-6	7-8	7-12	8-9	9-10	10-11	11-12	29-30	29-34	30-31
31-32	32-33	33-34	35-36	35-40	36-37	37-38	38-39	39-40	41-42	41-46	42-43	43-44		
44-45	45-46	47-48	47-52	48-49	49-50	50-51	51-52	53-54	53-58	54-55	55-56	56-57		
57-58	59-60	59-64	60-61	61-62	62-63	63-64	65-66	65-70	66-67	67-68	68-69	69-70		
71-72	71-76	72-73	73-74	74-75	75-76	77-78	77-82	78-79	79-80	80-81	81-82	88-89		
88-93	89-90	90-91	91-92	92-93	94-95	94-99	95-96	96-97	97-98	98-99				

isolated ring systems :

containing 1 : 29 : 35 : 41 : 47 : 53 : 59 : 65 : 71 : 77 :

G1: [*1], [*2], [*3], [*4], [*5], [*6]

G2: [*7-*8], [*9-*10]







Match level :

1:Atom	2:Atom	3:Atom	4:Atom	5:Atom	6:Atom	7:Atom	8:Atom	9:Atom	10:Atom	11:Atom
12:Atom	13:CLASS	14:CLASS	15:CLASS	16:CLASS	17:CLASS	18:CLASS	29:Atom	30:Atom		
31:Atom	32:Atom	33:Atom	34:Atom	35:Atom	36:Atom	37:Atom	38:Atom	39:Atom	40:Atom	
41:Atom	42:Atom	43:Atom	44:Atom	45:Atom	46:Atom	47:Atom	48:Atom	49:Atom	50:Atom	
51:Atom	52:Atom	53:Atom	54:Atom	55:Atom	56:Atom	57:Atom	58:Atom	59:Atom	60:Atom	
61:Atom	62:Atom	63:Atom	64:Atom	65:Atom	66:Atom	67:Atom	68:Atom	69:Atom	70:Atom	
71:Atom	72:Atom	73:Atom	74:Atom	75:Atom	76:Atom	77:Atom	78:Atom	79:Atom	80:Atom	
81:Atom	82:Atom	88:Atom	89:Atom	90:Atom	91:Atom	92:Atom	93:Atom	94:Atom	95:Atom	
96:Atom	97:Atom	98:Atom	99:Atom	103:CLASS	105:CLASS					

10/67,070
Q = ~~BA~~ $N(CH_2)_n$ and $(CH_2)_nN$.

=>

Uploading C:\Program Files\Stnexp\Queries\10671070.str



chain nodes :

13 14 16 17 18 19 21 22

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12

chain bonds :

5-13 8-14 13-14 16-17 16-21 18-19 18-22

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

exact/norm bonds :

5-13 8-14 13-14 16-21 18-22

exact bonds :

16-17 18-19

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

isolated ring systems :

containing 1 :

G1:O,S,N

G2:O,S,N,[*1-*2],[*3-*4]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:Atom 12:Atom 13:Atom 14:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS

21:CLASS 22:CLASS

Generic attributes :

13:

Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : 2 or more
Type of Ring System : Monocyclic

Element Count :
Node 13: Limited

C,C4
N,N2
O,O0
S,S0

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 13:09:29 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 584509 TO ITERATE

0.3% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

1 ANSWERS


FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**

PROJECTED ITERATIONS: 11647524 TO 11732836
PROJECTED ANSWERS: 4820 TO 6870

L2 1 SEA SSS SAM L1

=> =>

Uploading C:\Program Files\Stnexp\Queries\10671070 (a).str



isolated ring systems :

containing 1 : 32 : 38 : 44 : 50 : 56 : 62 : 68 : 74 : 80 : 90 : 96 : 104 : 110 :

G1:O,S,N

G2:O,S,N,[*1-*2],[*3-*4]

G3:[*5],[*6],[*7],[*8],[*9],[*10],[*11]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 19:CLASS
 20:CLASS 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom 38:Atom 39:Atom
 40:Atom 41:Atom 42:Atom 43:Atom 44:Atom 45:Atom 46:Atom 47:Atom 48:Atom
 49:Atom 50:Atom 51:Atom 52:Atom 53:Atom 54:Atom 55:Atom 56:Atom 57:Atom
 58:Atom 59:Atom 60:Atom 61:Atom 62:Atom 63:Atom 64:Atom 65:Atom 66:Atom
 67:Atom 68:Atom 69:Atom 70:Atom 71:Atom 72:Atom 73:Atom 74:Atom 75:Atom
 76:Atom 77:Atom 78:Atom 79:Atom 80:Atom 81:Atom 82:Atom 83:Atom 84:Atom
 85:Atom 90:Atom 91:Atom 92:Atom 93:Atom 94:Atom 95:Atom 96:Atom 97:Atom
 98:Atom 99:Atom 100:Atom 101:Atom 104:Atom 105:Atom 106:Atom 107:Atom
 108:Atom 109:Atom 110:Atom 111:Atom 112:Atom 113:Atom 114:Atom 115:Atom
 120:CLASS

L3 STRUCTURE UPLOADED

=> d 13

L3 HAS NO ANSWERS

L3 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 13 sss sam

SAMPLE SEARCH INITIATED 13:21:16 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 7357 TO ITERATE

27.2% PROCESSED . 2000 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**


PROJECTED ITERATIONS: 141998 TO 152282

PROJECTED ANSWERS: 8457 TO 11111

L4 50 SEA SSS SAM L3

=> =>

Uploading C:\Program Files\Stnexp\Queries\10671070 (b).str



chain nodes :

13 14 15 16 17 19 20 106

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 32 33 34 35 36 37 38 39 40 41 42
 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63
 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84
 85 91 92 93 94 95 96 97 98 99 100 101 102

chain bonds :

5-38 8-13 13-106 14-15 14-19 16-17 16-20 32-48 54-56 66-68 74-84 96-98

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 32-33 32-37
 33-34 34-35 35-36 36-37 38-39 38-43 39-40 40-41 41-42 42-43 44-45 44-49
 45-46 46-47 47-48 48-49 50-51 50-55 51-52 52-53 53-54 54-55 56-57 56-61
 57-58 58-59 59-60 60-61 62-63 62-67 63-64 64-65 65-66 66-67 68-69 68-73
 69-70 70-71 71-72 72-73 74-75 74-79 75-76 76-77 77-78 78-79 80-81 80-85
 81-82 82-83 83-84 84-85 91-92 91-96 92-93 93-94 94-95 95-96 97-98 97-102
 98-99 99-100 100-101 101-102

exact/norm bonds :

8-13 13-106 14-19 16-20

exact bonds :

5-38 14-15 16-17 32-48 54-56 66-68 74-84 96-98

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 32-33 32-37
 33-34 34-35 35-36 36-37 38-39 38-43 39-40 40-41 41-42 42-43 44-45 44-49
 45-46 46-47 47-48 48-49 50-51 50-55 51-52 52-53 53-54 54-55 56-57 56-61
 57-58 58-59 59-60 60-61 62-63 62-67 63-64 64-65 65-66 66-67 68-69 68-73
 69-70 70-71 71-72 72-73 74-75 74-79 75-76 76-77 77-78 78-79 80-81 80-85
 81-82 82-83 83-84 84-85 91-92 91-96 92-93 93-94 94-95 95-96 97-98 97-102
 98-99 99-100 100-101 101-102

isolated ring systems :
 containing 1 : 32 : 38 : 44 : 50 : 56 : 62 : 68 : 74 : 80 :

G1:O,S,N

G2:O,S,N,[*1-*2],[*3-*4]

G3:[*5],[*6],[*7],[*8],[*9],[*10]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 19:CLASS
 20:CLASS 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom 38:Atom 39:Atom
 40:Atom 41:Atom 42:Atom 43:Atom 44:Atom 45:Atom 46:Atom 47:Atom 48:Atom
 49:Atom 50:Atom 51:Atom 52:Atom 53:Atom 54:Atom 55:Atom 56:Atom 57:Atom
 58:Atom 59:Atom 60:Atom 61:Atom 62:Atom 63:Atom 64:Atom 65:Atom 66:Atom
 67:Atom 68:Atom 69:Atom 70:Atom 71:Atom 72:Atom 73:Atom 74:Atom 75:Atom
 76:Atom 77:Atom 78:Atom 79:Atom 80:Atom 81:Atom 82:Atom 83:Atom 84:Atom
 85:Atom 91:Atom 92:Atom 93:Atom 94:Atom 95:Atom 96:Atom 97:Atom 98:Atom
 99:Atom 100:Atom 101:Atom 102:Atom 106:CLASS

L5 STRUCTURE UPLOADED

=> d 15

L5 HAS NO ANSWERS

L5 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 15 sss sam

SAMPLE SEARCH INITIATED 13:35:22 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 7357 TO ITERATE

27.2% PROCESSED 2000 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**


PROJECTED ITERATIONS: 141998 TO 152282

PROJECTED ANSWERS: 8115 TO 10717

L6 50 SEA SSS SAM L5

=> =>

Uploading C:\Program Files\Stnexp\Queries\10671070 (Q=N).str



chain nodes :

13 14 15 16 17 18 103 105

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 29 30 31 32 33 34 35 36 37 38 39
 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81
 82 88 89 90 91 92 93 94 95 96 97 98 99

chain bonds :

5-35 8-105 13-14 13-17 15-16 15-18 29-45 51-53 63-65 71-81 93-95 103-105

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 29-30 29-34
 30-31 31-32 32-33 33-34 35-36 35-40 36-37 37-38 38-39 39-40 41-42 41-46
 42-43 43-44 44-45 45-46 47-48 47-52 48-49 49-50 50-51 51-52 53-54 53-58
 54-55 55-56 56-57 57-58 59-60 59-64 60-61 61-62 62-63 63-64 65-66 65-70
 66-67 67-68 68-69 69-70 71-72 71-76 72-73 73-74 74-75 75-76 77-78 77-82
 78-79 79-80 80-81 81-82 88-89 88-93 89-90 90-91 91-92 92-93 94-95 94-99
 95-96 96-97 97-98 98-99

exact/norm bonds :

8-105 103-105

exact bonds :

5-35 13-14 13-17 15-16 15-18 29-45 51-53 63-65 71-81 93-95

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 29-30 29-34
 30-31 31-32 32-33 33-34 35-36 35-40 36-37 37-38 38-39 39-40 41-42 41-46
 42-43 43-44 44-45 45-46 47-48 47-52 48-49 49-50 50-51 51-52 53-54 53-58
 54-55 55-56 56-57 57-58 59-60 59-64 60-61 61-62 62-63 63-64 65-66 65-70
 66-67 67-68 68-69 69-70 71-72 71-76 72-73 73-74 74-75 75-76 77-78 77-82
 78-79 79-80 80-81 81-82 88-89 88-93 89-90 90-91 91-92 92-93 94-95 94-99
 95-96 96-97 97-98 98-99

isolated ring systems :
 containing 1 : 29 : 35 : 41 : 47 : 53 : 59 : 65 : 71 : 77 :

G1:[*1],[*2],[*3],[*4],[*5],[*6]

G2:[*7-*8],[*9-*10]

Match level :

1:Atom	2:Atom	3:Atom	4:Atom	5:Atom	6:Atom	7:Atom	8:Atom	9:Atom	10:Atom
11:Atom	12:Atom	13:CLASS	14:CLASS	15:CLASS	16:CLASS	17:CLASS	18:CLASS		
29:Atom	30:Atom	31:Atom	32:Atom	33:Atom	34:Atom	35:Atom	36:Atom	37:Atom	
38:Atom	39:Atom	40:Atom	41:Atom	42:Atom	43:Atom	44:Atom	45:Atom	46:Atom	
47:Atom	48:Atom	49:Atom	50:Atom	51:Atom	52:Atom	53:Atom	54:Atom	55:Atom	
56:Atom	57:Atom	58:Atom	59:Atom	60:Atom	61:Atom	62:Atom	63:Atom	64:Atom	
65:Atom	66:Atom	67:Atom	68:Atom	69:Atom	70:Atom	71:Atom	72:Atom	73:Atom	
74:Atom	75:Atom	76:Atom	77:Atom	78:Atom	79:Atom	80:Atom	81:Atom	82:Atom	
88:Atom	89:Atom	90:Atom	91:Atom	92:Atom	93:Atom	94:Atom	95:Atom	96:Atom	
97:Atom	98:Atom	99:Atom	103:CLASS	105:CLASS					

L7 STRUCTURE UPLOADED

=> d 17

L7 HAS NO ANSWERS

L7 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 17 sss sam

SAMPLE SEARCH INITIATED 13:40:43 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 7357 TO ITERATE

27.2% PROCESSED	2000 ITERATIONS	23 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)		
SEARCH TIME: 00.00.01		

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 141998 TO 152282

PROJECTED ANSWERS: 1141 TO 2243

L8 23 SEA SSS SAM L7

=> => s 17 sss ful

FULL SEARCH INITIATED 13:44:45 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 147417 TO ITERATE

100.0% PROCESSED	147417 ITERATIONS	1779 ANSWERS
SEARCH TIME: 00.00.02		

L9 1779 SEA SSS FUL L7

10/671,070

=> => s 19

L10 151 L9

=> d 110 1-50 bib,ab,hitstr

L10 ANSWER 1 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:440209 CAPLUS

DN 144:468191

TI Preparation of phenylpyrimidinecarboxamides as modulators of voltage-gated sodium and calcium channels

IN Martinborough, Esther; Zimmermann, Nicole; Perni, Robert; Arnost, Michael; Bandarage, Upul; Maltais, Francois; Bemis, Guy

PA Vertex Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 166 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006050476	A2	20060511	WO 2005-US39881	20051103
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2004-624716P	P	20041103		
	US 2004-624718P	P	20041103		
	US 2004-624800P	P	20041103		

AB Title compds. I [wherein X = halo, cyano, Me, etc.; n = 1-4; R1, R2 = H, alkyl, cycloalkyl, etc.; R3, R4 = H, alkyl, heterocyclyl, etc.; Y = H or alkyl] and pharmaceutically acceptable salts thereof were prepared as ion channel modulators, especially as voltage-gated sodium and calcium channel inhibitors. For instance, II was synthesized in multiple steps and showed inhibitory activity for CaV 2.2, Nav 1.3 and Nav 1.8 with IC50 values of < 10.0 μ M. I and their pharmaceutical compns. are useful for the treatment of various diseases.

IT 886194-94-1P 886195-51-3P 886195-68-2P
 886196-06-1P 886196-52-7P 886196-53-8P
 886196-54-9P 886196-56-1P 886196-66-3P
 886196-67-4P 886196-68-5P 886196-70-9P
 886196-80-1P 886196-81-2P 886196-84-5P
 886196-87-8P 886196-90-3P 886196-92-5P
 886196-95-8P 886196-96-9P 886197-01-9P
 886197-03-1P 886197-12-2P 886197-17-7P
 886197-24-6P 886197-27-9P 886197-31-5P
 886197-33-7P 886197-36-0P 886197-37-1P
 886197-48-4P 886197-50-8P 886197-61-1P
 886197-63-3P 886197-74-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(inhibitor; preparation of phenylpyrimidinecarboxamides as inhibitors of voltage-gated sodium and calcium channels)

RN 886194-94-1 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(2-fluorophenyl)-N-[(3-methoxyphenyl)methyl]-N-

(1-methylethyl)-2-[(1-naphthalenylmethyl)amino]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 886195-51-3 CAPLUS
 CN 5-Pyrimidinecarboxamide, 4-(2-fluorophenyl)-2-[[2-(4-fluorophenyl)ethyl]amino]-N-(1-methylethyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 886195-68-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(2-fluorophenyl)-N-(1-methylethyl)-2-[(1-naphthalenylmethyl)amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 886196-06-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(2-fluorophenyl)-N-(1-methylethyl)-N-(phenylmethyl)-2-[[2-[3-(trifluoromethyl)phenyl]ethyl]amino]- (9CI) (CA INDEX NAME)




RN 886196-52-7 CAPLUS

CN Piperidine, 1-[[4-(4-cyanophenyl)-2-[[2-(3-fluorophenyl)ethyl]amino]-5-pyrimidinyl]carbonyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 886196-53-8 CAPLUS

CN Piperidine, 1-[[4-(4-cyanophenyl)-2-[[[2-(trifluoromethyl)phenyl]methyl]amino]-5-pyrimidinyl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 886196-54-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(1,3-benzodioxol-5-ylmethyl)amino]-N-ethyl-4-(2-fluorophenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 886196-56-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(2-fluorophenyl)-2-[[2-(3-fluorophenyl)ethyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 886196-66-3 CAPLUS

CN 5-Pyrimidinecarboxamide, N-ethyl-2-[[2-(4-methoxyphenyl)ethyl]amino]-N-methyl-4-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 886196-67-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[[3-chlorophenyl)methyl]amino]-N-methyl-4-(3-methylphenyl)-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 886196-68-5 CAPLUS

CN Morpholine, 4-[[[4-(2-fluorophenyl)-2-[[[3-(trifluoromethyl)phenyl]methyl]amino]-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 886196-70-9 CAPLUS

CN Piperidine, 1-[[2-[[[3-chlorophenyl]methyl]amino]-4-(4-cyanophenyl)-5-pyrimidinyl]carbonyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 886196-80-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-cyanophenyl)-N-(cyclopropylmethyl)-2-[[[2-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 886196-81-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-cyanophenyl)-2-[[2-(3-fluorophenyl)ethyl]amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 886196-84-5 CAPLUS

CN Piperidine, 1-[[4-(2-fluorophenyl)-2-[[[2-(trifluoromethyl)phenyl]methyl]amino]-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 886196-87-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[[2-(4-methoxyphenyl)ethyl]amino]-4-(2-fluorophenyl)-N-methyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 886196-90-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[[2-(4-methoxyphenyl)ethyl]amino]-N-(3-methoxypropyl)-4-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 886196-92-5 CAPLUS

CN Pyrrolidine, 1-[[2-[(1,3-benzodioxol-5-ylmethyl)amino]-4-(4-cyanophenyl)-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 886196-95-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(1,3-benzodioxol-5-ylmethyl)amino]-4-(4-cyanophenyl)-N-methyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 886196-96-9 CAPLUS

CN Morpholine, 4-[[2-[(1,3-benzodioxol-5-ylmethyl)amino]-4-(3-methylphenyl)-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 886197-01-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(1,3-benzodioxol-5-ylmethyl)amino]-4-(4-cyanophenyl)-N-ethyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 886197-03-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-cyanophenyl)-2-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]-N-methyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 886197-12-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-cyanophenyl)-N-cyclohexyl-2-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]-N-methyl- (9CI) (CA INDEX NAME)




RN 886197-17-7 CAPLUS

CN Piperidine, 1-[[4-(4-cyanophenyl)-2-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]-5-pyrimidinyl]carbonyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 886197-24-6 CAPLUS

CN Pyrrolidine, 1-[[4-(4-cyanophenyl)-2-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 886197-27-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-cyanophenyl)-2-[[2-(3-fluorophenyl)ethyl]amino]-N-methyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 886197-31-5 CAPLUS

CN 5-Pyrimidinecarboxamide, N-butyl-4-(4-cyanophenyl)-2-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]- (9CI) (CA INDEX NAME)




RN 886197-33-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(1,3-benzodioxol-5-ylmethyl)amino]-4-(2-fluorophenyl)-N-(1-methylethyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 886197-36-0 CAPLUS

CN Morpholine, 4-[[4-(3-methylphenyl)-2-[(phenylmethyl)amino]-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 886197-37-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-chlorophenyl)ethyl]amino]-4-(2-fluorophenyl)-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)




RN 886197-48-4 CAPLUS

CN Piperidine, 1-[[4-(4-cyanophenyl)-2-[[2-(4-methoxyphenyl)ethyl]amino]-5-pyrimidinyl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 886197-50-8 CAPLUS

CN Morpholine, 4-[[2-[[[(3-chlorophenyl)methyl]amino]-4-(3-methylphenyl)-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 886197-61-1 CAPLUS

CN Piperidine, 1-[[4-(4-cyanophenyl)-2-[[2-(4-methoxyphenyl)ethyl]amino]-5-pyrimidinyl]carbonyl]-5-ethyl-2-methyl- (9CI) (CA INDEX NAME)




RN 886197-63-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-cyanophenyl)-2-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]-N-(1-methylpropyl)- (9CI) (CA INDEX NAME)



RN 886197-74-6 CAPLUS

CN Piperidine, 1-[[2-[(1,3-benzodioxol-5-ylmethyl)amino]-4-[1,1'-biphenyl]-4-yl-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 2 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:411890 CAPLUS

DN 144:450725

TI Preparation of pyrazolopyrimidinones and analogs, and their compositions as cannabinoid CB1 receptor inhibitors

IN Liu, Hong; He, Xiaohui; Choi, Ha-Soon; Yang, Kunyong; Woodmansee, David; Wang, Zhicheng; Ellis, David Archer; Wu, Baogen; He, Yun; Nguyen, Truc Ngoc

PA Irm LLC, Bermuda

SO PCT Int. Appl., 259 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006047516	A2	20060504	WO 2005-US38361	20051026
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NE, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI US 2004-622508P P 20041026

US 2005-672670P P 20050418

AB Title compds. I [Y = O, NH and derivs., S; R1 = (un)substituted Ph, heteroaryl, cycloalkyl, benzyl; R2 = (un)substituted Ph, OPh, heterocycloalkyl, heteroaryl; R3 = H, halo, OH, CN, etc.; R4 = (un)substituted hetero/aryl, alkyl, etc.; and their pharmaceutically acceptable salts, hydrates, solvates and isomers; with the exception of certain compds.] were prepared as selective cannabinoid CB1 receptor inhibitors. Thus, II was prepared, in 3 steps, starting from 5-amino-1-phenyl-1H-pyrazole-4-carboxylic acid Et ester and 2,4-dichlorobenzoyl chloride. Preferred compds. I showed a 100 fold selectivity for CB1 over CB2 receptor. Pharmaceutical compns. comprising I are useful for preventing and treating diseases or disorders associated with the activity of CB1 receptor, e.g. metabolic disorders.


IT **885619-20-5P**, 5-(4-Chlorophenyl)-3-methylsulfonyl-6-[4-[2-[(4-methoxybenzyl)amino]pyrimidin-4-yl]phenyl]-1-phenyl-1,5-dihydropyrazolo[3,4-d]pyrimidin-4-one

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyrazolopyrimidinones and analogs as CB1 inhibitors)

RN 885619-20-5 CAPLUS

CN 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 5-(4-chlorophenyl)-1,5-dihydro-6-[4-[2-[[4-methoxyphenyl)methyl]amino]-4-pyrimidinyl]phenyl]-3-(methylsulfonyl)-1-phenyl- (9CI) (CA INDEX NAME)



L10 ANSWER 3 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:381409 CAPLUS
 DN 144:432829
 TI Preparation of 2,6-substituted-4-monosubstituted amino-pyrimidines as
 prostaglandin D2 receptor antagonists
 IN Lim, Sungtaek; Harris, Keith John; Stefany, David; Gardner, Charles J.;
 Cao, Bin; Boffey, Ray; Gillespy, Timothy A.; Aguiar, Joacy C.; Hunt, Hazel
 J.; Dechaux, Elsa A.
 PA Aventis Pharmaceuticals Inc., USA
 SO PCT Int. Appl., 272 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006044732	A2	20060427	WO 2005-US37148	20051014
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2004-619272P P 20041015

AB The invention is directed to the preparation of aminopyrimidines I [Cyl = (un)substituted cycloalkyl, heterocyclyl, hetero/aryl, etc.; Cy2 = (un)substituted cycloalkenyl, heterocyclyl, hetero/aryl, etc.; L1 = cyclo/alkylene, CH2-haloalkylene; or L1Cy2 = arylcycloalkyl, cycloalkylaryl; R1 = alkylthio, NH2 and derivs., alkoxy; L2 = a bond, O, CH2O; provided that when R1 = OMe, L1 = CH2CH2, L2 = a bond, and Cy2 = 2,4-dichlorophenyl, then Cyl is not 1-methyl-2-ethyloxycarbonylindol-5-yl], and their N-oxides, ester prodrugs, and their pharmaceutically acceptable salts, hydrates and solvates, and their use as prostaglandin D2 (PGD2) receptor antagonists in pharmaceutical compns. comprising a pharmaceutically effective amount of one or more compds. I in admixt. with a pharmaceutically acceptable carrier, and to a method of treating a patient suffering from a PGD2-mediated disorder. E.g., a 4-step synthesis, starting from from 3-fluoro-4-methoxybenzaldehyde, was given for pyrimidine II. Selected I produced 50% inhibition in the SPA cAMP assay in human LS174T cells expressing the endogenous DP receptor at concns. within the range of about 0.1 to about 30 nM. I are useful for treating allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch, diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which are generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis (no data).

IT 885066-02-4P, 3-[6-[[2-(3-Fluoro-4-methoxyphenyl)ethyl]amino]-2-

methoxypyrimidin-4-yl]benzonitrile **885066-03-5P**,
 [6-(3-Aminophenyl)-2-methoxypyrimidin-4-yl][2-(4-methoxyphenyl)ethyl]amine
885066-05-7P, 3-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyri
 midin-4-yl]benzenesulfonamide **885066-10-4P**, [6-(3-Aminophenyl)-2-
 methoxypyrimidin-4-yl][2-(4-trifluoromethoxyphenyl)ethyl]amine
885066-29-5P, 3-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyri
 midin-4-yl]benzaldehyde **885066-30-8P**, [3-[6-[[2-(2-Chloro-6-
 fluorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]methanol
885066-31-9P, 3-[6-[[2-(2-Chloro-6-fluorophenyl)ethyl]amino]-2-
 methoxypyrimidin-4-yl]benzaldehyde **885066-50-2P**,
 2-Fluoro-5-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-
 yl]benzaldehyde **885066-61-5P**, 3-[2-Methoxy-6-[[2-(4-
 methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenol **885066-63-7P**,
 3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]benzoic
 acid **885066-65-9P**, 3-[6-[[2-(2-Chloro-6-
 fluorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]benzoic acid
885066-67-1P, 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-
 methoxypyrimidin-4-yl]phenyl]-2-methylpropionic acid **885066-68-2P*****,
 [2-(3,4-Dimethoxyphenyl)ethyl][6-(3,4-dimethoxyphenyl)-2-
 methylsulfanylpymidin-4-yl]amine *****885066-71-7P**,
 [2-(4-Methoxyphenyl)ethyl][6-(3-methoxyphenyl)-2-methylsulfanylpymidin-4-
 yl]amine **885066-81-9P**, 2-Methoxy-5-[2-methoxy-6-[[2-(4-
 methoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzaldehyde **885066-86-4P**
 , 2-[3-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-
 yl]phenoxy]-2-methylpropionic acid ethyl ester **885066-87-5P**,
 [3-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-
 yl]phenoxy]acetic acid methyl ester **885066-89-7P**,
 3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenol
885066-92-2P, [3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-
 methoxypyrimidin-4-yl]phenoxy]acetonitrile **885066-93-3P**,
 [3-[6-[[2-(2-Chloro-6-fluorophenyl)ethyl]amino]-2-methoxypyrimidin-4-
 yl]phenoxy]acetonitrile **885066-94-4P**, 3-[6-[[2-(2-Chloro-6-
 fluorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenol
885066-99-9P, 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-
 methoxypyrimidin-4-yl]phenoxy]-2-methylpropionic acid ethyl ester
885067-01-6P, 2-Chloro-5-[2-methoxy-6-[[2-(4-
 methoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzoic acid ethyl ester
885067-02-7P, [2-(4-Methoxyphenyl)ethyl][2-methoxy-6-[3-(1H-
 tetrazol-5-yl)phenyl]pyrimidin-4-yl]amine **885067-03-8P**,
 3-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-
 yl]benzonitrile **885067-05-0P**, [3-[2-Methoxy-6-[[2-(4-
 methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenyl]acetonitrile
885067-07-2P, 2-Methoxy-5-[2-methoxy-6-[[2-(4-
 methoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzonitrile **885067-09-4P**
 , 3-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzoic
 acid **885067-11-8P**, 3-[6-[[2-(3,4-Dimethoxyphenyl)ethyl]amino]-2-
 methoxypyrimidin-4-yl]benzoic acid **885067-12-9P**,
 2-Fluoro-5-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-
 yl]benzaldehyde oxime **885067-14-1P**, 2-Methoxy-5-[2-methoxy-6-[[2-
 (4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzaldehyde oxime
885067-21-0P, [6-(3-Aminomethyl-4-fluorophenyl)-2-methoxypyrimidin-
 4-yl][2-(4-methoxyphenyl)ethyl]amine **885067-42-5P**,
 3-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzamide
885067-43-6P, 1-[3-[2-Methoxy-6-[[2-(4-
 methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenyl]ethanone
885068-16-6P, [3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-
 methoxypyrimidin-4-yl]benzoylamino]acetic acid ethyl ester
885068-69-9P, 4-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-

methoxypyrimidin-4-yl]phenyl]tetrahydropyran-4-carboxylic acid

885068-74-6P 885068-81-5P, [3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]acetonitrile


885068-82-6P, [3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]difluoroacetonitrile **885069-33-0P**, 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]-4-fluorophenyl]-2-methylpropionic acid

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of aminopyrimidines as prostaglandin D2 receptor antagonists)


RN 885066-02-4 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 885066-03-5 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 885066-05-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 885066-10-4 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 885066-29-5 CAPLUS

CN Benzaldehyde, 3-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 885066-30-8 CAPLUS

CN Benzenemethanol, 3-[6-[[2-(2-chloro-6-fluorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 885066-31-9 CAPLUS

CN Benzaldehyde, 3-[6-[[2-(2-chloro-6-fluorophenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 885066-50-2 CAPLUS


CN INDEX NAME NOT YET ASSIGNED




RN 885066-61-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885066-63-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885066-65-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885066-67-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885066-68-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885066-71-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885066-81-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885066-86-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885066-87-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885066-89-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885066-92-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885066-93-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885066-94-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885066-99-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885067-01-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885067-02-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885067-03-8 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 885067-05-0 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED



RN 885067-07-2 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 885067-09-4 CAPLUS
 CN Benzoic acid, 3-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 885067-11-8 CAPLUS

CN Benzoic acid, 3-[6-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 885067-12-9 CAPLUS

CN Benzaldehyde, 2-fluoro-5-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]-, oxime (9CI) (CA INDEX NAME)




RN 885067-14-1 CAPLUS

CN Benzaldehyde, 2-methoxy-5-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]-, oxime (9CI) (CA INDEX NAME)




RN 885067-21-0 CAPLUS


CN 4-Pyrimidinamine, 6-[3-(aminomethyl)-4-fluorophenyl]-2-methoxy-N-[2-(4-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 885067-42-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885067-43-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885068-16-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885068-69-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885068-74-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885068-81-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 885068-82-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 885069-33-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



IT **885066-07-9P**, 3-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]-N-methylbenzenesulfonamide **885066-08-0P**, N-Ethyl-3-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzenesulfonamide **885066-09-1P**, N-(Methoxycarbonyl)-3-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzenesulfonamide **885066-12-6P**, N-[3-[2-Methoxy-6-[[2-(4-trifluoromethoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenyl]acetamide **885066-13-7P**, N-[3-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenyl]acetamide **885066-14-8P**, [3-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenyl]carbamic acid ethyl ester **885066-17-1P**, 3-[6-[[2-(2,4-Difluorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]benzoic acid **885066-28-4P**, [3-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenyl]methanol **885066-35-3P**, N-[2-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenyl]methanesulfonamide **885066-36-4P**, 4-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzamide **885066-39-7P**, 1-[4-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenyl]ethanone **885066-40-0P**, [6-(3-Methylsulfonylphenyl)-2-methoxypyrimidin-4-yl][2-(4-methoxyphenyl)ethyl]amine **885066-42-2P**, [2-Methoxy-6-[4-(morpholin-4-yl)phenyl]pyrimidin-4-yl][2-(4-methoxyphenyl)ethyl]amine **885066-43-3P**, [6-(4-Dimethylaminophenyl)-2-methoxypyrimidin-4-yl][2-(4-methoxyphenyl)ethyl]amine **885066-46-6P**, [2-Methoxy-6-[3-(oxazol-5-yl)phenyl]pyrimidin-4-yl][2-(4-methoxyphenyl)ethyl]amine **885066-49-9P**, [6-[4-Fluoro-3-[(2-methoxyethylamino)methyl]phenyl]-2-methoxypyrimidin-4-yl][2-(4-methoxyphenyl)ethyl]amine monohydrochloride **885066-51-3P**, 4-[2-[3-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzyl]amino]ethyl]phenol monohydrochloride **885066-52-4P**, N-[2-Fluoro-5-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzyl]-N',N'-dimethylethane-1,2-diamine monohydrochloride **885066-60-4P**, 3-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenol hydrochloride **885066-62-6P**, 3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]benzoic acid monohydrochloride **885066-64-8P**, 3-[6-[[2-(2-Chloro-6-fluorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]benzoic acid monohydrochloride **885066-66-0P**, 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]-2-methylpropionic acid monohydrochloride **885066-70-6P**, 3-[6-[[2-(3,4-Dimethoxyphenyl)ethyl]amino]-2-methylsulfonylpyrimidin-4-yl]benzoic acid **885066-73-9P**, [2-(3,4-Dimethoxyphenyl)ethyl][6-(3,4-dimethoxyphenyl)-2-isopropoxypyrimidin-4-yl]amine **885066-75-1P**, [6-(3,4-Dimethoxyphenyl)-2-ethoxypyrimidin-4-yl][2-(3,4-dimethoxyphenyl)ethyl]amine **885066-76-2P**,

[2-Ethyl-6-(3-methoxyphenyl)pyrimidin-4-yl][2-(4-methoxyphenyl)ethyl]amine
885066-78-4P, 6-(3-Methoxyphenyl)-N'-[2-(4-methoxyphenyl)ethyl]-
N,N-dimethylpyrimidine-2,4-diamine monohydrochloride **885066-79-5P**
, 2-Fluoro-5-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-
yl]benzoic acid **885066-80-8P**, 2-Methoxy-5-[2-methoxy-6-[[2-(4-
methoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzoic acid **885066-88-6P**
, [3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-
yl]phenoxy]acetic acid methyl ester **885066-95-5P**,
2-[3-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenoxy]-
2-methylpropionic acid **885066-96-6P**, [3-[2-Methoxy-6-[[2-(4-
methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenoxy]acetic acid
885066-98-8P, 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-
methoxypyrimidin-4-yl]phenoxy]-2-methylpropionic acid **885067-00-5P**
, 2-Chloro-5-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-
yl]benzoic acid monohydrochloride **885067-04-9P**,
[2-(4-Methoxyphenyl)ethyl][2-methoxy-6-[3-[(1H-tetrazol-5-
yl)methyl]phenyl]pyrimidin-4-yl]amine monohydrochloride
885067-06-1P, [2-Methoxy-6-[4-methoxy-3-(1H-tetrazol-5-
yl)phenyl]pyrimidin-4-yl][2-(4-methoxyphenyl)ethyl]amine
885067-08-3P, N-[3-[2-Methoxy-6-[[2-(4-
methoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzoyl]methanesulfonamide
885067-10-7P, 3-[6-[[2-(3,4-Dimethoxyphenyl)ethyl]amino]-2-
methoxypyrimidin-4-yl]-N-[2-(pyrrolidin-1-yl)ethyl]benzamide
885067-13-0P, 3-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyri-
midin-4-yl]benzaldehyde oxime **885067-19-6P**, [6-(3-Aminomethyl-4-
fluorophenyl)-2-methoxypyrimidin-4-yl][2-(4-methoxyphenyl)ethyl]amine
monohydrochloride **885067-20-9P**, N-[2-Fluoro-5-[2-methoxy-6-[[2-
(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzyl]-2-methoxyacetamide
monohydrochloride **885067-29-8P**, 3-[[3-[6-[[2-(2,4-
Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenoxy]methyl]-4H-
[1,2,4]oxadiazol-5-one monohydrochloride **885067-31-2P**,
3-[3-[6-[[2-(2-Chloro-6-fluorophenyl)ethyl]amino]-2-methoxypyrimidin-4-
yl]benzyl]-4H-[1,2,4]oxadiazol-5-one monohydrochloride
885067-34-5P, 3-[[3-[6-[[2-(2-Chloro-6-fluorophenyl)ethyl]amino]-2-
methoxypyrimidin-4-yl]phenoxy]methyl]-4H-[1,2,4]oxadiazol-5-one
monohydrochloride **885067-36-7P**, 3-[2-Methoxy-6-[[2-(4-
trifluoromethoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzoic acid
885067-39-0P, [6-(Biphenyl-4-yl)-2-methoxypyrimidin-4-yl][2-(3,4-
dimethoxyphenyl)ethyl]amine **885067-40-3P**, 3-[6-[[2-(4-
Fluorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]benzoic acid
hydrochloride **885067-44-7P**, 3-[6-[[2-(4-
Chlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]benzoic acid
monohydrochloride **885067-48-1P**, 2-[2-Methoxy-6-[[2-(4-
methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenol **885067-52-7P**,
[2-Methoxy-6-[3-(3-methyl-[1,2,4]oxadiazol-5-yl)phenyl]pyrimidin-4-yl][2-
(4-methoxyphenyl)ethyl]amine **885067-54-9P**, [2-Methoxy-6-[3-(5-
methyl-4H-[1,2,4]triazol-3-yl)phenyl]pyrimidin-4-yl][2-(4-
methoxyphenyl)ethyl]amine **885067-55-0P**, [2-Methoxy-6-[3-(3-
methylisoxazol-5-yl)phenyl]pyrimidin-4-yl][2-(4-methoxyphenyl)ethyl]amine
885067-56-1P **885067-57-2P**, [2-(3-Fluoro-4-
methoxyphenyl)ethyl][2-methoxy-6-[3-(2H-tetrazol-5-yl)phenyl]pyrimidin-4-
yl]amine **885067-58-3P**, 1-Ethyl-3-[3-[2-methoxy-6-[[2-(4-
methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenyl]urea **885067-63-0P**
, [2-Methoxy-6-(3-methoxyphenyl)pyrimidin-4-yl][2-(4-
nitrophenyl)ethyl]amine **885067-65-2P**, [2-Methoxy-6-(3-
methoxyphenyl)pyrimidin-4-yl][2-(4-trifluoromethoxyphenyl)ethyl]amine
885067-66-3P, [2-(2-Chloro-6-fluorophenyl)ethyl][2-methoxy-6-(3-
methoxyphenyl)pyrimidin-4-yl]amine hydrochloride **885067-72-1P**,

[2-(4-Aminophenyl)ethyl][2-methoxy-6-(3-methoxyphenyl)pyrimidin-4-yl]amine monohydrochloride **885067-73-2P**, (4-Methoxybenzyl)[2-methoxy-6-(3-methoxyphenyl)pyrimidin-4-yl]amine monohydrochloride **885067-74-3P**, [2-Methoxy-6-(3-methoxyphenyl)pyrimidin-4-yl](3-phenylpropyl)amine monohydrochloride **885067-77-6P**, [2-Methoxy-6-(3-methoxyphenyl)pyrimidin-4-yl][2-(4-methoxyphenyl)ethyl]amine **885067-86-7P**, 3-[6-[[2-(2,2-Difluorobenzodioxol-5-yl)ethyl]amino]-2-methoxypyrimidin-4-yl]benzoic acid **885067-91-4P**, N-[3-[6-[[2-[4-(Difluoromethoxy)phenyl]ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]acetamide monohydrochloride **885067-92-5P**, [2-[4-(Difluoromethoxy)phenyl]ethyl][6-(3-methylsulfonylphenyl)-2-methoxypyrimidin-4-yl]amine monohydrochloride **885067-93-6P**, [2-(2,4-Dichlorophenyl)ethyl][2-methyl-6-[3-[1-methyl-1-(1H-tetrazol-5-yl)ethyl]phenyl]pyrimidin-4-yl]amine monohydrochloride **885067-99-2P**, 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]propionic acid monohydrochloride **885068-01-9P**, 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]-2-methylpropionic acid 1-(ethoxycarbonyloxy)ethyl ester monohydrochloride **885068-02-0P**, 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]-2-methylpropionic acid 2-dimethylaminoethyl ester dihydrochloride **885068-11-1P**, 3-[6-[[2-(2,6-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]benzoic acid **885068-12-2P** **885068-13-3P**, [[3-[6-[[2-(2-Chloro-6-fluorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]benzyl]oxy]acetic acid **885068-14-4P** **885068-17-7P**, [3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]benzoylamino]acetic acid **885068-18-8P**, Ethylcarbamic acid 3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl ester **885068-27-9P** **885068-28-0P**, N-[2-[3-[6-[[2-(2-Fluoro-4-trifluoromethylphenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]ethyl]acetamide monohydrochloride **885068-29-1P**, [2-(2-Fluoro-4-trifluoromethylphenyl)ethyl][2-methoxy-6-[3-[(oxiranyl)methoxy]phenyl]pyrimidin-4-yl]amine **885068-33-7P**, 2-[3-[2-Methoxy-6-[[2-[4-(5-methyl-[1,3,4]oxadiazol-2-yl)phenyl]ethyl]amino]pyrimidin-4-yl]phenyl]-2-methylpropionic acid **885068-37-1P** **885068-45-1P**, 2-[2-Fluoro-5-[2-methoxy-6-[[2-(4-trifluoromethoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenyl]-2-methylpropionic acid **885068-61-1P**, 1-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]cyclopentanecarboxylic acid monohydrochloride **885068-63-3P**, 3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]benzoic acid 2-(morpholin-4-yl)ethyl ester **885068-64-4P**, 3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]benzoic acid 2-(4-methylpiperazin-1-yl)ethyl ester **885068-65-5P**, 3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]benzoic acid ethyl ester **885068-66-6P**, [3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]methanol **885068-67-7P**, 1-[3'-Chloro-4'-[2-[6-(3-hydroxymethylphenyl)-2-methoxypyrimidin-4-yl]amino]ethyl]biphenyl-3-yl]methanol **885068-68-8P**, 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]-2-methylpropionic acid methyl ester **885068-72-4P**, N-[4-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]tetrahydropyran-4-yl]carbonyl]methanesulfonamide **885068-73-5P**, 4-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]tetrahydropyran-4-carboxylic acid ethyl ester **885068-78-0P** **885068-79-1P** **885068-83-7P**,

[2-(2,4-Dichlorophenyl)ethyl][6-[3-[difluoro(1H-tetrazol-5-yl)methyl]phenyl]-2-methoxypyrimidin-4-yl]amine **885068-88-2P**,
N-[[4-[3-[2-Methoxy-6-[[2-(4-trifluoromethoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenyl]tetrahydropyran-4-yl]carbonyl]methanesulfonamide
885068-90-6P, 4-[3-[2-Methoxy-6-[[2-(4-trifluoromethoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenyl]tetrahydropyran-4-carboxylic acid methyl ester **885068-91-7P**, 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-(methoxymethyl)pyrimidin-4-yl]phenyl]-2-methylpropionic acid **885068-93-9P**, 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-hydroxymethylpyrimidin-4-yl]phenyl]-2-methylpropionic acid **885069-05-6P**, 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]-2-methylpropionic acid 2,3-dihydroxypropyl ester **885069-12-5P**,
2-[3-[6-[(Benzofuran-5-ylmethyl)amino]-2-methoxypyrimidin-4-yl]phenyl]-2-methylpropionic acid **885069-16-9P**, Ethanesulfonic acid
N-[2-[3-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]-2-methylpropionyl]amide **885069-17-0P**,
N-[2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]-2-methylpropionyl]-1-phenylmethanesulfonamide
885069-18-1P, 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]-2-methyl-1-(morpholin-4-yl)propan-1-one
885069-19-2P, 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]-N-(tetrahydropyran-4-yl)isobutyramide
885069-20-5P, 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]-N-(1H-tetrazol-5-yl)isobutyramide
885069-28-3P, 2-[2-Chloro-5-[6-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]propan-2-ol
885069-31-8P, 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]-4-fluorophenyl]-2-methylpropionic acid
monohydrochloride **885069-35-2P**, [6-[4-Fluoro-3-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl][2-(4-methoxyphenyl)ethyl]amine **885069-36-3P**, 4-[2-[[3-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzyl]amino]ethyl]phenol
885069-37-4P, N-[2-Fluoro-5-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzyl]-N',N'-dimethylethane-1,2-diamine **885069-38-5P**, 6-(3-Methoxyphenyl)-N'-[2-(4-methoxyphenyl)ethyl]-N,N-dimethylpyrimidine-2,4-diamine
885069-39-6P, 2-Chloro-5-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzoic acid **885069-40-9P**,
[2-(4-Methoxyphenyl)ethyl][2-methoxy-6-[3-[(1H-tetrazol-5-yl)methyl]phenyl]pyrimidin-4-yl]amine **885069-41-0P**,
N-[2-Fluoro-5-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzyl]-2-methoxyacetamide **885069-42-1P**, 3-[[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenoxy]methyl]-4H-[1,2,4]oxadiazol-5-one **885069-43-2P**, 3-[3-[6-[[2-(2-Chloro-6-fluorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]benzyl]-4H-[1,2,4]oxadiazol-5-one **885069-44-3P**, 3-[[3-[6-[[2-(2-Chloro-6-fluorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenoxy]methyl]-4H-[1,2,4]oxadiazol-5-one **885069-45-4P**, 3-[6-[[2-(4-Fluorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]benzoic acid
885069-46-5P, 3-[6-[[2-(4-Chlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]benzoic acid **885069-47-6P**,
[2-(2-Chloro-6-fluorophenyl)ethyl][2-methoxy-6-(3-methoxyphenyl)pyrimidin-4-yl]amine **885069-52-3P**, [2-(4-Aminophenyl)ethyl][2-methoxy-6-(3-methoxyphenyl)pyrimidin-4-yl]amine **885069-53-4P**,
(4-Methoxybenzyl)[2-methoxy-6-(3-methoxyphenyl)pyrimidin-4-yl]amine
885069-54-5P, [2-Methoxy-6-(3-methoxyphenyl)pyrimidin-4-yl](3-phenylpropyl)amine **885069-55-6P**, N-[3-[6-[[2-[4-


(Difluoromethoxy)phenyl]ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]acetamide **885069-56-7P**, [2-[4-(Difluoromethoxy)phenyl]ethyl][6-(3-methylsulfonylphenyl)-2-methoxypyrimidin-4-yl]amine **885069-57-8P**, [2-(2,4-Dichlorophenyl)ethyl][2-methyl-6-[3-[1-methyl-1-(1H-tetrazol-5-yl)ethyl]phenyl]pyrimidin-4-yl]amine **885069-60-3P**, 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]propionic acid **885069-61-4P**, 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]-2-methylpropionic acid 1-(ethoxycarbonyloxy)ethyl ester **885069-62-5P**, 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]-2-methylpropionic acid 2-dimethylaminoethyl ester **885069-64-7P**, N-[2-[3-[6-[[2-(2-Fluoro-4-trifluoromethylphenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]ethyl]-2-methoxyacetamide **885069-65-8P**, N-[2-[3-[6-[[2-(2-Fluoro-4-trifluoromethylphenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]ethyl]acetamide **885069-67-0P**, 1-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]cyclopentanecarboxylic acid **885069-72-7P**, 3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenol hydrochloride

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of aminopyrimidines as prostaglandin D2 receptor antagonists)


RN 885066-07-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 885066-08-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 885066-09-1 CAPLUS


CN INDEX NAME NOT YET ASSIGNED




RN 885066-12-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885066-13-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 885066-14-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885066-17-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885066-28-4 CAPLUS

CN Benzenemethanol, 3-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 885066-35-3 CAPLUS

CN Methanesulfonamide, N-[2-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 885066-36-4 CAPLUS

CN Benzamide, 4-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 885066-39-7 CAPLUS

CN Ethanone, 1-[4-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 885066-40-0 CAPLUS

CN 4-Pyrimidinamine, 2-methoxy-N-[2-(4-methoxyphenyl)ethyl]-6-[3-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 885066-42-2 CAPLUS

CN 4-Pyrimidinamine, 2-methoxy-N-[2-(4-methoxyphenyl)ethyl]-6-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 885066-43-3 CAPLUS

CN 4-Pyrimidinamine, 6-[4-(dimethylamino)phenyl]-2-methoxy-N-[2-(4-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 885066-46-6 CAPLUS

CN 4-Pyrimidinamine, 2-methoxy-N-[2-(4-methoxyphenyl)ethyl]-6-[3-(5-oxazolyl)phenyl]- (9CI) (CA INDEX NAME)




RN 885066-49-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



● HCl


RN 885066-51-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

PAGE 1-A




● HCl

PAGE 1-B




RN 885066-52-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




● HCl

RN 885066-60-4 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




● HCl

RN 885066-62-6 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




● HCl

RN 885066-64-8 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




● HCl

RN 885066-66-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




● HCl


RN 885066-70-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885066-73-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885066-75-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 885066-76-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885066-78-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




● HCl


RN 885066-79-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885066-80-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885066-88-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885066-95-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885066-96-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 885066-98-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885067-00-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




● HCl

RN 885067-04-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




● HCl

RN 885067-06-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885067-08-3 CAPLUS

CN Benzamide, 3-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 885067-10-7 CAPLUS

CN Benzamide, 3-[6-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-methoxy-4-pyrimidinyl]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 885067-13-0 CAPLUS

CN Benzaldehyde, 3-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]-, oxime (9CI) (CA INDEX NAME)



RN 885067-19-6 CAPLUS


CN 4-Pyrimidinamine, 6-[3-(aminomethyl)-4-fluorophenyl]-2-methoxy-N-[2-(4-methoxyphenyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 885067-20-9 CAPLUS


CN Acetamide, N-[[2-fluoro-5-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 885067-29-8 CAPLUS


CN INDEX NAME NOT YET ASSIGNED



● HCl

RN 885067-31-2 CAPLUS


CN INDEX NAME NOT YET ASSIGNED



● HCl

RN 885067-34-5 CAPLUS


CN INDEX NAME NOT YET ASSIGNED



● HCl


RN 885067-36-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 885067-39-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



RN 885067-40-3 CAPLUS


CN INDEX NAME NOT YET ASSIGNED



● HCl

RN 885067-44-7 CAPLUS


CN INDEX NAME NOT YET ASSIGNED



● HCl


RN 885067-48-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 885067-52-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 885067-54-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 885067-55-0 CAPLUS


CN INDEX NAME NOT YET ASSIGNED




RN 885067-56-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885067-57-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885067-58-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885067-63-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 885067-65-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885067-66-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



● HCl


RN 885067-72-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



● HCl

RN 885067-73-2 CAPLUS


CN INDEX NAME NOT YET ASSIGNED



● HCl

RN 885067-74-3 CAPLUS


CN INDEX NAME NOT YET ASSIGNED



● HCl


RN 885067-77-6 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 885067-86-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 885067-91-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




● HCl

RN 885067-92-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




● HCl

RN 885067-93-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




● HCl

RN 885067-99-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




● HCl

RN 885068-01-9 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




● HCl

RN 885068-02-0 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




● 2 HCl

RN 885068-11-1 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 885068-12-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




● Na

RN 885068-13-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885068-14-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




● Na


RN 885068-17-7 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED



RN 885068-18-8 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 885068-27-9 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




● x HCl

RN 885068-28-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




● HCl


RN 885068-29-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885068-33-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885068-37-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 885068-45-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885068-61-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




● HCl

RN 885068-63-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 885068-64-4 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A




PAGE 1-B

Me


RN 885068-65-5 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 885068-66-6 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 885068-67-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885068-68-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885068-72-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885068-73-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885068-78-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885068-79-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885068-83-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885068-88-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885068-90-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885068-91-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885068-93-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885069-05-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885069-12-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885069-16-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885069-17-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885069-18-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885069-19-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885069-20-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 885069-28-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885069-31-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




● HCl

RN 885069-35-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885069-36-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A




PAGE 1-B




RN 885069-37-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885069-38-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885069-39-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885069-40-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885069-41-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885069-42-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885069-43-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885069-44-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885069-45-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885069-46-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885069-47-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885069-52-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885069-53-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885069-54-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885069-55-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885069-56-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885069-57-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885069-60-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885069-61-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885069-62-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885069-64-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885069-65-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 885069-67-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 885069-72-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



● HCl

IT **885066-06-8P**, 3-[2-Methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzenesulfonyl chloride **885066-74-0P**, [2-(3,4-Dimethoxyphenyl)ethyl][6-(3,4-dimethoxyphenyl)-2-methylsulfonylpyrimidin-4-yl]amine **885066-77-3P**, [2-Methylsulfonyl-6-(3-methoxyphenyl)pyrimidin-4-yl][2-(4-methoxyphenyl)ethyl]amine **885067-30-1P 885067-33-4P 885067-35-6P 885067-53-8P**, N-(1-Iminoethyl)-3-[2-methoxy-6-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzamide **885067-96-9P**, 2-[3-[6-[[2-(2,4-Dichlorophenyl)ethyl]amino]-2-methylpyrimidin-4-yl]phenyl]-2-methylpropionitrile **885068-19-9P 885068-25-7P**, [3-[6-[[2-(2-Fluoro-4-trifluoromethylphenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenyl]acetonitrile **885068-26-8P**, [6-[3-(2-Aminoethyl)phenyl]-2-methoxypyrimidin-4-yl][2-(2-fluoro-4-trifluoromethylphenyl)ethyl]amine **885068-30-4P**,


3-[6-[[2-(2-Fluoro-4-trifluoromethylphenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenol **885068-40-6P**, 3-[6-[[2-(3,4-Difluorophenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenol **885068-53-1P**, 2-[2-Fluoro-5-[2-methoxy-6-[[2-(4-trifluoromethoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenyl]-2-methylpropionic acid methyl ester

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of aminopyrimidines as prostaglandin D2 receptor antagonists)


RN 885066-06-8 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 885066-74-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 885066-77-3 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 885067-30-1 CAPLUS


CN INDEX NAME NOT YET ASSIGNED




RN 885067-33-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885067-35-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885067-53-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885067-96-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885068-19-9 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 885068-25-7 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 885068-26-8 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 885068-30-4 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 885068-40-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 885068-53-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




IT **885067-32-3**, [3-[2-Methoxy-6-[[2-(2-chloro-6-fluorophenyl)ethyl]amino]pyrimidin-4-yl]phenyl]acetonitrile
885068-43-9, 3-[6-[[2-(3-Fluoro-4-methoxyphenyl)ethyl]amino]-2-methoxypyrimidin-4-yl]phenol **885068-89-3**
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of aminopyrimidines as prostaglandin D2 receptor antagonists)
 RN 885067-32-3 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED



RN 885068-43-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 885068-89-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



L10 ANSWER 4 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:301346 CAPLUS

DN 144:350708

TI Novel pyrimidine compounds, process for their preparation, pharmaceutical compositions, and their use as antiinflammatory, cytotoxic, rheumatic, immunosuppressive and cardiovascular agents for treatment of diseases

IN Kalleda, Srinivas; Padakanti, Srinivas; Kumar Swamy, Nalivela; Yeleswarapu, Koteswar Rao; Alexander, Christopher W.; Khanna, Ish Kumar; Iqbal, Javed; Pillarisetti, Sivaram; Pal, Manojit; Barange, Deepak

PA Reddy US Therapeutics, Inc., USA

SO PCT Int. Appl., 336 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006034473	A2	20060330	WO 2005-US34243	20050923
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, IL, IN, IS, JP, KE, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SN, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006084644	A1	20060420	US 2005-234257	20050923
US 2006084645	A1	20060420	US 2005-234695	20050923
PRAI US 2004-612374P	P	20040923		

AB The invention provides heterocyclic compds., particularly substituted pyrimidines of formula I, methods and compns. for making and using these heterocyclic compds., and methods for treating a variety of diseases and disease states, including atherosclerosis, arthritis, restenosis, diabetic nephropathy, or dyslipidemia, or disease states mediated by the low expression of Perlecan. Compds. of formula I wherein R1, R2 and R4 are independently (un)substituted (hetero)aryl or (un)substituted heterocyclyl; and their pharmaceutically acceptable salts, prodrugs, diastereoisomeric mixts., enantiomers, tautomers, and racemic mixts. thereof are claimed in this invention. Example compound II was prepared by acylation of 4-methoxyacetophenone with di-Et carbonate; the resulting Et 4-methoxybenzoylacetate underwent cyclization with guanidine carbonate to give 2-amino-6-(4-methoxyphenyl)pyrimidin-4-ol, which was converted to 4-chloro-6-(methoxyphenyl)pyrimidin-2-ylamine, which underwent amination with 3-chloro-4-methoxyaniline to give compound II. The invention compds. were evaluated for their antiinflammatory, proliferative, cardiovascular, and immunosuppressive activity (no data).

IT 881193-27-7P 881194-61-2P 881194-64-5P


881194-67-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidine compds. and their use as antiinflammatory, proliferative, rheumatic, immunosuppressive and cardiovascular agents for treatment of diseases)


RN 881193-27-7 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(3-chloro-4-methoxyphenyl)-6-phenyl-N4-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 881194-61-2 CAPLUS

CN 4-Pyrimidinamine, 2-(ethylthio)-6-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 881194-64-5 CAPLUS

CN 2(1H)-Pyrimidinone, 4-phenyl-6-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 881194-67-8 CAPLUS

CN 4-Pyrimidinamine, 2-chloro-6-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 5 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:292375 CAPLUS

DN 144:350703

TI Preparation of 4-aminomethylpyrimidines as ppar-alpha modulators

IN Dittrich-Wengenroth, Elke; Baerfacker, Lars; Kretschmer, Axel;
Hirth-Dietrich, Claudia; Ellinghaus, Peter; Raabe, Martin; Bischoff,
Hilmar; Pilger, Christian; Rosentreter, Ulrich; Bartel, Stephan; Lustig,
Klemens; Kern, Armin; Lang, Dieter; Bauser, Marcus

PA Bayer Healthcare AG, Germany

SO PCT Int. Appl., 140 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006032384	A1	20060330	WO 2005-EP9734	20050910
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

DE 102004046623 A1 20060330 DE 2004-102004046623 20040925
PRAI DE 2004-102004046623 A 20040925

AB Title compds. I [X = (CH₂)_n; n = 0-2; A = O, S; Z = (CH₂)_m; O, NR₉; m = 0-2; R₉ = H, alkyl; R₁ = aryl, 5- to 10-membered heteroaryl; R₂ = H, aryl, alkyl, etc.; R₃, R₄ = H, alkyl, alkenyl, etc.; R₅, R₆ = H, alkyl, alkoxy, etc.; R₇ = NHR₁₆, OR₁₇; R₁₆ = H, alkyl, alkylsulfonyl; R₁₇ = H, O-protecting group with provisos; R₈ = H, alkyl; D, E = N, CH with provisos] and their pharmaceutically acceptable salts and formulations were prepared. For example, HCl-mediated deprotection of of t-Bu ester II [Y = O-tBu] afforded claimed aminomethylpyrimidine II [Y = OH] in 31% yield. In ppar-α receptor EC₅₀ assays, compds. I exhibited values from 1 μM to 1 nM.

IT 881686-45-9P 881686-46-0P 881686-47-1P
881686-48-2P 881686-49-3P 881686-50-6P
881686-51-7P 881686-52-8P 881686-53-9P
881686-54-0P 881686-55-1P 881686-56-2P
881686-57-3P 881686-58-4P 881686-59-5P
881686-64-2P 881686-65-3P 881686-77-7P
881686-78-8P 881686-79-9P 881687-03-2P
881687-04-3P 881687-05-4P 881687-06-5P
881687-07-6P 881687-08-7P 881687-09-8P
881687-10-1P 881687-11-2P 881687-12-3P
881687-13-4P 881687-15-6P



RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-aminomethylpyrimidines as ppar-alpha modulators)

RN 881686-45-9 CAPLUS

CN Propanoic acid, 2-[[4-[[2-methoxyethyl][6-[3-(trifluoromethyl)phenyl]-4-



pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 881686-46-0 CAPLUS



CN Propanoic acid, 2-[[4-[[[6-(3-chlorophenyl)-4-pyrimidinyl](2-methoxyethyl)amino]methyl]phenyl]thio]-2-methyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl



RN 881686-47-1 CAPLUS

CN Propanoic acid, 2-[[4-[[[(2-methoxyethyl)[6-(3-methylphenyl)-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)




RN 881686-48-2 CAPLUS

CN Propanoic acid, 2-[[4-[[[(2-methoxyethyl)[6-(4-methylphenyl)-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)



RN 881686-49-3 CAPLUS


CN Propanoic acid, 2-[[4-[[[(2-furanylmethyl)[6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 881686-50-6 CAPLUS


CN Propanoic acid, 2-[[4-[[[6-(3-chlorophenyl)-4-pyrimidinyl](2-furanylmethyl)amino]methyl]phenyl]thio]-2-methyl-, hydrochloride (9CI)
(CA INDEX NAME)



● x HCl

RN 881686-51-7 CAPLUS


CN Propanoic acid, 2-methyl-2-[[4-[[[6-(3-methylphenyl)-4-pyrimidinyl]amino]methyl]phenyl]thio]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 881686-52-8 CAPLUS

CN Propanoic acid, 2-[[4-[[[6-(4-fluoro-3-methylphenyl)-4-pyrimidinyl](2-furanylmethyl)amino]methyl]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)




RN 881686-53-9 CAPLUS

CN Propanoic acid, 2-[[4-[[[6-(3-methylphenyl)-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)




RN 881686-54-0 CAPLUS

CN Propanoic acid, 2-[[4-[[[(2-furanylmethyl)[6-(2-methylphenyl)-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)





RN 881686-55-1 CAPLUS

CN Propanoic acid, 2-[[4-[[[(2-furanylmethyl)[6-(4-methylphenyl)-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)





RN 881686-56-2 CAPLUS

CN Propanoic acid, 2-[[4-[[[6-(2-fluoro-5-methylphenyl)-4-pyrimidinyl](2-methoxyethyl)amino]methyl]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)



RN 881686-57-3 CAPLUS



CN Propanoic acid, 2-[[4-[[[(2-methoxyethyl)[2-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 881686-58-4 CAPLUS



CN Propanoic acid, 2-[[4-[[[(2-methoxyethyl)[2-(3-methylphenyl)-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 881686-59-5 CAPLUS


CN Propanoic acid, 2-[[4-[[[2-(3-chlorophenyl)-4-pyrimidinyl](2-methoxyethyl)amino]methyl]phenyl]thio]-2-methyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 881686-64-2 CAPLUS

CN Propanoic acid, 2-[[4-[[[6-(3-chlorophenyl)-4-pyrimidinyl]-2-propynylamino]methyl]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)





RN 881686-65-3 CAPLUS

CN Propanoic acid, 2-methyl-2-[[4-[[(2-thiazolylmethyl) [6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]- (9CI)
(CA INDEX NAME)




RN 881686-77-7 CAPLUS

CN Propanoic acid, 2-[[[4-[[[(2-methoxyethyl)[6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)




RN 881686-78-8 CAPLUS

CN Propanoic acid, 2-[[4-[[[(3,5-dimethyl-4-isoxazolyl)methyl][6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-
(9CI) (CA INDEX NAME)





RN 881686-79-9 CAPLUS

CN Propanoic acid, 2-[[4-[[[(2-fluoroethyl)[6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)





RN 881687-03-2 CAPLUS

CN Propanoic acid, 2-[[4-[[[(2-methoxyethyl)[6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)





RN 881687-04-3 CAPLUS

CN Propanoic acid, 2-[[4-[[[(2-methoxyethyl)[6-[4-(trifluoromethoxy)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)





RN 881687-05-4 CAPLUS

CN Propanoic acid, 2-[[4-[[2-methoxyethyl][6-[3-(trifluoromethoxy)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)



RN 881687-06-5 CAPLUS


CN Propanoic acid, 2-[[4-[[6-(4-fluoro-3-methylphenyl)-4-pyrimidinyl](2-methoxyethyl)amino]methyl]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)



RN 881687-07-6 CAPLUS


CN Propanoic acid, 2-methyl-2-[[4-[[[(2-methyl-4-thiazolyl)methyl][6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]- (9CI)

(CA INDEX NAME)




RN 881687-08-7 CAPLUS

CN Propanoic acid, 2-methyl-2-[[4-[[[(2-methyl-4-thiazolyl)methyl][6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]- (9CI)
(CA INDEX NAME)




RN 881687-09-8 CAPLUS

CN Propanoic acid, 2-methyl-2-[[4-[[[(1-methyl-1H-imidazol-2-yl)methyl][6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]- (9CI)
(CA INDEX NAME)




RN 881687-10-1 CAPLUS

CN Propanoic acid, 2-methyl-2-[[4-[[[(1-methyl-1H-imidazol-2-yl)methyl][6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]- (9CI)
(CA INDEX NAME)




RN 881687-11-2 CAPLUS

CN Propanoic acid, 2-[[4-[[[(2,4-dimethyl-5-thiazolyl)methyl][6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)




RN 881687-12-3 CAPLUS

CN Propanoic acid, 2-[[4-[[[(2,4-dimethyl-5-thiazolyl)methyl][6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)



RN 881687-13-4 CAPLUS


CN Propanoic acid, 2-[[4-[[[(2,4-dimethyl-5-thiazolyl)methyl][6-(4-methylphenyl)-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)



RN 881687-15-6 CAPLUS

CN Propanoic acid, 2-[[4-[[[(cyclopropylmethyl)[6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)

4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl- (9CI) (CA INDEX NAME)





IT 881687-25-8P 881687-26-9P 881687-27-0P
 881687-28-1P 881687-29-2P 881687-30-5P
 881687-31-6P 881687-32-7P 881687-33-8P
 881687-34-9P 881687-35-0P 881687-36-1P
 881687-38-3P 881687-39-4P 881687-40-7P
 881687-45-2P 881687-49-6P 881687-67-8P
 881687-68-9P 881687-69-0P 881687-97-4P
 881687-99-6P 881688-01-3P 881688-03-5P
 881688-05-7P 881688-06-8P 881688-07-9P
 881688-08-0P 881688-09-1P 881688-10-4P
 881688-11-5P 881688-12-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 4-aminomethylpyrimidines as ppar-alpha modulators)



RN 881687-25-8 CAPLUS

CN Propanoic acid, 2-[[4-[[2-methoxyethyl][6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 881687-26-9 CAPLUS

CN Propanoic acid, 2-[[4-[[[6-(3-chlorophenyl)-4-pyrimidinyl](2-methoxyethyl)amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 881687-27-0 CAPLUS

CN Propanoic acid, 2-[[4-[[[(2-methoxyethyl)[6-(3-methylphenyl)-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 881687-28-1 CAPLUS


CN Propanoic acid, 2-[[4-[[[(2-methoxyethyl)[6-(4-methylphenyl)-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 881687-29-2 CAPLUS


CN Propanoic acid, 2-[[4-[[[(2-furanylmethyl)[6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester

(9CI) (CA INDEX NAME)




RN 881687-30-5 CAPLUS

CN Propanoic acid, 2-[[4-[[[6-(3-chlorophenyl)-4-pyrimidinyl](2-furanylmethyl)amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 881687-31-6 CAPLUS


CN Propanoic acid, 2-methyl-2-[[4-[[[6-(3-methylphenyl)-4-pyrimidinyl]amino]methyl]phenyl]thio]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 881687-32-7 CAPLUS


CN Propanoic acid, 2-[[4-[[[6-(4-fluoro-3-methylphenyl)-4-pyrimidinyl](2-furanylmethyl)amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester

(9CI) (CA INDEX NAME)




RN 881687-33-8 CAPLUS

CN Propanoic acid, 2-[[4-[[[(2-furanylmethyl)[6-(3-methylphenyl)-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)




RN 881687-34-9 CAPLUS

CN Propanoic acid, 2-[[4-[[[(2-furanylmethyl)[6-(2-methylphenyl)-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)





RN 881687-35-0 CAPLUS

CN Propanoic acid, 2-[[4-[[[(2-furanylmethyl)[6-(4-methylphenyl)-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 881687-36-1 CAPLUS

CN Propanoic acid, 2-[[4-[[[6-(2-fluoro-5-methylphenyl)-4-pyrimidinyl](2-methoxyethyl)amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 881687-38-3 CAPLUS

CN Propanoic acid, 2-[[4-[[[(2-methoxyethyl)[2-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 881687-39-4 CAPLUS

CN Propanoic acid, 2-[[4-[[[(2-methoxyethyl)[2-(3-methylphenyl)-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 881687-40-7 CAPLUS

CN Propanoic acid, 2-[[4-[[[2-(3-chlorophenyl)-4-pyrimidinyl](2-methoxyethyl)amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 881687-45-2 CAPLUS

CN Propanoic acid, 2-[[4-[[[6-(3-chlorophenyl)-4-pyrimidinyl]-2-propynylamino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 881687-49-6 CAPLUS

CN Propanoic acid, 2-methyl-2-[[4-[[2-thiazolylmethyl][6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 881687-67-8 CAPLUS

CN Propanoic acid, 2-[[4-[[[(3,5-dimethyl-4-isoxazolyl)methyl][6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 881687-68-9 CAPLUS

CN Propanoic acid, 2-methyl-2-[[4-[[[6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 881687-69-0 CAPLUS

CN Propanoic acid, 2-[[4-[[[(2-fluoroethyl)[6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)





RN 881687-97-4 CAPLUS

CN Propanoic acid, 2-[[4-[[[(2-methoxyethyl)[6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)



RN 881687-99-6 CAPLUS



CN Propanoic acid, 2-[[4-[[[(2-methoxyethyl)[6-[4-(trifluoromethoxy)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)



RN 881688-01-3 CAPLUS



CN Propanoic acid, 2-[[4-[[[(2-methoxyethyl)[6-[3-(trifluoromethoxy)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester

(9CI) (CA INDEX NAME)




RN 881688-03-5 CAPLUS

CN Propanoic acid, 2-[[4-[[[6-(4-fluoro-3-methylphenyl)-4-pyrimidinyl](2-methoxyethyl)amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)




RN 881688-05-7 CAPLUS

CN Propanoic acid, 2-methyl-2-[[4-[[[(2-methyl-4-thiazolyl)methyl][6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 881688-06-8 CAPLUS

CN Propanoic acid, 2-methyl-2-[[4-[[[(2-methyl-4-thiazolyl)methyl][6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 881688-07-9 CAPLUS

CN Propanoic acid, 2-methyl-2-[[4-[[[(1-methyl-1H-imidazol-2-yl)methyl][6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 881688-08-0 CAPLUS

CN Propanoic acid, 2-methyl-2-[[4-[[[(1-methyl-1H-imidazol-2-yl)methyl][6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 881688-09-1 CAPLUS

CN Propanoic acid, 2-[[4-[[[(2,4-dimethyl-5-thiazolyl)methyl][6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 881688-10-4 CAPLUS

CN Propanoic acid, 2-[[4-[[[(2,4-dimethyl-5-thiazolyl)methyl][6-[3-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 881688-11-5 CAPLUS

CN Propanoic acid, 2-[[4-[[[(2,4-dimethyl-5-thiazolyl)methyl][6-(4-methylphenyl)-4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 881688-12-6 CAPLUS

CN Propanoic acid, 2-[[4-[[[(cyclopropylmethyl)[6-[3-(trifluoromethyl)phenyl]-

10/671,070

4-pyrimidinyl]amino]methyl]phenyl]thio]-2-methyl-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:269060 CAPLUS
 DN 144:311786
 TI Substituted aniline derivatives as KCNQ subtype potassium ion channel
 openers, their preparation, pharmaceutical compositions, and use in
 therapy
 IN Tornoee, Christian Wenzel; Rottlaender, Mario; Greve, Daniel Rodriguez;
 Khanzhin, Nikolay; Ritzen, Andreas; Watson, William Patrick
 PA H. Lundbeck A/S, Den.
 SO PCT Int. Appl., 101 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006029623	A1	20060323	WO 2005-DK560	20050902
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MG, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI DK 2004-1394 A 20040913
 US 2004-609856P P 20040913

OS MARPAT 144:311786

AB The invention relates to aniline derivs. of formula I, which are openers of the KCNQ family of potassium ion channels. In compds. I, Z is O or S; q is 0 or 1; R1 and R2 are independently selected from halo, cyano, amino, C1-6 alkyl, C2-6 alkenyl, C3-8 cycloalkyl, C3-8 heterocyclyl, aryl, heteroaryl, etc.; R3 is selected from C1-8 alkyl, C2-8 alkenyl, C3-8 cycloalkyl, aryl-C1-6 alkyl, aryl-C3-8 cycloalkyl, C3-8 heterocyclyl-C1-6 alkyl, heteroaryl-C1-6 alkyl, etc.; and R4 is selected from halo, cyano, C1-6 alkyl, C2-6 alkenyl, C3-8 cycloalkyl, C3-8 heterocyclyl, aryl, heteroaryl, aryl-C1-6 alkyl, (un)substituted amino, etc. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I with one or more pharmaceutically acceptable carriers or diluents, as well as to the use of the compns. for the treatment of a disorder or disease being responsive to an increased ion flow in a potassium channel, such as epilepsy. Amidation of cyclopentaneacetyl chloride with 4-bromo-2,6-dimethylaniline gave acetamide II, which underwent substitution with pyrrole to give acetanilide III. Some compds. of the invention express EC50 values below 200 nM in an assay for affinity for the KCNQ2 receptor subtype.


IT **879648-61-OP**, [2,6-Dimethyl-4-[(4-methyl-2-phenylpyrimidin-5-ylmethyl)amino]phenyl]carbamic acid propyl ester

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of aniline derivs. as openers of KCNQ family potassium ion channels)

RN 879648-61-0 CAPLUS

CN Carbamic acid, [2,6-dimethyl-4-[[[4-methyl-2-phenyl-5-pyrimidinyl)methyl]amino]phenyl]-, propyl ester (9CI) (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 7 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:232088 CAPLUS
 DN 144:312100
 TI Preparation of substituted pyridines and pyrimidines as vanilloid receptor ligands
 IN Norman, Mark H.; Pettus, Liping H.; Wang, Xianghong; Zhu, Jiawang
 PA USA
 SO U.S. Pat. Appl. Publ., 96 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006058308	A1	20060316	US 2005-226844	20050913
	WO 2006031852	A1	20060323	WO 2005-US32660	20050913
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2004-609718P	P	20040913		

OS MARPAT 144:312100

AB Title compds. I [J = NH, O or S; X = N or CR2; Y = N or CR2, wherein at least one of X and Y = N; R1 = (un)saturated or partially saturated 5-7 membered

monocyclic or 6-11 membered bicyclic ring containing 0-4 heteroatoms, wherein the available carbon atoms are substituted by 0-2 oxo or thioxo groups, the ring may contain addnl. substituents; R2 = halo, (un)substituted alkyl, benzyl, etc.; R3 = CN, alkoxy, (un)substituted alkyl, etc.; R4 = 6-11 membered bicyclic ring containing 0-4 atoms selected from N, O and S, wherein the available carbon atoms are substituted by 0-2 oxo or thioxo groups, the ring may contain addnl. substituents], and their pharmaceutically acceptable salts, are prepared and disclosed as vanilloid receptor ligands. Thus, e.g., II was prepared by coupling of 4-tert-butylphenylboronic acid with 2,4,6-trichloropyrimidine followed by subsequent substitutions with 1,4-benzodioxane-6-amine and 4-methylpiperazine. Selected compds. of the invention exhibited IC50 values of less than 10 nM in the human VR1 capsaicin antagonist assay. I should prove useful in treating pain and inflammatory conditions.


IT **879603-63-1P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted pyridines and pyrimidines as vanilloid receptor ligands)

RN 879603-63-1 CAPLUS

CN Methanesulfonamide, N-[3-[[[4-[(3-amino-1,2-dihydro-2-oxo-5-quinoxalinyloxy)-6-[4-(trifluoromethyl)phenyl]-2-pyrimidinyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 8 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:188882 CAPLUS

DN 144:432768

TI Optimization of 2,4-diaminopyrimidines as GHS-R antagonists: Side chain exploration

AU Liu, Bo; Liu, Mei; Xin, Zhili; Zhao, Hongyu; Serby, Michael D.; Kosogof, Christi; Nelson, Lissa T. J.; Szczepankiewicz, Bruce G.; Kaszubska, Wiweka; Schaefer, Verlyn G.; Falls, H. Douglas; Lin, Chun Wel; Collins, Christine A.; Sham, Hing L.; Liu, Gang

CS Metabolic Disease Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL, 60064-6098, USA

SO Bioorganic & Medicinal Chemistry Letters (2006) 16(7), 1864-1868
CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier B.V.

DT Journal

LA English

OS CASREACT 144:432768

AB The synthesis and structure-activity relationships of the 4- and 6-substituents of 2,4-diaminopyrimidine-based growth hormone secretagogue receptor (GHS-R) antagonists are described. Diaminopyrimidines I [R = 2-norbornenyl, 2-tetrahydrofuran-2-yl] exhibit potent GHS-R antagonism and good selectivity (.apprx.1000-fold) against dihydrofolate reductase.

IT 861102-94-5P 861102-96-7P 885040-55-1P


885040-56-2P 885040-68-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of (methanesulfonylbenzyl)aminophenyl diaminopyrimidines as growth hormone secretagogue receptor antagonists)


RN 861102-94-5 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[(methylphenylamino)methyl]-5-[4-[[[4-(methylsulfonyl)phenyl]methyl]amino]phenyl]- (9CI) (CA INDEX NAME)





RN 861102-96-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-[4-[[[4-(methylsulfonyl)phenyl]methyl]amino]phenyl]-6-[(phenylamino)methyl]- (9CI) (CA INDEX NAME)




RN 885040-55-1 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[[[4-(4-fluorophenyl)amino]methyl]-5-[4-[[[4-(methylsulfonyl)phenyl]methyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 885040-56-2 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[[[4-(4-fluorophenyl)methylamino]methyl]-5-[4-[[[4-(methylsulfonyl)phenyl]methyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 885040-68-6 CAPLUS

CN 2,4-Pyrimidinediamine, 6-ethyl-5-[4-[[[4-(methylsulfonyl)phenyl]methyl]amino]phenyl]-N4-(phenylmethyl)- (9CI) (CA INDEX NAME)




RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 9 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:111075 CAPLUS
 DN 144:246539
 TI Parallel synthesis of 5-cyano-6-aryl-2-thiouracil derivatives as
 inhibitors for hepatitis C viral NS5B RNA-dependent RNA polymerase
 AU Ding, Yili; Girardet, Jean-Luc; Smith, Kenneth L.; Larson, Gary; Prigaro,
 Brett; Wu, Jim Z.; Yao, Nanhua
 CS Valeant Pharmaceuticals International, Costa Mesa, CA, 92626, USA
 SO Bioorganic Chemistry (2006), 34(1), 26-38
 CODEN: BOCMBM; ISSN: 0045-2068
 PB Elsevier
 DT Journal
 LA English
 AB From random screening of our compound libraries, we identified a hit compound
 (I) with an IC₅₀ of 27 μ M against hepatitis C viral NS5B RNA-dependent
 RNA polymerase. By using a parallel synthetic strategy, a series of its
 derivs. were synthesized. From their anti-HCV activity screening, compds.
 with single digit 3.8 micromolar activity were obtained.
 IT **877460-76-9P 877460-78-1P 877460-81-6P**
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (cyano aryl thiouracil derivs. as inhibitors for hepatitis C viral NS5B
 RNA-dependent RNA polymerase)
 RN 877460-76-9 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 4-(4-bromophenyl)-6-[[2-(3-
 methoxyphenyl)ethyl]amino]-2-[[[2-(trifluoromethyl)phenyl]methyl]thio]-
 (9CI) (CA INDEX NAME)




RN 877460-78-1 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 4-(4-bromophenyl)-6-[(2-phenylethyl)amino]-2-
 [[2-(trifluoromethyl)phenyl]methyl]thio]- (9CI) (CA INDEX NAME)




RN 877460-81-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(4-bromophenyl)-6-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-[[[2-(trifluoromethyl)phenyl]methyl]thio]- (9CI) (CA INDEX NAME)




RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 10 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2006:38998 CAPLUS
 DN 144:292704
 TI A Highly Regioselective Amination of 6-Aryl-2,4-dichloropyrimidine
 AU Peng, Zhi-Hui; Journet, Michel; Humphrey, Guy
 CS Department of Process Research, Merck & Co., Inc., Rahway, NJ, 07065, USA
 SO Organic Letters (2006), 8(3), 395-398
 CODEN: ORLEF7; ISSN: 1523-7060
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 144:292704
 AB A highly regioselective amination of 6-aryl-2,4-dichloropyrimidines with aliphatic secondary amines and aromatic amines which strongly favors the formation of the C4-substituted product has been developed. The reactions with aliphatic amines are carried out using LiHMDS as the base and are catalyzed by Pd, while the aromatic amines require no catalyst.
 IT **878199-61-2P 878199-62-3P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (regioselective amination of 6-aryl-2,4-dichloropyrimidines)
 RN 878199-61-2 CAPLUS
 CN 4-Pyrimidinamine, 2-chloro-6-(4-fluorophenyl)-N-methyl-N-(phenylmethyl)-
 (9CI) (CA INDEX NAME)



RN 878199-62-3 CAPLUS
 CN 2-Pyrimidinamine, 4-chloro-6-(4-fluorophenyl)-N-methyl-N-(phenylmethyl)-
 (9CI) (CA INDEX NAME)



RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 11 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1346218 CAPLUS

DN 144:88321

TI Preparation of triazinyl and other carboxamides as inhibitors of histone deacetylase

IN Delorme, Daniel; Woo, Soon Hyung; Vaisburg, Arkadii; Moradei, Oscar; Leit, Silvana; Raepfel, Stephane; Frechette, Sylvie; Bouchain, Giliane

PA Methylgene, Inc., Can.

SO U.S. Pat. Appl. Publ., 324 pp., Cont.-in-part of U.S. Ser. No. 358,556.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005288282	A1	20051229	US 2005-91025	20050325
	US 2004106599	A1	20040603	US 2002-242304	20020912
	US 2004142953	A1	20040722	US 2003-358556	20030204
	US 6897220	B2	20050524		
	JP 2005255683	A2	20050922	JP 2005-80310	20050318
PRAI	US 2001-322402P	P	20010914		
	US 2002-391728P	P	20020626		
	US 2002-242304	A2	20020912		
	US 2003-358556	A2	20030204		
	JP 2003-528544	A3	20020912		

OS MARPAT 144:88321

AB The invention provides compds. and methods for inhibiting histone deacetylase enzymic activity. Such compds. include carboxamides I [Cy2 = (un)substituted cycloalkyl, aryl, heteroaryl, heterocyclyl (each of which is optionally fused to one or two aryl or heteroaryl rings, or to one or two (un)saturated cycloalkyl or heterocyclic rings); X1 = a bond, M1L2M1, L2M2L2 (wherein L2 = a bond, alkylene, alkenylene, alkynylene; M1 = O, S, SO, NHCO, etc.; M2 = M1, heteroarylene, heterocyclylene); Ar2 = (un)substituted (hetero)arylene; R5, R6 = H, alkyl, aryl, aralkyl; q = 0-1; Ay2 = (un)substituted 5-6 membered cycloalkyl, heterocyclyl or heteroaryl substituted with an amino or hydroxy moiety; with provisos] which were prepared and claimed. E.g., a multi-step synthesis of II, starting from Me 4-(aminomethyl)benzoate.HCl, was given. The invention also provides compns. and methods for treating cell proliferative diseases and conditions. Antineoplastic effects of some I are illustrated for colorectal, pulmonary and pancreatic neoplasms; also the combined antineoplastic effect of histone deacetylase inhibitors and histone deacetylase antisense oligonucleotides on tumor cells in vivo was demonstrated. Although the methods of preparation are not claimed, hundreds of example preps. are included.

IT 503043-79-6P 503043-80-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of triazinyl and other carboxamides as inhibitors of histone deacetylase for treating cell proliferative disorders)

RN 503043-79-6 CAPLUS

CN Benzamide, N-(2-aminophenyl)-4-[[[4-chloro-6-(3,4-dimethoxyphenyl)-2-pyrimidinyl]amino]methyl]- (9CI) (CA INDEX NAME)


10/671,070



*R₄, R₅ & R₆
do not represent
this group*


RN 503043-80-9 CAPLUS

CN Benzamide, N-(2-aminophenyl)-4-[[[4-(3,4-dimethoxyphenyl)-2-pyrimidinyl]amino]methyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 12 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:1331285 CAPLUS
 DN 144:69847
 TI Preparation of 4-phenylpyridine-2-carbonitrile derivs. as inhibitors of
 cathepsin K and cathepsin S
 IN Cai, Jiaqiang; Rankovic, Zoran; Moir, Jennifer Helen
 PA Akzo Nobel N.V., Neth.
 SO PCT Int. Appl., 71 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005121106	A1	20051222	WO 2005-EP6266	20050609
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	EP 2004-253491	A	20040611		
	EP 2004-106949	A	20041223		
OS	MARPAT 144:69847				
AB	Title compds. I [wherein R (one to three) = (un)substituted alkyl, alkoxy, cyano, etc.; R1 = H or alkyl; R2 = (un)substituted alkyl, alkoxy, aryloxy, etc., and pharmaceutically acceptable salts thereof] were prepared as inhibitors of cathepsin K and cathepsin S. For instance, 3'-trifluoromethylacetophenone underwent successive condensation with Et butyrate (76%), cyclization with urea in the presence of HCl (72%), chlorination with POCl3 (100%) and substitution with CuCN (8%) to give II. I showed inhibition of human cathepsin K with pIC50 > 6 (pIC50 > 7 for II). Therefore, I and their pharmaceutical compns. are useful for the treatment of cathepsin K and cathepsin S related diseases, such as atherosclerosis, bone diseases, inflammation, immune disorders and pain.				
IT	871793-50-9P , 4-(3-Phenylaminopropyl)-6-(3-trifluoromethylphenyl)pyrimidine-2-carbonitrile RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (inhibitor; preparation of phenylpyridinecarbonitrile derivs. as inhibitors of cathepsin K and cathepsin S)				
RN	871793-50-9 CAPLUS				
CN	2-Pyrimidinecarbonitrile, 4-[3-(phenylamino)propyl]-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)				



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 13 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:1170507 CAPLUS
 DN 143:440431
 TI Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators
 IN Mjalli, Adnan M. M.; Gaddam, Bapu R.; Qabaja, Ghassan; Subramanian, Govindan; Zhu, Jeff; Dankwardt, John; Arimilli, Murty N.; Andrews, Robert C.; Victory, Samuel; Tian, Ye E.
 PA Transtech Pharma, Inc., USA
 SO PCT Int. Appl., 179 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005103022	A1	20051103	WO 2005-US13386	20050420
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 2005261294 A1 20051124 US 2005-110499 20050420
 PRAI US 2004-563882P P 20040420
 OS MARPAT 143:440431

AB Title compds. I [A = substituted amine, substituted alkyl, substituted sulfonamide, etc.; m = 0-2; R1 and R2 independently = H, halo, alkyl, etc., or R1 and R2 may be taken together to form part of a fused carbocyclic ring, aromatic ring, heteroarom. ring, etc.; W = S, N=N, or CR3=N; R3 = H, halo, alkyl, etc.], methods of their preparation, pharmaceutical compns. comprising the compds. of Formula (I), and methods of use in treating human or animal disorders are disclosed. Thus, e.g., II was prepared by cyclocondensation of 2-bromo-1(4-isopropylphenyl)ethanone (preparation given) with thiourea followed by reaction with chlorosulfonyl-acetic acid tert-Bu ester (preparation given). I showed an increase in cAMP production and a reduction in fluorescence polarization in assays

and possess an effective concentration for half maximal effect (EC50) in the assay of less than 14 μ M. The compds. of the invention can be useful as inhibitors of action of AgRP on a melanocortin receptor and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases which may be responsive to the modulation of melanocortin receptors including obesity-related disorders.

IT 868590-55-0P 868590-72-1P 868590-73-2P
 868590-74-3P 868590-75-4P 868590-76-5P
 868590-77-6P 868590-78-7P 868590-79-8P
 868590-80-1P 868590-81-2P 868590-82-3P
 868590-83-4P 868590-84-5P 868590-85-6P
 868590-86-7P 868590-87-8P 868590-88-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(preparation of thiazole and pyrimidine derivs. as melanocortin receptor modulators)

RN 868590-55-0 CAPLUS

CN Glycine, N-[(4-chlorophenyl)methyl]-N-[2-[4-(1-methylethyl)phenyl]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 868590-72-1 CAPLUS

CN Benzoic acid, 3-[[[cyclopentyl[4-[4-[(cis-4-methylcyclohexyl)oxy]phenyl]-2-pyrimidinyl]amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 868590-73-2 CAPLUS


CN Benzoic acid, 3-[[[2-[4-(cyclohexylmethoxy)phenyl]-4-pyrimidinyl]cyclopentylamino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 868590-74-3 CAPLUS


CN Benzoic acid, 4-[[[2-[4-(1-methylethyl)phenyl]-4-pyrimidinyl](2-thienylmethyl)amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 868590-75-4 CAPLUS


CN Benzoic acid, 2-[[[4-[4-(1-methylethyl)phenyl]-2-pyrimidinyl](2-thienylmethyl)amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 868590-76-5 CAPLUS


CN Benzoic acid, 3-[[[4-[4-(1-methylethyl)phenyl]-2-pyrimidinyl](2-thienylmethyl)amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 868590-77-6 CAPLUS


CN Benzoic acid, 2-[[[4-[4-(1-methylethoxy)phenyl]-2-pyrimidinyl](2-thienylmethyl)amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 868590-78-7 CAPLUS


CN Benzoic acid, 2-[[[2-(2-thienylmethyl)[4-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 868590-79-8 CAPLUS


CN Benzoic acid, 2-[[[4-(4-phenoxyphenyl)-2-pyrimidinyl](2-thienylmethyl)amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 868590-80-1 CAPLUS


CN Benzoic acid, 2-[[[4-(4-methoxyphenyl)-2-pyrimidinyl](2-thienylmethyl)amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 868590-81-2 CAPLUS

CN Benzoic acid, 2-[[[4-(4-fluorophenyl)-2-pyrimidinyl](2-thienylmethyl)amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 868590-82-3 CAPLUS

CN Benzoic acid, 3-[[cyclopentyl[4-[4-[(trans-4-methylcyclohexyl)oxy]phenyl]-2-pyrimidinyl]amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 868590-83-4 CAPLUS


CN Benzoic acid, 4-[[[4-(1-methylethyl)phenyl]-2-pyrimidinyl](2-thienylmethyl)amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 868590-84-5 CAPLUS


CN Benzoic acid, 2-[[[2-[4-(1-methylethyl)phenyl]-4-pyrimidinyl](2-thienylmethyl)amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 868590-85-6 CAPLUS


CN Benzoic acid, 3-[[[2-[4-(1-methylethyl)phenyl]-4-pyrimidinyl](2-thienylmethyl)amino]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 868590-86-7 CAPLUS


CN Benzoic acid, 2-[[[2-[4-(phenylmethoxy)phenyl]-4-pyrimidinyl](2-thienylmethyl)amino]methyl]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 868590-87-8 CAPLUS


CN Benzoic acid, 3-[[[2-[4-(phenylmethoxy)phenyl]-4-pyrimidinyl](2-thienylmethyl)amino]methyl]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 868590-88-9 CAPLUS

CN Benzoic acid, 4-[[[2-[4-(phenylmethoxy)phenyl]-4-pyrimidinyl](2-thienylmethyl)amino]methyl]-, sodium salt (9CI) (CA INDEX NAME)



● Na

IT 868591-56-4P, (2,4-Dimethoxybenzyl)[2-(4-isopropylphenyl)pyrimidin-4-yl]amine 868591-61-1P 868591-62-2P

868591-64-4P 868591-65-5P 868591-66-6P


868591-67-7P 868591-68-8P 868591-69-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of thiazole and pyrimidine derivs. as melanocortin receptor modulators)


RN 868591-56-4 CAPLUS

CN 4-Pyrimidinamine, N-[(2,4-dimethoxyphenyl)methyl]-2-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 868591-61-1 CAPLUS


CN Benzoic acid, 3-[[cyclopentyl[4-(4-hydroxyphenyl)-2-pyrimidinyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 868591-62-2 CAPLUS


CN Benzoic acid, 3-[[cyclopentyl[4-[4-[(cis-4-methylcyclohexyl)oxy]phenyl]-2-pyrimidinyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 868591-64-4 CAPLUS

CN Benzoic acid, 3-[[cyclopentyl[2-[4-(phenylmethoxy)phenyl]-4-pyrimidinyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 868591-65-5 CAPLUS

CN Benzoic acid, 3-[[cyclopentyl[2-(4-hydroxyphenyl)-4-pyrimidinyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 868591-66-6 CAPLUS

CN Benzoic acid, 3-[[[2-[4-(cyclohexylmethoxy)phenyl]-4-pyrimidinyl]cyclopentylamino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 868591-67-7 CAPLUS


CN Benzoic acid, 4-[[[2-[4-(1-methylethyl)phenyl]-4-pyrimidinyl](2-thienylmethyl)amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 868591-68-8 CAPLUS


CN Benzoic acid, 3-[[cyclopentyl[4-[4-[(trans-4-methylcyclohexyl)oxy]phenyl]-2-pyrimidinyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 868591-69-9 CAPLUS

CN Benzoic acid, 4-[[[4-[4-(1-methylethyl)phenyl]-2-pyrimidinyl](2-thienylmethyl)amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L10 ANSWER 14 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:1075803 CAPLUS
 DN 143:367317
 TI Preparation of N-(2-amino and 2-hydroxy)phenyl carboxamides as inhibitors of histone deacetylase
 IN Delorme, Daniel; Vaisburg, Arkadii; Moradei, Oscar; Leit, Silvana; Raeppe, Stephane; Frechette, Sylvie; Bouchain, Giliane; Zhou, Zhihong; Paquin, Isabelle; Gaudette, Frederic; Isakovic, Ljubomir
 PA Methylgene Inc., Can.
 SO PCT Int. Appl., 245 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005092899	A1	20051006	WO 2005-CA454	20050329
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2005245518	A1	20051103	US 2005-90713	20050325
PRAI	US 2004-556828P	P	20040326		
	US 2005-90713	A	20050325		
	WO 2005-IB802	A	20050325		


OS MARPAT 143:367317

AB The invention relates to N-(2-amino and 2-hydroxy)phenyl carboxamides (2-TC6H4NHC(O)(CH:CH)qAr-X-Cy (I); variables defined below; e.g. (E)-N-(2-Aminophenyl)-3-[4-[[2-(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]acrylamide (shown as II)) useful for inhibiting histone deacetylase (HDAC) enzymic activity. The invention also provides a method for inhibiting histone deacetylase in a cell using said compds. as well as a method for treating cell proliferative diseases and conditions using said HDAC inhibitors. Further, the invention provides pharmaceutical compns. comprising the HDAC inhibiting compds. and a pharmaceutically acceptable carrier. For I: Cy is aryl, heteroaryl, cycloalkyl, or heterocyclyl, each of which is (un)substituted and each of which is optionally fused to ≥1 aryl or heteroaryl rings, or to ≥1 saturated or partially unsatd. cycloalkyl or heterocyclic rings, each of which rings is (un)substituted; X = a chemical bond, L, W-L, L-W, and L-W-L, wherein W, at each occurrence, is S, O, C:O, or N(R9), where R9 = H, alkyl, hydroxyalkyl, and tert-butoxycarbonyl; and L = C1-C4 alkylene; Ar is arylene or heteroarylene, each of which is (un)substituted; q = 0-1; and T is NH2 or OH, provided that when Cy is naphthyl, X is -CH2-, Ar is Ph, and q = 0-1, T is not OH. Although the methods of preparation are not claimed, 215 example preps. and/or characterization data are included. For example, II was prepared in 6 steps (59, 83, 97, 79, 96 and 80 % yields) starting from (E)-4-formylcinnamic acid and involving intermediates Me (E)-3-(4-formylphenyl)acrylate, Me (E)-3-[4-[[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]acrylate, Me (E)-3-[4-[[2-(tert-butyl)dimethylsilyl]oxy]ethyl][2-(1H-indol-3-

- yl)ethyl]amino]methyl]phenyl]acrylate, (E)-3-[4-[[[2-[(tert-butyl)dimethylsilyl]oxy]ethyl][2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]acrylic acid and (E)-N-(2-aminophenyl)-3-[4-[[[2-[(tert-butyl)dimethylsilyl]oxy]ethyl][2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]acrylamide.
- IT **866000-02-4P**, N-(2-Aminophenyl)-4-[[[4-(4-methoxyphenyl)pyrimidin-2-yl]amino]methyl]benzamide **866000-03-5P**, 4-[[[4-(3-Acetylphenyl)pyrimidin-2-yl]amino]methyl]-N-(2-aminophenyl)benzamide **866000-04-6P**, N-(2-Aminophenyl)-4-[[[4-(3,4-difluorophenyl)pyrimidin-2-yl]amino]methyl]benzamide **866000-05-7P**, N-(2-Aminophenyl)-4-[[[4-(3-trifluoromethoxyphenyl)pyrimidin-2-yl]amino]methyl]benzamide **866000-07-9P**, N-(2-Aminophenyl)-4-[[[4-(3,4,5-trimethoxyphenyl)pyrimidin-2-yl]amino]methyl]benzamide **866000-08-0P**, N-(2-Aminophenyl)-4-[[[4-(3-fluoro-4-methoxyphenyl)pyrimidin-2-yl]amino]methyl]benzamide **866000-09-1P**, N-(2-Aminophenyl)-4-[[[4-[4-[2-(morpholin-4-yl)ethoxy]phenyl]pyrimidin-2-yl]amino]methyl]benzamide **866000-13-7P**, N-(2-Aminophenyl)-4-[[[4-[3-(2-dimethylaminoethoxy)phenyl]pyrimidin-2-yl]amino]methyl]benzamide hydrochloride **866000-14-8P**, N-(2-Aminophenyl)-4-[[[4-[3-[2-(morpholin-4-yl)ethoxy]phenyl]pyrimidin-2-yl]amino]methyl]benzamide **866000-15-9P**, N-(2-Aminophenyl)-4-[[[4-[4-(2-dimethylaminoethoxy)phenyl]pyrimidin-2-yl]amino]methyl]benzamide **866000-31-9P**, N-(2-Aminophenyl)-4-[[[4-[4-(2-dimethylaminoethoxy)-3-fluorophenyl]pyrimidin-2-yl]amino]methyl]benzamide **866000-35-3P**, N-(2-Aminophenyl)-4-[[[4-[4-(morpholin-4-yl)methyl]phenyl]pyrimidin-2-yl]amino]methyl]benzamide hydrochloride
- RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
- (drug candidate; preparation of N-(2-amino and 2-hydroxy)phenyl carboxamides as inhibitors of histone deacetylase)
- RN 866000-02-4 CAPLUS
- CN Benzamide, N-(2-aminophenyl)-4-[[[4-(4-methoxyphenyl)-2-pyrimidinyl]amino]methyl]- (9CI) (CA INDEX NAME)




- RN 866000-03-5 CAPLUS
- CN Benzamide, 4-[[[4-(3-acetylphenyl)-2-pyrimidinyl]amino]methyl]-N-(2-aminophenyl)- (9CI) (CA INDEX NAME)




- RN 866000-04-6 CAPLUS

CN Benzamide, N-(2-aminophenyl)-4-[[[4-(3,4-difluorophenyl)-2-pyrimidinyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 866000-05-7 CAPLUS

CN Benzamide, N-(2-aminophenyl)-4-[[[4-[3-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 866000-07-9 CAPLUS

CN Benzamide, N-(2-aminophenyl)-4-[[[4-(3,4,5-trimethoxyphenyl)-2-pyrimidinyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 866000-08-0 CAPLUS

CN Benzamide, N-(2-aminophenyl)-4-[[[4-(3-fluoro-4-methoxyphenyl)-2-pyrimidinyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 866000-09-1 CAPLUS

CN Benzamide, N-(2-aminophenyl)-4-[[[4-[4-[2-(4-morpholinyl)ethoxy]phenyl]-2-pyrimidinyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 866000-13-7 CAPLUS


CN Benzamide, N-(2-aminophenyl)-4-[[[4-[3-[2-(dimethylamino)ethoxy]phenyl]-2-pyrimidinyl]amino]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 866000-14-8 CAPLUS

CN Benzamide, N-(2-aminophenyl)-4-[[[4-[3-[2-(4-morpholinyl)ethoxy]phenyl]-2-pyrimidinyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 866000-15-9 CAPLUS

CN Benzamide, N-(2-aminophenyl)-4-[[[4-[4-[2-(dimethylamino)ethoxy]phenyl]-2-pyrimidinyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 866000-31-9 CAPLUS

CN Benzamide, N-(2-aminophenyl)-4-[[[4-[4-[2-(dimethylamino)ethoxy]-3-fluorophenyl]-2-pyrimidinyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 866000-35-3 CAPLUS

CN Benzamide, N-(2-aminophenyl)-4-[[[4-[4-(4-morpholinylmethyl)phenyl]-2-pyrimidinyl]amino]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


IT **866000-11-5P**, Methyl 4-[[[4-[4-[2-(morpholin-4-yl)ethoxy]phenyl]pyrimidin-2-yl]amino]methyl]benzoate **866000-12-6P**, 4-[[[4-[4-[2-(Morpholin-4-yl)ethoxy]phenyl]pyrimidin-2-yl]amino]methyl]benzoic acid **866000-33-1P**, Methyl 4-[[[4-(3-fluoro-4-hydroxyphenyl)pyrimidin-2-yl]amino]methyl]benzoate **866000-34-2P**, Methyl 4-[[[4-[4-(2-dimethylaminoethoxy)-3-fluorophenyl]pyrimidin-2-yl]amino]methyl]benzoate

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-(2-amino and 2-hydroxy)phenyl carboxamides as inhibitors of histone deacetylase)


RN 866000-11-5 CAPLUS

CN Benzoic acid, 4-[[[4-[4-[2-(4-morpholinyl)ethoxy]phenyl]-2-pyrimidinyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 866000-12-6 CAPLUS

CN Benzoic acid, 4-[[[4-[4-[2-(4-morpholinyl)ethoxy]phenyl]-2-pyrimidinyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 866000-33-1 CAPLUS

CN Benzoic acid, 4-[[[4-(3-fluoro-4-hydroxyphenyl)-2-pyrimidinyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 866000-34-2 CAPLUS

CN Benzoic acid, 4-[[[4-[4-[2-(dimethylamino)ethoxy]-3-fluorophenyl]-2-pyrimidinyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 15 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:823690 CAPLUS

DN 143:229874

TI Preparation of pyrimidine derivatives as orexin receptors antagonists

IN Aranyi, Peter; Balogh, Maria; Batori, Sandor; Bence, Judit; Finet, Michel; Kapui, Zoltan; Philippo, Christophe; Szabo, Tibor; Szlavik, Zoltan; Toemoeskoezi, Zsuzsanna; Urban-Szabo, Katalin; Venier, Olivier

PA Sanofi-Aventis, Fr.

SO PCT Int. Appl., 104 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005075458	A1	20050818	WO 2005-HU10	20050208
	WO 2005075458	C1	20060119		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI HU 2004-405

A

20040210

OS MARPAT 143:229874

AB The title compds. I [Ar = Ph or a 5-6 membered heterocyclic ring containing 1-3 identical or different heteroatoms or methylenedioxyphenyl group (these groups may optionally be substituted with one or more identical or different alkyl group, halo, hydroxy, alkoxy, trihalomethyl, NHalkyl, N(alkyl)2 or NHC(O)alkyl group); X = alkyl, (un)substituted NH2, alkylthio, etc.; R, Y, W = H, alkyl; Z = OH, halo, alkoxy, etc.; or R + Y may represent II (together with the included N and C atoms; wherein A = CH2, O, NH, N(alkyl); n = 0-2); or R + Z together may represent a (CH2)mG (m = 1-3; G = O, CH2, NH, N(alkyl)); Z + W together may represent an oxo group; Q = (un)substituted Ph or 5-6 membered heterocyclic ring containing 1-3 heteroatoms], useful as orexin receptor antagonists which are selective to orexin I receptors, were prepared Thus, reacting 2-dimethylamino-4-phenylpyrimidine-5-carboxylic acid with L-phenylephrine hydrochloride afforded L-I [Ar = Ph; X = NMe2; R = Me; Y, W = H; Z = OH; Z = 3-(HO)C6H4]. The compds. I exhibit IC50 values of < 1000 nM with the preferred compds. I having IC50 of < 100 nM (specific IC50 values against Orexin-1 and Orexin-2 were given for six representative compds. I). The pharmaceutical composition comprising the compound I is disclosed.


IT 862837-38-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrimidine derivs. as orexin receptors antagonists)

RN 862837-38-5 CAPLUS

CN 2-Piperidinemethanol, α -(3-methoxyphenyl)-1-[[2-methyl(phenylmethyl)amino]-4-phenyl-5-pyrimidinyl]carbonyl]-, (α R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 862836-09-7P 862836-10-0P 862836-11-1P
 862836-12-2P 862836-13-3P 862836-14-4P
 862836-15-5P 862836-19-9P 862836-20-2P
 862836-23-5P 862836-25-7P 862836-54-2P
 862836-56-4P 862836-65-5P 862836-66-6P
 862836-67-7P 862836-72-4P 862837-06-7P
 862837-07-8P 862837-08-9P 862837-09-0P
 862837-10-3P 862837-11-4P 862837-12-5P
 862837-13-6P 862837-14-7P 862837-16-9P
 862837-17-0P 862837-19-2P 862837-20-5P
 862837-21-6P 862837-37-4P 862837-39-6P
 862837-40-9P 862837-41-0P 862837-42-1P
 862837-43-2P 862837-44-3P 862837-45-4P
 862837-46-5P 862837-48-7P 862837-49-8P
 862837-50-1P 862837-51-2P 862837-52-3P
 862837-53-4P 862837-54-5P 862837-55-6P
 862837-56-7P 862837-57-8P 862837-58-9P
 862837-59-0P 862837-60-3P 862837-62-5P
 862837-63-6P 862837-64-7P 862837-66-9P
 862837-67-0P 862837-68-1P 862837-69-2P
 862837-70-5P 862837-71-6P 862837-72-7P
 862837-73-8P 862837-74-9P 862837-75-0P
 862837-76-1P 862837-77-2P 862837-78-3P
 862837-79-4P 862837-80-7P 862837-81-8P
 862837-82-9P 862837-83-0P 862837-84-1P
 862837-85-2P 862837-86-3P 862837-87-4P
 862837-88-5P 862837-89-6P 862837-90-9P
 862837-91-0P 862837-92-1P 862837-93-2P
 862837-94-3P 862837-95-4P 862837-96-5P
 862837-97-6P 862839-35-8P 862839-37-0P
 862839-39-2P 862839-41-6P 862839-50-7P
 862839-69-8P 862839-71-2P 862839-73-4P
 862839-95-0P 862839-98-3P 862840-00-4P
 862840-02-6P 862840-04-8P 862840-06-0P
 862840-08-2P 862840-11-7P 862840-13-9P
 862840-17-3P 862840-19-5P 862840-21-9P
 862840-30-0P 862840-33-3P 862840-39-9P
 862840-44-6P 862840-49-1P 862840-54-8P
 862840-58-2P 862840-62-8P 862840-66-2P
 862840-70-8P 862840-74-2P 862840-78-6P
 862840-82-2P 862840-85-5P 862840-91-3P

862840-94-6P 862840-97-9P 862841-00-7P

862841-03-0P 862841-06-3P 862841-09-6P


862841-12-1P 862841-15-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine derivs. as orexin receptors antagonists)


RN 862836-09-7 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-N-methyl-2-[methyl(phenylmethyl)amino]-4-phenyl-, hydrate (2:1) (9CI) (CA INDEX NAME)

● 1/2 H₂O


RN 862836-10-0 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-N-methyl-4-phenyl-2-[(phenylmethyl)amino]-, monohydrate (9CI) (CA INDEX NAME)


● H₂O

RN 862836-11-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(2-hydroxyethyl)(phenylmethyl)amino]-N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-N-methyl-4-phenyl-, monohydrate (9CI) (CA INDEX NAME)


● H₂O

RN 862836-12-2 CAPLUS
 CN 5-Pyrimidinecarboxamide, 4-(2-chlorophenyl)-N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-N-methyl-2-[methyl(phenylmethyl)amino]-, monohydrate (9CI) (CA INDEX NAME)

● H₂O


RN 862836-13-3 CAPLUS
 CN 5-Pyrimidinecarboxamide, 4-(2-chlorophenyl)-N-[(2S)-2-hydroxy-2-(3-hydroxyphenyl)ethyl]-N-methyl-2-[methyl(phenylmethyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 862836-14-4 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-N-methyl-4-(2-methylphenyl)-2-[methyl(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 862836-15-5 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-4-(2-methoxyphenyl)-N-methyl-2-[methyl(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 862836-19-9 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-N-methyl-4-phenyl-2-[(2-phenylethyl)amino]-, monohydrate (9CI) (CA INDEX NAME)

● H₂O


RN 862836-20-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-N-methyl-4-phenyl-, dihydrate (9CI) (CA INDEX NAME)

● 2 H₂O


RN 862836-23-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(2-chlorophenyl)methyl]amino]-N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-N-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 862836-25-7 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-4-(2-iodophenyl)-N-methyl-2-[methyl(phenylmethyl)amino]-, hydrate (2:1) (9CI) (CA INDEX NAME)

● 1/2 H₂O


RN 862836-54-2 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-hydroxy-2-[3-(phenylmethoxy)phenyl]ethyl]-N-methyl-2-[methyl(phenylmethyl)amino]-4-phenyl-, hydrate (5:1) (9CI) (CA INDEX NAME)

● 1/5 H₂O

RN 862836-56-4 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(2-chlorophenyl)-N-[2-hydroxy-2-[3-(phenylmethoxy)phenyl]ethyl]-N-methyl-2-[methyl(phenylmethyl)amino]- (9CI)
(CA INDEX NAME)



RN 862836-65-5 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]-N-methyl-2-[methyl(phenylmethyl)amino]-4-phenyl-, hydrate (4:1), rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.

● 1/4 H₂O

RN 862836-66-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(2-chlorophenyl)-N-[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]-N-methyl-2-[methyl(phenylmethyl)amino]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 862836-67-7 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]-N-methyl-4-phenyl-2-[(phenylmethyl)amino]-, hydrate (2:1), rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● 1/2 H₂O

RN 862836-72-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-chlorophenyl)methyl]amino]-N-[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]-N-methyl-4-phenyl-, hydrate (2:1), rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● 1/2 H₂O

RN 862837-06-7 CAPLUS


CN 5-Pyrimidinecarboxamide, N-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]-N-methyl-2-[methyl(phenylmethyl)amino]-4-phenyl-, monohydrate (9CI) (CA INDEX NAME)



● H₂O

RN 862837-07-8 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-hydroxy-2-(2-hydroxyphenyl)ethyl]-N-methyl-2-[methyl(phenylmethyl)amino]-4-phenyl-, hydrate (4:1) (9CI) (CA INDEX NAME)




● 1/4 H₂O

RN 862837-08-9 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-hydroxy-2-(2-methoxyphenyl)ethyl]-N-methyl-2-


[methyl(phenylmethyl)amino]-4-phenyl-, hydrate (5:1) (9CI) (CA INDEX NAME)



● 1/5 H₂O


RN 862837-09-0 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-(3-fluorophenyl)-2-hydroxyethyl]-N-methyl-2-[methyl(phenylmethyl)amino]-4-phenyl- (9CI) (CA INDEX NAME)



RN 862837-10-3 CAPLUS


CN 5-Pyrimidinecarboxamide, N-[2-(4-fluorophenyl)-2-hydroxyethyl]-N-methyl-2-[methyl(phenylmethyl)amino]-4-phenyl-, monohydrate (9CI) (CA INDEX NAME)




● H₂O

RN 862837-11-4 CAPLUS


CN 5-Pyrimidinecarboxamide, N-[2-hydroxy-2-(3-methoxyphenyl)ethyl]-N-methyl-2-[methyl(phenylmethyl)amino]-4-phenyl-, monohydrate (9CI) (CA INDEX NAME)

● H₂O


RN 862837-12-5 CAPLUS
 CN 5-Pyrimidinecarboxamide, N-[2-hydroxy-2-(4-methoxyphenyl)ethyl]-N-methyl-2-[methyl(phenylmethyl)amino]-4-phenyl-, hydrate (4:1) (9CI) (CA INDEX NAME)

● 1/4 H₂O

RN 862837-13-6 CAPLUS
 CN 5-Pyrimidinecarboxamide, N-(2-hydroxy-2-phenylethyl)-N-methyl-2-[methyl(phenylmethyl)amino]-4-phenyl-, monohydrate (9CI) (CA INDEX NAME)


● H₂O

RN 862837-14-7 CAPLUS
 CN 5-Pyrimidinecarboxamide, N-[2-hydroxy-2-[3-(1-methylethoxy)phenyl]ethyl]-N-methyl-2-[methyl(phenylmethyl)amino]-4-phenyl-, hydrate (5:1) (9CI) (CA INDEX NAME)

● 1/5 H₂O


RN 862837-16-9 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-(3-aminophenyl)-2-hydroxyethyl]-N-methyl-2-[methyl(phenylmethyl)amino]-4-phenyl-, hydrate (2:1) (9CI) (CA INDEX NAME)

● 1/2 H₂O

RN 862837-17-0 CAPLUS


CN 5-Pyrimidinecarboxamide, N-[2-[3-[(2,2-dimethyl-1-oxopropyl)amino]phenyl]-2-hydroxyethyl]-N-methyl-2-[methyl(phenylmethyl)amino]-4-phenyl-, monohydrate (9CI) (CA INDEX NAME)

● H₂O

RN 862837-19-2 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]-N-


methyl-4-phenyl-2-[(phenylmethyl)amino]-, monohydrate (9CI) (CA INDEX NAME)



● H₂O

RN 862837-20-5 CAPLUS


CN 5-Pyrimidinecarboxamide, N-[2-hydroxy-2-(3-nitrophenyl)ethyl]-N-methyl-4-phenyl-2-[(phenylmethyl)amino]-, monohydrate (9CI) (CA INDEX NAME)



● H₂O

RN 862837-21-6 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-(3-aminophenyl)-2-hydroxyethyl]-N-methyl-4-phenyl-2-[(phenylmethyl)amino]-, dihydrochloride, dihydrate (9CI) (CA INDEX NAME)




● 2 HCl

● 2 H₂O

RN 862837-37-4 CAPLUS

CN 2-Piperidinemethanol, 1-[[2-[methyl(phenylmethyl)amino]-4-phenyl-5-pyrimidinyl]carbonyl]- α -phenyl-, (α R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 862837-39-6 CAPLUS

CN 2-Piperidinemethanol, α -(3-hydroxyphenyl)-1-[[2-[methyl(phenylmethyl)amino]-4-phenyl-5-pyrimidinyl]carbonyl]-, (α R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 862837-40-9 CAPLUS

CN 2-Piperidinemethanol, α -(3-fluorophenyl)-1-[[2-[methyl(phenylmethyl)amino]-4-phenyl-5-pyrimidinyl]carbonyl]-, (α R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 862837-41-0 CAPLUS

CN 2-Piperidinemethanol, 1-[[2-[methyl(phenylmethyl)amino]-4-phenyl-5-pyrimidinyl]carbonyl]-α-3-pyridinyl-, (αR,2R)-rel- (9CI) (CA
INDEX NAME)


Relative stereochemistry.



RN 862837-42-1 CAPLUS

CN 2-Piperidinemethanol, 1-[[4-(2-chlorophenyl)-2-[methyl(phenylmethyl)amino]-5-pyrimidinyl]carbonyl]-α-phenyl-, (αR,2R)-rel- (9CI) (CA
INDEX NAME)


Relative stereochemistry.



RN 862837-43-2 CAPLUS


CN 2-Piperidinemethanol, 1-[[2-[methyl(phenylmethyl)amino]-4-phenyl-5-pyrimidinyl]carbonyl]- α -2-pyridinyl-, (α R,2S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 862837-44-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(2-bromophenyl)-N-[2-(3,4-dichlorophenyl)-2-hydroxyethyl]-N-methyl-2-[methyl(phenylmethyl)amino]-, monohydrate (9CI) (CA INDEX NAME)

● H₂O

RN 862837-45-4 CAPLUS


CN 5-Pyrimidinecarboxamide, N-[2-(3,4-dichlorophenyl)-2-hydroxyethyl]-4-(2-fluorophenyl)-N-methyl-2-[methyl(phenylmethyl)amino]-, hydrate (2:1) (9CI) (CA INDEX NAME)



● 1/2 H₂O

RN 862837-46-5 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(2-bromophenyl)-N-[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]-N-methyl-2-[methyl(phenylmethyl)amino]-, monohydrate (9CI)
(CA INDEX NAME)



● H₂O

RN 862837-48-7 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(2-bromophenyl)-N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-N-methyl-2-[methyl(phenylmethyl)amino]-, monohydrate (9CI) (CA INDEX NAME)



● H₂O


RN 862837-49-8 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-(4-chlorophenyl)-2-hydroxyethyl]-4-(2-fluorophenyl)-N-methyl-2-[methyl(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 862837-50-1 CAPLUS


CN 5-Pyrimidinecarboxamide, N-[2-(3-chlorophenyl)-2-hydroxyethyl]-N-methyl-2-[methyl(phenylmethyl)amino]-4-phenyl-, hydrate (2:1) (9CI) (CA INDEX NAME)



● 1/2 H₂O

RN 862837-51-2 CAPLUS


CN 5-Pyrimidinecarboxamide, N-[2-(3,4-difluorophenyl)-2-hydroxyethyl]-N-methyl-2-[methyl(phenylmethyl)amino]-4-phenyl-, hydrate (2:1) (9CI) (CA INDEX NAME)



● 1/2 H₂O

RN 862837-52-3 CAPLUS


CN 5-Pyrimidinecarboxamide, N-[2-(3-chlorophenyl)-2-hydroxyethyl]-N-methyl-4-phenyl-2-[(phenylmethyl)amino]-, hydrate (2:3) (9CI) (CA INDEX NAME)



● 3/2 H₂O


RN 862837-53-4 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-(4-chlorophenyl)-2-hydroxyethyl]-N-methyl-2-[methyl(phenylmethyl)amino]-4-phenyl- (9CI) (CA INDEX NAME)




RN 862837-54-5 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-(4-cyanophenyl)-2-hydroxyethyl]-N-methyl-4-phenyl-2-[(phenylmethyl)amino]-, monohydrate (9CI) (CA INDEX NAME)

● H₂O


RN 862837-55-6 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-(4-chlorophenyl)-2-hydroxyethyl]-N-methyl-4-phenyl-2-[(phenylmethyl)amino]-, monohydrate (9CI) (CA INDEX NAME)

● H₂O


RN 862837-56-7 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]-N-methyl-4-phenyl-2-[(phenylmethyl)amino]-, hydrate (2:3) (9CI) (CA INDEX NAME)

● 3/2 H₂O

RN 862837-57-8 CAPLUS


CN 5-Pyrimidinecarboxamide, N-[2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]-N-methyl-2-[methyl(phenylmethyl)amino]-4-phenyl-, monohydrate (9CI) (CA INDEX NAME)



● H₂O

RN 862837-58-9 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(2-chlorophenyl)-N-[2-(4-chlorophenyl)-2-hydroxyethyl]-N-methyl-2-[methyl(phenylmethyl)amino]-, monohydrate (9CI)
(CA INDEX NAME)



● H₂O


RN 862837-59-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(2-chlorophenyl)-N-[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]-N-methyl-2-[methyl(phenylmethyl)amino]-, monohydrate (9CI)
(CA INDEX NAME)

● H₂O


RN 862837-60-3 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-(4-cyanophenyl)-2-hydroxyethyl]-N-methyl-2-[methyl(phenylmethyl)amino]-4-phenyl-, hydrate (2:1) (9CI) (CA INDEX NAME)

● 1/2 H₂O


RN 862837-62-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(2-fluorophenyl)-N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-N-methyl-2-[methyl(phenylmethyl)amino]-, monohydrate (9CI) (CA INDEX NAME)

● H₂O


RN 862837-63-6 CAPLUS

CN 2-Piperidinemethanol, α -(4-fluorophenyl)-1-[[2-[methyl(phenylmethyl)amino]-4-phenyl-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 862837-64-7 CAPLUS

CN 2-Piperidinemethanol, α -(4-methylphenyl)-1-[[2-[methyl(phenylmethyl)amino]-4-phenyl-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 862837-66-9 CAPLUS


CN 2-Piperidinemethanol, 1-[[2-[[3-methoxyphenyl)methyl]amino]-4-phenyl-5-pyrimidinyl]carbonyl]- α -phenyl- (9CI) (CA INDEX NAME)



RN 862837-67-0 CAPLUS


CN 2-Piperidinemethanol, α -(3-chlorophenyl)-1-[[2-[methyl(phenylmethyl)amino]-4-phenyl-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)

INDEX NAME)




RN 862837-68-1 CAPLUS

CN 2-Piperidinemethanol, 1-[[2-[[[(2-methoxyphenyl)methyl]amino]-4-phenyl-5-pyrimidinyl]carbonyl]-α-phenyl- (9CI) (CA INDEX NAME)



RN 862837-69-2 CAPLUS


CN 2-Piperidinemethanol, 1-[[2-[[[(4-chlorophenyl)methyl]methylamino]-4-phenyl-5-pyrimidinyl]carbonyl]-α-phenyl- (9CI) (CA INDEX NAME)



RN 862837-70-5 CAPLUS


CN 2-Piperidinemethanol, α-(3-methylphenyl)-1-[[2-[methyl(phenylmethyl)amino]-4-phenyl-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)

INDEX NAME)




RN 862837-71-6 CAPLUS

CN 2-Piperidinemethanol, 1-[[2-[[2-(2-chlorophenyl)methyl]methylamino]-4-phenyl-5-pyrimidinyl]carbonyl]-α-phenyl- (9CI) (CA INDEX NAME)




RN 862837-72-7 CAPLUS

CN 2-Piperidinemethanol, 1-[[2-[[2-(4-fluorophenyl)methyl]methylamino]-4-phenyl-5-pyrimidinyl]carbonyl]-α-phenyl- (9CI) (CA INDEX NAME)





RN 862837-73-8 CAPLUS

CN 2-Piperidinemethanol, 1-[[2-[methyl[(4-methylphenyl)methyl]amino]-4-phenyl-5-pyrimidinyl]carbonyl]-α-phenyl- (9CI) (CA INDEX NAME)





RN 862837-74-9 CAPLUS

CN 2-Piperidinemethanol, α -(2-methylphenyl)-1-[[2-[methyl(phenylmethyl)amino]-4-phenyl-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 862837-75-0 CAPLUS

CN 2-Piperidinemethanol, α -(2-fluorophenyl)-1-[[2-[methyl(phenylmethyl)amino]-4-phenyl-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 862837-76-1 CAPLUS

CN 2-Piperidinemethanol, α-(4-methoxyphenyl)-1-[[2-[methyl(phenylmethyl)amino]-4-phenyl-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 862837-77-2 CAPLUS

CN 2-Piperidinemethanol, α-(4-chlorophenyl)-1-[[2-[methyl(phenylmethyl)amino]-4-phenyl-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 862837-78-3 CAPLUS

CN 2-Piperidinemethanol, 1-[[2-[[[4-fluorophenyl)methyl]amino]-4-phenyl-5-pyrimidinyl]carbonyl]-α-phenyl- (9CI) (CA INDEX NAME)




RN 862837-79-4 CAPLUS

CN 2-Piperidinemethanol, 1-[[2-[[4-(4-fluorophenyl)methyl]amino]-4-phenyl-5-pyrimidinyl]carbonyl]-α-phenyl- (9CI) (CA INDEX NAME)



RN 862837-80-7 CAPLUS


CN 2-Piperidinemethanol, α-(3-chloro-4-fluorophenyl)-1-[[2-[methyl(phenylmethyl)amino]-4-phenyl-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 862837-81-8 CAPLUS


CN 2-Piperidinemethanol, α-(3,4-difluorophenyl)-1-[[2-[methyl(phenylmethyl)amino]-4-phenyl-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)

INDEX NAME)




RN 862837-82-9 CAPLUS

CN 2-Piperidinemethanol, 1-[[2-[[[(3-chlorophenyl)methyl]amino]-4-phenyl-5-pyrimidinyl]carbonyl]-α-phenyl- (9CI) (CA INDEX NAME)




RN 862837-83-0 CAPLUS

CN 2-Piperidinemethanol, 1-[[2-[[[(4-methoxyphenyl)methyl]methylamino]-4-phenyl-5-pyrimidinyl]carbonyl]-α-phenyl- (9CI) (CA INDEX NAME)




RN 862837-84-1 CAPLUS

CN 2-Piperidinemethanol, α-(4-chloro-3-fluorophenyl)-1-[[2-[methyl(phenylmethyl)amino]-4-phenyl-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)





RN 862837-85-2 CAPLUS

CN 2-Piperidinemethanol, 1-[[2-[[4-methoxyphenyl)methyl]amino]-4-phenyl-5-pyrimidinyl]carbonyl]-α-phenyl- (9CI) (CA INDEX NAME)




RN 862837-86-3 CAPLUS

CN 2-Piperidinemethanol, 1-[[2-[methyl(phenylmethyl)amino]-4-phenyl-5-pyrimidinyl]carbonyl]-α-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 862837-87-4 CAPLUS



CN 2-Piperidinemethanol, 1-[[4-(2-fluorophenyl)-2-[methyl(phenylmethyl)amino]-

5-pyrimidinyl]carbonyl]- α -phenyl- (9CI) (CA INDEX NAME)


RN 862837-88-5 CAPLUS

CN 2-Piperidinemethanol, 1-[[2-[[[3-chlorophenyl)methyl]methylamino]-4-phenyl-5-pyrimidinyl]carbonyl]- α -phenyl- (9CI) (CA INDEX NAME)


RN 862837-89-6 CAPLUS

CN 2-Piperidinemethanol, α -(2-chlorophenyl)-1-[[2-[methyl(phenylmethyl)amino]-4-phenyl-5-pyrimidinyl]carbonyl]- (9CI) (CA INDEX NAME)

RN 862837-90-9 CAPLUS


CN 2-Piperidinemethanol, 1-[[2-[methyl(phenylmethyl)amino]-4-phenyl-5-pyrimidinyl]carbonyl]- α -3-thienyl- (9CI) (CA INDEX NAME)

RN 862837-91-0 CAPLUS

CN 2-Piperidinemethanol, 1-[[2-[[[(3-chloro-4-fluorophenyl)methyl]amino]-4-phenyl-5-pyrimidinyl]carbonyl]- α -phenyl- (9CI) (CA INDEX NAME)


RN 862837-92-1 CAPLUS

CN 2-Piperidinemethanol, 1-[[2-[[[(3-chloro-4-fluorophenyl)methyl]methylamino]-4-phenyl-5-pyrimidinyl]carbonyl]- α -phenyl- (9CI) (CA INDEX NAME)




RN 862837-93-2 CAPLUS

CN 2-Piperidinemethanol, 1-[[4-(4-chlorophenyl)-2-[methyl(phenylmethyl)amino]-5-pyrimidinyl]carbonyl]-α-phenyl- (9CI) (CA INDEX NAME)



RN 862837-94-3 CAPLUS


CN 2-Piperidinemethanol, 1-[[2-[[4-(4-chlorophenyl)methyl]amino]-4-(2-fluorophenyl)-5-pyrimidinyl]carbonyl]-α-(3,4-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 862837-95-4 CAPLUS


CN 2-Piperidinemethanol, 1-[[4-(2-chlorophenyl)-2-[[4-(2-chlorophenyl)methyl]amino]-5-pyrimidinyl]carbonyl]-α-(3,4-

difluorophenyl)- (9CI) (CA INDEX NAME)




RN 862837-96-5 CAPLUS

CN 2-Piperidinemethanol, 1-[[2-[[[(4-chlorophenyl)methyl]methylamino]-4-(2-fluorophenyl)-5-pyrimidinyl]carbonyl]-α-(3,4-difluorophenyl)- (9CI)
(CA INDEX NAME)




RN 862837-97-6 CAPLUS

CN 2-Piperidinemethanol, 1-[[2-[[[(3-chloro-4-fluorophenyl)methyl]amino]-4-phenyl-5-pyrimidinyl]carbonyl]-α-3-thienyl- (9CI) (CA INDEX NAME)




RN 862839-35-8 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-N-methyl-2-[methyl(phenylmethyl)amino]-4-phenyl- (9CI) (CA INDEX NAME)




RN 862839-37-0 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-N-methyl-4-phenyl-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 862839-39-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(2-hydroxyethyl)(phenylmethyl)amino]-N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-N-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 862839-41-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(2-chlorophenyl)-N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-N-methyl-2-[methyl(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 862839-50-7 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-4-(2-iodophenyl)-N-methyl-2-[methyl(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 862839-69-8 CAPLUS

CN 5-Pyrimidinecarboxamide, N-(2-hydroxy-1-methyl-2-phenylethyl)-N-methyl-2-[methyl(phenylmethyl)amino]-4-phenyl- (9CI) (CA INDEX NAME)




RN 862839-71-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(2-chlorophenyl)-N-(2-hydroxy-1-methyl-2-phenylethyl)-N-methyl-2-[methyl(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 862839-73-4 CAPLUS

CN 5-Pyrimidinecarboxamide, N-(2-hydroxy-1-methyl-2-phenylethyl)-N-methyl-4-phenyl-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 862839-95-0 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]-N-methyl-2-[methyl(phenylmethyl)amino]-4-phenyl- (9CI) (CA INDEX NAME)




RN 862839-98-3 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-(4-fluorophenyl)-2-hydroxyethyl]-N-methyl-2-[methyl(phenylmethyl)amino]-4-phenyl- (9CI) (CA INDEX NAME)




RN 862840-00-4 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-hydroxy-2-(3-methoxyphenyl)ethyl]-N-methyl-2-[methyl(phenylmethyl)amino]-4-phenyl- (9CI) (CA INDEX NAME)




RN 862840-02-6 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-hydroxy-2-(4-methoxyphenyl)ethyl]-N-methyl-2-[methyl(phenylmethyl)amino]-4-phenyl- (9CI) (CA INDEX NAME)




RN 862840-04-8 CAPLUS

CN 5-Pyrimidinecarboxamide, N-(2-hydroxy-2-phenylethyl)-N-methyl-2-[methyl(phenylmethyl)amino]-4-phenyl- (9CI) (CA INDEX NAME)




RN 862840-06-0 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-(3-aminophenyl)-2-hydroxyethyl]-N-methyl-2-[methyl(phenylmethyl)amino]-4-phenyl- (9CI) (CA INDEX NAME)




RN 862840-08-2 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]-N-methyl-4-phenyl-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 862840-11-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(2-bromophenyl)-N-[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]-N-methyl-2-[methyl(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 862840-13-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(2-bromophenyl)-N-[2-hydroxy-2-(3-hydroxyphenyl)ethyl]-N-methyl-2-[methyl(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 862840-17-3 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-(1,3-benzodioxol-5-yl)-2-hydroxyethyl]-N-methyl-2-[methyl(phenylmethyl)amino]-4-phenyl- (9CI) (CA INDEX NAME)




RN 862840-19-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(2-chlorophenyl)-N-[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]-N-methyl-2-[methyl(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 862840-21-9 CAPLUS


CN 5-Pyrimidinecarboxamide, N-[2-(4-cyanophenyl)-2-hydroxyethyl]-N-methyl-2-[methyl(phenylmethyl)amino]-4-phenyl- (9CI) (CA INDEX NAME)



RN 862840-30-0 CAPLUS

CN 2-Piperidinemethanol, α-(4-fluorophenyl)-1-[[2-[methyl(phenylmethyl)amino]-4-phenyl-5-pyrimidinyl]carbonyl]-, (αR,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 862840-33-3 CAPLUS

CN 2-Piperidinemethanol, α-(4-methylphenyl)-1-[[2-[methyl(phenylmethyl)amino]-4-phenyl-5-pyrimidinyl]carbonyl]-, (αR,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 862840-39-9 CAPLUS

CN 2-Piperidinemethanol, 1-[[2-[[[3-methoxyphenyl)methyl]amino]-4-phenyl-5-pyrimidinyl]carbonyl]-α-phenyl-, (αR,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 862840-44-6 CAPLUS

CN 2-Piperidinemethanol, α -(3-chlorophenyl)-1-[[2-[methyl(phenylmethyl)amino]-4-phenyl-5-pyrimidinyl]carbonyl]-, (α R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 862840-49-1 CAPLUS

CN 2-Piperidinemethanol, 1-[[2-[[[4-chlorophenyl)methyl]methylamino]-4-phenyl-5-pyrimidinyl]carbonyl]- α -phenyl-, (α R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 862840-54-8 CAPLUS

CN 2-Piperidinemethanol, α -(3-methylphenyl)-1-[[2-[methyl(phenylmethyl)amino]-4-phenyl-5-pyrimidinyl]carbonyl]-, (α R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 862840-58-2 CAPLUS

CN 2-Piperidinemethanol, 1-[[2-[[[(4-fluorophenyl)methyl]methylamino]-4-phenyl-5-pyrimidinyl]carbonyl]-α-phenyl-, (αR,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 862840-62-8 CAPLUS

CN 2-Piperidinemethanol, α-(2-methylphenyl)-1-[[2-[methyl(phenylmethyl)amino]-4-phenyl-5-pyrimidinyl]carbonyl]-, (αR,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 862840-66-2 CAPLUS

CN 2-Piperidinemethanol, α -(2-fluorophenyl)-1-[[2-[methyl(phenylmethyl)amino]-4-phenyl-5-pyrimidinyl]carbonyl]-, (α R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 862840-70-8 CAPLUS

CN 2-Piperidinemethanol, α -(4-methoxyphenyl)-1-[[2-[methyl(phenylmethyl)amino]-4-phenyl-5-pyrimidinyl]carbonyl]-, (α R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 862840-74-2 CAPLUS

CN 2-Piperidinemethanol, 1-[[2-[[[(4-fluorophenyl)methyl]amino]-4-phenyl-5-pyrimidinyl]carbonyl]-α-phenyl-, (αR,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 862840-78-6 CAPLUS

CN 2-Piperidinemethanol, α-(3-chloro-4-fluorophenyl)-1-[[2-[methyl(phenylmethyl)amino]-4-phenyl-5-pyrimidinyl]carbonyl]-, (αR,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 862840-82-2 CAPLUS

CN 2-Piperidinemethanol, α -(3,4-difluorophenyl)-1-[[2-[methyl(phenylmethyl)amino]-4-phenyl-5-pyrimidinyl]carbonyl]-, (α R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 862840-85-5 CAPLUS

CN 2-Piperidinemethanol, 1-[[2-[[[3-chlorophenyl)methyl]amino]-4-phenyl-5-pyrimidinyl]carbonyl]- α -phenyl-, (α R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 862840-91-3 CAPLUS

CN 2-Piperidinemethanol, 1-[[2-[methyl(phenylmethyl)amino]-4-phenyl-5-pyrimidinyl]carbonyl]-α-4-pyridinyl-, (αR,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 862840-94-6 CAPLUS

CN 2-Piperidinemethanol, 1-[[4-(2-fluorophenyl)-2-[methyl(phenylmethyl)amino]-5-pyrimidinyl]carbonyl]-α-phenyl-, (αR,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 862840-97-9 CAPLUS

CN 2-Piperidinemethanol, 1-[[2-[[[(3-chlorophenyl)methyl]methylamino]-4-phenyl-5-pyrimidinyl]carbonyl]-α-phenyl-, (αR,2R)-rel- (9CI) (CA

INDEX NAME)


Relative stereochemistry.



RN 862841-00-7 CAPLUS

CN 2-Piperidinemethanol, α -(2-chlorophenyl)-1-[[2-[methyl(phenylmethyl)amino]-4-phenyl-5-pyrimidinyl]carbonyl]-, (α R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 862841-03-0 CAPLUS

CN 2-Piperidinemethanol, 1-[[2-[methyl(phenylmethyl)amino]-4-phenyl-5-pyrimidinyl]carbonyl]- α -3-thienyl-, (α R,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 862841-06-3 CAPLUS

CN 2-Piperidinemethanol, 1-[[2-[[[(3-chloro-4-fluorophenyl)methyl]amino]-4-phenyl-5-pyrimidinyl]carbonyl]-α-phenyl-, (αR,2R)-rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 862841-09-6 CAPLUS

CN 2-Piperidinemethanol, 1-[[2-[[[(3-chloro-4-fluorophenyl)methyl]methylamino]-4-phenyl-5-pyrimidinyl]carbonyl]-α-phenyl-, (αR,2R)-rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 862841-12-1 CAPLUS

CN 2-Piperidinemethanol, 1-[[4-(4-chlorophenyl)-2-[methyl(phenylmethyl)amino]-5-pyrimidinyl]carbonyl]-α-phenyl-, (αR,2R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 862841-15-4 CAPLUS

CN 2-Piperidinemethanol, 1-[[2-[[[3-chloro-4-fluorophenyl)methyl]amino]-4-phenyl-5-pyrimidinyl]carbonyl]-α-3-thienyl-, (αR,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 862838-01-5P 862838-06-0P 862838-07-1P
 862838-12-8P 862838-15-1P 862838-16-2P
 862838-18-4P 862838-25-3P 862838-26-4P
 862838-31-1P 862838-39-9P 862838-40-2P
 862838-41-3P 862838-42-4P 862838-44-6P
 862838-60-6P 862838-62-8P 862838-99-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidine derivs. as orexin receptors antagonists)


RN 862838-01-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-2-[methyl(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 862838-06-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-[methyl(phenylmethyl)amino]-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 862838-07-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-[methyl(phenylmethyl)amino]-4-phenyl- (9CI)
(CA INDEX NAME)


RN 862838-12-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-chlorophenyl)-2-[methyl(phenylmethyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 862838-15-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-phenyl-2-[(phenylmethyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 862838-16-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-[(2-hydroxyethyl)(phenylmethyl)amino]-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 862838-18-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-[[2-(2-chlorophenyl)methyl]amino]-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 862838-25-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-phenyl-2-[(2-phenylethyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 862838-26-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 862838-31-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-iodophenyl)-2-[methyl(phenylmethyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 862838-39-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-phenyl-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 862838-40-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-[(2-hydroxyethyl)(phenylmethyl)amino]-4-phenyl- (9CI) (CA INDEX NAME)




RN 862838-41-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-methylphenyl)-2-[methyl(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 862838-42-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-methoxyphenyl)-2-[methyl(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 862838-44-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-[[2-(2-chlorophenyl)methyl]methylamino]-4-phenyl- (9CI) (CA INDEX NAME)




RN 862838-60-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-phenyl-2-[(2-phenylethyl)amino]- (9CI) (CA INDEX NAME)



RN 862838-62-8 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-4-phenyl- (9CI) (CA INDEX NAME)



10/671,070

RN 862838-99-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-iodophenyl)-2-[methyl(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 16 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:698362 CAPLUS

DN 143:172891

TI Preparation of diaminopyrimidines as growth hormone secretagogue receptor (GHS-R) antagonists

IN Kosogof, Christi; Liu, Bo; Liu, Gang; Liu, Mei; Nelson, Lissa T. J.; Serby, Michael D.; Sham, Hing L.; Szczepankiewicz, Bruce G.; Xin, Zhili; Zhao, Hongyu

PA USA

SO U.S. Pat. Appl. Publ., 63 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005171131	A1	20050804	US 2004-947823	20040923
	US 2005171132	A1	20050804	US 2004-948042	20040923
PRAI	US 2003-506663P	P	20030926		

OS MARPAT 143:172891

AB Title compds. I [A = (hetero)aryl, heterocycle; R₂ = alkenyl, alkenyloxyalkyl, alkoxy, alkoxyalkoxy, etc.; R = H, alkenyl, alkenyloxy, etc.; n = 1-4; X = O, amino, CH₂NH; R₃ = H, alkenyl, alkoxy, etc.] are prepared For instance, 5-[4-[(4-chlorobenzyl)amino]phenyl]-6-ethylpyrimidine-2,4-diamine is prepared in 4 steps from 4-nitrophenylacetonitrile, propionyl chloride, guanidine hydrochloride and 4-chlorobenzaldehyde. Compds. of the present invention are found to antagonize the function of ghrelin in a range of 0.001 μ M to about 0.1 μ M and inhibit dihydrofolate reductase in a range of about 0.0001 μ M to about 0.1 μ M. I are useful in the treatment of disorders regulated by the action of ghrelin receptor, including Prader-Willi syndrome, eating disorder, weight gain, weight-loss maintenance following diet and exercise, obesity, and disorders associated with obesity such as noninsulin dependent diabetes mellitus.

IT **861102-94-5P**, 6-[[Methyl(phenyl)amino]methyl]-5-[4-[[4-(methanesulfonyl)benzyl]amino]phenyl]pyrimidine-2,4-diamine

861102-96-7P, 6-(Anilinomethyl)-5-[4-[[4-(methanesulfonyl)benzyl]amino]phenyl]pyrimidine-2,4-diamine

861103-06-2P, 6-[[2,3-Dimethoxyphenyl]amino]methyl]-5-[4-[[4-(methanesulfonyl)benzyl]amino]phenyl]pyrimidine-2,4-diamine


861103-36-8P 861103-55-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diaminopyrimidines as growth hormone secretagogue receptor (GHS-R) antagonists)


RN 861102-94-5 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[(methylphenylamino)methyl]-5-[4-[[4-(methylsulfonyl)phenyl]methyl]amino]phenyl]- (9CI) (CA INDEX NAME)





RN 861102-96-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-[4-[[[4-(methylsulfonyl)phenyl]methyl]amino]phenyl]-6-[(phenylamino)methyl]- (9CI) (CA INDEX NAME)




RN 861103-06-2 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[[[(2,3-dimethoxyphenyl)amino]methyl]-5-[4-[[[4-(methylsulfonyl)phenyl]methyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 861103-36-8 CAPLUS

CN 2,4,6-Pyrimidinetriamine, 5-[4-[[[4-(methylsulfonyl)phenyl]methyl]amino]phenyl]-N4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 861103-55-1 CAPLUS

CN 2,4,6-Pyrimidinetriamine, 5-[4-[[[4-(methylsulfonyl)phenyl]methyl]amino]phenyl]-N4-(2-phenylethyl)- (9CI) (CA INDEX NAME)




IT 861103-38-0P, N'-Benzyl-5-(4-nitrophenyl)pyrimidine-2,4,6-triamine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of diaminopyrimidines as growth hormone secretagogue receptor (GHS-R) antagonists)

RN 861103-38-0 CAPLUS

CN 2,4,6-Pyrimidinetriamine, 5-(4-nitrophenyl)-N4-(phenylmethyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 17 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:638854 CAPLUS
 DN 143:153392
 TI Preparation of aryl pyrimidines as protein kinase C inhibitors
 IN Fleming, Paul E.; Shi, Zhan; Chen, Shaowu; Schmidt, Jane F.; Reader, John C.; Hone, Neal D.; Ciavarri, Jefrey P.
 PA Millennium Pharmaceuticals, Inc., USA; Millennium Pharm Inc
 SO PCT Int. Appl., 177 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005066139	A2	20050721	WO 2005-US663	20050110
	WO 2005066139	A3	20051013		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2006040968	A1	20060223	US 2005-32299	20050110
PRAI	US 2004-534898P	P	20040108		

OS MARPAT 143:153392

AB Title compds. I [R1 and R2 independently = H, alkyl, cycloalkyl; R3 = H or F; R4 = H, F, C(O)R, etc., or R3 and R4 together = carbonyl; R = H, alkyl, cycloalkyl; ring A is optionally substituted with R5; R5 = halo, CN, aliphatic, etc.; Cyl = (un)substituted 6-membered aryl or heteroaryl, 5-membered heteroaryl; Q = bond, CH2, CO; Cy2 = (un)substituted aryl, heteroaryl, heterocycle] and their pharmaceutically acceptable salts, are prepared and disclosed as protein kinase C (PKC) inhibitors. Thus, e.g., II was prepared by coupling of (3-{[3-(2-chloro-pyrimidin-4-yl)-benzyl]-ethyl-amino}-propyl)carbamic acid tert-Bu ester (preparation given) with tyramine and subsequent deprotection. The inhibitory activity of I against PKC-theta isoform was evaluated in an enzyme assay following the emission of europium cryptate (at 615 nm) and streptavidin-allophycocyanin (at 665 nm) and it was revealed that selected compds. of the invention display IC50 values less than 100 nM. I as PKC inhibitor should prove useful in the treatment of inflammatory diseases such as, but not limited to, rheumatoid arthritis, asthma, and multiple sclerosis. Pharmaceutical compns. comprising I are disclosed.


IT 859513-71-6P 859513-88-5P 859513-93-2P
 859513-95-4P 859514-05-9P 859514-07-1P
 859514-13-9P 859514-24-2P 859514-32-2P
 859514-46-8P 859514-64-0P 859514-76-4P
 859514-78-6P 859514-84-4P 859514-85-5P
 859515-07-4P 859515-15-4P 859515-18-7P
 859515-24-5P 859515-52-9P 859515-57-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of aryl pyrimidines as protein kinase C inhibitors)


RN 859513-71-6 CAPLUS

CN Methanesulfonamide, N-(3-aminopropyl)-N-[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 859513-88-5 CAPLUS

CN Carbamic acid, [3-[[[3-[2-[[2-(4-hydroxy-3-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl] (methylsulfonyl)amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 859513-93-2 CAPLUS

CN Carbamic acid, [3-[[[3-[2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl] (methylsulfonyl)amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 859513-95-4 CAPLUS

CN Carbamic acid, [3-[[[3-[2-[[2-(3-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl] (methylsulfonyl)amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 859514-05-9 CAPLUS

CN Carbamic acid, [3-[[[3-[2-[[2-(3-bromo-4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl](methylsulfonyl)amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 859514-07-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 859514-13-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[3-[2-[[2-(4-hydroxy-3-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 859514-24-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[3-[2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 859514-32-2 CAPLUS

CN Phenol, 4-[2-[[4-(3-nitrophenyl)-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859514-46-8 CAPLUS


CN Benzoic acid, 3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 859514-64-0 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[[3-[[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-3-methyl-, 1,1-dimethylethyl ester, (3R)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 859514-76-4 CAPLUS

CN Methanesulfonamide, N-[[3-[[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-3-pyrrolidinyl-, (9CI) (CA INDEX NAME)




RN 859514-78-6 CAPLUS

CN 2-Pyrimidinamine, 4-[3-[(ethylamino)methyl]phenyl]-N-[2-(3-fluorophenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 859514-84-4 CAPLUS

CN 1,3-Propanediamine, N-[1-[3-[2-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 859514-85-5 CAPLUS

CN Methanesulfonamide, N-(3-aminopropyl)-N-[1-[3-[2-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 859515-07-4 CAPLUS

CN Phenol, 4-[2-[[4-[3-[[[3-(diethylamino)propyl]amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859515-15-4 CAPLUS


CN Phenol, 2-chloro-4-[2-[[4-[3-[[[1-methylethyl]amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859515-18-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[3-[5-fluoro-2-[[2-(3-fluoro-4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl] (methylsulfonyl) amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— OBU-t

RN 859515-24-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[3-[2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-5-fluoro-4-pyrimidinyl]phenyl]methyl] (methanesulfonyl)amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— OBU-t


RN 859515-52-9 CAPLUS

CN Methanesulfonamide, N-[[3-[2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)



RN 859515-57-4 CAPLUS

CN Phenol, 2-chloro-4-[2-[[4-[3-[(ethyl-4-piperidinylamino)methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



IT 859513-70-5P 859513-72-7P 859513-73-8P
 859513-74-9P 859513-75-0P 859513-76-1P
 859513-77-2P 859513-78-3P 859513-79-4P
 859513-82-9P 859513-83-0P 859513-84-1P
 859513-85-2P 859513-90-9P 859513-91-0P
 859513-92-1P 859513-94-3P 859513-96-5P
 859513-97-6P 859513-98-7P 859513-99-8P
 859514-00-4P 859514-01-5P 859514-02-6P
 859514-03-7P 859514-04-8P 859514-06-0P
 859514-10-6P 859514-16-2P 859514-22-0P
 859514-23-1P 859514-25-3P 859514-26-4P
 859514-27-5P 859514-28-6P 859514-29-7P
 859514-30-0P 859514-31-1P 859514-33-3P
 859514-34-4P 859514-35-5P 859514-36-6P
 859514-37-7P 859514-38-8P 859514-39-9P
 859514-40-2P 859514-41-3P 859514-42-4P
 859514-43-5P 859514-44-6P 859514-45-7P
 859514-47-9P 859514-48-0P 859514-49-1P
 859514-50-4P 859514-51-5P 859514-52-6P
 859514-53-7P 859514-54-8P 859514-55-9P
 859514-56-0P 859514-57-1P 859514-58-2P
 859514-60-6P 859514-61-7P 859514-62-8P
 859514-63-9P 859514-65-1P 859514-66-2P
 859514-67-3P 859514-68-4P 859514-69-5P
 859514-70-8P 859514-72-0P 859514-73-1P
 859514-74-2P 859514-75-3P 859514-77-5P
 859514-79-7P 859514-80-0P 859514-81-1P
 859514-82-2P 859514-83-3P 859514-86-6P
 859514-87-7P 859514-88-8P 859514-89-9P
 859514-90-2P 859514-91-3P 859514-92-4P
 859514-93-5P 859514-94-6P 859514-95-7P
 859514-96-8P 859514-97-9P 859514-98-0P
 859514-99-1P 859515-00-7P 859515-01-8P
 859515-02-9P 859515-03-0P 859515-04-1P


859515-05-2P 859515-08-5P 859515-09-6P
 859515-10-9P 859515-11-0P 859515-12-1P
 859515-14-3P 859515-16-5P 859515-17-6P
 859515-19-8P 859515-20-1P 859515-21-2P
 859515-22-3P 859515-23-4P 859515-25-6P
 859515-26-7P 859515-27-8P 859515-28-9P
 859515-29-0P 859515-30-3P 859515-31-4P
 859515-32-5P 859515-33-6P 859515-34-7P
 859515-35-8P 859515-36-9P 859515-37-0P
 859515-38-1P 859515-39-2P 859515-40-5P
 859515-41-6P 859515-42-7P 859515-43-8P
 859515-44-9P 859515-45-0P 859515-46-1P
 859515-47-2P 859515-48-3P 859515-49-4P
 859515-50-7P 859515-51-8P 859515-53-0P
 859515-54-1P 859515-55-2P 859515-56-3P
 859515-58-5P 859515-61-0P 859515-63-2P
 859515-64-3P 859515-65-4P 859515-66-5P
 859515-67-6P 859515-68-7P 859515-69-8P
 859515-70-1P 859515-71-2P 859515-73-4P
 859515-75-6P 859515-77-8P 859515-78-9P
 859515-79-0P 859515-80-3P 859515-81-4P
 859515-82-5P 859515-83-6P 859515-84-7P
 859515-85-8P 859515-86-9P 859515-87-0P
 859515-88-1P 859515-90-5P 859515-91-6P
 859515-92-7P 859515-93-8P 859515-94-9P
 859515-95-0P 859515-96-1P 859515-98-3P
 859515-99-4P 859516-00-0P 859516-01-1P
 859516-02-2P 859516-03-3P 859516-05-5P
 859516-06-6P 859516-07-7P 859516-08-8P
 859516-09-9P 859516-10-2P 859516-11-3P
 859516-12-4P 859516-13-5P 859516-14-6P
 859516-15-7P 859516-16-8P 859516-17-9P
 859516-18-0P 859516-19-1P 859516-20-4P
 859516-21-5P 859516-22-6P 859516-23-7P
 859516-25-9P 859516-26-0P 859516-28-2P
 859516-29-3P 859516-32-8P 859516-33-9P
 859516-34-0P 859516-35-1P 859516-36-2P
 859516-37-3P 859516-38-4P 859516-39-5P
 859516-40-8P 859516-41-9P 859516-42-0P
 859516-43-1P 859516-44-2P 859516-45-3P
 859516-46-4P 859516-47-5P 859516-48-6P
 859516-49-7P 859516-50-0P 859516-51-1P
 859516-52-2P 859516-53-3P 859516-54-4P
 859516-55-5P 859516-59-9P 859516-60-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of aryl pyrimidines as protein kinase C inhibitors)


RN 859513-70-5 CAPLUS

CN Phenol, 4-[2-[[4-[3-[(3-aminopropyl)ethylamino]methyl]phenyl]-2-
 pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859513-72-7 CAPLUS

CN Acetamide, N-[4-[2-[[4-[3-[(3-aminopropyl)(methylsulfonyl)amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 859513-73-8 CAPLUS

CN Methanesulfonamide, N-(3-aminopropyl)-N-[[3-[2-[[2-[4-[(methylsulfonyl)amino]phenyl]ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 859513-74-9 CAPLUS

CN Methanesulfonamide, N-[[3-[2-[[2-(4-aminophenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-(3-aminopropyl)- (9CI) (CA INDEX NAME)




RN 859513-75-0 CAPLUS

CN Methanesulfonamide, N-(3-aminopropyl)-N-[[3-[2-[[2-(3,4-dihydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 859513-76-1 CAPLUS

CN Methanesulfonamide, N-(3-aminopropyl)-N-[[3-[2-[[2-(3,4-dihydroxyphenyl)ethyl]methylamino]-4-pyrimidinyl]phenyl]methyl]- (9CI)
(CA INDEX NAME)




RN 859513-77-2 CAPLUS

CN Methanesulfonamide, N-(3-aminopropyl)-N-[[3-[2-[[2-(3-hydroxy-4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 859513-78-3 CAPLUS

CN Methanesulfonamide, N-(3-aminopropyl)-N-[[3-[2-[[4-(3-hydroxyphenyl)methyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 859513-79-4 CAPLUS

CN Benzenesulfonamide, 4-[2-[[4-[3-[[3-(aminopropyl)(methylsulfonyl)amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859513-82-9 CAPLUS

CN Methanesulfonamide, N-(3-aminopropyl)-N-[[3-[2-[[2-(4-hydroxy-3,5-dimethoxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 859513-83-0 CAPLUS

CN Methanesulfonamide, N-(3-aminopropyl)-N-[[3-[2-[(2-phenylethyl)amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 859513-84-1 CAPLUS

CN Methanesulfonamide, N-(3-aminopropyl)-N-[[3-[2-[[2-(4-fluorophenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 859513-85-2 CAPLUS

CN Methanesulfonamide, N-(3-aminopropyl)-N-[[3-[2-[[2-(4-hydroxy-3-methoxyphenyl)methyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 859513-90-9 CAPLUS

CN Methanesulfonamide, N-(3-aminopropyl)-N-[[3-[2-[[2-(4-hydroxy-3-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 859513-91-0 CAPLUS

CN Methanesulfonamide, N-(3-aminopropyl)-N-[[3-[2-[[2-(4-methylphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 859513-92-1 CAPLUS

CN Methanesulfonamide, N-(3-aminopropyl)-N-[[3-[2-[[2-(4-hydroxy-3-nitrophenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 859513-94-3 CAPLUS

CN Methanesulfonamide, N-(3-aminopropyl)-N-[[3-[2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 859513-96-5 CAPLUS

CN Methanesulfonamide, N-(3-aminopropyl)-N-[[3-[2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 859513-97-6 CAPLUS


CN Methanesulfonamide, N-(3-aminopropyl)-N-[[3-[2-[[2-(2-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 859513-98-7 CAPLUS


CN Carbamic acid, [3-[(methylsulfonyl)[[3-[2-[[2-(3,4,5-trihydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]amino]propyl]-,

1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 859513-99-8 CAPLUS

CN Methanesulfonamide, N-(3-aminopropyl)-N-[[3-[2-[[2-(3,5-dichloro-4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 859514-00-4 CAPLUS

CN Methanesulfonamide, N-(3-aminopropyl)-N-[[3-[2-[[2-(3-chlorophenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 859514-01-5 CAPLUS

CN Methanesulfonamide, N-(3-aminopropyl)-N-[[3-[2-[[2-(2-chlorophenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 859514-02-6 CAPLUS

CN Methanesulfonamide, N-(3-aminopropyl)-N-[[3-[2-[[2-(4-chlorophenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 859514-03-7 CAPLUS

CN Methanesulfonamide, N-(3-aminopropyl)-N-[[3-[2-[[2-(3-hydroxy-4-nitrophenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 859514-04-8 CAPLUS

CN Methanesulfonamide, N-(3-aminopropyl)-N-[[3-[2-[[2-(2,3-dihydro-2-oxo-5-benzoxazolyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 859514-06-0 CAPLUS

CN Methanesulfonamide, N-(3-aminopropyl)-N-[[3-[2-[[2-(3-bromo-4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 859514-10-6 CAPLUS

CN Phenol, 4-[2-[[4-[3-(4-piperidinylamino)phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859514-16-2 CAPLUS

CN Phenol, 2-methoxy-4-[2-[[4-[3-(4-piperidinylamino)phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859514-22-0 CAPLUS

CN 2-Pyrimidinamine, N-(1-naphthalenylmethyl)-4-[3-(4-piperidinylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 859514-23-1 CAPLUS

CN Phenol, 2-methoxy-5-[2-[[4-[3-(4-piperidinylamino)phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859514-25-3 CAPLUS

CN Phenol, 2-chloro-4-[2-[[4-[3-(4-piperidinylamino)phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859514-26-4 CAPLUS


CN 2-Pyrimidinamine, N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-[3-(4-piperidinylamino)phenyl]- (9CI) (CA INDEX NAME)



RN 859514-27-5 CAPLUS


CN 2-Pyrimidinamine, N-[2-(3-fluorophenyl)ethyl]-4-[3-(4-

piperidinylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 859514-28-6 CAPLUS

CN Phenol, 2,6-dichloro-4-[2-[[4-[3-(4-piperidinylamino)phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859514-29-7 CAPLUS

CN Phenol, 3-[2-[[4-[3-(4-piperidinylamino)phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859514-30-0 CAPLUS

CN Phenol, 2-bromo-4-[2-[[4-[3-(4-piperidinylamino)phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859514-31-1 CAPLUS

CN 2-Pyrimidinamine, N-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-4-[3-(4-piperidinylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 859514-33-3 CAPLUS

CN Phenol, 4-[2-[[4-[3-(3-piperidinylamino)phenyl]-2-pyrimidinyl]amino]ethyl]-
(9CI) (CA INDEX NAME)




RN 859514-34-4 CAPLUS

CN Phenol, 2-chloro-4-[2-[[4-[3-(3-piperidinylamino)phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859514-35-5 CAPLUS

CN Phenol, 4-[2-[[4-[3-(3-pyrrolidinylamino)phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859514-36-6 CAPLUS


CN Benzamide, N-[3-[[[3-[2-[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl](methylsulfonyl)amino]propyl]- (9CI) (CA INDEX NAME)



RN 859514-37-7 CAPLUS

CN Benzamide, N-[3-[[[3-[2-[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl](methylsulfonyl)amino]propyl]-2-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OH


RN 859514-38-8 CAPLUS

CN Benzamide, 4-chloro-N-[3-[[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl](methylsulfonyl)amino]propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 859514-39-9 CAPLUS

CN Benzamide, N-[3-[[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl](methylsulfonyl)amino]propyl]-4-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 859514-40-2 CAPLUS

CN 2-Pyridinecarboxamide, N-[3-[[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl] (methanesulfonyl)amino]propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 859514-41-3 CAPLUS

CN Benzamide, 3-chloro-N-[3-[[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl] (methanesulfonyl)amino]propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 859514-42-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl] (methylsulfonyl)amino]propyl]-2-methyl- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 859514-43-5 CAPLUS

CN Benzamide, N-[3-[[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl] (methylsulfonyl)amino]propyl]-2-methoxy- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OH


RN 859514-44-6 CAPLUS

CN Benzenemethanesulfonamide, N-[3-[[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl](methanesulfonyl)amino]propyl]- (9CI) (CA INDEX NAME)




RN 859514-45-7 CAPLUS

CN Benzenesulfonamide, N-[3-[[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl](methanesulfonyl)amino]propyl]- (9CI) (CA INDEX NAME)




RN 859514-47-9 CAPLUS

CN Benzamide, 3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]-N-(3-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)




RN 859514-48-0 CAPLUS

CN Benzamide, N-(3-aminopropyl)-3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 859514-49-1 CAPLUS

CN Benzamide, 3-[[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]-N-(2-piperidinylmethyl)- (9CI) (CA INDEX NAME)




RN 859514-50-4 CAPLUS

CN Methanesulfonamide, N-[[3-[[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-(2-piperidinylmethyl)- (9CI) (CA INDEX NAME)




RN 859514-51-5 CAPLUS

CN Methanesulfonamide, N-[[3-[[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 859514-52-6 CAPLUS

CN Methanesulfonamide, N-[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 859514-53-7 CAPLUS

CN Methanesulfonamide, N-[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 859514-54-8 CAPLUS

CN Methanesulfonamide, N-[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 859514-55-9 CAPLUS

CN Methanesulfonamide, N-[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 859514-56-0 CAPLUS

CN Phenol, 4-[2-[[4-[3-[[ethyl(3-pyridinylmethyl)amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859514-57-1 CAPLUS

CN Propanamide, 3-amino-N-[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 859514-58-2 CAPLUS

CN 3-Pyridinepropanamide, N-[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 859514-60-6 CAPLUS

CN Benzenemethanesulfonamide, N-[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 859514-61-7 CAPLUS

CN Phenol, 4-[2-[[4-[3-[ethyl(3-pyridinylmethyl)amino]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859514-62-8 CAPLUS


CN Phenol, 4-[2-[[4-[3-[(4-methyl-1-piperazinyl)methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859514-63-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-3-methyl-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859514-65-1 CAPLUS

CN Phenol, 4-[2-[[4-[3-[(2S)-2-methyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859514-66-2 CAPLUS


CN Phenol, 4-[2-[[4-[3-[(2R)-2-methyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 859514-67-3 CAPLUS

CN Methanesulfonamide, N-[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 859514-68-4 CAPLUS

CN Methanesulfonamide, N-[[3-[2-[[2-(3-fluorophenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 859514-69-5 CAPLUS

CN Methanesulfonamide, N-[[3-[2-[(2-phenylethyl)amino]-4-pyrimidinyl]phenyl]methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 859514-70-8 CAPLUS

CN Methanesulfonamide, N-[[3-[2-[[2-(3-chlorophenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 859514-72-0 CAPLUS

CN Methanesulfonamide, N-[[3-[2-[[2-(4-hydroxy-3-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 859514-73-1 CAPLUS

CN Methanesulfonamide, N-[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-3-piperidinyl- (9CI) (CA INDEX NAME)




RN 859514-74-2 CAPLUS

CN Methanesulfonamide, N-[[3-[2-[[2-(4-hydroxy-3-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-3-piperidinyl- (9CI) (CA INDEX NAME)




RN 859514-75-3 CAPLUS

CN Methanesulfonamide, N-[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)




RN 859514-77-5 CAPLUS

CN Phenol, 2-chloro-4-[2-[[4-[3-[(ethylamino)methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859514-79-7 CAPLUS

CN Methanesulfonamide, N-[[3-[2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 859514-80-0 CAPLUS

CN Phenol, 2-chloro-4-[2-[[4-[3-[[ethyl(1-methylethyl)amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859514-81-1 CAPLUS

CN Phenol, 2-chloro-4-[2-[[4-[3-[[ethyl(3-methylbutyl)amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859514-82-2 CAPLUS

CN Phenol, 2-chloro-4-[2-[[4-[3-[[ethyl(2-methylpropyl)amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859514-83-3 CAPLUS

CN Phenol, 2-chloro-4-[2-[[4-[3-[(ethylpropylamino)methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859514-86-6 CAPLUS

CN Methanesulfonamide, N-(3-aminopropyl)-N-[1-[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 859514-87-7 CAPLUS

CN Benzamide, N-[3-[ethyl[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]amino]propyl]- (9CI) (CA INDEX NAME)




RN 859514-88-8 CAPLUS

CN Phenol, 4-[2-[[4-[3-(1-methylethoxy)phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859514-89-9 CAPLUS

CN Phenol, 2-methoxy-4-[2-[[4-[3-(1-methylethoxy)phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859514-90-2 CAPLUS

CN Phenol, 4-[2-[[4-(3-butoxyphenyl)-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859514-91-3 CAPLUS

CN Phenol, 4-[2-[[4-(3-butoxyphenyl)-2-pyrimidinyl]amino]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 859514-92-4 CAPLUS

CN Phenol, 4-[2-[[4-(4-ethoxyphenyl)-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859514-93-5 CAPLUS

CN Phenol, 4-[2-[[4-(4-ethoxyphenyl)-2-pyrimidinyl]amino]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 859514-94-6 CAPLUS

CN Carbamic acid, [4-[2-[[2-(4-hydroxy-3-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 859514-95-7 CAPLUS

CN Phenol, 2-methoxy-4-[2-[[4-[4-(2-methylpropyl)phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859514-96-8 CAPLUS

CN Phenol, 2-methoxy-4-[2-[[4-(4-propoxyphenyl)-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859514-97-9 CAPLUS

CN Methanesulfonamide, N-[[3-[2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-3-piperidinyl- (9CI) (CA INDEX NAME)




RN 859514-98-0 CAPLUS

CN Methanesulfonamide, N-[[3-[2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-3-pyrrolidinyl- (9CI) (CA INDEX NAME)




RN 859514-99-1 CAPLUS

CN Methanesulfonamide, N-[[3-[2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-(4-piperidinyl)methyl- (9CI) (CA INDEX NAME)




RN 859515-00-7 CAPLUS

CN Methanesulfonamide, N-[[3-[2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-[2-(2-piperidiny)ethyl]- (9CI) (CA INDEX NAME)




RN 859515-01-8 CAPLUS

CN 1,3-Propanediamine, N-ethyl-N-[[3-[2-[[2-(4-methoxy-3-methylphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 859515-02-9 CAPLUS

CN Acetamide, N-[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-(3-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)




RN 859515-03-0 CAPLUS

CN Benzenemethanol, 3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]-
α-methyl- (9CI) (CA INDEX NAME)




RN 859515-04-1 CAPLUS

CN Phenol, 4-[2-[[4-[3-[(pyrazinylamino)methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859515-05-2 CAPLUS

CN Phenol, 4-[2-[[4-[3-[(3-pyridinylamino)methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859515-08-5 CAPLUS

CN Phenol, 4-[2-[[4-[3-[[[3-(diethylamino)propyl]ethylamino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859515-09-6 CAPLUS


CN Phenol, 4-[2-[[4-[4-[[[1-methylethyl]amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859515-10-9 CAPLUS

CN 3-Piperidinecarboxamide, N-ethyl-N-[[3-[2-[2-(3-fluorophenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859515-11-0 CAPLUS

CN 3-Piperidinecarboxamide, N-ethyl-N-[[3-[[2-[[2-(3-fluorophenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859515-12-1 CAPLUS


CN 2-Pyrimidinamine, N-[2-(3-fluorophenyl)ethyl]-4-[3-[[2-(3-fluorophenyl)ethyl]amino]-4-pyrimidinyl]methyl]phenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859515-14-3 CAPLUS


CN Phenol, 4-[2-[[4-[3-[(ethylamino)methyl]phenyl]-2-pyrimidinyl]amino]ethyl]-(9CI) (CA INDEX NAME)



RN 859515-16-5 CAPLUS


CN Piperazinone, 1-[[3-[2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-4,6-dimethyl-, (6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 859515-17-6 CAPLUS

CN Methanesulfonamide, N-[[3-[5-fluoro-2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 859515-19-8 CAPLUS

CN Methanesulfonamide, N-[[3-[5-fluoro-2-[[2-(3-fluoro-4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 859515-20-1 CAPLUS

CN Methanesulfonamide, N-[[3-[5-fluoro-2-[[2-(3-fluorophenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 859515-21-2 CAPLUS

CN Methanesulfonamide, N-[[3-[5-fluoro-2-[[2-(4-hydroxy-3-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 859515-22-3 CAPLUS

CN Methanesulfonamide, N-[[3-[2-[[2-(3-chlorophenyl)ethyl]amino]-5-fluoro-4-pyrimidinyl]phenyl]methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 859515-23-4 CAPLUS

CN Methanesulfonamide, N-[[3-[5-fluoro-2-[(2-phenylethyl)amino]-4-pyrimidinyl]phenyl]methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 859515-25-6 CAPLUS

CN Methanesulfonamide, N-[[3-[2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-5-fluoro-4-pyrimidinyl]phenyl]methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 859515-26-7 CAPLUS

CN Phenol, 4-[2-[[4-[3-[[3-(aminopropyl)ethylamino)methyl]phenyl]-5-fluoro-2-pyrimidinyl]amino]ethyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 859515-27-8 CAPLUS

CN 1,3-Propanediamine, N-ethyl-N-[[3-[5-fluoro-2-[[2-(3-fluorophenyl)ethyl]amino]-4-pyrimidinyl]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 859515-28-9 CAPLUS

CN 1,3-Propanediamine, N-[[3-[2-[[2-(3-chlorophenyl)ethyl]amino]-5-fluoro-4-pyrimidinyl]phenyl)methyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 859515-29-0 CAPLUS

CN Phenol, 4-[2-[[4-[3-[(3-aminopropyl)ethylamino)methyl]phenyl]-5-fluoro-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859515-30-3 CAPLUS

CN Phenol, 4-[2-[[4-[3-[(3-aminopropyl)ethylamino)methyl]phenyl]-5-fluoro-2-pyrimidinyl]amino]ethyl]-2-chloro- (9CI) (CA INDEX NAME)




RN 859515-31-4 CAPLUS

CN Phenol, 4-[2-[[5-fluoro-4-[3-[2-(4-piperidinyl)ethyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859515-32-5 CAPLUS

CN Phenol, 2-chloro-4-[2-[[5-fluoro-4-[3-[2-(4-piperidinyl)ethyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859515-33-6 CAPLUS

CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[3-(4-piperidinylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 859515-34-7 CAPLUS

CN Phenol, 2-fluoro-4-[2-[[4-[3-(4-piperidinylamino)phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859515-35-8 CAPLUS


CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[3-[(ethyl-4-piperidinylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 859515-36-9 CAPLUS

CN Phenol, 2-chloro-4-[2-[[4-[3-[[[(2S)-2-methyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859515-37-0 CAPLUS


CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[3-[[[(2S)-2-methyl-1-piperazinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 859515-38-1 CAPLUS

CN 2-Pyrimidinamine, 4-[3-[(ethyl-4-piperidinylamino)methyl]phenyl]-N-[2-(3-fluorophenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 859515-39-2 CAPLUS

CN Methanesulfonamide, N-[[3-[2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-(1-ethyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 859515-40-5 CAPLUS

CN Methanesulfonamide, N-[[3-[2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-(1-propyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 859515-41-6 CAPLUS

CN Phenol, 2-chloro-4-[2-[[4-[3-[[ethyl(1-ethyl-4-piperidinyl)amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859515-42-7 CAPLUS

CN Phenol, 2-chloro-4-[2-[[4-[3-[[ethyl(1-propyl-4-piperidinyl)amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859515-43-8 CAPLUS


CN Phenol, 2-chloro-4-[2-[[4-[3-[[ethyl(1-(4-pyridinylmethyl)-4-piperidinyl)amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




PAGE 1-A

—OH


RN 859515-44-9 CAPLUS
 CN Methanesulfonamide, N-[[5-[2-[[2-(3-fluorophenyl)ethyl]amino]-4-pyrimidinyl]-2-methoxyphenyl]methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 859515-45-0 CAPLUS
 CN Methanesulfonamide, N-[[2-methoxy-5-[2-[(2-phenylethyl)amino]-4-pyrimidinyl]phenyl]methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)



RN 859515-46-1 CAPLUS
 CN Methanesulfonamide, N-[[5-[2-[[2-(3-fluoro-4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]-2-methoxyphenyl]methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 859515-47-2 CAPLUS
 CN Methanesulfonamide, N-[[2-fluoro-5-[2-[[2-(3-fluorophenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 859515-48-3 CAPLUS

CN Methanesulfonamide, N-[[2-fluoro-5-[2-[[2-(3-fluoro-4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-4-piperidinyl-(9CI) (CA INDEX NAME)



RN 859515-49-4 CAPLUS


CN Phenol, 4-[2-[[4-[3-[[ethyl(1-propyl-4-piperidinyl)amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 859515-50-7 CAPLUS

CN Phenol, 4-[2-[[4-[3-[[ethyl[1-(4-pyridinylmethyl)-4-piperidinyl]amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]-2-fluoro- (9CI) (CA INDEX NAME)


PAGE 1-A



—OH


RN 859515-51-8 CAPLUS

CN Methanesulfonamide, N-[[3-[2-[[2-(3-fluoro-4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-4-piperidiny]- (9CI) (CA INDEX NAME)




RN 859515-53-0 CAPLUS

CN Phenol, 2-fluoro-4-[2-[[4-[3-[(4-piperidinypropylamino)methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859515-54-1 CAPLUS

CN Phenol, 2-chloro-4-[2-[[4-[3-[(4-piperidinypropylamino)methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859515-55-2 CAPLUS

CN 2-Pyrimidinamine, N-[2-(3-fluorophenyl)ethyl]-4-[3-[(4-piperidinypropylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 859515-56-3 CAPLUS


Phenol, 2-chloro-4-[2-[[4-[3-[2-(4-piperidinyl)ethyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859515-58-5 CAPLUS


CN Phenol, 4-[2-[[4-[3-[[ethyl[(3S)-3-piperidinylmethyl]amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 859515-61-0 CAPLUS

CN Phenol, 4-[2-[[4-[3-[(ethyl-4-piperidinylamino)methyl]phenyl]-2-pyrimidinyl]amino]ethyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 859515-63-2 CAPLUS

CN Phenol, 2-chloro-4-[[2-[[4-[[3-[[2-(1-methylethyl)-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859515-64-3 CAPLUS


CN Methanesulfonamide, N-(3-aminopropyl)-N-[[3-[2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-5-fluoro-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 859515-65-4 CAPLUS


CN Phenol, 2-methyl-4-[[2-[[4-[[3-[[[(2S)-2-methyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 859515-66-5 CAPLUS

CN Phenol, 4-[2-[[4-[[3-[(3-azetidinyloethylamino)methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859515-67-6 CAPLUS

CN Phenol, 4-[2-[[4-[[3-[[2-(1-methylethyl)-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859515-68-7 CAPLUS


CN 1-Naphthalenol, 4-[2-[[4-[3-[(ethyl-4-piperidinylamino)methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859515-69-8 CAPLUS

CN Phenol, 4-[2-[[4-[3-[[ethyl[2-(2S)-2-pyrrolidiny]ethyl]amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859515-70-1 CAPLUS

CN Phenol, 2-chloro-4-[2-[[4-[3-[[2S)-2-methyl-1-piperidinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859515-71-2 CAPLUS

CN Phenol, 4-[2-[[4-[3-[[(3S)-3-(1H-indol-3-ylmethyl)-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859515-73-4 CAPLUS

CN Phenol, 4-[2-[[4-[3-[[(3R)-3-(phenylmethyl)-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859515-75-6 CAPLUS

CN Phenol, 3-[2-[[4-[3-[[ethyl[2-(2S)-2-pyrrolidinylethyl]amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859515-77-8 CAPLUS


CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[3-[[(2R)-2-methyl-1-piperazinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859515-78-9 CAPLUS


CN Methanesulfonamide, N-(3-aminopropyl)-N-[[3-[5-fluoro-2-[[2-(3-fluorophenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 859515-79-0 CAPLUS

CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[3-[[(2S)-2-ethyl-1-piperazinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859515-80-3 CAPLUS

CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[3-[[(2R)-2-ethyl-1-piperazinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859515-81-4 CAPLUS


CN Phenol, 4-[2-[[4-[3-[[(3S)-3-(2-methylpropyl)-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859515-82-5 CAPLUS


CN 2-Pyrimidinamine, N-[2-(3-fluorophenyl)ethyl]-4-[3-[2-(4-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 859515-83-6 CAPLUS


CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[3-[[2,6-dimethyl-1-piperazinyl]methyl]phenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 859515-84-7 CAPLUS


CN Methanesulfonamide, N-(3-aminopropyl)-N-[[3-[2-[[2-(3-chlorophenyl)ethyl]amino]-5-fluoro-4-pyrimidinyl]phenyl]methyl]- (9CI)
(CA INDEX NAME)



RN 859515-85-8 CAPLUS


CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl-2,2-d2]-4-[3-[[2-(2S)-2-methyl-1-piperazinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 859515-86-9 CAPLUS

CN 2-Pyrimidinamine, 4-[3-[(3-azetidinylethylamino)methyl]phenyl]-N-[2-(3,5-difluorophenyl)ethyl]-2,2-d2- (9CI) (CA INDEX NAME)




RN 859515-87-0 CAPLUS

CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[3-[[2-(1-methylethyl)-1-piperazinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 859515-88-1 CAPLUS

CN 2-Pyrimidinamine, 4-[3-[(ethyl-4-piperidinylamino)methyl]phenyl]-N-[2-[3-(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 859515-90-5 CAPLUS

CN 2-Pyrimidinamine, N-[2-(3-chlorophenyl)ethyl]-5-fluoro-4-[3-[2-(4-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 859515-91-6 CAPLUS


CN 2-Pyrimidinamine, 5-fluoro-N-[2-(3-fluorophenyl)ethyl]-4-[3-[2-(4-piperidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 859515-92-7 CAPLUS


CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[3-[[3-(1H-indol-3-ylmethyl)-1-piperazinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 859515-93-8 CAPLUS

CN 2-Pyrimidinamine, 5-fluoro-N-(2-phenylethyl)-4-[3-[2-(4-piperidinylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 859515-94-9 CAPLUS

CN 2-Pyrimidinamine, 4-[3-[(3-azetidinyloethylamino)methyl]phenyl]-N-[2-(3-fluorophenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 859515-95-0 CAPLUS


CN 2-Pyrimidinamine, N-[2-(3-fluorophenyl)ethyl]-4-[3-[[2-(1-methylethyl)-1-piperazinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 859515-96-1 CAPLUS


CN 2-Pyrimidinamine, 4-[3-[[ethyl[(3S)-3-piperidinylmethyl]amino]methyl]phenyl]-N-[2-(3-fluorophenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859515-98-3 CAPLUS


CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[3-[(2-ethyl-4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 859515-99-4 CAPLUS

CN Phenol, 4-[2-[[4-[3-[[[(3R)-3-phenyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859516-00-0 CAPLUS


CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[3-[[(2S)-4-ethyl-2-methyl-1-piperazinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 859516-01-1 CAPLUS

CN Phenol, 4-[2-[[4-[3-[[(1,1-dimethylethyl)amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859516-02-2 CAPLUS

CN Phenol, 2-chloro-4-[2-[[4-[3-[[1,1-dimethylethyl]amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859516-03-3 CAPLUS


CN Phenol, 2-chloro-4-[[[4-[3-[[1-methylethyl]amino]methyl]phenyl]-2-pyrimidinyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 859516-05-5 CAPLUS

CN 2-Pyrimidinamine, N-[2-(3-chloro-4-methoxyphenyl)ethyl]-4-[3-[[2-(2-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859516-06-6 CAPLUS


CN 2-Pyrimidinamine, N-[2-(4-amino-3-chlorophenyl)ethyl]-4-[3-[(2S)-2-methyl-1-piperazinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 859516-07-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3-[2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-2-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 859516-08-8 CAPLUS

CN 2-Pyridinecarboxamide, N-[[3-[[2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-3-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 859516-09-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3-[[2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-5-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 859516-10-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3-[[2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-6-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 859516-11-3 CAPLUS

CN 4-Pyridinecarboxamide, N-[[3-[[2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 859516-12-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3-[2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-(1-methylethyl)-6-(trifluoromethyl)- (9CI)
(CA INDEX NAME)




RN 859516-13-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[[3-[2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-(1-methylethyl)-4-(trifluoromethyl)- (9CI)
(CA INDEX NAME)




RN 859516-14-6 CAPLUS

CN 3-Pyridinecarboxamide, 5-bromo-N-[[3-[2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 859516-15-7 CAPLUS


CN 4-Piperidinecarboxamide, N-[[3-[2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-1-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 859516-16-8 CAPLUS


CN 1H-Indole-5-ethanamine, N-[4-[3-[[[(2S)-2-methyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859516-17-9 CAPLUS


CN 1H-Indole-5-ethanamine, N-[4-[3-[(ethyl-4-piperidinylamino)methyl]phenyl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 859516-18-0 CAPLUS

CN Phenol, 4-[2-[[4-[3-[[[(3S)-3-methyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859516-19-1 CAPLUS

CN Phenol, 4-[2-[[4-[3-[[(3R)-3-methyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859516-20-4 CAPLUS

CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[3-[[(3S)-3-methyl-1-piperazinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859516-21-5 CAPLUS


CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[3-[(3R)-3-methyl-1-piperazinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 859516-22-6 CAPLUS

CN Phenol, 4-[2-[[4-[3-[(2-ethyl-1-piperazinyl)methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859516-23-7 CAPLUS

CN Phenol, 4-[2-[[4-[3-[(2-propyl-1-piperazinyl)methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859516-25-9 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 859516-26-0 CAPLUS


CN 2-Pyrimidinamine, N-[2-(3-chlorophenyl)ethyl]-4-[3-[(ethyl-4-piperidinylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 859516-28-2 CAPLUS


CN 2-Pyrimidinamine, N-[2-(2,5-difluorophenyl)ethyl]-4-[3-[[[(2S)-2-methyl-1-piperazinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859516-29-3 CAPLUS


CN 2-Pyrimidinamine, 4-[3-[(2-ethyl-1-piperazinyl)methyl]phenyl]-N-[2-(3-fluorophenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 859516-32-8 CAPLUS

CN Phenol, 4-[2-[[4-[3-[[[(3S,4R)-3-methyl-4-piperidinyl]amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 859516-33-9 CAPLUS

CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[3-[[[(3S,4R)-3-methyl-

4-piperidinyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859516-34-0 CAPLUS


CN 2-Pyrimidinamine, N-[2-(4-bromophenyl)ethyl]-4-[3-[[[(3S,4R)-3-methyl-4-piperidinyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 859516-35-1 CAPLUS

CN 2-Piperazinecarboxylic acid, 1-[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 859516-36-2 CAPLUS

CN 2-Piperazinecarboxylic acid, 1-[[3-[2-[[2-(3,5-dihydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 859516-37-3 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 859516-38-4 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[3-[2-[[2-(3-fluorophenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 859516-39-5 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[3-[2-[[2-(3,5-difluorophenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 859516-40-8 CAPLUS

CN 2-Piperazinecarboxitrile, 4-[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 859516-41-9 CAPLUS

CN 2-Piperazinecarboxitrile, 1-[[3-[2-[[2-(3,5-difluorophenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 859516-42-0 CAPLUS

CN 2-Pyrimidinamine, 4-[3-[(2,2-dimethyl-1-piperazinyl)methyl]phenyl]-N-[2-(3-fluorophenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 859516-43-1 CAPLUS

CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[3-[(2,2-dimethyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 859516-44-2 CAPLUS

CN Phenol, 4-[2-[[4-[3-[(2,2-dimethyl-1-piperazinyl)methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859516-45-3 CAPLUS

CN Phenol, 4-[2-[[4-[3-[(3,5-dimethyl-1-piperazinyl)methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859516-46-4 CAPLUS

CN Phenol, 2-chloro-4-[2-[[4-[3-[(3,5-dimethyl-1-piperazinyl)methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859516-47-5 CAPLUS

CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[3-[(3,5-dimethyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 859516-48-6 CAPLUS

CN Phenol, 2-chloro-4-[2-[[4-[3-(2,5-diazabicyclo[2.2.1]hept-2-ylmethyl)phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859516-49-7 CAPLUS

CN Phenol, 4-[2-[[4-[3-(2,5-diazabicyclo[2.2.1]hept-2-ylmethyl)phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859516-50-0 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(2,5-diazabicyclo[2.2.1]hept-2-ylmethyl)phenyl]-N-[2-(3-fluorophenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 859516-51-1 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(2,5-diazabicyclo[2.2.1]hept-2-ylmethyl)phenyl]-N-[2-(3,5-difluorophenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 859516-52-2 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(2,5-diazabicyclo[2.2.1]hept-2-ylmethyl)phenyl]-N-[2-(3,5-difluorophenyl)ethyl]-2,2-d2- (9CI) (CA INDEX NAME)



RN 859516-53-3 CAPLUS


CN Phenol, 4-[2-[[4-[3-[(tetrahydro-1,1-dioxido-1,2,5-thiadiazepin-2(3H)-yl)methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859516-54-4 CAPLUS

CN Phenol, 4-[2-[[4-[2-methoxy-5-[[[(2S)-2-methyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859516-55-5 CAPLUS

CN Phenol, 2-chloro-4-[2-[[4-[2-methoxy-5-[[(2S)-2-methyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859516-59-9 CAPLUS

CN Phenol, 2-chloro-4-[2-[[4-methyl-6-[3-[[(2S)-2-methyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859516-60-2 CAPLUS

CN Piperazine, 1-[[3-[2-[[2-(3,5-difluorophenyl)ethyl]amino]-4-pyrimidinyl]phenyl]sulfonyl]-2-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 859516-61-3P 859516-62-4P 859516-63-5P
 859516-64-6P 859516-65-7P 859516-66-8P
 859516-67-9P 859516-68-0P 859516-69-1P
 859516-71-5P 859516-73-7P 859516-74-8P
 859516-75-9P 859516-76-0P 859518-37-9P
 859518-38-0P 859518-39-1P 859518-40-4P
 859518-42-6P 859518-44-8P 859518-45-9P
 859518-46-0P 859518-47-1P 859518-48-2P
 859518-49-3P 859518-50-6P 859518-51-7P
 859518-52-8P 859518-53-9P 859518-54-0P

859518-55-1P 859518-56-2P 859518-57-3P
 859518-58-4P 859518-59-5P 859518-60-8P
 859518-61-9P 859518-63-1P 859518-64-2P
 859518-65-3P 859518-66-4P 859518-67-5P
 859518-68-6P 859518-69-7P 859518-70-0P
 859518-71-1P 859518-72-2P 859518-73-3P
 859518-74-4P 859518-75-5P 859518-76-6P
 859518-78-8P 859518-79-9P 859518-80-2P
 859518-81-3P 859518-82-4P 859518-83-5P
 859518-84-6P 859518-85-7P 859518-86-8P
 859518-87-9P 859518-88-0P 859518-89-1P
 859518-90-4P 859518-92-6P 859518-93-7P
 859518-94-8P 859518-96-0P 859518-97-1P
 859518-98-2P 859518-99-3P 859519-00-9P
 859519-01-0P 859519-02-1P 859519-03-2P
 859519-04-3P 859519-06-5P 859519-07-6P
 859519-08-7P 859519-09-8P 859519-10-1P
 859519-11-2P 859519-12-3P 859519-13-4P
 859519-14-5P 859519-15-6P 859519-16-7P
 859519-17-8P 859519-18-9P 859519-19-0P
 859519-20-3P 859519-21-4P 859519-22-5P
 859519-23-6P 859519-24-7P 859519-25-8P
 859519-26-9P 859519-27-0P 859519-28-1P
 859519-29-2P 859519-30-5P 859519-31-6P
 859519-33-8P 859519-34-9P 859519-35-0P
 859519-36-1P 859519-37-2P 859519-38-3P
 859519-40-7P 859519-41-8P 859519-42-9P
 859519-43-0P 859519-44-1P 859519-45-2P
 859519-46-3P 859519-47-4P 859519-48-5P
 859519-49-6P 859519-50-9P 859519-51-0P
 859519-52-1P 859519-53-2P 859519-54-3P
 859519-55-4P 859519-56-5P 859519-57-6P
 859519-58-7P 859519-59-8P 859519-60-1P
 859519-61-2P 859519-62-3P 859519-63-4P
 859519-64-5P 859519-65-6P 859519-66-7P
 859519-67-8P 859519-68-9P 859519-69-0P
 859519-70-3P 859519-71-4P 859708-81-9P
 859708-86-4P 859708-88-6P 859708-91-1P
 859708-93-3P 859708-95-5P 859708-97-7P
 859708-99-9P 859709-01-6P 859709-04-9P
 859709-07-2P 859712-89-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of aryl pyrimidines as protein kinase C inhibitors)

RN 859516-61-3 CAPLUS

CN Piperazine, 1-[[3-[2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-
 pyrimidinyl]phenyl]sulfonyl]-2-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859516-62-4 CAPLUS

CN Piperazine, 1-[[3-[2-[[2-(3-fluorophenyl)ethyl]amino]-4-pyrimidinyl]phenyl]sulfonyl]-2-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859516-63-5 CAPLUS

CN Piperazine, 1-[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]sulfonyl]-2-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859516-64-6 CAPLUS

CN Phenol, 4-[2-[[4-[2-methyl-5-[(2S)-2-methyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859516-65-7 CAPLUS

CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[2-methyl-5-[(2S)-2-methyl-1-piperazinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859516-66-8 CAPLUS

CN Phenol, 4-[2-[[4-[2-methyl-3-[(2S)-2-methyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859516-67-9 CAPLUS

CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[4-fluoro-3-[(2S)-2-methyl-1-piperazinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859516-68-0 CAPLUS

CN Phenol, 4-[2-[[4-[4-fluoro-3-[(2S)-2-methyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859516-69-1 CAPLUS


CN 2-Pyrimidinamine, 4-[4-fluoro-3-[(2S)-2-methyl-1-piperazinyl]methyl]phenyl]-N-[2-(3-fluorophenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 859516-71-5 CAPLUS

CN Phenol, 2-chloro-4-[2-[[4-[3-[[ethyl[2-(2-piperidinyl)ethyl]amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859516-73-7 CAPLUS

CN 2-Pyrimidinamine, 4-[3-[[ethyl[2-(2-piperidinyl)ethyl]amino]methyl]phenyl]-N-[2-(3-fluorophenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 859516-74-8 CAPLUS

CN Phenol, 2-chloro-4-[2-[[4-[3-[[[2-(2-pyridinyl)ethyl]amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859516-75-9 CAPLUS

CN Phenol, 2-chloro-4-[2-[[4-[3-[[[2-(3-pyridinyl)ethyl]amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859516-76-0 CAPLUS


CN Phenol, 2-chloro-4-[2-[[4-[3-[[[2-(4-pyridinyl)ethyl]amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859518-37-9 CAPLUS

CN Phenol, 2-chloro-4-[2-[[4-[3-[[ethyl (3S)-3-pyrrolidinylamino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859518-38-0 CAPLUS

CN Phenol, 2-chloro-4-[2-[[4-[5-[[[(2R,5R)-2,5-dimethyl-1-piperazinyl]methyl]-2-fluorophenyl]-2-pyrimidinyl]amino]ethyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 859518-39-1 CAPLUS

CN Phenol, 2-chloro-4-[2-[[4-[3-[[ethyl (3R)-3-pyrrolidinylamino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859518-40-4 CAPLUS


CN Phenol, 2-chloro-4-[2-[[4-[5-[[(2R,5S)-2,5-dimethyl-1-piperazinyl]methyl]-2-fluorophenyl]-2-pyrimidinyl]amino]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 859518-42-6 CAPLUS

CN Phenol, 4-[2-[[4-[3-[(ethyl-4-piperidinylamino)methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859518-44-8 CAPLUS


CN Phenol, 2-chloro-4-[2-[[4-[3-(1-piperazinylmethyl)phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859518-45-9 CAPLUS

CN Phenol, 4-[2-[[4-[2-fluoro-5-[(2S)-2-methyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859518-46-0 CAPLUS

Phenol, 4-[2-[[4-[3-[[[2R,5R]-2,5-dimethyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 859518-47-1 CAPLUS

Phenol, 4-[2-[[4-[3-[[ethyl (3S)-3-pyrrolidinylamino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859518-48-2 CAPLUS


CN Phenol, 4-[2-[[4-[3-[[ethyl(3R)-3-pyrrolidinylamino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859518-49-3 CAPLUS


CN Phenol, 3-[2-[[4-[3-[(ethyl-4-piperidinylamino)methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859518-50-6 CAPLUS

CN Phenol, 3-[2-[[4-[3-[[ethyl(3S)-3-pyrrolidinylamino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859518-51-7 CAPLUS

CN Phenol, 4-[2-[[4-[3-[[ethyl[(3R)-3-piperidinylmethyl]amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859518-52-8 CAPLUS

CN Phenol, 3-[2-[[4-[5-[[(2R,5S)-2,5-dimethyl-1-piperazinyl]methyl]-2-fluorophenyl]-2-pyrimidinyl]amino]ethyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 859518-53-9 CAPLUS

CN Phenol, 3-[2-[[4-[2-fluoro-5-[[(2S)-2-methyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859518-54-0 CAPLUS

CN Phenol, 3-[2-[[4-[3-[[ethyl[(3S)-3-piperidinylmethyl]amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859518-55-1 CAPLUS

CN Phenol, 4-[2-[[4-[3-[[ethyl[(2S)-2-pyrrolidinylmethyl]amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859518-56-2 CAPLUS


CN Phenol, 4-[2-[[4-[3-[[ethyl[(3S)-3-pyrrolidinylmethyl]amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859518-57-3 CAPLUS


CN Phenol, 4-[2-[[4-[3-[[cyclopropyl(1-methyl-4-piperidinyl)amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859518-58-4 CAPLUS

CN Phenol, 4-[2-[[4-[5-[(2R,5S)-2,5-dimethyl-1-piperazinyl]methyl]-2-fluorophenyl]-2-pyrimidinyl]amino]ethyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 859518-59-5 CAPLUS

CN Phenol, 3-[2-[[4-[3-[[ethyl[(3R)-3-pyrrolidinylmethyl]amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859518-60-8 CAPLUS


CN Phenol, 3-[2-[[4-[3-[[[(2S)-2-methyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859518-61-9 CAPLUS


CN Phenol, 4-[2-[[4-[3-[[2-(aminomethyl)-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859518-63-1 CAPLUS

CN Butanoic acid, 2-amino-4-[ethyl[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859518-64-2 CAPLUS

CN Phenol, 3-[2-[[4-[3-[[ethyl[(3S)-3-pyrrolidinylmethyl]amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859518-65-3 CAPLUS

CN Phenol, 4-[2-[[4-[3-[[ethyl[(2R)-2-pyrrolidinylmethyl]amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859518-66-4 CAPLUS

CN Methanesulfonamide, N-[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-[(2S)-2-pyrrolidinylmethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859518-67-5 CAPLUS


CN Phenol, 4-[2-[[4-[3-[[[(3R,4R)-3-methyl-4-piperidinyl]amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 859518-68-6 CAPLUS

CN Phenol, 4-[2-[[4-[3-(1-piperazinylmethyl)phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859518-69-7 CAPLUS

CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[5-[[(2R,5R)-2,5-

dimethyl-1-piperazinyl)methyl]-2-fluorophenyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 859518-70-0 CAPLUS

CN Phenol, 3-[2-[[4-[5-[[ethyl[(3S)-3-piperidinylmethyl]amino]methyl]-2-fluorophenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859518-71-1 CAPLUS

CN 2-Pyrimidinamine, 4-[3-[[ethyl[2-(2R)-2-pyrrolidinyethyl]amino]methyl]phenyl]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859518-72-2 CAPLUS


CN Phenol, 4-[2-[[4-[5-[(2R,5R)-2,5-dimethyl-1-piperazinyl]methyl]-2-methylphenyl]-2-pyrimidinyl]amino]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 859518-73-3 CAPLUS

CN Methanesulfonamide, N-[[3-[2-[[2-[4-(acetyloxy)phenyl]ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-(3-aminopropyl)- (9CI) (CA INDEX NAME)




RN 859518-74-4 CAPLUS

CN Phenol, 4-[2-[[4-[3-[(2,3-dimethyl-1-piperazinyl)methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859518-75-5 CAPLUS


CN Phenol, 3-[2-[[4-[3-[[ethyl[2-(1-piperazinyl)ethyl]amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859518-76-6 CAPLUS

CN Phenol, 4-[2-[[4-[3-[[[(1S)-2-hydroxy-1-methylethyl]amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859518-78-8 CAPLUS

CN D-Proline, 4-[ethyl[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]amino]-, methyl ester, (4R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 859518-79-9 CAPLUS


CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[3-[[ethyl[(3R)-3-piperidinylmethyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 859518-80-2 CAPLUS

CN Phenol, 4-[2-[[4-[3-[[ethyl[2-(1-piperazinyl)ethyl]amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859518-81-3 CAPLUS

CN Phenol, 4-[2-[[4-[3-[[1-(4-pyridinylmethyl)-4-piperidinyl]amino]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859518-82-4 CAPLUS


CN Phenol, 4-[2-[[4-[3-[[3-(ethylamino)-8-azabicyclo[3.2.1]oct-8-yl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859518-83-5 CAPLUS


CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[3-[[2,5-dimethyl-1-piperazinyl]methyl]phenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 859518-84-6 CAPLUS

CN 2-Piperazinepropanoic acid, 4-[[3-[2-[[2-(3-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 859518-85-7 CAPLUS


CN Phenol, 4-[2-[[4-[5-[(2-ethyl-1-piperazinyl)methyl]-2-methylphenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859518-86-8 CAPLUS

CN Phenol, 5-[2-[[4-[5-[(2R,5S)-2,5-dimethyl-1-piperazinyl]methyl]-2-fluorophenyl]-2-pyrimidinyl]amino]ethyl]-2-methoxy-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 859518-87-9 CAPLUS


CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[3-[[ethyl[(2S)-2-pyrrolidinylmethyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859518-88-0 CAPLUS


CN Phenol, 3-[2-[[4-[3-[[3-(ethylamino)-8-azabicyclo[3.2.1]oct-8-yl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859518-89-1 CAPLUS


CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[2-methoxy-5-[[2-(2-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859518-90-4 CAPLUS


CN 2-Piperazinepropanoic acid, 4-[[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 859518-92-6 CAPLUS


CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[3-[[ethyl[(3S)-3-pyrrolidinylmethyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859518-93-7 CAPLUS


CN Phenol, 4-[2-[[4-[3-[(4-amino-1-ethylbutyl)amino]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859518-94-8 CAPLUS

CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[2-fluoro-5-[[(2S)-2-methyl-1-piperazinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859518-96-0 CAPLUS

CN Methanesulfonamide, N-[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-[2-(2R)-2-pyrrolidinyethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859518-97-1 CAPLUS

CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[3-[[ethyl(3S)-3-pyrrolidinylamino]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859518-98-2 CAPLUS

CN Phenol, 3-[2-[[4-[5-[[(2R,5R)-2,5-dimethyl-1-piperazinyl]methyl]-2-methylphenyl]-2-pyrimidinyl]amino]ethyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 859518-99-3 CAPLUS


CN 2-Pyrimidinamine, 4-[3-[[ethyl (3S)-3-pyrrolidinylamino]methyl]phenyl]-N-[2-(3-fluorophenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 859519-00-9 CAPLUS

CN 2-Piperazinepropanoic acid, 1-[[3-[2-[[2-(3-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 859519-01-0 CAPLUS


CN Phenol, 4-[2-[[4-[4-methyl-3-(4-piperidinylamino)phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859519-02-1 CAPLUS

CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[3-[[ethyl[(3S)-3-piperidinylmethyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859519-03-2 CAPLUS

CN Methanesulfonamide, N-[[3-[2-[[2-(3,5-difluorophenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859519-04-3 CAPLUS


CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[5-[[ethyl[(3S)-3-piperidinylmethyl]amino]methyl]-2-fluorophenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859519-06-5 CAPLUS


CN 2-Piperazinepropanoic acid, 1-[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 859519-07-6 CAPLUS


CN 2-Pyrimidinamine, 4-[3-[[ethyl[(2S)-2-pyrrolidinylmethyl]amino]methyl]phenyl]-N-[2-(3-fluorophenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 859519-08-7 CAPLUS

CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[3-[(2,3-dimethyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 859519-09-8 CAPLUS

CN Phenol, 2-methoxy-5-[2-[[4-[3-[(2S)-2-methyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859519-10-1 CAPLUS

CN 2-Pyrimidinamine, 4-[3-[(ethyl-4-piperidinylamino)methyl]phenyl]-N-[2-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 859519-11-2 CAPLUS


CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[3-[[ethyl[2-(1-piperazinyl)ethyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 859519-12-3 CAPLUS


CN Phenol, 4-[2-[[4-[3-[[[2-(2R)-2-pyrrolidinylethyl]amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 859519-13-4 CAPLUS

CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[3-(1-piperazinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 859519-14-5 CAPLUS


CN 2-Piperazinecarboxylic acid, 4-[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 859519-15-6 CAPLUS


2-Pyrimidinamine, 4-[3-[[ethyl(3S)-3-pyrrolidinylamino]methyl]phenyl]-N-[2-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859519-16-7 CAPLUS


CN Methanesulfonamide, N-(3-aminopropyl)-N-[[3-[6-[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl)- (9CI) (CA INDEX NAME)



RN 859519-17-8 CAPLUS


CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[3-[[ethyl(2R)-2-pyrrolidinylmethyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 859519-18-9 CAPLUS


CN 2-Piperazinepropanoic acid, 4-[[3-[2-[[2-(3,5-difluorophenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 859519-19-0 CAPLUS


CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[3-[[[(3R,4R)-3-methyl-4-piperidinyl]amino]methyl]phenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 859519-20-3 CAPLUS


CN 2-Pyrimidinamine, 4-[3-[[2-(aminomethyl)-1-piperazinyl]methyl]phenyl]-N-[2-(3-fluorophenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 859519-21-4 CAPLUS


CN 2-Pyrimidinamine, 4-[3-[[ethyl (3R)-3-pyrrolidinylamino]methyl]phenyl]-N-[2-(3-fluorophenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 859519-22-5 CAPLUS

CN Phenol, 3-[2-[[4-[3-[(2,3-dimethyl-1-piperazinyl)methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859519-23-6 CAPLUS


CN 8-Azabicyclo[3.2.1]octan-3-amine, 8-[[3-[2-[[2-(3,5-difluorophenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 859519-24-7 CAPLUS


CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[5-[[(2R,5R)-2,5-dimethyl-1-piperazinyl]methyl]-2-methylphenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 859519-25-8 CAPLUS

CN 2-Pyrimidinamine, 4-[3-[[2-(aminomethyl)-1-piperazinyl]methyl]phenyl]-N-[2-(3,5-difluorophenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 859519-26-9 CAPLUS


CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[3-[(2-ethyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 859519-27-0 CAPLUS


CN Methanesulfonamide, N-[[3-[2-[[2-(3,5-difluorophenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-[(2S)-2-pyrrolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 859519-28-1 CAPLUS

CN Phenol, 4-[2-[[4-[3-[(1-propyl-4-piperidinyl)amino]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859519-29-2 CAPLUS


CN 2-Pyrimidinamine, N-[2-(3-fluorophenyl)ethyl]-4-[3-(1-piperazinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 859519-30-5 CAPLUS


CN Methanesulfonamide, N-[[3-[2-[[2-(3-fluorophenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-[(2S)-2-pyrrolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 859519-31-6 CAPLUS

CN Phenol, 3-[2-[[4-[5-[(2-ethyl-1-piperazinyl)methyl]-2-methylphenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 859519-33-8 CAPLUS


CN 2-Pyrimidinamine, N-[2-(3-fluorophenyl)ethyl]-4-[3-[(hexahydro-1H-1,4-diazepin-1-yl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 859519-34-9 CAPLUS


CN 2-Pyrimidinamine, N-[2-(3-fluorophenyl)ethyl]-4-[3-[[[(3R,4R)-3-methyl-4-piperidinyl]amino]methyl]phenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 859519-35-0 CAPLUS


CN Phenol, 4-[2-[[4-[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-pyrimidinyl]amino]ethyl]-, acetate (ester) (9CI) (CA INDEX NAME)



RN 859519-36-1 CAPLUS

CN Methanesulfonamide, N-[[3-[2-[[2-(3,5-difluorophenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-N-[2-(2R)-2-pyrrolidinylolethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859519-37-2 CAPLUS

CN 2H-Indol-2-one, 3,3-difluoro-1,3-dihydro-5-[2-[[4-[3-[[2-methyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859519-38-3 CAPLUS

CN 2-Pyrimidinamine, 4-[3-[[ethyl[2-(2R)-2-pyrrolidiny]ethyl]amino]methyl]phenyl]-N-[2-(3-fluorophenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859519-40-7 CAPLUS

CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[2-methyl-3-[[2-(2S)-2-methyl-1-piperazinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859519-41-8 CAPLUS


CN 2-Pyrimidinamine, 4-[3-[[ethyl (3R)-3-pyrrolidinylamino]methyl]phenyl]-N-[2-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 859519-42-9 CAPLUS

CN 2-Piperazinepropanoic acid, 1-[[3-[2-[[2-(3,5-difluorophenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 859519-43-0 CAPLUS


CN Phenol, 4-[2-[[2-[3-[(3-aminopropyl)ethylamino]methyl]phenyl]-5-fluoro-4-pyrimidinyl]amino]ethyl)- (9CI) (CA INDEX NAME)



RN 859519-44-1 CAPLUS


CN 1H-Indole-5-ethanamine, 3,7-dichloro-N-[4-[3-[[(2R,5R)-2,5-dimethyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 859519-45-2 CAPLUS


CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[5-[(2-ethyl-1-piperazinyl)methyl]-2-methylphenyl]- (9CI) (CA INDEX NAME)



RN 859519-46-3 CAPLUS

CN Phenol, 4-[2-[[4-[3-[[(2R,5S)-2-methyl-5-(trifluoromethyl)-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 859519-47-4 CAPLUS

CN Phenol, 4-[2-[[4-[3-[[(2R,5R)-2,5-dimethyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]-2-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 859519-48-5 CAPLUS

CN 2-Piperazinecarboxamide, 4-[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-5-methyl-, (2R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 859519-49-6 CAPLUS

CN 2-Piperazinecarboxamide, 4-[[3-[[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-5-methyl-N-1H-tetrazol-5-yl]-, (2R,5R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 859519-50-9 CAPLUS

CN 2-Piperazinecarboxamide, 4-[[3-[[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-5-methyl-N-1H-tetrazol-5-yl]-, (2R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 859519-51-0 CAPLUS

CN Phenol, 2-(1,1-dimethylethyl)-4-[2-[[4-[3-[[(2R,5R)-2,5-dimethyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 859519-52-1 CAPLUS

CN Phenol, 4-[2-[[4-[3-[[(2R,5R)-2,5-dimethyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]-2-(1-methylethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 859519-53-2 CAPLUS

CN Phenol, 4-[2-[[4-[3-[[(2R,5R)-2,5-dimethyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]-2-ethyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 859519-54-3 CAPLUS

CN Phenol, 5-[2-[[4-[3-[[(2R,5R)-2,5-dimethyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]-2-(methylsulfinyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 859519-55-4 CAPLUS

CN Phenol, 5-[2-[[4-[3-[(2R,5R)-2,5-dimethyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]-2-(methylsulfonyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 859519-56-5 CAPLUS

CN Sulfamic acid, 4-[2-[[4-[3-[(2R,5R)-2,5-dimethyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]-2-hydroxyphenyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 859519-57-6 CAPLUS

CN Sulfamic acid, 5-[2-[[4-[3-[(2R,5R)-2,5-dimethyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]-2-hydroxyphenyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 859519-58-7 CAPLUS

CN Phenol, 4-[2-[[4-[3-[(2R,5R)-2,5-dimethyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]-2-(methylsulfonyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 859519-59-8 CAPLUS

CN Phenol, 4-[2-[[4-[3-[(2R,5R)-2,5-dimethyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]-2-(methylsulfinyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 859519-60-1 CAPLUS

CN Benzenesulfonamide, 4-[2-[[4-[3-[(2R,5R)-2,5-dimethyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]-2-hydroxy-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 859519-61-2 CAPLUS

CN Benzenesulfonamide, 5-[2-[[4-[3-[(2R,5R)-2,5-dimethyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]-2-hydroxy-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 859519-62-3 CAPLUS

CN Benzenesulfinamide, 4-[2-[[4-[5-[(2R,5R)-2,5-dimethyl-1-piperazinyl]methyl]-2-fluorophenyl]-2-pyrimidinyl]amino]ethyl]-2-hydroxy-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 859519-63-4 CAPLUS

CN Phenol, 5-[2-[[4-[5-[[(2R,5R)-2,5-dimethyl-1-piperazinyl]methyl]-2-fluorophenyl]-2-pyrimidinyl]amino]ethyl]-2-(methylsulfinyl)-, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 859519-64-5 CAPLUS

CN Phenol, 5-[2-[[4-[5-[[[2R,5R]-2,5-dimethyl-1-piperazinyl]methyl]-2-fluorophenyl]-2-pyrimidinyl]amino]ethyl]-2-(methylsulfonyl)-, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 859519-65-6 CAPLUS

CN Sulfamic acid, 4-[2-[[4-[5-[(2R,5R)-2,5-dimethyl-1-piperazinyl]methyl]-2-fluorophenyl]-2-pyrimidinyl]amino]ethyl]-2-hydroxyphenyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 859519-66-7 CAPLUS

CN Sulfamic acid, 5-[2-[[4-[5-[(2R,5R)-2,5-dimethyl-1-piperazinyl]methyl]-2-fluorophenyl]-2-pyrimidinyl]amino]ethyl]-2-hydroxyphenyl ester, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 859519-67-8 CAPLUS

CN Benzenesulfinamide, 5-[2-[[4-[5-[(2R,5R)-2,5-dimethyl-1-piperazinyl]methyl]-2-fluorophenyl]-2-pyrimidinyl]amino]ethyl]-2-hydroxy-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 859519-68-9 CAPLUS

CN Phenol, 4-[2-[[4-[5-[(2R,5R)-2,5-dimethyl-1-piperazinyl]methyl]-2-fluorophenyl]-2-pyrimidinyl]amino]ethyl]-2-(methylsulfonyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 859519-69-0 CAPLUS

CN Phenol, 4-[2-[[4-[5-[[(2R,5R)-2,5-dimethyl-1-piperazinyl]methyl]-2-fluorophenyl]-2-pyrimidinyl]amino]ethyl]-2-(methylsulfinyl)-, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.



RN 859519-70-3 CAPLUS

CN Benzenesulfonamide, 4-[2-[[4-[5-[[(2R,5R)-2,5-dimethyl-1-piperazinyl]methyl]-2-fluorophenyl]-2-pyrimidinyl]amino]ethyl]-2-hydroxy-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 859519-71-4 CAPLUS

CN Benzenesulfonamide, 5-[2-[[4-[5-[[(2R,5R)-2,5-dimethyl-1-piperazinyl]methyl]-2-fluorophenyl]-2-pyrimidinyl]amino]ethyl]-2-hydroxy-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 859708-81-9 CAPLUS

CN Phenol, 4-[2-[[4-[3-[[(2S)-2-methyl-1-piperidinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859708-86-4 CAPLUS

CN Phenol, 4-[2-[[4-[5-[(2S,5S)-2,5-dimethyl-1-piperazinyl]methyl]-2-fluorophenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859708-88-6 CAPLUS

CN Phenol, 4-[2-[[4-[5-[(2R,5R)-2,5-dimethyl-1-piperazinyl]methyl]-2-fluorophenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859708-91-1 CAPLUS

CN Phenol, 3-[2-[[4-[5-[[(2R,5R)-2,5-dimethyl-1-piperazinyl]methyl]-2-fluorophenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859708-93-3 CAPLUS

CN Phenol, 3-[2-[[4-[5-[[(2S,5S)-2,5-dimethyl-1-piperazinyl]methyl]-2-fluorophenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859708-95-5 CAPLUS

CN Phenol, 4-[2-[[4-[3-[[ethyl[(3R)-3-pyrrolidinylmethyl]amino]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859708-97-7 CAPLUS

CN Phenol, 4-[2-[[4-[3-[[[(2S,5R)-2,5-dimethyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859708-99-9 CAPLUS

CN Phenol, 4-[2-[[4-[3-[[(2R,5S)-2,5-dimethyl-1-piperazinyl]methyl]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859709-01-6 CAPLUS

CN Phenol, 5-[2-[[4-[5-[[[2S,5S]-2,5-dimethyl-1-piperazinyl]methyl]-2-fluorophenyl]-2-pyrimidinyl]amino]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859709-04-9 CAPLUS

CN Phenol, 5-[2-[[4-[5-[(2R,5R)-2,5-dimethyl-1-piperazinyl]methyl]-2-fluorophenyl]-2-pyrimidinyl]amino]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859709-07-2 CAPLUS

CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[3-[(2S,5R)-2,5-dimethyl-1-piperazinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859712-89-3 CAPLUS

CN 2-Pyrimidinamine, N-[2-(3,5-difluorophenyl)ethyl]-4-[3-[[(2R,5S)-2,5-dimethyl-1-piperazinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 859516-87-3P 859517-02-5P 859517-03-6P

859517-05-8P, 4-[2-[4-(3-(Dimethoxymethyl)-phenyl)pyrimidin-2-ylamino]ethyl]phenol 859517-06-9P 859517-17-2P,
1-(3-[2-[[2-(4-Methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenyl)ethanone
859517-31-0P 859517-35-4P 859517-36-5P


859517-38-7P 859517-40-1P 859517-47-8P

859517-55-8P 859517-82-1P 859517-83-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of aryl pyrimidines as protein kinase C inhibitors)

RN 859516-87-3 CAPLUS

CN Benzoic acid, 3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)


RN 859517-02-5 CAPLUS

CN Phenol, 4-[2-[[4-(3-aminophenyl)-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859517-03-6 CAPLUS

CN Phenol, 4-[2-[[4-[3-[(3-pyridinylmethyl)amino]phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859517-05-8 CAPLUS

CN Phenol, 4-[2-[[4-[3-(dimethoxymethyl)phenyl]-2-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 859517-06-9 CAPLUS

CN Benzaldehyde, 3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 859517-17-2 CAPLUS

CN Ethanone, 1-[3-[2-[[2-(4-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 859517-31-0 CAPLUS


CN Ethanone, 1-[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 859517-35-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[ethyl[[3-[2-[[2-(3-fluorophenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859517-36-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[ethyl[[3-[2-[[2-(3-fluorophenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 859517-38-7 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[[[3-[2-[[2-(3-fluorophenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-3-methyl-, 1,1-dimethylethyl ester, (3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 859517-40-1 CAPLUS


CN Carbamic acid, [[3-[2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl](1-methylethyl)-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)



RN 859517-47-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[3-[5-fluoro-2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— OBU-t


RN 859517-55-8 CAPLUS

CN Phenol, 4-[2-[[4-[3-[(ethyl-4-piperidinylamino)methyl]phenyl]-2-pyrimidinyl]amino]ethyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 859517-82-1 CAPLUS

CN Carbamic acid, (1,1-dimethylethyl)[[3-[2-[[2-(4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)



RN 859517-83-2 CAPLUS

CN Carbamic acid, [[3-[2-[[2-(3-chloro-4-hydroxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]methyl](1,1-dimethylethyl)-, 2-propenyl ester (9CI)
(CA INDEX NAME)



L10 ANSWER 18 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:395285 CAPLUS
 DN 142:430294
 TI Preparation of pyrimidine compounds as antistress agents
 IN Ohmoto, Kazuyuki; Kato, Masashi; Katsumata, Seishi; Manako, Junichiro
 PA Ono Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 133 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005040135	A1	20050506	WO 2004-JP16056	20041022
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI JP 2003-365237 A 20031024

OS MARPAT 142:430294

AB Title compds. I [ring A = (un)substituted cyclic group; Q = (un)substituted alkyl; (un)substituted cyclic group; ring D = (un)substituted cyclic group; W = bond, spacer with a principal chain of 1 to 4 atoms; Y = spacer with a principal chain of 1 to 4 atoms] were prepared. For example, benzyloxyacetylation of 4-phenyl-2-aminopyrimidine, e.g., prepared from acetophenone in 2 steps, afforded compound II. In MBR (mitochondrial benzodiazepine receptor) binding assays, the K_i value of compound III was 0.01 $\mu\text{mol/L}$. Compounds I are claimed useful for the treatment of depression, asthma etc. Formulations are given.


IT 850925-11-0P 850925-24-5P 850925-25-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine compds. for treatment of depression, asthma etc.)

RN 850925-11-0 CAPLUS


CN Methanesulfonamide, N-[4-[2,5-bis(difluoromethoxy)phenyl]-2-pyrimidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 850925-24-5 CAPLUS


CN 2-Pyrimidinamine, 4-[2,5-bis(2,2,2-trifluoroethoxy)phenyl]-N-methyl-N-

(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 850925-25-6 CAPLUS

CN 2-Pyrimidinamine, 4-[2,5-bis(2,2,2-trifluoroethoxy)phenyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RE.CNT 116 THERE ARE 116 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 19 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:394833 CAPLUS

DN 142:447114

TI A preparation of (indol-1-yl)acetate derivatives, useful as PPAR activators

IN Ackermann, Jean; Aebi, Johannes; Binggeli, Alfred; Grether, Uwe; Hirth, Georges; Kuhn, Bernd; Maerki, Hans-Peter; Meyer, Markus; Mohr, Peter; Wright, Matthew Blake

PA Hoffmann-La Roche Inc., USA

SO U.S. Pat. Appl. Publ., 39 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005096353	A1	20050505	US 2004-978144	20041029
	US 6995263	B2	20060207		
	WO 2005049606	A1	20050602	WO 2004-EP12197	20041028
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI EP 2003-104083 A 20031105

OS CASREACT 142:447114; MARPAT 142:447114


AB The invention relates to a preparation of (indol-1-yl)acetate derivs. R1OC(O)CH(R2)(R3)R4 [wherein: R1, R2, and R3 are independently selected from H or alkyl; R4 is a derivative of indol-1-yl], useful as PPAR activators. For instance, (indol-1-yl)acetate I [IC50 (μmol/L): PPARα - 1.32, PPARγ - >10, PPARδ - 0.083] was prepared via etherification of Et (5-hydroxyindol-1-yl)acetate by (chloromethyl)pyrimidine derivative II and subsequent hydrolysis.

IT **851069-70-0P**, (5-[Methyl-[4-methyl-2-(4-trifluoromethylphenyl)pyrimidin-5-ylmethyl]amino]indol-1-yl)acetic acid
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of (indol-1-yl)acetate derivs. useful as PPAR activators)

RN 851069-70-0 CAPLUS

CN 1H-Indole-1-acetic acid, 5-[methyl[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-pyrimidinyl]methyl]amino]- (9CI) (CA INDEX NAME)



IT **851069-76-6P**, (5-[Methyl-[4-methyl-2-(4-trifluoromethylphenyl)pyrimidin-5-ylmethyl]amino]indol-1-yl)acetic acid methyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of (indol-1-yl)acetate derivs. useful as PPAR activators)
 RN 851069-76-6 CAPLUS
 CN 1H-Indole-1-acetic acid, 5-[methyl[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-pyrimidinyl]methyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 20 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:394829 CAPLUS
 DN 142:463605
 TI Preparation aryloxyacetic acids and related compounds as PPAR δ and PPAR α agonists
 IN Ackermann, Jean; Aebi, Johannes; Binggeli, Alfred; Grether, Uwe; Hirth, Georges; Kuhn, Bernd; Maerki, Hans-Peter; Meyer, Markus; Mohr, Peter; Wright, Matthew Blake
 PA Switz.
 SO U.S. Pat. Appl. Publ., 89 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005096337	A1	20050505	US 2004-978155	20041029
	AU 2004291262	A1	20050602	AU 2004-291262	20041028
	WO 2005049573	A1	20050602	WO 2004-EP12217	20041028
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	EP 2003-104081	A	20031105		
	EP 2004-100759	A	20040226		
	WO 2004-EP12217	W	20041028		

OS MARPAT 142:463605

AB Title compds. I [X = O, S, CH₂; R₁ = H, alkyl; R₂ = H, alkyl with provisos; R₃ = H, alkyl; R₄, R₈ = H, alkyl, cycloalkyl, etc.; R₅, R₆, R₇ = H, alkyl, cycloalkyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, saponification of Et ester II (Z = OEt), afforded acid II (Z = OH) as a light yellow solid. In PPAR α receptor binding assays, 3-examples of compds. I exhibited IC₅₀ values ranging from 0.013-0.289 μ mol/l. Compds. I are claimed to be useful for the treatment of diseases modulated by PPAR δ and PPAR α agonist.


IT 851506-16-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation aryloxyacetic acids and related compds. as PPAR δ and PPAR α agonists)

RN 851506-16-6 CAPLUS

CN Acetic acid, [4-[[[4-cyclopropyl-2-[4-(trifluoromethyl)phenyl]-5-pyrimidinyl)methyl]methylamino]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




IT **851507-63-6P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation aryloxyacetic acids and related compds. as PPAR α and PPAR γ agonists)

RN 851507-63-6 CAPLUS

CN Acetic acid, [4-[[[4-cyclopropyl-2-[4-(trifluoromethyl)phenyl]-5-pyrimidinyl]methyl]methylamino]-2-methylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)



L10 ANSWER 21 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:371230 CAPLUS
 DN 142:430289
 TI Preparation of pyrimidine compounds as mixed lymphocyte reaction (MLR) inhibitors
 IN Tsuruoka, Hiroyuki; Matsuda, Akihisa; Sugano, Yuichi; Tatsuta, Toru
 PA Sankyo Company, Limited, Japan
 SO PCT Int. Appl., 350 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005037801	A1	20050428	WO 2004-JP15955	20041021
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2005145956	A2	20050609	JP 2004-302344	20041018
PRAI	JP 2003-360967	A	20031021		
OS	MARPAT 142:430289				

AB Disclosed is a pyrimidine derivative with excellent MLR inhibitory effect or a pharmacol. acceptable salt thereof. Pyrimidine derivs. represented by the general formula (I) or pharmacol. acceptable salts thereof [R1 = lower alkyl; R2 = each (un)substituted aryl or heterocyclyl; A = NH, O; R3 = H, lower alkyl, heterocyclyl, aryl, heterocyclyl, -NHR6 (wherein R6 = lower alkyl, cycloalkyl-lower alkyl, aralkyl, each (un)substituted cycloalkyl, aryl, or heterocyclyl); R4 = H, lower alkyl, lower alkoxy, cycloalkyl-lower alkyl, aralkyl, each (un)substituted aryl or heterocyclyl; provided that R3 = R4 ≠ H; R5 = H, halo, lower alkyl, cycloalkyl, (un)substituted heterocyclyl, NR7R8, OR7 (wherein R7, R8 = H, cycloalkyl, (un)substituted aryl or lower alkyl)] are prepared These compds. exhibit excellent MLR inhibitory effect and are useful as inhibitors of allograft rejection in bone marrow and organ transplant or for the prevention and/or treatment of inflammatory diseases, organ-specific or organ-nonspecific autoimmune diseases, allergic diseases, chronic rheumatism, multiple sclerosis, inflammatory bowel disease, diabetes, glomerulonephritis, primary biliary liver cirrhosis, chronic active hepatitis, pernicious anemia, chronic thyroiditis, atrophic gastritis, myasthenia gravis, psoriasis, Sjogren's syndrome, systemic lupus erythematosus, rhinitis, asthma, or atopic dermatitis. Thus, 0.1 mmol 4-hydrazino-2,6-bis(2-methoxyphenylamino)pyrimidine was dissolved in 1 mL ethanol, treated with 0.1 mmol 4-acetylpyridine, and stirred for 18 h to give 4-[N'-[1-(pyridin-4-yl)ethylidene]hydrazino]-2,6-bis(2-methoxyphenylamino)pyrimidine. N-methyl-4-[1-[[5-phenyl-2-phenylamino-6-[4-(pyridin-4-yl)pyrazol-1-yl]pyrimidin-4-yl]hydrazono]ethyl]benzenesulfonamide (II) inhibited MLR in human peripheral hemolymphocyte offered from two healthy people with IC50 of 1.0 ng/mL.


IT 850757-99-2P 850758-00-8P 850758-01-9P
 850758-06-4P 850758-07-5P 850758-08-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine compds. as mixed lymphocyte reaction (MLR) inhibitors)


RN 850757-99-2 CAPLUS

CN 4(1H)-Pyrimidinone, 6-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-5-phenyl-2-(phenylamino)-, [1-(4-pyridinyl)ethylidene]hydrazone (9CI) (CA INDEX NAME)




RN 850758-00-8 CAPLUS

CN Benzenesulfonamide, 4-[1-[[6-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-5-phenyl-2-(phenylamino)-4-pyrimidinyl]hydrazono]ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 850758-01-9 CAPLUS

CN 4(1H)-Pyrimidinone, 6-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-5-phenyl-2-(phenylamino)-, [1-[4-(methylsulfonyl)phenyl]ethylidene]hydrazone (9CI) (CA INDEX NAME)




RN 850758-06-4 CAPLUS

CN 4(1H)-Pyrimidinone, 6-[[3-(3,4-dimethoxyphenyl)methyl]amino]-5-phenyl-2-(phenylamino)-, [1-(4-pyridinyl)ethylidene]hydrazone (9CI) (CA INDEX NAME)




RN 850758-07-5 CAPLUS

CN Benzenesulfonamide, 4-[1-[[6-[[[(3,4-dimethoxyphenyl)methyl]amino]-5-phenyl-2-(phenylamino)-4-pyrimidinyl]hydrazone]ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 850758-08-6 CAPLUS

CN 4(1H)-Pyrimidinone, 6-[[[(3,4-dimethoxyphenyl)methyl]amino]-5-phenyl-2-(phenylamino)-, [1-[4-(methylsulfonyl)phenyl]ethylidene]hydrazone (9CI) (CA INDEX NAME)




IT 850760-30-4P 850760-57-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidine compds. as mixed lymphocyte reaction (MLR) inhibitors)


RN 850760-30-4 CAPLUS

CN 4(1H)-Pyrimidinone, 6-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-5-phenyl-2-(phenylamino)-, hydrazone (9CI) (CA INDEX NAME)



RN 850760-57-5 CAPLUS

CN 4(1H)-Pyrimidinone, 6-[[[(3,4-dimethoxyphenyl)methyl]amino]-5-phenyl-2-(phenylamino)-, hydrazone (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 22 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:340499 CAPLUS

DN 142:392564

TI Preparation of pyridopyrimidine-fused steroids anticoccidial agents via cyclocondensation

IN Nagamatsu, Tomofumi

PA Okayama University, Japan

SO Jpn. Kokai Tokkyo Koho, 25 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2005104868	A2	20050421	JP 2003-337640	20030929
PRAI	JP 2003-337640		20030929		

OS MARPAT 142:392564

AB Pyridopyrimidine-fused steroids, e.g. of formula I [R1 = H, alkyl; R2 = alkyl, (substituted) Ph, etc.], are prepared via cyclocondensation. The compds. are useful as anticoccidial agents (no data). Thus, II was prepared from 6-(methylamino)-2-phenyl-4(1H)pyrimidinone and 2-(hydroxymethylene)dihydrotestosterone in 76% yield.


IT **66487-67-0**

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of pyridopyrimidine-fused steroids as anticoccidial agents)

RN 66487-67-0 CAPLUS

CN 4(1H)-Pyrimidinone, 2-phenyl-6-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



L10 ANSWER 23 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:329965 CAPLUS
 DN 143:41343
 TI A small-molecule agonist of the Wnt signaling pathway
 AU Liu, Jun; Wu, Xu; Mitchell, Brian; Kintner, Chris; Ding, Sheng; Schultz, Peter G.
 CS Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
 SO Angewandte Chemie, International Edition (2005), 44(13), 1987-1990
 CODEN: ACIEF5; ISSN: 1433-7851
 PB Wiley-VCH Verlag GmbH & Co. KGaA
 DT Journal
 LA English
 OS CASREACT 143:41343
 AB A new tool for developmental biol.: A screen of combinatorial chemical libraries identified the 2-amino-4,6-disubstituted pyrimidine 1 as a dose-dependent agonist of Wnt signaling. Tadpoles that developed from embryos treated with 1 had substantial head defects (see right-hand image; left=control). Compound 1 appears to mimic the effects of a Wnt ligand in a Xenopus model and may be a useful tool in the study of physiol. processes that involve the Wnt pathway.
 IT **853220-52-7P**
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (identification of substituted pyrimidine compound as small-mol. agonist of Wnt signaling pathway in human cells and Xenopus model)
 RN 853220-52-7 CAPLUS
 CN 2,4-Pyrimidinediamine, N4-(1,3-benzodioxol-5-ylmethyl)-6-(3-methoxyphenyl)-(9CI) (CA INDEX NAME)



RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 24 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:300435 CAPLUS

DN 142:373859

TI Preparation of pyrimidine and pyridine derivatives useful as HMG-CoA reductase inhibitors

IN Ahmad, Saleem; Robl, Jeffrey A.; Ngu, Khehyong

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 103 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005030758	A1	20050407	WO 2004-US31212	20040922
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005085497	A1	20050421	US 2004-946055	20040921
	EP 1667997	A1	20060614	EP 2004-784885	20040922
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI	US 2003-505893P	P	20030925		
	WO 2004-US31212	W	20040922		

OS MARPAT 142:373859

AB Title compds. I [X = N, CR5; R1-2 = H, alkyl, alkoxyalkyl, etc.; R3 = (hetero)aryl, cycloalkyl, etc.; R4 = H, (cyclo)alkyl, haloalkyl, etc.; R5 = H, alkyl; Z = hydroxyalkyl, etc.] are prepared For instance, II is prepared in 5 steps from a substituted pyrimidine, 2-methyl-2H-[1,2,4]triazol-3-ylamine, and a prior art homochiral dihydroxy acetone derivative I are HMG-CoA reductase inhibitors and are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, dyslipidemia, hormone replacement therapy, hypercholesterolemia, hypertriglyceridemia and atherosclerosis as well as Alzheimer's disease and osteoporosis [no data].

IT 849469-56-3P 849470-51-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of pyrimidine and pyridine derivs. useful as HMG-CoA reductase inhibitors)

RN 849469-56-3 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-2-[[[4-methoxyphenyl)methyl](1-methyl-1H-pyrazol-5-yl)amino]-6-(1-methylethyl)-5-pyrimidinyl]-3,5-dihydroxy-, monosodium salt, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




● Na

RN 849470-51-5 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-2-[[(4-methoxyphenyl)methyl] (1-methyl-1H-pyrazol-5-yl)amino]-6-(1-methylethyl)-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



IT 849470-74-2P 849470-76-4P 849470-78-6P


849470-80-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidine and pyridine derivs. useful as HMG-CoA reductase inhibitors)


RN 849470-74-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-fluorophenyl)-2-[[(4-methoxyphenyl)methyl] (1-methyl-1H-pyrazol-5-yl)amino]-6-(1-methylethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 849470-76-4 CAPLUS

CN 5-Pyrimidinemethanol, 4-(4-fluorophenyl)-2-[[[4-methoxyphenyl)methyl](1-methyl-1H-pyrazol-5-yl)amino]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 849470-78-6 CAPLUS

CN 5-Pyrimidinecarboxaldehyde, 4-(4-fluorophenyl)-2-[[[4-methoxyphenyl)methyl](1-methyl-1H-pyrazol-5-yl)amino]-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 849470-80-0 CAPLUS

CN 2H-Pyran-2-one, 6-[(1E)-2-[4-(4-fluorophenyl)-2-[[4-methoxyphenyl)methyl](1-methyl-1H-pyrazol-5-yl)amino]-6-(1-methylethyl)-5-pyrimidinyl]ethenyl]tetrahydro-4-hydroxy-, (4S,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 25 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:260034 CAPLUS

DN 142:336376

TI Preparation of pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases

IN Choidas, Axel; Backes, Alexander; Cotten, Matt; Engkvist, Ola; Felber, Beatrice; Freisleben, Achim; Godl, Klaus; Greff, Zoltan; Habenberger, Peter; Hafenbradl, Doris; Hartung, Christian; Herget, Thomas; Hoppe, Edmund; Klebl, Bert; Missio, Andrea; Mueller, Gerhard; Schwab, Wilfried; Zech, Birgit; Bravo, Jose; Harris, John; Le, Joelle; Macritchie, Jackie; Savic, Vladimir; Sherborne, Brad; Simpson, Don; Simpson, Don

PA Axxima Pharmaceuticals AG, Germany

SO PCT Int. Appl., 211 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005026129	A1	20050324	WO 2004-EP10353	20040915
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	EP 2003-20888	A	20030915		
	US 2003-504527P	P	20030922		
	EP 2004-10308	A	20040430		
	US 2004-569806P	P	20040512		

OS MARPAT 142:336376


AB The invention is related to the preparation of title compds. I, and/or stereoisomeric forms and/or pharmaceutically acceptable salts [wherein R1 = H, (un)substituted alk(en/yn)yl; R2, R4 = independently H, F, Cl, Br, I, CN, NH2, NO2, (un)substituted alk(en/yn)yl; R3 = F, Cl, Br, I, (un)substituted hetero/aryl, etc.; X = R5-[LR6]m; R5 = (un)substituted hetero/aryl, heterocyclyl, cycloalkyl, etc.; R6 = H, (un)substituted alkyl, hetero/aryl, heterocyclyl, etc.; L = NRSO2, NRSO; R = H, (un)substituted alkyl, SO2-alkyl, etc.] as protein kinase inhibitors for use in the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunol. diseases, autoimmune diseases, bipolar and clin. disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke. The invention is also related to a medium comprising at least one of compds. I in an immobilized form and its use for enriching, purifying and/or depleting nucleotide binding proteins which bind to the immobilized I. General preparation procedures and 5 individual synthetic examples are given. I have an inhibitory effect on the protein kinase activity of various protein kinases, such as Abl, CDK1, CDK5, etc. Selected I had an inhibitory effect on CDK9 and CDK2 with IC50 values in the range of 1 to 1000 nM. I were potent inhibitors of HIV and HCMV replication in cell cultures; for example II showed inhibition of HCMV replication in HFF

cells.


IT **848638-78-8P**, [6-(2-Methoxyphenyl)pyrimidin-4-yl](4-phenoxybenzyl)amine **848638-97-1P**, 4-[[6-(2-Methoxyphenyl)pyrimidin-4-ylamino]methyl]benzenesulfonamide **848639-71-4P**, (4-Methylsulfonylbenzyl)[6-(2-methoxyphenyl)pyrimidin-4-yl]amine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of 4,6-disubstituted aminopyrimidines as modulators of protein kinases)
 RN 848638-78-8 CAPLUS
 CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[(4-phenoxyphenyl)methyl]- (9CI)
 (CA INDEX NAME)



RN 848638-97-1 CAPLUS
 CN Benzenesulfonamide, 4-[[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 848639-71-4 CAPLUS
 CN 4-Pyrimidinamine, 6-(2-methoxyphenyl)-N-[[4-(methylsulfonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 26 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:120896 CAPLUS

DN 142:198096

TI Preparation of 2-acyl-4-amino-5-arylpyrimidines as pesticides and fungicides.

IN Schwoegler, Anja; Gewehr, Markus; Mueller, Bernd; Grote, Thomas; Grammenos, Wassilios; Tormo I. Blasco, Jordi; Gypser, Andreas; Rheinheimer, Joachim; Blettner, Carsten; Schaefer, Peter; Schieweck, Frank; Wagner, Oliver; Stierl, Reinhard; Schoefl, Ulrich; Strathmann, Siegfried; Scherer, Maria

PA BASF Aktiengesellschaft, Germany

SO PCT Int. Appl., 79 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012261	A1	20050210	WO 2004-EP7877	20040715
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004261373	A1	20050210	AU 2004-261373	20040715
CA 2532718	AA	20050210	CA 2004-2532718	20040715
EP 1651618	A1	20060503	EP 2004-741053	20040715
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI DE 2003-10333857	A	20030724		
DE 2003-10357714	A	20031209		
WO 2004-EP7877	W	20040715		

OS MARPAT 142:198096


AB Title compds. [I; n = 1-5; L = halo, cyano, cyanato, alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy, cycloalkyl, cycloalkoxy, etc.; R1, R2 = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, halocycloalkyl; R1R2N = atoms to form 5-6 membered (substituted) heterocyclyl; R3 = halo, cyano, alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkenyloxy, alkynyloxy, alkylthio, etc.; R4 = CONHXRa, C(ORb):NXRa; X = bond, CO, CONH, CO2, O, imino, etc.; Ra = H, alkyl, alkenyl, alkynyl, PhCH2; Rb = H, alkyl, alkenyl, alkynyl], were prepared Thus, (S)-4-chloro-6-(2,2,2-trifluoro-1-methylethylamino)-5-(2,4,6-trifluorophenyl)pyrimidine-2-carbonitrile was stirred with K2CO3 and H2O2 in Me2SO at 10°-room temperature to give (S)-4-chloro-6-(2,2,2-trifluoro-1-methylethylamino)-5-(2,4,6-trifluorophenyl)pyrimidine-2-carboxamide. The latter at 250 ppm on tomatoes gave complete protection against Phytophthora infestans.

IT 838838-75-8P 838838-77-0P


RL: AGR (Agricultural use); BSU (Biological study, unclassified); BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of acylaminoarylpyrimidines as pesticides and fungicides)

RN 838838-75-8 CAPLUS


CN 2-Pyrimidinecarboxamide, 4-chloro-5-(2-chloro-4-fluorophenyl)-6-
[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)

RN 838838-77-0 CAPLUS

CN 2-Pyrimidinecarboxamide, 4-chloro-5-(2,4-difluorophenyl)-6-
[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L10 ANSWER 27 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:120774 CAPLUS
 DN 142:194227
 TI Synthesis of 2,4-bis(alkylamino)pyrimidines and their use as
 antimicrobials
 IN Marquais-Bienewald, Sophie; Hoelzl, Werner; Preuss, Andrea; Mehlin,
 Andreas
 PA Ciba Specialty Chemicals Holding Inc., Switz.
 SO PCT Int. Appl., 38 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005011758	A2	20050210	WO 2004-EP51516	20040716
	WO 2005011758	A3	20050428		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1648524	A2	20060426	EP 2004-766240	20040716
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
PRAI	EP 2003-102296	A	20030725		
	WO 2004-EP51516	W	20040716		
OS	MARPAT 142:194227				
AB	Provided are various 2,4-bis(alkylamino)pyrimidines and their use as antimicrobials. The synthesized compds. were demonstrated to have antimicrobial activity against bacteria such as Staphylococcus aureus and Escherichia coli as well as fungi such as Candida albicans and Aspergillus niger. The intended use of these 2,4-bis(alkylamino)pyrimidines are as biocides or preservatives in numerous products such as paints, textiles, and plastics. Some of the compds. may also find use in cosmetic formulations or in mouthwashes.				
IT	838903-20-1 838903-22-3 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (synthesis of 2,4-bis(alkylamino)pyrimidines and their use as antimicrobials)				
RN	838903-20-1 CAPLUS				
CN	2,4-Pyrimidinediamine, N2,N2-dimethyl-6-phenyl-N4-(2-phenylethyl)- (9CI) (CA INDEX NAME)				



RN 838903-22-3 CAPLUS

CN 2,4-Pyrimidinediamine, N2-octyl-6-phenyl-N4-(2-phenylethyl)- (9CI) (CA INDEX NAME)




IT **838902-75-3P**


RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis of 2,4-bis(alkylamino)pyrimidines and their use as antimicrobials)

RN 838902-75-3 CAPLUS


CN 2,4-Pyrimidinediamine, N2,6-diphenyl-N4-(phenylmethyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 28 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:93051 CAPLUS
 DN 142:316792
 TI Efficient conversion of Biginelli 3,4-dihydropyrimidin-2(1H)-one to
 pyrimidines via PyBroP-mediated coupling
 AU Kang, Fu-An; Kodah, Jason; Guan, Qunying; Li, Xiaobing; Murray, William V.
 CS Johnson Johnson Pharmaceutical Research and Development, LLC, Raritan, NJ,
 08869, USA
 SO Journal of Organic Chemistry (2005), 70(5), 1957-1960
 CODEN: JOCEAH; ISSN: 0022-3263
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 142:316792
 AB An efficient two-step procedure to convert the Biginelli
 3,4-dihydropyrimidin-2(1H)-one to various multifunctionalized pyrimidines,
 e.g., I, is described. The Biginelli 3,4-dihydropyrimidin-2(1H)-one
 underwent Kappe dehydrogenation followed by a mild PyBroP-mediated
 coupling with C, N, O, and S nucleophiles, which provided a readily
 accessible multifunctionalized pyrimidine template for diversity-oriented
 synthesis.
 IT **848301-51-9P 848301-52-0P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of pyrimidines via Biginelli reaction of benzaldehyde with
 malonate and urea followed by Kappe dehydration, and PyBroP-mediated
 coupling with nucleophiles)
 RN 848301-51-9 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-methyl-6-phenyl-2-[(phenylmethyl)amino]-,
 methyl ester (9CI) (CA INDEX NAME)



RN 848301-52-0 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-methyl-2-[methyl(phenylmethyl)amino]-6-
 phenyl-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 29 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:71173 CAPLUS

DN 142:176866

TI Preparation of biaryl piperazinyl-pyridine analogues as capsaicin receptor modulators

IN Bakthavatchalam, Rajagopal; Blum, Charles A.; Brielmann, Harry; Chenard, Bertrand L.; De Lombaert, Stephane; Hodgetts, Kevin J.; Hutchison, Alan; Yoon, Taeyoung; Zheng, Xiaozhang

PA Neurogen Corporation, USA

SO PCT Int. Appl., 381 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005007648	A2	20050127	WO 2004-US23064	20040716
	WO 2005007648	A3	20050324		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004257289	A1	20050127	AU 2004-257289	20040716
	CA 2531619	AA	20050127	CA 2004-2531619	20040716
	EP 1644358	A2	20060412	EP 2004-778532	20040716
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
PRAI	US 2003-488564P	P	20030716		
	US 2003-516135P	P	20031031		
	WO 2004-US23064	W	20040716		

OS MARPAT 142:176866

AB The title compds. I [Ar2 = (un)substituted Ph, 6-membered aromatic heterocycle; X, Y, Z = CRx, N (at least one of X, Y and Z = N); K, J, F = N, CH or carbon substituted with R1; Rx = H, alkyl, NH2, CN, mono or dialkylamino; R1 = halo, OH, NH2, CN, etc.; R3 = H, halo, phenylalkyl, cycloalkylalkyl, etc.; R4 = H, alkyl, haloalkyl, oxo], useful for treating conditions related to capsaicin receptor activation, were prepared E.g., a 2-step synthesis of II, starting from 2,4,6-trichloropyrimidine and morpholine, was given. The compds. I were evaluated for agonist and antagonist capsaicin receptor activity (data given). Pharmaceutical compns. and methods for using compds. I to treat disorders related to capsaicin receptor activation (pain, asthma, etc.), are provided, as are methods for using such ligands, for receptor localization studies.

IT 833462-80-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of biaryl piperazinyl-pyridine analogs as capsaicin receptor modulators)

RN 833462-80-9 CAPLUS

CN 2-Pyrimidinamine, 4-(3-chlorophenyl)-N-(cycloheptylmethyl)-N-(2-

phenylethyl)-6-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI)
(CA INDEX NAME)



L10 ANSWER 30 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:29315 CAPLUS

DN 142:114092

TI Preparation of pyrimidines as modulators of voltage-gated ion channels

IN Wilson, Dean Mitchell; Martinborough, Esther; Neubert, Timothy Donald; Termin, Andreas Peter; Gonzales, Jesus E., III; Zimmermann, Nicole

PA Vertex Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 195 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005003099	A2	20050113	WO 2004-US21440	20040702
	WO 2005003099	A3	20050512		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004253962	A1	20050113	AU 2004-253962	20040702
	CA 2531061	AA	20050113	CA 2004-2531061	20040702
	US 2005049247	A1	20050303	US 2004-884865	20040702
	EP 1638955	A2	20060329	EP 2004-777512	20040702
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI	US 2003-484362P	P	20030702		
	US 2003-500200P	P	20030904		
	WO 2004-US21440	W	20040702		

OS MARPAT 142:114092

AB The title compds. [I; R5 = COR3, CO2R3, or R5'; R5' = CONH2 and derivs., SO2H and derivs., CON(CN)H and derivs., etc.; R1, R2 = independently H, (un)substituted aliphatic, 5-6-membered aryl ring containing 0-5 heteroatoms,

or

a 3-7-membered saturated or partially unsatd. ring containing 0-3 heteroatoms;

or

R1NR2 = (un)substituted 3-8-membered heterocyclyl or heteroaryl containing 1-3 heteroatoms; A = (un)substituted 5-6-membered aryl ring, or 8-10-membered bicyclic aryl ring containing 0-5 heteroatoms, or a 3-7-membered saturated or partially unsatd. ring containing 0-3 heteroatoms; R4 = Q-Rx; Q = a bond, alkylidene chain wherein up to two non-adjacent methylene units of Q are optionally replaced by CO, CO2, COCO, CONH and derivs., SO, SO2, O, S, NH and derivs., etc. with proviso; and their pharmaceutically acceptable salts], useful as inhibitors of voltage-gated sodium channels and calcium channels, were prepared. Thus, Pd-cross coupling of 5-ethoxycarbonyl-2-chloro-4-(N,N-dimethylamino)pyrimidine (preparation given) with phenylboronic acid gave II in 92% yield. Representative compds. I were found to possess desired N-type calcium channel modulation activity and selectivity (no specific data given). Also, representative compds. I were found to possess desired voltage gated sodium channel activity and selectivity (no specific data given). The invention also provides pharmaceutically

acceptable compns. comprising the compds. I and methods of using the compns. in the treatment of various disorders.

IT 823792-42-3P 823792-55-8P 823792-99-0P

823794-38-3P 823794-57-6P 823794-78-1P


823794-84-9P 823795-27-3P 823796-16-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidines as modulators of voltage-gated ion channels)


RN 823792-42-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-(2-hydroxyphenyl)-4-[(phenylmethyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 823792-55-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-(2-chlorophenyl)-4-[(phenylmethyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 823792-99-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-phenyl-4-[(phenylmethyl)amino]-6-(4-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 823794-38-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-(2-methoxyphenyl)-4-[(phenylmethyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 823794-57-6 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-methyl-2-phenyl-6-[(phenylmethyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 823794-78-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-(2-methylphenyl)-4-[(phenylmethyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 823794-84-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[methyl(phenylmethyl)amino]-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 823795-27-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2,4-diphenyl-6-[(phenylmethyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 823796-16-3 CAPLUS

CN 4-Pyrimidinamine, 5-chloro-2-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




L10 ANSWER 31 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:1059317 CAPLUS
 DN 142:23305
 TI Preparation of trisubstituted heteroaromatic compounds as calcium sensing
 receptor modulators
 IN Yang, Wu; Dickson, John K.; Cooper, Christopher B.; Dodd, Dharmpal S.;
 Ruan, Zheming; Schnur, Dora M.
 PA Bristol-Myers Squibb Company, USA
 SO PCT Int. Appl., 83 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004106296	A2	20041209	WO 2004-US16713	20040527
	WO 2004106296	A3	20051222		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2005004151	A1	20050106	US 2004-854484	20040526
PRAI	US 2003-473904P	P	20030528		
OS	MARPAT 142:23305				
AB	Title compds. I [X = C, N; A, B = CH, N and A and B cannot both be CH; R1 = ArL; R2 = H, alkyl or R1 and R2 can be joined to form a cycloheteroalkyl ring; Ar = (hetero)aryl; L = linking group; R3, R4, R6 = H, alkyl, cycloalkyl, etc.; R4 = alkyl, cycloalkyl, alkenyl, alkynyl, etc.; R7 = alkyl, cycloalkyl, etc.; R8 = H, alkyl or R7 and R8 can be joined together to form a 4-7 membered cycloheteroalkyl ring] are prepared For instance, II is prepared in 5 steps from pyrazole-1-carboxyimidine and benzylmethylamine. I are calcium-sensing receptor modulators; they are useful for the treatment of diseases associated with abnormal bone or mineral homeostasis.				
IT	802915-58-8P 802915-59-9P 802915-60-2P 802915-61-3P 802915-62-4P 802915-68-0P 802915-69-1P 802915-72-6P 802915-73-7P 802915-74-8P 802915-79-3P 802915-84-0P 802915-86-2P 802915-88-4P 802915-91-9P 802915-95-3P 802915-99-7P 802916-03-6P 802916-06-9P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of trisubstituted heteroarom. compds. as calcium sensing receptor modulators)				
RN	802915-58-8 CAPLUS				
CN	5-Pyrimidinecarboxamide, 2-[methyl(phenylmethyl)amino]-N-(2-phenoxyethyl)-4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)				




RN 802915-59-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[[3-chlorophenyl)methyl]amino]-N-(2-phenoxyethyl)-4-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 802915-60-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[[3-chlorophenyl)methyl]amino]-4-(2-chloro-3,4,5-trimethoxyphenyl)-N-(2-phenoxyethyl)- (9CI) (CA INDEX NAME)




RN 802915-61-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[ethyl(phenylmethyl)amino]-N-(2-phenoxyethyl)-4-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 802915-62-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(1,3-benzodioxol-5-ylmethyl)amino]-N-(2-phenoxyethyl)-4-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 802915-68-0 CAPLUS

CN 5-Pyrimidinecarboxamide, N-(2-phenoxyethyl)-2-[(2-phenylethyl)amino]-4-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 802915-69-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[3-methoxyphenyl)methyl]amino]-N-(2-phenoxyethyl)-4-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 802915-72-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[2-(4-fluorophenyl)ethyl]amino]-N-(2-phenoxyethyl)-4-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 802915-73-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[[3,5-dichlorophenyl)methyl]amino]-N-(2-phenoxyethyl)-4-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 802915-74-8 CAPLUS

CN 5-Pyrimidinecarboxamide, N-(2-phenoxyethyl)-2-[(phenylmethyl)amino]-4-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 802915-79-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(2-hydroxyethyl)(phenylmethyl)amino]-N-(2-phenoxyethyl)-4-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 802915-84-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(1,3-benzodioxol-5-ylmethyl)amino]-N-(4-phenylbutyl)-4-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 802915-86-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(1,3-benzodioxol-5-ylmethyl)amino]-N-(3-phenylpropyl)-4-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 802915-88-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[[3-(methylthio)phenyl]methyl]amino]-N-(2-phenoxyethyl)-4-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 802915-91-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[ethyl(phenylmethyl)amino]-N-(4-phenylbutyl)-4-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 802915-95-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[[2-chloro-6-methylphenyl]methyl]amino]-N-(2-phenoxyethyl)-4-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 802915-99-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[[4-(3,4,5-trimethoxyphenyl)methyl]amino]-N-(2-phenoxyethyl)-4-(3,4,5-trimethoxyphenyl)-(9CI) (CA INDEX NAME)




RN 802916-03-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[[4-(4-hydroxy-3-methoxyphenyl)methyl]amino]-N-(2-phenoxyethyl)-4-(3,4,5-trimethoxyphenyl)-(9CI) (CA INDEX NAME)



RN 802916-06-9 CAPLUS

CN 5-Pyrimidinecarboxamide, N-(2-phenoxyethyl)-2-[[[3-(trifluoromethoxy)phenyl]methyl]amino]-4-(3,4,5-trimethoxyphenyl)- (9CI)
(CA INDEX NAME)



L10 ANSWER 32 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:802711 CAPLUS
 DN 141:314020
 TI Preparation of substituted p-diaminobenzene derivatives as openers of the
 KCNQ family potassium ion channels
 IN Khanzhin, Nikolay; Rottlaender, Mario; Ritzen, Andreas; Watson, William
 Patrick
 PA H. Lundbeck A/S, Den.
 SO PCT Int. Appl., 176 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004082677	A1	20040930	WO 2004-DK186	20040318
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004222626	A1	20040930	AU 2004-222626	20040318
	CA 2519582	AA	20040930	CA 2004-2519582	20040318
	EP 1613303	A1	20060111	EP 2004-721472	20040318
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004008437	A	20060404	BR 2004-8437	20040318
	CN 1761464	A	20060419	CN 2004-80007507	20040318
	NO 2005004848	A	20051020	NO 2005-4848	20051020
PRAI	DK 2003-441	A	20030321		
	US 2003-456698P	P	20030321		
	WO 2004-DK186	W	20040318		

OS MARPAT 141:314020

AB The title anilines I [s = 0-1; U = O, S, SO₂, etc.; q = 0-1; X = CO, SO₂; with the proviso that q = 0 when X = SO₂; Z = O, S; R₁ = H, alk(en/yn)yl, cycloalk(en)yl, etc.; R₂ = H, alk(en/yn)yl, cycloalk(en)yl, etc.; R₃ = alk(en/yn)yl, cycloalk(en)yl, heterocycloalk(en)yl, etc.; Y = (un)substituted Ph, naphthyl, thienyl, etc.], useful for the prevention, treatment or inhibition of a disorder being responsive to an increased ion flow in a potassium channel, were prepared and formulated. Thus, reductive amination of Pr (4-amino-2-methylphenyl)carbamate (preparation given) with benzofuran-2-carbaldehyde in the presence of NaBH₃CN afforded 43% Pr {4-[(benzofuran-2-ylmethyl)amino]-2-methylphenyl}carbamate. The compds. I have an EC₅₀ of <20000nM, in most cases <2000nM and in many cases <200nM in KCNQ2 channel assay.


IT 766518-59-6P 766518-60-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted p-diaminobenzene derivs. as openers of the KCNQ family potassium ion channels)


RN 766518-59-6 CAPLUS

CN Benzeneacetamide, 4-fluoro-N-[2-methyl-4-[[(4-methyl-2-phenyl-5-pyrimidinyl)methyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 766518-60-9 CAPLUS

CN Butanamide, 3,3-dimethyl-N-[2-methyl-4-[[(2-phenyl-5-pyrimidinyl)methyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 33 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:734313 CAPLUS

DN 141:366072

TI Preparation of new N6,9-disubstituted 2-phenyl-adenines and corresponding 8-azaadenines. A feasibility study for application to solid-phase synthesis. I [1]

AU Biagi, Giuliana; Giorgi, Irene; Livi, Oreste; Pacchini, Federica; Scartoni, Valerio; Salerni, Oreste LeRoy

CS Dipartimento di Scienze Farmaceutiche, Università di Pisa, Pisa, 56126, Italy

SO Journal of Heterocyclic Chemistry (2004), 41(4), 575-580
CODEN: JHTCAD; ISSN: 0022-152X

PB HeteroCorporation

DT Journal

LA English

OS CASREACT 141:366072

AB A suitably substituted pyrimidine I was converted to a number of title compds. Nucleophilic substitution involving of chlorine by treatment with phenylmethanethiol yielded II or III, depending on the reaction temperature. Treatment of III with an amine afforded 6-phenylmethanesulfanyl-N4-substituted-2-phenyl-pyrimidine-4,5-diamines. These pyrimidines were converted into 2-phenylpurines and 2-phenyl-8-azapurines, by treatment with tri-Et orthoformate in the presence of hydrochloric acid (or acetic anhydride), or with potassium nitrite and acetic acid resp. The thioether function on C(6) was then converted into a sulfonyl group by oxidation with m-chloroperoxybenzoic acid affording purines and their 8-azaanalogs; these compds., as crude products, were treated with an amine to yield the corresponding adenines or 8-azaadenines. All reactions were performed under conditions compatible with the possible use of a thiomethyl resin in place of phenylmethanethiol to bind the pyrimidine ring of I to a solid phase.


IT 778594-76-6P 778594-77-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of new N6,9-disubstituted 2-phenyl-adenines and corresponding 8-azaadenines from a pyrimidine via nucleophilic substitution for evaluation of feasibility of their solid-phase synthesis)


RN 778594-76-6 CAPLUS

CN 4,5-Pyrimidinediamine, 2-phenyl-N4-(phenylmethyl)-6-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)



RN 778594-77-7 CAPLUS

CN 4,5-Pyrimidinediamine, N4-[(4-methoxyphenyl)methyl]-2-phenyl-6-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 34 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:718520 CAPLUS

DN 141:243558

TI Preparation of pyrimidine derivatives as antiinflammatory agents

IN Ohshima, Etsuo; Miyama, Motoki; Yanagawa, Koji; Aratake, Seiji; Miki, Ichiro; Kobayashi, Katsuya; Sato, Takashi; Kawabe, Ari; Iwase, Miho

PA Kyowa Hakko Kogyo Co., Ltd., Japan

SO PCT Int. Appl., 87 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004074260	A1	20040902	WO 2004-JP1962	20040220
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1595869	A1	20051116	EP 2004-713192	20040220
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	JP 2003-44174	A	20030221		
	JP 2003-314058	A	20030905		
	WO 2004-JP1962	W	20040220		

OS MARPAT 141:243558

AB The title pyrimidine derivs. with general formula of I [wherein Ar = (un)substituted aryl or heteroaryl; R1 = (un)substituted amino; A = a single bond, (un)substituted piperidinyl, or piperazinyl; Q = (un)substituted amino, piperidin-4-ylamino, etc.] or quaternary ammonium salts or pharmaceutically acceptable salts thereof are prepared For example, the compound II was prepared in a multi-step synthesis in good yield. II inhibited 91% binding of thymus and activation-regulated chemokine (TARC) towards Hut78 cell in cow. I have an antiinflammatory effect and a TARC and/or MDC function-controlling effect and are useful in treating and/or preventing various diseases in which T cells participate, for example, allergic diseases, autoimmune diseases, rejection at transplantation, etc. (no data). Formulations containing I as an active ingredient were also described.

IT 749859-72-1P 749859-73-2P 749859-74-3P


749860-06-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of pyrimidine derivs. as antiinflammatory agents)


RN 749859-72-1 CAPLUS

CN 4-Pyrimidinamine, 5-(2,4-difluorophenyl)-N-[(2,4-difluorophenyl)methyl]-2-(3-methyl[1,4'-bipiperidin]-1'-yl)- (9CI) (CA INDEX NAME)




RN 749859-73-2 CAPLUS

CN 4-Pyrimidinamine, 2-[1,4'-bipiperidin]-1'-yl-5-(2,4-difluorophenyl)-N-[(2,4-difluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 749859-74-3 CAPLUS

CN 4-Pyrimidinamine, 5-(2,4-difluorophenyl)-N-[(2,4-difluorophenyl)methyl]-2-(2-methyl[1,4'-bipiperidin]-1'-yl)- (9CI) (CA INDEX NAME)



RN 749860-06-8 CAPLUS

CN 4-Pyrimidinamine, 2-[1,4'-bipiperidin]-1'-yl-N-[(2,6-difluorophenyl)methyl]-5-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




IT 749859-75-4P 749859-76-5P 749859-77-6P
 749859-78-7P 749859-79-8P 749859-80-1P
 749859-81-2P 749859-82-3P 749859-83-4P
 749859-84-5P 749859-85-6P 749859-86-7P
 749859-87-8P 749859-88-9P 749859-89-0P
 749859-90-3P 749859-91-4P 749859-92-5P
 749859-93-6P 749859-97-0P 749859-98-1P
 749859-99-2P 749860-00-2P 749860-01-3P
 749860-02-4P 749860-03-5P 749860-04-6P
 749860-05-7P 749860-07-9P 749860-08-0P
 749860-11-5P 749860-12-6P 749860-13-7P
 749860-14-8P 749860-16-0P 749860-17-1P
 749860-18-2P 749860-22-8P 749860-23-9P
 749860-29-5P 749860-30-8P 749860-31-9P
 749860-32-0P 749860-33-1P 749860-34-2P
 749860-35-3P 749860-36-4P 749860-41-1P
 749860-42-2P 749860-43-3P 749860-44-4P
 749860-45-5P 749860-46-6P 749860-47-7P
 749860-48-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidine derivs. as antiinflammatory agents)

RN 749859-75-4 CAPLUS


CN 4-Pyrimidinamine, 5-(2,4-difluorophenyl)-N-[(2,4-difluorophenyl)methyl]-2-(4-methyl[1,4'-bipiperidin]-1'-yl)- (9CI) (CA INDEX NAME)



RN 749859-76-5 CAPLUS


CN 4-Pyrimidinamine, 5-(2,4-difluorophenyl)-N-[(2,4-difluorophenyl)methyl]-2-[(3R,5S)-3,5-dimethyl[1,4'-bipiperidin]-1'-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 749859-77-6 CAPLUS

CN 4-Pyrimidinamine, 5-(2,4-difluorophenyl)-N-[(2,4-difluorophenyl)methyl]-2-(3-ethyl[1,4'-bipiperidin]-1'-yl)- (9CI) (CA INDEX NAME)




RN 749859-78-7 CAPLUS

CN [1,4'-Bipiperidine]-3-methanol, 1'-[5-(2,4-difluorophenyl)-4-[(2,4-difluorophenyl)methyl]amino]-2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 749859-79-8 CAPLUS

CN [1,4'-Bipiperidine]-3-carboxamide, 1'-[5-(2,4-difluorophenyl)-4-[(2,4-difluorophenyl)methyl]amino]-2-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 749859-80-1 CAPLUS

CN [1,4'-Bipiperidine]-3-carboxylic acid, 1'-[5-(2,4-difluorophenyl)-4-[(2,4-difluorophenyl)methyl]amino]-2-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 749859-81-2 CAPLUS

CN 4-Pyrimidinamine, 2-[4-(butylmethylamino)-1-piperidinyl]-5-(2,4-difluorophenyl)-N-[(2,4-difluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 749859-82-3 CAPLUS


CN 4-Pyrimidinamine, N-[(2,4-difluorophenyl)methyl]-5-(2-fluorophenyl)-2-(3-methyl[1,4'-bipiperidin]-1'-yl)- (9CI) (CA INDEX NAME)



RN 749859-83-4 CAPLUS


CN 4-Pyrimidinamine, N-[(2,4-difluorophenyl)methyl]-2-[(3R,5S)-3,5-dimethyl[1,4'-bipiperidin]-1'-yl]-5-(2-fluorophenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 749859-84-5 CAPLUS

CN 4-Pyrimidinamine, N-[(2,4-dichlorophenyl)methyl]-5-(2,4-difluorophenyl)-2-(3-methyl[1,4'-bipiperidin]-1'-yl)- (9CI) (CA INDEX NAME)




RN 749859-85-6 CAPLUS

CN 4-Pyrimidinamine, N-[(2,4-dichlorophenyl)methyl]-5-(2,4-difluorophenyl)-2-[4-[2-(1-piperidinyl)ethyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 749859-86-7 CAPLUS


CN 4-Pyrimidinamine, 5-(2,4-difluorophenyl)-N-[(2,6-difluorophenyl)methyl]-2-[(3-methyl[1,4'-bipiperidin]-1'-yl)- (9CI) (CA INDEX NAME)



RN 749859-87-8 CAPLUS

CN 4-Pyrimidinamine, 5-(2,4-difluorophenyl)-N-[(2,6-difluorophenyl)methyl]-2-[(3R,5S)-3,5-dimethyl[1,4'-bipiperidin]-1'-yl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 749859-88-9 CAPLUS


CN 4-Pyrimidinamine, N-[(2,6-difluorophenyl)methyl]-2-[(3R,5S)-3,5-dimethyl[1,4'-bipiperidin]-1'-yl]-5-(2-fluorophenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 749859-89-0 CAPLUS

CN 4-Pyrimidinamine, 2-[1,4'-bipiperidin]-1'-yl-N-[(2,6-difluorophenyl)methyl]-5-(2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 749859-90-3 CAPLUS

CN 4-Pyrimidinamine, 2-[1,4'-bipiperidin]-1'-yl-N-[(2,6-difluorophenyl)methyl]-5-(1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 749859-91-4 CAPLUS

CN 4-Pyrimidinamine, 5-[1,1'-biphenyl]-2-yl-2-[1,4'-bipiperidin]-1'-yl-N-[(2,6-difluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 749859-92-5 CAPLUS

CN 4-Pyrimidinamine, 5-[1,1'-biphenyl]-3-yl-2-[1,4'-bipiperidin]-1'-yl-N-[(2,6-difluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 749859-93-6 CAPLUS

CN 4-Pyrimidinamine, 5-[1,1'-biphenyl]-4-yl-2-[1,4'-bipiperidin]-1'-yl-N-[(2,6-difluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 749859-97-0 CAPLUS

CN 4-Pyrimidinamine, 2-[1,4'-bipiperidin]-1'-yl-N-[(2,6-difluorophenyl)methyl]-5-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 749859-98-1 CAPLUS

CN 4-Pyrimidinamine, 2-[1,4'-bipiperidin]-1'-yl-N-[(2,6-difluorophenyl)methyl]-5-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 749859-99-2 CAPLUS

CN 4-Pyrimidinamine, 2-[1,4'-bipiperidin]-1'-yl-N-[(2,6-difluorophenyl)methyl]-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 749860-00-2 CAPLUS


CN 4-Pyrimidinamine, 2-[1,4'-bipiperidin]-1'-yl-N-[(2,6-difluorophenyl)methyl]-5-(2-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 749860-01-3 CAPLUS


CN 4-Pyrimidinamine, 2-[1,4'-bipiperidin]-1'-yl-N-[(2,6-

difluorophenyl)methyl]-5-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 749860-02-4 CAPLUS

CN 4-Pyrimidinamine, 2-[1,4'-bipiperidin]-1'-yl-N-[(2,6-difluorophenyl)methyl]-5-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 749860-03-5 CAPLUS

CN 4-Pyrimidinamine, 2-[1,4'-bipiperidin]-1'-yl-5-(2-chlorophenyl)-N-[(2,6-difluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 749860-04-6 CAPLUS

CN 4-Pyrimidinamine, 2-[1,4'-bipiperidin]-1'-yl-5-(3-chlorophenyl)-N-[(2,6-difluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 749860-05-7 CAPLUS

CN 4-Pyrimidinamine, 2-[1,4'-bipiperidin]-1'-yl-5-(4-chlorophenyl)-N-[(2,6-difluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 749860-07-9 CAPLUS

CN 4-Pyrimidinamine, 2-[1,4'-bipiperidin]-1'-yl-N-[(2,6-difluorophenyl)methyl]-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 749860-08-0 CAPLUS

CN 4-Pyrimidinamine, 2-[1,4'-bipiperidin]-1'-yl-N-[(2,6-difluorophenyl)methyl]-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 749860-11-5 CAPLUS

CN 4-Pyrimidinamine, 2-[1,4'-bipiperidin]-1'-yl-5-(2,4-difluorophenyl)-N-[(2,6-difluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 749860-12-6 CAPLUS


CN 4-Pyrimidinamine, 2-[1,4'-bipiperidin]-1'-yl-5-(2,5-difluorophenyl)-N-[(2,6-difluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 749860-13-7 CAPLUS


CN 4-Pyrimidinamine, 2-[1,4'-bipiperidin]-1'-yl-N-[(2,6-difluorophenyl)methyl]-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

NAME)




RN 749860-14-8 CAPLUS

CN Benzonitrile, 3-[2-[1,4'-bipiperidin]-1'-yl-4-[[2,6-difluorophenyl)methyl]amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 749860-16-0 CAPLUS

CN Phenol, 2-[2-[1,4'-bipiperidin]-1'-yl-4-[[2,6-difluorophenyl)methyl]amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 749860-17-1 CAPLUS

CN 4-Pyrimidinamine, 2-[1,4'-bipiperidin]-1'-yl-N-[(2,6-difluorophenyl)methyl]-5-(2-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 749860-18-2 CAPLUS

CN 4-Pyrimidinamine, 2-[1,4'-bipiperidin]-1'-yl-N-[(2,6-difluorophenyl)methyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 749860-22-8 CAPLUS

CN 4-Pyrimidinamine, 2-[1,4'-bipiperidin]-1'-yl-N-[(2,4-difluorophenyl)methyl]-5-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 749860-23-9 CAPLUS

CN 4-Pyrimidinamine, 2-[1,4'-bipiperidin]-1'-yl-N-[(2,6-dichlorophenyl)methyl]-5-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 749860-29-5 CAPLUS

CN 4-Pyrimidinamine, 2-[1,4'-bipiperidin]-1'-yl-N-[(4-chloro-2-fluorophenyl)methyl]-5-(2,4-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 749860-30-8 CAPLUS

CN 4-Pyrimidinamine, 2-[1,4'-bipiperidin]-1'-yl-5-(2,4-difluorophenyl)-N-[(2-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 749860-31-9 CAPLUS

CN 4-Pyrimidinamine, 2-[1,4'-bipiperidin]-1'-yl-5-(2,4-difluorophenyl)-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 749860-32-0 CAPLUS

CN 4-Pyrimidinamine, 2-[1,4'-bipiperidin]-1'-yl-N-[(2-chloro-6-fluorophenyl)methyl]-5-(2,4-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 749860-33-1 CAPLUS

CN 4-Pyrimidinamine, 2-[1,4'-bipiperidin]-1'-yl-N-[2-(4-chlorophenyl)ethyl]-5-(2,4-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 749860-34-2 CAPLUS

CN 4-Pyrimidinamine, 2-[1,4'-bipiperidin]-1'-yl-N-[2-(2-chlorophenyl)ethyl]-5-(2,4-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 749860-35-3 CAPLUS

CN 4-Pyrimidinamine, 2-[1,4'-bipiperidin]-1'-yl-N-[2-(2,4-dichlorophenyl)ethyl]-5-(2,4-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 749860-36-4 CAPLUS

CN 4-Pyrimidinamine, 2-[1,4'-bipiperidin]-1'-yl-5-(2,4-difluorophenyl)-N-[2-(4-fluorophenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 749860-41-1 CAPLUS

CN 4-Pyrimidinamine, 2-[1,4'-bipiperidin]-1'-yl-5-(2,4-difluorophenyl)-N-[4-(methylsulfonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 749860-42-2 CAPLUS

CN 4-Pyrimidinamine, 2-[1,4'-bipiperidin]-1'-yl-N-[2-(2,6-dichlorophenyl)ethyl]-5-(2,4-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 749860-43-3 CAPLUS


CN 1,4'-Bipiperidinium, 1'-[5-(2,4-difluorophenyl)-4-[[2,4-difluorophenyl)methyl]amino]-2-pyrimidinyl]-1-methyl-, iodide (9CI) (CA INDEX NAME)

● I⁻


RN 749860-44-4 CAPLUS
 CN 1,4'-Bipiperidinium, 1'-[5-(2,4-difluorophenyl)-4-[(2,4-difluorophenyl)methyl]amino]-2-pyrimidinyl]-1-ethyl-, iodide (9CI) (CA INDEX NAME)

● I⁻


RN 749860-45-5 CAPLUS
 CN 1,4'-Bipiperidinium, 1'-[5-(2,4-difluorophenyl)-4-[(2,4-difluorophenyl)methyl]amino]-2-pyrimidinyl]-1-propyl-, iodide (9CI) (CA INDEX NAME)

● I⁻


RN 749860-46-6 CAPLUS
 CN 1,4'-Bipiperidinium, 1'-[5-(2,4-difluorophenyl)-4-[(2,4-difluorophenyl)methyl]amino]-2-pyrimidinyl]-1-(2-propenyl)-, bromide (9CI)
 (CA INDEX NAME)

● Br⁻


RN 749860-47-7 CAPLUS
 CN 1,4'-Bipiperidinium, 1'-[5-(2,4-difluorophenyl)-4-[(2,4-difluorophenyl)methyl]amino]-2-pyrimidinyl]-1,2-dimethyl-, iodide (9CI)
 (CA INDEX NAME)

● I⁻

RN 749860-48-8 CAPLUS
 CN 1,4'-Bipiperidinium, 1'-[5-(2,4-difluorophenyl)-4-[(2,4-difluorophenyl)methyl]amino]-2-pyrimidinyl]-1,3-dimethyl-, iodide (9CI)
 (CA INDEX NAME)


● I⁻

IT 749860-49-9P 749860-51-3P 749860-52-4P
 749860-57-9P 749860-60-4P 749860-66-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; preparation of pyrimidine derivs. as antiinflammatory agents)
 RN 749860-49-9 CAPLUS
 CN 4-Pyrimidinamine, 2-chloro-5-(2,4-difluorophenyl)-N-[(2,4-difluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 749860-51-3 CAPLUS

CN 4-Pyrimidinamine, 2-chloro-N-[(2,4-difluorophenyl)methyl]-5-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 749860-52-4 CAPLUS

CN 4-Pyrimidinamine, 2-chloro-N-[(2,4-dichlorophenyl)methyl]-5-(2,4-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 749860-57-9 CAPLUS

CN 4-Pyrimidinamine, 2-chloro-N-[(2,6-difluorophenyl)methyl]-5-(2-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 749860-60-4 CAPLUS

CN 4-Pyrimidinamine, 2-chloro-N-[(2,6-difluorophenyl)methyl]-5-phenyl- (9CI)
(CA INDEX NAME)




RN 749860-66-0 CAPLUS

CN 4-Pyrimidinamine, N-[(2,4-difluorophenyl)methyl]-5-(2-fluorophenyl)-2-(methylthio)- (9CI) (CA INDEX NAME)




RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 35 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:626175 CAPLUS
 DN 141:260694
 TI Substituted benzylamino-6-(trifluoromethyl)pyrimidin-4(1H)-ones: a novel class of selective human A-FABP inhibitors
 AU Ringom, Rune; Axen, Eva; Uppenberg, Jonas; Lundbaeck, Thomas; Rondahl, Lena; Barf, Tjeerd
 CS Department of Medicinal Chemistry, Biovitrum AB, Uppsala, SE-751 37, Swed.
 SO Bioorganic & Medicinal Chemistry Letters (2004), 14(17), 4449-4452
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier B.V.
 DT Journal
 LA English
 OS CASREACT 141:260694
 AB The synthesis and evaluation of human A-FABP inhibitors based on 6-(trifluoromethyl)pyrimidine-4(1H)-ones, e.g., I, is described. Two series of compds., bearing either an amino or carbon substituent in the 2-position of the pyrimidine ring were investigated. Modification of substituents and chain length optimization led to compds. with low micromolar activity and good selectivity for human A-FABP.
 IT **756525-63-0P 756525-64-1P**
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation, human A-FABP binding affinity, and structure-activity relationship of (benzylamino)pyrimidinones via condensation of chlorobenzylamine with methylisothiurea sulfate followed by heterocyclization with acetoacetates)
 RN 756525-63-0 CAPLUS
 CN 4(1H)-Pyrimidinone, 2-[[(4-chlorophenyl)methyl]amino]-6-phenyl- (9CI) (CA INDEX NAME)



RN 756525-64-1 CAPLUS
 CN 4(1H)-Pyrimidinone, 2-[[(4-chlorophenyl)methyl]amino]-6-(2-fluorophenyl)- (9CI) (CA INDEX NAME)



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 36 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:589250 CAPLUS
 DN 141:140470
 TI Preparation of aminophenylbenzamides as inhibitors of histone deacetylase
 IN Delorme, Daniel; Zhou, Zhihong
 PA Methylgene, Inc., Can.
 SO U.S. Pat. Appl. Publ., 318 pp., Cont.-in-part of U.S. Ser. No. 242,304.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004142953	A1	20040722	US 2003-358556	20030204
	US 6897220	B2	20050524		
	US 2004106599	A1	20040603	US 2002-242304	20020912
	AU 2004210016	A1	20040819	AU 2004-210016	20040204
	CA 2515338	AA	20040819	CA 2004-2515338	20040204
	WO 2004069823	A1	20040819	WO 2004-CA139	20040204
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP	1590340	A1	20051102	EP 2004-707852	20040204
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN	1723207	A	20060118	CN 2004-80001769	20040204
BR	2004007195	A	20060214	BR 2004-7195	20040204
JP	2006514998	T2	20060518	JP 2005-518241	20040204
US	2006058298	A1	20060316	US 2005-81095	20050315
JP	2005255683	A2	20050922	JP 2005-80310	20050318
US	2005288282	A1	20051229	US 2005-91025	20050325
PRAI	US 2001-322402P	P	20010914		
	US 2002-391728P	P	20020626		
	US 2002-242304	A2	20020912		
	JP 2003-528544	A3	20020912		
	US 2003-358556	A	20030204		
	WO 2004-CA139	W	20040204		

OS MARPAT 141:140470

AB Title compds. e.g. (I; Y, Z = N, CH; W = Q1, Q2, Q3, etc.), were prepared Thus, 4-[[[(4-Amino-6-(2-indanylamino)-[1,3,5]triazin-2-yl)amino)methyl]benzoic acid (preparation given) in DMF was stirred with Et3N, BOP, and 1,2-phenylenediamine to give 63% 4-[[[(4-Amino-6-(2-indanylamino)-[1,3,5]triazin-2-yl)amino)methyl]-N-(2-aminophenyl)benzamide. The latter inhibited human histone deacetylase HDAC-1 with IC50 = 0.4 μ M.


IT **503043-79-6P**, N-(2-Aminophenyl)-4-(((4-chloro-6-(3,4-dimethoxyphenyl)pyrimidin-2-yl)amino)methyl)benzamide **503043-80-9P**, N-(2-Aminophenyl)-4-(((4-(3,4-dimethoxyphenyl)pyrimidin-2-yl)amino)methyl)benzamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of aminophenylbenzamides as inhibitors of histone deacetylase for treating cell proliferative disorders)


RN 503043-79-6 CAPLUS

CN Benzamide, N-(2-aminophenyl)-4-[[[4-chloro-6-(3,4-dimethoxyphenyl)-2-pyrimidinyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 503043-80-9 CAPLUS

CN Benzamide, N-(2-aminophenyl)-4-[[[4-(3,4-dimethoxyphenyl)-2-pyrimidinyl]amino]methyl]- (9CI) (CA INDEX NAME)



RE.CNT 27

THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 37 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:589247 CAPLUS
 DN 141:140463
 TI Preparation of heterocyclic compounds as selective phosphodiesterase V inhibitors
 IN Yamada, Koichiro; Matsuki, Kenji; Omori, Kenji; Kikkawa, Kohei
 PA Japan
 SO U.S. Pat. Appl. Publ., 116 pp., Cont.-in-part of U.S. Ser. No. 258,545.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004142930	A1	20040722	US 2003-699804	20031104
	JP 2002012587	A2	20020115	JP 2000-277652	20000913
	JP 3637961	B2	20050413		
	WO 2001083460	A1	20011108	WO 2001-JP2034	20010315
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2003229089	A1	20031211	US 2002-258545	20021025
PRAI	JP 2000-130371	A	20000428		
	JP 2000-277652	A	20000913		
	WO 2001-JP2034	W	20010315		
	US 2002-258545	A2	20021025		
	JP 1999-261852	A	19990916		

OS MARPAT 141:140463

AB The title compds. (I) [X = CH, N; Y = NH, NR, S, O, CH:N, N:CH, N:N, CH:CHC(:R5)N, CH:C(R5), N:C(R7)]; R1 = each (un)substituted lower alkoxy, amino, heterocyclyl containing N atom(s), HO, or heterocycloxy containing N atom(s), cyano; R2 = lower alkylamino or lower alkoxy each optionally substituted by an (un)substituted aryl, lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), lower alkylamino group substituted by a (un)substituted heterocyclic ring, (un)substituted arylamino; R3 = each (un)substituted aryl, heterocyclyl containing N atom(s), lower alkyl, lower alkoxy, lower cycloalkoxy, heterocycloxy containing N atom(s), or NH2; R4-R7 = each (un)substituted aryl, heterocyclyl containing N atom(s), lower alkoxy, or NH2; R4, R5, R6 or R7 may combine with R3 to form a lactone ring Q or Q1; when X = N, Y = CH:N, or N:CH, R2 = an amino group monosubstituted by an (un)substituted arylmethyl, and R3 = (un)substituted lower alkyl, amino monosubstituted by an (un)substituted heterocyclyl-lower alkyl containing N atom(s) in the ring, heterocyclylamino containing N atom(s) in the ring, or (un)substituted lower cycloalkylamino, R1 = each (un)substituted lower alkoxy, amino, heterocycloxy containing N atom(s) in the ring, or cyano group] or pharmacol. acceptable salts thereof are prepared These compds. have excellent selective PDE V inhibitory activity and therefore, are useful as therapeutic or prophylactic drugs for treating various diseases due to functional disorders on cGMP-signaling, such as erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis. Thus, 2-(hydroxymethyl)pyridine was treated with NaH in THF and etherified with 2-chloro-5-(3,4,5-

trimethoxyphenylcarbonyl)-4-(3-chloro-4-methoxybenzylamino)pyrimidine to give 2-(2-pyridylmethoxy)-5-(3,4,5-trimethoxyphenylcarbonyl)-4-(3-chloro-4-methoxybenzylamino)pyrimidine.

IT 372117-36-7P 372117-37-8P 372117-38-9P

372117-39-0P 372117-40-3P 372117-41-4P


372117-44-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

```
(preparation of heterocyclic compds. as selective phosphodiesterase V
inhibitors for treating various diseases due to functional disorders on
cGMP-signaling)
```


RN 372117-36-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[[[3-chloro-4-methoxyphenyl)methyl]amino]-2-(2-pyridinylmethoxy)-6-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 372117-37-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[[[3-chloro-4-methoxyphenyl)methyl]amino]-2-(4-hydroxy-1-piperidinyl)-6-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI)
(CA INDEX NAME)




RN 372117-38-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[[[3-chloro-4-methoxyphenyl)methyl]amino]-2-[2-(hydroxymethyl)-4-morpholinyl]-6-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 372117-39-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[[[3-chloro-4-methoxyphenyl)methyl]amino]-2-[[2-methoxyethyl)methylamino]-6-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 372117-40-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[[[3-chloro-4-methoxyphenyl)methyl]amino]-2-[2-(dimethylamino)ethoxy]-6-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 372117-41-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[[[3-chloro-4-methoxyphenyl)methyl]amino]-2-(1-piperazinyl)-6-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 372117-44-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-[bis(2-hydroxyethyl)amino]-4-[[[3-chloro-4-methoxyphenyl)methyl]amino]-6-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)



L10 ANSWER 38 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:467883 CAPLUS
 DN 141:38627
 TI Preparation of 2,4,6-trisubstituted pyrimidines as phosphatidylinositol
 (pi) 3-kinase inhibitors and their use in the treatment of cancer
 IN Nuss, John M.; Pecchi, Sabina; Renhowe, Paul A.
 PA Chiron Corporation, USA
 SO PCT Int. Appl., 151 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004048365	A1	20040610	WO 2003-US37294	20031121
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2507100	AA	20040610	CA 2003-2507100	20031121
	AU 2003295776	A1	20040618	AU 2003-295776	20031121
	US 2004176385	A1	20040909	US 2003-719896	20031121
	EP 1575940	A1	20050921	EP 2003-786980	20031121
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003016485	A	20051011	BR 2003-16485	20031121
	CN 1735607	A	20060215	CN 2003-80108239	20031121
	JP 2006514118	T2	20060427	JP 2005-510381	20031121
	NO 2005002927	A	20050708	NO 2005-2927	20050615
PRAI	US 2002-428473P	P	20021121		
	US 2003-438568P	P	20030107		
	US 2003-523081P	P	20031119		
	WO 2003-US37294	W	20031121		

OS MARPAT 141:38627

AB Title compds. I [Y = (un)substituted alk(en/yn)yl, hetero/aryl, heterocyclyl; X = a direct link, NH and derivs., CH2 and derivs., O, S, SO, SO2, etc.; R1 = H, alkyl, CO2H, halo, OH and derivs., NH2 and derivs.; R2 = (un)substituted hetero/aryl, heterocyclyl; W = NH2 and derivs., (un)substituted alkyl, cyclyl containing at least one heteroatom; with provisos; their stereoisomers, tautomers, pharmaceutically acceptable salts, esters, or prodrugs] were prepared as phosphatidylinositol (pi) 3-kinase inhibitors for treating neoplasm. A solid phase synthesis is given for pyrimidine II•2CF3CO2H. Selected I displayed an IC50 < 20 µM in a cell proliferation assay.


IT **701243-19-8P**, 3-[6-[(4-Methylbenzyl) [(pyridin-2-yl)methyl]amino]-2-(morpholin-4-yl)pyrimidin-4-yl]phenol **701243-23-4P**, 3-[6-(Dibenzylamino)-2-(morpholin-4-yl)pyrimidin-4-yl]phenol **701243-24-5P**, 3-[6-[(Benzyl) (1,3-thiazol-2-yl)methyl]amino]-2-(morpholin-4-yl)pyrimidin-4-yl]phenol **701243-58-5P**, 3-[6-[(4-Methylbenzyl) [(pyridin-3-yl)methyl]amino]-2-(morpholin-4-yl)pyrimidin-4-yl]phenol
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(phosphatidylinositol 3-kinase inhibitor; preparation of 2,4,6-trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors for treating neoplasm)


RN 701243-19-8 CAPLUS

CN Phenol, 3-[6-[[4-methylphenyl)methyl] (2-pyridinylmethyl)amino]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 701243-23-4 CAPLUS

CN Phenol, 3-[6-[bis(phenylmethyl)amino]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 701243-24-5 CAPLUS

CN Phenol, 3-[2-(4-morpholinyl)-6-[(phenylmethyl) (2-thiazolylmethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 701243-58-5 CAPLUS

CN Phenol, 3-[6-[[[4-methylphenyl)methyl] (3-pyridinylmethyl)amino]-2-(4-morpholinyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 39 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:331949 CAPLUS
 DN 140:339318
 TI Preparation of 1,3-oxazol-2-amines as VEGFR2, CDK2, and CDK4 inhibitors
 IN Brown, Matthew Lee; Cheung, Mui; Dickerson, Scott Howard; Gauthier, Cassandra; Harris, Philip Anthony; Hunter, Robert Neil, III; Pacofsky, Gregory; Peel, Michael Robert; Stafford, Jeffrey Alan
 PA Smithkline Beecham Corporation, USA
 SO PCT Int. Appl., 213 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004032882	A2	20040422	WO 2003-US33317	20031010
	WO 2004032882	A3	20040708		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003287178	A1	20040504	AU 2003-287178	20031010
	EP 1551813	A2	20050713	EP 2003-781357	20031010
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006503081	T2	20060126	JP 2004-543799	20031010
	US 2005288515	A1	20051229	US 2005-530810	20050408
PRAI	US 2002-417548P	P	20021010		
	WO 2003-US33317	W	20031010		

OS MARPAT 140:339318


AB The title compds. [I; D1 = (un)substituted aryl, heteroaryl, heterocyclyl; D2 = H, alkyl; D3 = (un)substituted aryl, heteroaryl] which are useful as VEGFR2, CDK2, and CDK4 inhibitors in the treatment of hyperproliferative diseases, were prepared E.g., a 5-step synthesis of I [D1 = 3-MeOC6H4; D2 = H; D3 = Ph], starting from 2-bromo-1-(3-methoxyphenyl)ethanone, was given. Different compds. I are particularly effective at inhibiting CDK2 and/or CDK4 enzymes at 0.0001 to 1 μ M and addnl. show specificity relative to other kinases. The specific data for representative compds. I are given. The pharmaceutical compns. comprising the compound I are claimed.

IT **681004-26-2P**, N-Benzyl-4-[3-(2-[[5-(ethylsulfonyl)-2-methoxyphenyl]amino]-1,3-oxazol-5-yl)phenyl]pyrimidin-2-amine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of 1,3-oxazol-2-amines as VEGFR2, CDK2, and CDK4 inhibitors for treating cancer)

RN 681004-26-2 CAPLUS

CN 2-Pyrimidinamine, 4-[3-[2-[[5-(ethylsulfonyl)-2-methoxyphenyl]amino]-5-oxazolyl]phenyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 40 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:298615 CAPLUS
 DN 142:74519
 TI Synthesis of pyrimido[4,5-d]pyrimidine derivatives
 AU Cieplik, J.
 CS Department of Organic Chemistry, Medical Academy, Wroclaw, 50-137, Pol.
 SO Annales Universitatis Mariae Curie-Sklodowska, Sectio AA: Chemia (2003),
 58, 105-111
 CODEN: AUMCD7; ISSN: 0137-6853
 PB Wydawnictwo Uniwersytetu Marii Curie-Sklodowskiej
 DT Journal
 LA English
 OS CASREACT 142:74519
 AB The synthesis of pyrimido[4,5-d]pyrimidine derivs. I (R = H, Et, Ph),
 where identical structures have been obtained by different methods, is
 presented.
 IT **812665-65-9P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of pyrimidopyrimidines via substitution of
 anilino(chloromethyl)pyrimidines with amines followed by intramol.
 Mannich reaction with formaldehyde)
 RN 812665-65-9 CAPLUS
 CN 5-Pyrimidinemethanamine, 4-methyl-N,2-diphenyl-6-(phenylamino)- (9CI) (CA
 INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 41 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:292069 CAPLUS
 DN 140:303694
 TI Preparation of substituted pyrimidines for treating disorders mediated by
 the Cannabinoid-1 receptor
 IN Kopka, Ihor E.; Li, Bing; Hagmann, William K.
 PA Merck & Co., Inc., USA
 SO PCT Int. Appl., 181 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004029204	A2	20040408	WO 2003-US30161	20030923
	WO 2004029204	A3	20040617		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,				
	GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,				
	PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,				
	TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				
	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2499497	AA	20040408	CA 2003-2499497	20030923
	AU 2003275242	A1	20040419	AU 2003-275242	20030923
	EP 1546115	A2	20050629	EP 2003-759514	20030923
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006510597	T2	20060330	JP 2004-539876	20030923
	US 2005245554	A1	20051103	US 2005-527561	20050311
PRAI	US 2002-414144P	P	20020927		
	WO 2003-US30161	W	20030923		

OS MARPAT 140:303694

AB Novel pyrimidines (shown as I; variables defined below; e.g. II) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor (no data) and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor (no data). The compds. of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compds. are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver. Although the methods of preparation are not claimed, .apprx.130 example preps. of I and 17 example preps. of intermediates are included. For example, 2-(4-fluorobenzyloxy)-4-(4-chlorophenyl)-5-(2,4-dichlorophenyl)pyrimidine was prepared from 2-methylthio-5-(2,4-dichlorophenyl)-4-(4-chlorophenyl)pyrimidine by displacement with 4-fluorobenzyl alc. in the presence of NaH in DMF; the pyrimidine reactant was prepared by cyclization of pseudothiourea sulfate with 3-dimethylamino-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)prop-2-ene, which was prepared by condensation of DMF dimethylacetal with 4-chlorobenzyl

2,4-dichlorophenyl ketone, which was prepared from 2,4-dichlorobenzonitrile and a Grignard solution derived from 4-chlorobenzyl bromide. For I: R1 = H, C1-10alkyl, -ORa, -NRaRb, -NRbC(O)Ra, -CO2Ra, -C(O)NRaRb, cyano, -SRb, and -SO2Rb; R2 = H, C1-10alkyl, -ORa, -NRaRb, -NRaC(O)Rb, -CO2Ra, -C(O)NRaRb, cyano, -SRa, and -SO2Ra; R3 = aryl, and heteroaryl, wherein each is (un)substituted with 1-4 Rg; R4 = aryl, and heteroaryl, wherein each is (un)substituted with 1-4 Rg; each Ra = H, C1-10alkyl, C2-10 alkenyl, etc.; each Rb = H, C1-10alkyl, C2-10 alkenyl, cycloalkyl, etc. or Ra and Rb together with the N atom to which they are attached form a bridged or unbridged heterocyclic ring = 4-7 members containing 0-2 addnl. O, S and NRd; each Rg = halogen, C1-10alkyl, -O-C1-4alkyl, -S-C1-4-alkyl, -CN, -CF3, and -OCF3; and m = 1 or 2; addnl. details are given in the claims.


IT **676563-51-2P**, 2-(3-Chlorobenzylamino)-4-(2,4-dichlorophenyl)-5-(4-chlorophenyl)pyrimidine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of substituted pyrimidines for treating disorders mediated by the cannabinoid-1 receptor)

RN 676563-51-2 CAPLUS

CN 2-Pyrimidinamine, 5-(4-chlorophenyl)-N-[(3-chlorophenyl)methyl]-4-(2,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 42 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:264063 CAPLUS

DN 140:423223

TI Combinatorial Synthesis of Substituted Biaryls and Heterocyclic Arylamines

AU Ma, Yao; Margarida, Laura; Brookes, Jeseca; Makara, Gergely M.; Berk, Scott C.

CS NeoGenesis Pharmaceuticals, Inc., Cambridge, MA, 02139, USA

SO Journal of Combinatorial Chemistry (2004), 6(3), 426-430

CODEN: JCCHFF; ISSN: 1520-4766

PB American Chemical Society

DT Journal

LA English

OS CASREACT 140:423223

AB In this paper, we report very general conditions that enable palladium-mediated coupling reactions on the solid support. A wide variety of biaryls and arylamines (including pyrimidines) have been synthesized using this protocol. The chemical facilitates a combinatorial approach to the production of large nos. of medicinally relevant heterocyclic structures.


IT 691858-65-8P 691858-68-1P

RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)

(combinatorial synthesis of substituted biaryls and heterocyclic arylamines via palladium-mediated coupling reactions on a solid support)


RN 691858-65-8 CAPLUS

CN 4-Pyrimidinamine, N-[(4-methylphenyl)methyl]-2-(2-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 691858-68-1 CAPLUS

CN 2,4-Pyrimidinediamine, N2,N2-dimethyl-N4-[(4-methylphenyl)methyl]-6-phenyl- (9CI) (CA INDEX NAME)




RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 43 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:205964 CAPLUS
 DN 142:74474
 TI Product class 12: pyrimidines
 AU von Angerer, S.
 CS Germany
 SO Science of Synthesis (2004), 16, 379-572
 CODEN: SSCYJ9
 PB Georg Thieme Verlag
 DT Journal; General Review
 LA English
 AB A review. Methods for preparing pyrimidines are reviewed including cyclization, ring transformation, aromatization and substituent modification.
 IT **76990-15-3P 811450-01-8P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of pyrimidines via cyclization, ring transformation, aromatization and substituent modification)
 RN 76990-15-3 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 4-phenyl-6-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 811450-01-8 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 1,4-dihydro-4-oxo-2-phenyl-6-[(phenylmethyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 856 THERE ARE 856 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 44 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:83424 CAPLUS

DN 141:314277

TI Synthesis and antibacterial activity of 1,3-diarylpyrimido[4,5-d]pyrimidines

AU Cieplik, J.; Pluta, J.; Gubrynowicz, O.

CS Department of Organic Chemistry, Medical Academy, Wroclaw, Pol.

SO Bollettino Chimico Farmaceutico (2003), 142(4), 146-150

CODEN: BCFAAI; ISSN: 0006-6648

PB Societa Editoriale Farmaceutica

DT Journal

LA English

OS CASREACT 141:314277

AB This paper describes the synthesis of 4,5-diaminoderivatives of pyrimidine and pyrimido[4,5-d]pyrimidines and evaluation of their antibacterial activity on 9 selected bacterial species relating the changes in the chemical structure to an increase in the bioactive properties.

IT 769141-35-7P 769141-36-8P 769141-37-9P


769141-38-0P 769141-39-1P 769141-40-4P

RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(cyclization of; preparation and antibacterial activity-structure relationships of diarylpyrimidopyrimidines)


RN 769141-35-7 CAPLUS

CN 5-Pyrimidinemethanamine, N-(3,5-dichlorophenyl)-4-[(3,5-dichlorophenyl)amino]-6-methyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 769141-36-8 CAPLUS

CN 5-Pyrimidinemethanamine, N-(3,4-dichlorophenyl)-4-[(3,4-dichlorophenyl)amino]-6-methyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 769141-37-9 CAPLUS

CN 5-Pyrimidinemethanamine, 4-[(3,4-dichlorophenyl)amino]-N-(4-ethoxyphenyl)-6-methyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 769141-38-0 CAPLUS

CN 5-Pyrimidinemethanamine, N-(3,4-dichlorophenyl)-4-[(4-ethoxyphenyl)amino]-6-methyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 769141-39-1 CAPLUS

CN 5-Pyrimidinemethanamine, N-(3,5-dichlorophenyl)-4-[(4-ethoxyphenyl)amino]-6-methyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 769141-40-4 CAPLUS

CN Phenol, 4-[[5-[[[(4-chlorophenyl)amino]methyl]-6-methyl-2-phenyl-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 45 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:41642 CAPLUS

DN 140:105256

TI Antisense oligonucleotides for inhibiting human histone deacetylase 7, 8, and 1 expression, benzamide inhibitors of HDAC-7, HDAC-8, and HDAC-1 isoenzymes, and their use as antitumor agents

IN Besterman, Jeffrey M.; Li, Zuomei; Delorme, Daniel; Bonfils, Claire

PA Methylgene, Inc., Can.

SO PCT Int. Appl., 98 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004005513	A2	20040115	WO 2003-IB3052	20030612
	WO 2004005513	A3	20040701		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004072770	A1	20040415	US 2002-189818	20020703
	CA 2490579	AA	20040115	CA 2003-2490579	20030612
	AU 2003281299	A1	20040123	AU 2003-281299	20030612
PRAI	US 2002-189818	A	20020703		
	WO 2003-IB3052	W	20030612		

AB This invention relates to the inhibition of histone deacetylase (HDAC) expression and enzymic activity. The invention provides methods and reagents for inhibiting HDAC-7 and HDAC-8 by inhibiting expression at the nucleic acid level or inhibiting enzymic activity at the protein level. Specifically, the invention claims three antisense oligonucleotides and benzamide compds. which lead to inhibition of proliferation and cell death of contacted cells. The invention further claims chimeric or hybrid HDAC-7, HDAC-8, or HDAC-1 antisense oligonucleotides and small mol. inhibitors for inhibiting neoplastic cell proliferation in an animal or human. Antisense oligonucleotides AS1 and AS2 inhibited HDAC7 mRNA expression in human A549 bladder carcinoma cells. AS2 also inhibited HDAC8 mRNA expression. An antisense oligonucleotide against HDAC1 acted synergistically with HDAC7 and HDAC8 antisense inhibitors to induce apoptosis in A549 cells. Small mol. inhibitors of HDAC7 and HDAC8 together with HDAC1 inhibited human tumor growth in a mouse disease model.


IT 503043-80-9p, N-(2-Aminophenyl)-4-[[4-(3,4-dimethoxy-phenyl)-pyrimidin-2-ylamino]-methyl]-benzamide

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antisense oligonucleotides for inhibiting human histone deacetylase 7, 8, and 1 expression, benzamide inhibitors of HDAC-7, HDAC-8, and HDAC-1 isoenzymes, and their use as antitumor agents)

RN 503043-80-9 CAPLUS

CN Benzamide, N-(2-aminophenyl)-4-[[[4-(3,4-dimethoxyphenyl)-2-pyrimidinyl]amino]methyl]- (9CI) (CA INDEX NAME)




IT **645401-62-3P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(benzamide inhibitors of HDAC-7, HDAC-8, and HDAC-1 isoenzymes, and their use as antitumor agents)

RN 645401-62-3 CAPLUS

CN Benzoic acid, 4-[[[4-(3,4-dimethoxyphenyl)-2-pyrimidinyl]amino]methyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 46 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:14825 CAPLUS
 DN 140:181645
 TI New synthesis and biologically active molecular design of
 deazapteridine-steroid hybrid compounds
 AU Nagamatsu, Tomohisa; Yamada, Hiroki; Shiromoto, Kazuyuki
 CS Faculty of Pharmaceutical Sciences, Okayama University, Okayama, 700-8530,
 Japan
 SO Heterocycles (2004), 63(1), 9-16
 CODEN: HTCYAM; ISSN: 0385-5414
 PB Japan Institute of Heterocyclic Chemistry
 DT Journal
 LA English
 OS CASREACT 140:181645
 AB This paper describes a facile and general synthesis of a new class of the
 hybrid compds. possessing a 5-deazapteridine and a steroid unit in the
 same ring system. These compds. were prepared by condensation of
 6-aminouracil derivs. with (5 α ,17 β)-3-(4-morpholinyl)androst-2-
 en-17-ol or 4,5 α -dihydro-2-(hydroxymethylene)testosterone
 [(5 α ,17 β)-17-hydroxy-2-(hydroxymethylene)androstan-3-one] under
 heating in the presence of p-toluenesulfonic acid monohydrate. These
 compds. are potential anti-coccidiosis agents and some compds. were more
 active in vitro than robenidine.
 IT **66487-67-0**, 2-Phenyl-6-[(phenylmethyl)amino]-4(1H)-pyrimidinone
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation and biol. active mol. design of deazapteridine-steroid hybrid
 compds.)
 RN 66487-67-0 CAPLUS
 CN 4(1H)-Pyrimidinone, 2-phenyl-6-[(phenylmethyl)amino]- (9CI) (CA INDEX
 NAME)



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 47 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:2818 CAPLUS

DN 140:59406

TI Preparation of [[[hetero)arylamino]methyl]phenoxy]acetic acid derivatives as hPPAR activators for treatment of cardiovascular disease and related disorders

IN Beswick, Paul John; Harling, John David; Kleanthous, Savvas; Patel, Vipulkumar Kantibhai; Simpson, Juliet

PA Smithkline Beecham Corporation, USA

SO PCT Int. Appl., 98 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004000762	A2	20031231	WO 2003-EP6416	20030618
	WO 2004000762	A3	20041014		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2489359	AA	20031231	CA 2003-2489359	20030618
	AU 2003245963	A1	20040106	AU 2003-245963	20030618
	EP 1513795	A2	20050316	EP 2003-738057	20030618
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	BR 2003011935	A	20050322	BR 2003-11935	20030618
	JP 2005534673	T2	20051117	JP 2004-514762	20030618
	NO 2004005327	A	20050310	NO 2004-5327	20041203
	US 2006074111	A1	20060406	US 2004-518778	20041217
PRAI	GB 2002-14254	A	20020620		
	WO 2003-EP6416	W	20030618		


OS MARPAT 140:59406

AB Title compds. I [wherein R1 and R2 = independently H or alkyl; X = a bond, CH2, or O; R3 and R4 = independently H, alkyl, OCH3, CF3, allyl, or halo; X1 = CH2, SO2, or CO; R5 = alkenyl, alkanoyl, alkylsulfonyl, or (un)substituted alkyl(phenyl); R6 = (un)substituted Ph or 6-membered heteroaryl; or pharmaceutically acceptable salts, solvates, or hydrolyzable esters thereof] were prepared as human peroxisome proliferator activated receptor (hPPAR) activators. For example, coupling of Et 2-methyl-2-[2-methyl-4-[[[4-(trifluoromethyl)benzyl]amino]methyl]phenoxy]p ropanoate with 2-bromo-6-[4-(trifluoromethyl)phenyl]pyridine in the presence of Pd(OAc)2, (R)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, and cesium carbonate in toluene gave the tertiary amine. Saponification with NaOH


in

THF provided the acid II. Compds. of the invention showed at least 50% activation of hPPAR δ relative to the pos. control at concns. of 10⁻⁷ M or less. Thus, I and their pharmaceutical compns. are useful for the treatment of hPPAR mediated conditions, such as dyslipidemia, syndrome X, heart failure, hypercholesterolemia, cardiovascular disease, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia,

- obesity, anorexia bulimia, or anorexia nervosa (no data).
- IT **637353-48-1P**, [4-[[Butyl[4-[4-(trifluoromethyl)phenyl]pyrimidin-2-yl]amino]methyl]-2-methylphenoxy]acetic acid **637353-49-2P**, [4-[[Butyl[4-(4-chlorophenyl)pyrimidin-2-yl]amino]methyl]-2-methylphenoxy]acetic acid **637353-50-5P**, [4-[[2-Methoxyethyl][4-(4-(trifluoromethyl)phenyl)pyrimidin-2-yl]amino]methyl]-2-methylphenoxy]acetic acid **637353-51-6P**, [4-[[[4-(4-Chlorophenyl)pyrimidin-2-yl](2-methoxyethyl)amino]methyl]-2-methylphenoxy]acetic acid **637353-52-7P**, [2-Methyl-4-[[propyl[4-(4-(trifluoromethyl)phenyl)pyrimidin-2-yl]amino]methyl]phenoxy]acetic acid **637353-70-9P**, [4-[[Butyl[5-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]amino]methyl]-2-methylphenoxy]acetic acid **637353-71-0P**, [4-[[Butyl[6-(4-methoxyphenyl)-5-methylpyrimidin-4-yl]amino]methyl]-2-methylphenoxy]acetic acid **637353-72-1P**, [4-[[Butyl[5-methyl-6-(4-methylphenyl)pyrimidin-4-yl]amino]methyl]-2-methylphenoxy]acetic acid **637353-73-2P**, [4-[[Butyl[6-(4-chlorophenyl)-5-methylpyrimidin-4-yl]amino]methyl]-2-methylphenoxy]acetic acid **637353-77-6P**, [2-Methyl-4-[[[5-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl](propyl)amino]methyl]phenoxy]acetic acid **637353-78-7P**, [4-[[[6-(4-Chlorophenyl)-5-methylpyrimidin-4-yl](propyl)amino]methyl]-2-methylphenoxy]acetic acid **637353-79-8P**, [2-Methyl-4-[[[5-methyl-6-(4-methylphenyl)pyrimidin-4-yl](propyl)amino]methyl]phenoxy]acetic acid **637353-80-1P**, [2-Methyl-4-[[[5-methyl-6-[4-(methyloxy)phenyl]pyrimidin-4-yl](propyl)amino]methyl]phenoxy]acetic acid **637353-83-4P**, [4-[[Butyl[5-methyl-6-(4-methylphenyl)pyrimidin-4-yl]amino]methyl]-2-ethylphenoxy]acetic acid **637353-85-6P**, [4-[[Butyl[6-(4-chlorophenyl)-5-methylpyrimidin-4-yl]amino]methyl]-2-ethylphenoxy]acetic acid **637353-86-7P**, [4-[[Butyl[5-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]amino]methyl]-2-ethylphenoxy]acetic acid **637353-87-8P**, [2-Ethyl-4-[[[2-(methyloxy)ethyl][4-[4-(trifluoromethyl)phenyl]pyrimidin-2-yl]amino]methyl]phenoxy]acetic acid
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (hPPAR activator; preparation of [[[hetero)arylamino]methyl]phenoxy]acetic acid derivs. as hPPAR activators for treatment of cardiovascular disease and related disorders)
- RN **637353-48-1** CAPLUS
 CN Acetic acid, [4-[[butyl[4-[4-(trifluoromethyl)phenyl]-2-pyrimidinyl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)





- RN **637353-49-2** CAPLUS
 CN Acetic acid, [4-[[butyl[4-(4-chlorophenyl)-2-pyrimidinyl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)





RN 637353-50-5 CAPLUS

CN Acetic acid, [4-[[[(2-methoxyethyl)[4-[4-(trifluoromethyl)phenyl]-2-pyrimidinyl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 637353-51-6 CAPLUS

CN Acetic acid, [4-[[[4-(4-chlorophenyl)-2-pyrimidinyl](2-methoxyethyl)amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 637353-52-7 CAPLUS

CN Acetic acid, [2-methyl-4-[[propyl[4-[4-(trifluoromethyl)phenyl]-2-pyrimidinyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 637353-70-9 CAPLUS

CN Acetic acid, [4-[[butyl[5-methyl-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 637353-71-0 CAPLUS

CN Acetic acid, [4-[[butyl[6-(4-methoxyphenyl)-5-methyl-4-pyrimidinyl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 637353-72-1 CAPLUS

CN Acetic acid, [4-[[butyl[5-methyl-6-(4-methylphenyl)-4-pyrimidinyl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 637353-73-2 CAPLUS

CN Acetic acid, [4-[[butyl[6-(4-chlorophenyl)-5-methyl-4-pyrimidinyl]amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 637353-77-6 CAPLUS

CN Acetic acid, [2-methyl-4-[[[5-methyl-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]propylamino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 637353-78-7 CAPLUS

CN Acetic acid, [4-[[[6-(4-chlorophenyl)-5-methyl-4-pyrimidinyl]propylamino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-79-8 CAPLUS


CN Acetic acid, [2-methyl-4-[[[5-methyl-6-(4-methylphenyl)-4-pyrimidinyl]propylamino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 637353-80-1 CAPLUS


CN Acetic acid, [4-[[[6-(4-methoxyphenyl)-5-methyl-4-

pyrimidinyl]propylamino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 637353-83-4 CAPLUS

CN Acetic acid, [4-[[butyl[5-methyl-6-(4-methylphenoxy)]-4-pyrimidinyl]amino]methyl]-2-ethylphenoxy]- (9CI) (CA INDEX NAME)




RN 637353-85-6 CAPLUS

CN Acetic acid, [4-[[butyl[6-(4-chlorophenyl)-5-methyl-4-pyrimidinyl]amino]methyl]-2-ethylphenoxy]- (9CI) (CA INDEX NAME)





RN 637353-86-7 CAPLUS

CN Acetic acid, [4-[[butyl[5-methyl-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]-2-ethylphenoxy]- (9CI) (CA INDEX NAME)



RN 637353-87-8 CAPLUS

CN Acetic acid, [2-ethyl-4-[[2-methoxyethyl][4-[4-(trifluoromethyl)phenyl]-2-pyrimidinyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



IT **637352-79-5P**, Ethyl 2-[4-[[butyl[4-[4-(trifluoromethyl)phenyl]pyrimidin-2-yl]amino]methyl]-2-methylphenoxy]acetate **637352-80-8P**, Ethyl 2-[4-[[butyl[4-(4-chlorophenyl)pyrimidin-2-yl]amino]methyl]-2-methylphenoxy]acetate **637352-81-9P**, Ethyl 2-[4-[[2-methoxyethyl][4-[4-(trifluoromethyl)phenyl]pyrimidin-2-yl]amino]methyl]-2-methylphenoxy]acetate **637352-82-0P**, Ethyl 2-[4-[[4-(4-chlorophenyl)pyrimidin-2-yl](2-methoxyethyl)amino]methyl]-2-methylphenoxy]acetate **637352-83-1P**, Ethyl 2-[2-methyl-4-[[propyl[4-[4-(trifluoromethyl)phenyl]pyrimidin-2-yl]amino]methyl]phenoxy]acetate **637353-01-6P**, Ethyl 2-[4-[[butyl[5-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]amino]methyl]-2-methylphenoxy]acetate **637353-02-7P**, Ethyl 2-[4-[[butyl[6-(4-methoxyphenyl)-5-methylpyrimidin-4-yl]amino]methyl]-2-methylphenoxy]acetate **637353-03-8P**, Ethyl 2-[4-[[butyl[6-(4-chlorophenyl)-5-methylpyrimidin-4-yl]amino]methyl]-2-methylphenoxy]acetate **637353-04-9P**, Ethyl 2-[4-[[butyl[5-methyl-6-(4-methylphenyl)pyrimidin-4-yl]amino]methyl]-2-methylphenoxy]acetate **637353-14-1P**, Ethyl 2-[2-methyl-4-[[5-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl](propyl)amino]methyl]phenoxy]acetate **637353-15-2P**, Ethyl 2-[4-[[6-(4-chlorophenyl)-5-methylpyrimidin-4-yl](propyl)amino]methyl]-2-methylphenoxy]acetate **637353-16-3P**, Ethyl 2-[2-methyl-4-[[5-methyl-6-(4-methylphenyl)pyrimidin-4-yl](propyl)amino]methyl]phenoxy]acetate **637353-17-4P**, Ethyl 2-[2-methyl-4-[[5-methyl-6-[4-(methyloxy)phenyl]pyrimidin-4-yl](propyl)amino]methyl]phenoxy]acetate **637353-25-4P**, Ethyl 2-[4-[[butyl[5-methyl-6-(4-methylphenyl)pyrimidin-4-yl]amino]methyl]-2-ethylphenoxy]acetate **637353-28-7P**, Ethyl 2-[4-[[butyl[6-(4-chlorophenyl)-5-methylpyrimidin-4-yl]amino]methyl]-2-ethylphenoxy]acetate **637353-29-8P**, Ethyl 2-[4-[[butyl[5-methyl-6-[4-(trifluoromethyl)phenyl]pyrimidin-4-yl]amino]methyl]-2-ethylphenoxy]acetate **637353-30-1P**, Ethyl 2-[2-ethyl-4-[[2-(methyloxy)ethyl][4-[4-(trifluoromethyl)phenyl]pyrimidin-2-yl]amino]methyl]phenoxy]acetate


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of [[[hetero)arylamino]methyl]phenoxy]acetic acid derivs. as hPPAR activators for treatment of cardiovascular

disease and related disorders)


RN 637352-79-5 CAPLUS

CN Acetic acid, [4-[[butyl[4-[4-(trifluoromethyl)phenyl]-2-pyrimidinyl]amino]methyl]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)





RN 637352-80-8 CAPLUS

CN Acetic acid, [4-[[butyl[4-(4-chlorophenyl)-2-pyrimidinyl]amino]methyl]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)





RN 637352-81-9 CAPLUS

CN Acetic acid, [4-[[[2-methoxyethyl][4-[4-(trifluoromethyl)phenyl]-2-pyrimidinyl]amino]methyl]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 637352-82-0 CAPLUS

CN Acetic acid, [4-[[[4-(4-chlorophenyl)-2-pyrimidinyl](2-methoxyethyl)amino]methyl]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 637352-83-1 CAPLUS

CN Acetic acid, [2-methyl-4-[[propyl[4-[4-(trifluoromethyl)phenyl]-2-pyrimidinyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 637353-01-6 CAPLUS

CN Acetic acid, [4-[[butyl[5-methyl-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 637353-02-7 CAPLUS

CN Acetic acid, [4-[[butyl[6-(4-methoxyphenyl)-5-methyl-4-pyrimidinyl]amino]methyl]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 637353-03-8 CAPLUS

CN Acetic acid, [4-[[butyl[6-(4-chlorophenyl)-5-methyl-4-pyrimidinyl]amino]methyl]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 637353-04-9 CAPLUS

CN Acetic acid, [4-[[butyl[5-methyl-6-(4-methylphenyl)-4-pyrimidinyl]amino]methyl]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 637353-14-1 CAPLUS

CN Acetic acid, [2-methyl-4-[[[5-methyl-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]propylamino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 637353-15-2 CAPLUS

CN Acetic acid, [4-[[[6-(4-chlorophenyl)-5-methyl-4-pyrimidinyl]propylamino]methyl]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 637353-16-3 CAPLUS

CN Acetic acid, [2-methyl-4-[[[5-methyl-6-(4-methylphenyl)-4-pyrimidinyl]propylamino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 637353-17-4 CAPLUS

CN Acetic acid, [4-[[[6-(4-methoxyphenyl)-5-methyl-4-pyrimidinyl]propylamino]methyl]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 637353-25-4 CAPLUS

CN Acetic acid, [4-[[[butyl[5-methyl-6-(4-methylphenyl)-4-pyrimidinyl]amino]methyl]-2-ethylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 637353-28-7 CAPLUS

CN Acetic acid, [4-[[butyl[6-(4-chlorophenyl)-5-methyl-4-pyrimidinyl]amino]methyl]-2-ethylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)





RN 637353-29-8 CAPLUS

CN Acetic acid, [4-[[butyl[5-methyl-6-[4-(trifluoromethyl)phenyl]-4-pyrimidinyl]amino]methyl]-2-ethylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 637353-30-1 CAPLUS

CN Acetic acid, [2-ethyl-4-[[2-methoxyethyl][4-[4-(trifluoromethyl)phenyl]-2-pyrimidinyl]amino]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



L10 ANSWER 48 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:2701 CAPLUS
 DN 140:53404
 TI Amino-substituted monocycles as AKT-1 kinase modulators
 IN Darrow, James W.; Desimone, Robert W.; Pippin, Douglas A.; Mitchell, Scott A.
 PA Cellular Genomics, Inc., USA
 SO PCT Int. Appl., 43 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004000318	A2	20031231	WO 2003-US19978	20030623
	WO 2004000318	A3	20040408		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003249369	A1	20040106	AU 2003-249369	20030623
	US 2004053927	A1	20040318	US 2003-602560	20030623
	US 7015227	B2	20060321		
PRAI	US 2002-390628P	P	20020621		
	WO 2003-US19978	W	20030623		

OS MARPAT 140:53404

AB A composition comprises amino-substituted monocycle, a pharmaceutically acceptable salt, hydrate, solvate, crystal form, diastereomer, prodrug, or mixture thereof. The compds. are of utility as modulators of kinase activity.


IT **639450-14-9P 639450-15-0P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino-substituted monocycles as AKT-1 kinase modulators)


RN 639450-14-9 CAPLUS

CN Benzamide, N-[3-[4-[(4-methoxyphenyl)methyl]methylamino]-2-pyrimidinyl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 639450-15-0 CAPLUS


CN Benzamide, 4-methyl-N-[3-[4-[methyl[[4-(trifluoromethyl)phenyl]methyl]amino]-2-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)



IT **639450-14-9D**, prodrugs and diastereoisomers **639450-15-0D**
 , prodrugs and diastereoisomers
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (amino-substituted monocycles as AKT-1 kinase modulators)
 RN 639450-14-9 CAPLUS
 CN Benzamide, N-[3-[4-[[4-(trifluoromethyl)phenyl)methyl]methylamino]-2-
 pyrimidinyl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 639450-15-0 CAPLUS
 CN Benzamide, 4-methyl-N-[3-[4-[methyl[[4-(trifluoromethyl)phenyl)methyl]amin
 o]-2-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 49 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:551510 CAPLUS
 DN 139:117434
 TI Aminopyrimidines as adenosine receptor antagonists, processes for their
 preparation and pharmaceutical compositions
 IN Tsutsumi, Hideo; Yonishi, Satoshi; Akahane, Atsushi
 PA Fujisawa Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 220 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003057689	A1	20030717	WO 2002-JP13796	20021227
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002358999	A1	20030724	AU 2002-358999	20021227
	US 2005043315	A1	20050224	US 2004-498016	20040616
PRAI	AU 2002-9796	A	20020102		
	AU 2002-1724	A	20020412		
	AU 2002-951403	A	20020916		
	WO 2002-JP13796	W	20021227		


AB Title compound I [wherein Q = Q1, Q2; R, R4 = (un)substituted aryl, heterocyclyl; R5 = H, halogen, alkyl, (un)substituted hydroxy, amino, mercapto, alkylsulfinyl, alkylsulfonyl, X = O, S; R1 = H, (un)substituted alkyl and cycloalkyl optionally interrupted by an O; R2, R3 = independently H, alkyl, acyl, aryl, heterocyclylalkyl; NR2R3 = N-heterocyclyl] and their salts were prepared as adenosine receptor antagonists. For example, compound II was prepared from 3-(phenylethynyl)-6-(phenylsulfonyl)pyridazine in five steps by methanolysis, water addition to the triple bond, condensation with N,N-dimethylformamide di-Me acetal, cyclocondensation with guanidine hydrochloride and demethylation. II showed binding to the human A1 adenosine receptor with Ki = 11.35 nM and to the human A2a adenosine receptor with Ki = 3.85 nM. Thus, I are useful as A1 receptor and A2a receptor dual antagonists and for the prevention and/or treatment of depression, dementia (e.g. Alzheimer's disease, cerebrovascular dementia, dementia accompanying Parkinson's disease, etc.), Parkinson's disease, anxiety, pain, cerebrovascular disease (e.g. stroke, etc.), heart failure and the like (no data).

IT **560113-07-7P**, 6-[2-Amino-4-(benzylamino)-6-phenyl-5-pyrimidinyl]-2-isopropyl-3(2H)-pyridazinone **560113-08-8P**, 6-[2-Amino-4-(benzyl(methyl)amino)-6-phenyl-5-pyrimidinyl]-2-isopropyl-3(2H)-pyridazinone **560113-35-1P**, 6-[2-Amino-4-(benzylamino)-6-phenyl-5-pyrimidinyl]-2-methyl-3(2H)-pyridazinone **560113-50-0P**, 6-[2-Amino-4-(benzylamino)-6-(4-fluorophenyl)-5-pyrimidinyl]-2-isopropyl-3(2H)-pyridazinone
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(A1 and A2a adenosine receptor ligand; preparation of aminopyrimidines as adenosine receptor antagonists)


RN 560113-07-7 CAPLUS

CN 3(2H)-Pyridazinone, 6-[2-amino-4-phenyl-6-[(phenylmethyl)amino]-5-pyrimidinyl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 560113-08-8 CAPLUS

CN 3(2H)-Pyridazinone, 6-[2-amino-4-[methyl(phenylmethyl)amino]-6-phenyl-5-pyrimidinyl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 560113-35-1 CAPLUS

CN 3(2H)-Pyridazinone, 6-[2-amino-4-phenyl-6-[(phenylmethyl)amino]-5-pyrimidinyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 560113-50-0 CAPLUS

CN 3(2H)-Pyridazinone, 6-[2-amino-4-(4-fluorophenyl)-6-[(phenylmethyl)amino]-5-pyrimidinyl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 50 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:417726 CAPLUS

DN 138:401748

TI Preparation of 5-phenylpyrimidines as agricultural fungicides

IN Gypser, Andreas; Grote, Thomas; Schwoegler, Anja; Rheinheimer, Joachim;
 Schieweck, Frank; Tormo i Blasco, Jordi; Rose, Ingo; Schaefer, Peter;
 Gewehr, Markus; Grammenos, Wassilios; Mueller, Bernd; Ammermann, Eberhard;
 Strathmann, Siegfried; Lorenz, Gisela; Stierl, Reinhard

PA Basf Aktiengesellschaft, Germany

SO PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003043993	A1	20030530	WO 2002-EP12807	20021115
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2467683	AA	20030530	CA 2002-2467683	20021115
	AU 2002352015	A1	20030610	AU 2002-352015	20021115
	EP 1448532	A1	20040825	EP 2002-787691	20021115
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002014253	A	20041214	BR 2002-14253	20021115
	CN 1606547	A	20050413	CN 2002-825535	20021115
	JP 2005514363	T2	20050519	JP 2003-545630	20021115
	ZA 2004004835	A	20050620	ZA 2004-4835	20040618
PRAI	DE 2001-10156279	A	20011119		
	WO 2002-EP12807	W	20021115		

OS MARPAT 138:401748

AB Title compds. [I; R1, R2 = H, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl; or NR1R2 = (saturated) (ether-, thio-, sulfoxy-, sulfonyl-interrupted) (R5, R6-substituted) ring; R3 = H, halo, cyano, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyloxy, R4 = H, halo, cyano, OH, mercapto, azido, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, alkenyloxy, alkynyloxy, haloalkoxy, alkylthio, alkenylthio, alkynylthio, haloalkylthio, ON:CR5R6, CR7:NOR5, NR7N:CR5R6, NR5R6, NR7NR5R6, etc.; R5-R7 = H, alkyl, alkenyl, alkynyl, haloalkyl, etc.; X = halo, alkyl, alkoxy, haloalkyl; m = 1-5], were prepared Thus, NaH in DMF was treated with acetoxime followed by stirring for 1 h at 20°-25°. The reaction mixture was treated with 1 g [6-chloro-2-methanesulfonyl-5-(2,4,6-trifluorophenyl)pyrimidin-4-yl]-((S)-1-trifluoromethylethyl)amine followed by stirring for 14 h at 20°-25° to give 0.6 g [6-chloro-2-(N-isopropylidienehydrazino)-5-(2,4,6-trifluorophenyl)-pyrimidin-4-yl]-((S)-1-trifluoromethylethyl)amine. The latter at 250 ppm gave 93% control of Septoria tritici on wheat.

IT 531518-39-5P


RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN

(Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phenylpyrimidines as agricultural fungicides)

RN 531518-39-5 CAPLUS

CN 4-Pyrimidinamine, 6-chloro-5-(2-fluorophenyl)-2-(methylthio)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 51 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:301049 CAPLUS

DN 138:321058

TI C2-, C6- and 9-Aryl-substituted purine and other heteroaryl kinase inhibitor scaffolds and methods for their preparation

IN Ding, Sheng; Ding, Qiang; Gray, Nathanael S.

PA IRM LLC, Bermuda

SO PCT Int. Appl., 68 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003031406	A2	20030417	WO 2002-US32680	20021012
	WO 2003031406	A3	20060105		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2463563	AA	20030417	CA 2002-2463563	20021012
	US 2003191312	A1	20031009	US 2002-270030	20021012
	JP 2005512972	T2	20050512	JP 2003-534390	20021012
	EP 1578722	A2	20050928	EP 2002-776216	20021012
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
	US 2006009642	A1	20060112	US 2005-223429	20050909
PRAI	US 2001-328763P	P	20011012		
	US 2001-331835P	P	20011120		
	US 2002-346480P	P	20020107		
	US 2002-348089P	P	20020110		
	US 2001-328741P	P	20011012		
	US 2002-346552P	P	20020107		
	US 2002-347037P	P	20020108		
	US 2002-170031	A3	20020612		
	WO 2002-US32680	W	20021012		

OS CASREACT 138:321058; MARPAT 138:321058

AB General methods for the solution phase as well as solid phase synthesis of various substituted heteroaryls, particularly C2-, C6- and 9-aryl-substituted purines (e.g. 2-(2,4-dimethoxyphenyl)-6-(4-methoxybenzylamino)-9-isopropylpurine), was demonstrated. These substituted heteroaryls can be further elaborated by aromatic substitution with amines at elevated temperature or by anilines, boronic acids and phenols via Pd catalyzed cross-coupling reactions. The 1st claim comprises a method of preparing a C2-substituted purine compound, said method comprising: reacting a C2-halogenated purine with A-X (X = -B(OH)₂, -OH, and -NHR₁; R₁ = H, (un)substituted alkyl; A = (un)substituted alkyl, (un)substituted aryl, (un)substituted heterocyclyl) in the presence of a solvent, a base, a carbene ligand and a Pd catalyst. The 2nd claims narrows the 1st claim to purines I wherein R₂ = H, (un)substituted alkyl, (un)substituted aryl, (un)substituted heterocyclyl; X' = direct bond, NR₁ and O; X'' = direct bond, O and NR₃, with the proviso that when X' is NR₃, Y is R₄ or A', and


when X' is O or a direct bond, Y is A'; A' = (un)substituted alkyl, (un)substituted aryl, (un)substituted arylalkyl, (un)substituted heterocyclyl; R3 = H, (un)substituted alkyl; and R4 = (un)substituted alkyl. Similar claims pertain to C6-substituted purines. Also claimed is a method of preparing a 9-aryl substituted purines, the method comprising: reacting a 2,6-dihalogenated purine with Ar-B(OH)₂ (Ar = (un)substituted aryl, and (un)substituted heterocyclyl) in the presence of a solvent and a Cu catalyst. Also claimed is a method for synthesizing a substituted heteroaryl, the method comprising: providing a dihaloheteroaryl scaffold moiety and capturing the dihaloheteroaryl scaffold moiety on a resin by nucleophilic substitution of a 1st halogen by a resin-bound amine nucleophile to afford a resin-bound amine substituted monohaloheteroaryl. Substitution of the 2nd halogen is done by nucleophilic displacement (e.g. by aniline, phenol, amine, boronic acid) or coupling (e.g. palladium-mediated). An initial substitution (e.g. alkylation, acylation, coupling) can be done prior to substitution of the 1st halogen. Example procedures are included for: boronic acid coupling, aniline coupling, phenol coupling, purine N9 arylation via boronic acids/cupric acetate, reductive amination for synthesis of PAL-resin-bound amine, resin capture of dichloroheterocycles, substitution of remaining chloro group with boronic acids via Suzuki coupling and product cleavage, substitution of remaining chloro group with anilines or amines via palladium-catalyzed reaction and product cleavage, substitution of remaining chloro group with phenols via palladium-catalyzed reaction and product cleavage, substitution of remaining chloro group with amines via non-palladium-catalyzed amination reaction without base and product cleavage, and substitution of remaining chloro group with amines via non-palladium-catalyzed amination reaction with KOtBu as base and product cleavage. Tables of purity and yields for various heteroaryl combinatorial libraries are included as validation of the following methods: palladium catalyzed cross-coupling reactions for derivatizing resin-bound 2-chloro-6-aminopurine with boronic acids, anilines, amines and phenols, resin-bound chloroheterocyclic scaffolds which can be derivatized via Suzuki coupling reaction, resin-bound chloroheterocyclic scaffolds which can be derivatized via palladium catalyzed amination reaction, and resin-bound chloroheterocyclic scaffolds which can be derivatized via palladium catalyzed C-O bond formation reaction.

IT **406932-41-0P**, 4-(4-Methoxybenzylamino)-2-(3-methoxyphenyl)pyrimidine **406932-42-1P**, 4-(4-Methoxybenzylamino)-2-(3-methoxyphenyl)-5-methylpyrimidine **406932-43-2P**, 4-(4-Methoxybenzylamino)-2-(3-methoxyphenyl)-6-methylpyrimidine **406932-44-3P**, 4-(4-Methoxybenzylamino)-6-(3-methoxyphenyl)pyrimidine **406932-45-4P**, 4-(4-Methoxybenzylamino)-6-(3-methoxyphenyl)pyrimidin-2-amine
 RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)
 (C2-, C6- and 9-Aryl-substituted purine and other heteroaryl kinase inhibitor scaffolds and methods for their preparation)
 RN **406932-41-0** CAPLUS
 CN 4-Pyrimidinamine, 2-(3-methoxyphenyl)-N-[(4-methoxyphenyl)methyl]- (9CI)
 (CA INDEX NAME)




RN 406932-42-1 CAPLUS

CN 4-Pyrimidinamine, 2-(3-methoxyphenyl)-N-[(4-methoxyphenyl)methyl]-5-methyl-
(9CI) (CA INDEX NAME)




RN 406932-43-2 CAPLUS

CN 4-Pyrimidinamine, 2-(3-methoxyphenyl)-N-[(4-methoxyphenyl)methyl]-6-methyl-
(9CI) (CA INDEX NAME)



RN 406932-44-3 CAPLUS

CN 4-Pyrimidinamine, 6-(3-methoxyphenyl)-N-[(4-methoxyphenyl)methyl]- (9CI)
(CA INDEX NAME)




RN 406932-45-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(3-methoxyphenyl)-N4-[(4-methoxyphenyl)methyl]-

10/671,070

(9CI) (CA INDEX NAME)



L10 ANSWER 52 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:261678 CAPLUS

DN 138:287691

TI Preparation of 4-aminopyrimidine derivatives as insulin secretion accelerators

IN Yonetoku, Yasuhiro; Maruyama, Tatsuya; Negoro, Kenji; Moritomo, Hiroyuki; Imanishi, Naoki; Shimada, Itsuro; Moritomo, Ayako; Hamaguchi, Wataru; Misawa, Hana; Yoshida, Shigeru; Ohishi, Takahide

PA Yamanouchi Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003026661	A1	20030403	WO 2002-JP9350	20020912
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI JP 2001-279671 A 20010914

JP 2002-121012 A 20020423

OS MARPAT 138:287691

AB Disclosed are insulin secretion accelerators containing the 4-aminopyrimidine derivs. [I; R11 = A11-D11 (wherein A11 = single bond, lower alkylene, lower alkenylene; D11 = each (un)substituted aryl, cycloalkyl, or aromatic or non-aromatic heterocyclyl); R12 = H, lower alkyl optionally substituted by ≥ 1 groups selected from aryl, halo, lower alkoxy, and OH; R13 = H, Me, F; R14 = H, lower alkyl optionally substituted by ≥ 1 halogens; R15 = A15-D15 (wherein A15 = single bond, lower alkylene, lower alkenylene; D15 = H, lower alkoxy, amino optionally substituted by 1 or 2 groups selected from lower alkyl and aryl, each (un)substituted aryl, cycloalkyl, or aromatic or non-aromatic heterocyclyl)] or pharmaceutically acceptable salts thereof as the active ingredients. These compds. are highly effective in promoting insulin secretion, increasing insulin content, and inhibiting blood sugar level from increasing and are usable for treatments for insulin-dependent diabetes, non-insulin-dependent diabetes, insulin-resistant diseases, and obesity. Thus, a mixture of 284 mg 2-(4-bromophenyl)-4-chloro-6-methylpyrimidine, 1 mL 70% aqueous ethylamine solution, 2 mL MeOH was stirred at room temperature for 2 h and at 60° for 3 h, treated again with 1 mL 70% aqueous ethylamine solution, and stirred at 60° for 5 h to give 198 mg N-[2-(4-bromophenyl)-6-methylpyrimidin-4-yl]ethylamine (II). II in vitro promoted the secretion of insulin in mouse spleen β -cells by 159% vs. 122% for Glibenclamide.

IT 504401-70-1P 504401-72-3P 504401-74-5P

504401-76-7P 504401-78-9P 504401-80-3P

504401-82-5P 504401-84-7P 504401-86-9P

504401-88-1P 504401-90-5P 504401-91-6P

504401-93-8P 504401-95-0P 504402-60-2P

504403-06-9P 504403-07-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of 4-aminopyrimidine derivs. as insulin secretion accelerators
for treating diabetes, insulin-resistant diseases, and obesity)


RN 504401-70-1 CAPLUS

CN 4-Pyrimidinamine, 2-(4-bromophenyl)-6-ethyl-N-(phenylmethyl)-,
ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 504401-69-8


CMF C19 H18 Br N3



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 504401-72-3 CAPLUS

CN 4-Pyrimidinamine, 2-(4-bromophenyl)-6-ethyl-N-[(4-fluorophenyl)methyl]-,
ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 504401-71-2

CMF C19 H17 Br F N3



CM 2


CRN 144-62-7
CMF C2 H2 O4



RN 504401-74-5 CAPLUS
CN 4-Pyrimidinamine, 2-(4-bromophenyl)-6-ethyl-N-[(4-methylphenyl)methyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 504401-73-4
CMF C20 H20 Br N3



CM 2


CRN 144-62-7
CMF C2 H2 O4



RN 504401-76-7 CAPLUS
CN 4-Pyrimidinamine, 2-(4-bromophenyl)-6-ethyl-N-[(4-methoxyphenyl)methyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 504401-75-6
CMF C20 H20 Br N3 O



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 504401-78-9 CAPLUS

CN 4-Pyrimidinamine, 2-(4-bromophenyl)-6-ethyl-N-(2-phenylethyl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 504401-77-8


CMF C20 H20 Br N3



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 504401-80-3 CAPLUS

CN 4-Pyrimidinamine, 2-(4-bromophenyl)-6-ethyl-N-[2-(4-fluorophenyl)ethyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 504401-79-0


CMF C20 H19 Br F N3



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 504401-82-5 CAPLUS

CN 4-Pyrimidinamine, 2-(4-bromophenyl)-N-[2-(4-chlorophenyl)ethyl]-6-ethyl-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 504401-81-4


CMF C20 H19 Br Cl N3



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 504401-84-7 CAPLUS

CN 4-Pyrimidinamine, 2-(4-bromophenyl)-N-[2-(4-bromophenyl)ethyl]-6-ethyl-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 504401-83-6


CMF C20 H19 Br2 N3



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 504401-86-9 CAPLUS

CN 4-Pyrimidinamine, 2-(4-bromophenyl)-6-ethyl-N-[2-(4-methylphenyl)ethyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 504401-85-8


CMF C21 H22 Br N3



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 504401-88-1 CAPLUS

CN Phenol, 4-[2-[[2-(4-bromophenyl)-6-ethyl-4-pyrimidinyl]amino]ethyl]-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 504401-87-0


CMF C20 H20 Br N3 O



CM 2

CRN 144-62-7


CMF C2 H2 O4



RN 504401-90-5 CAPLUS
 CN 4-Pyrimidinamine, 2-(4-bromophenyl)-6-ethyl-N-[2-(2-methoxyphenyl)ethyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 504401-89-2
 CMF C21 H22 Br N3 O




CM 2

CRN 144-62-7
 CMF C2 H2 O4




RN 504401-91-6 CAPLUS
 CN 4-Pyrimidinamine, 2-(4-bromophenyl)-N-[2-(4-methoxyphenyl)ethyl]-6-methyl-, (9CI) (CA INDEX NAME)



RN 504401-93-8 CAPLUS
 CN 4-Pyrimidinamine, 2-(4-bromophenyl)-6-ethyl-N-[2-(4-methoxyphenyl)ethyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 504401-92-7
CMF C21 H22 Br N3 O



CM 2


CRN 144-62-7
CMF C2 H2 O4



RN 504401-95-0 CAPLUS
CN 4-Pyrimidinamine, 2-(4-bromophenyl)-6-ethyl-N-(3-phenylpropyl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 504401-94-9
CMF C21 H22 Br N3




CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 504402-60-2 CAPLUS

CN 8-Quinolineethanamine, N-[2-(4-bromophenyl)-6-methyl-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)


RN 504403-06-9 CAPLUS

CN 4-Pyrimidinamine, N-(1,3-benzodioxol-5-ylmethyl)-2-(3-chloro-4-fluorophenyl)-6-ethyl- (9CI) (CA INDEX NAME)



RN 504403-07-0 CAPLUS

CN Phenol, 4-[2-[[2-(3-chloro-4-fluorophenyl)-6-ethyl-4-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 53 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:242160 CAPLUS

DN 138:271705

TI Preparation of triazinyl and other carboxamides as inhibitors of histone deacetylase

IN Delorme, Daniel; Woo, Soon Hyung; Vaisburg, Arkadii; Moradel, Oscar; Leit, Silvana; Raepfel, Stephane; Frechette, Sylvie; Bouchain, Giliane

PA Methylgene, Inc., Can.

SO PCT Int. Appl., 347 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003024448	A2	20030327	WO 2002-US29017	20020912
	WO 2003024448	A3	20031113		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2465978	AA	20030327	CA 2002-2465978	20020912
	EP 1429765	A2	20040623	EP 2002-763627	20020912
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
	BR 2002012510	A	20040824	BR 2002-12510	20020912
	CN 1578663	A	20050209	CN 2002-822690	20020912
	JP 2005508905	T2	20050407	JP 2003-528544	20020912
	JP 2005255683	A2	20050922	JP 2005-80310	20050318
PRAI	US 2001-322402P	P	20010914		
	US 2002-391728P	P	20020626		
	JP 2003-528544	A3	20020912		
	WO 2002-US29017	W	20020912		

OS MARPAT 138:271705

AB The invention relates to triazines (shown as I; variables defined below; e.g. 4-[[4-amino-6-(2-indanylamino)-[1,3,5]triazin-2-ylamino]methyl]-N-(2-aminophenyl)benzamide) and Cy3-X1-Ar2-(C(R5):C(R6))qC(O)NH-Ay2 (II; variables defined below; e.g.), many of which are N-(o-aminophenyl)carboxamides, as inhibitors of histone deacetylase (data included for many I and II). The invention provides compds. and methods for inhibiting histone deacetylase enzymic activity. The invention also provides compns. and methods for treating cell proliferative diseases and conditions. Antineoplastic effects of some I and II are illustrated for colorectal, pulmonary and pancreatic neoplasms; also the combined antineoplastic effect of histone deacetylase inhibitors and histone deacetylase antisense oligonucleotides on tumor cells in vivo was demonstrated. For I: R3 and R4 = H, L1, Cyl and -L1-Cyl (L1 = C1-C6 alkyl, C2-C6 heteroalkyl, or C3-C6 alkenyl; Cyl = cycloalkyl, aryl, heteroaryl, or heterocyclyl) or R3 and R4 are taken together with the adjacent N atom to form a 5-, 6-, or 7-membered ring, wherein the ring atoms = C, O, S, and N, and wherein the ring is optionally substituted, and optionally forms part of a bicyclic ring system, or is optionally

fused to one or two aryl or heteroaryl rings, or to one or two saturated or partially unsatd. cycloalkyl or heterocyclic rings, each of which rings and ring systems is optionally substituted. Y1 = -N(R1)(R2), -CH₂-C(O)-N(R1)(R2), halogen, and H (R1 and R2 = H, L1, Cy1, and -L1-Cy1). Y2 = chemical bond or N(R0) (R0 = H, alkyl, aryl, aralkyl, and acyl); Ak1 = C1-C6 alkylene, C1-C6-heteroalkylene (preferably, in which one -CH₂- is replaced with -NH-, and more preferably -NH-CH₂), C2-C6 alkenylene or C2-C6 alkynylene; Ar1 = arylene or heteroarylene, either of which is optionally substituted; and Z1 = C(O)NH-Ay1 and CH:CHC(O)NH-Ay1 (Ay1 = aryl or heteroaryl, each of which is optionally substituted). For II: Cy2 = cycloalkyl, aryl, heteroaryl, or heterocyclyl; X1 = covalent bond, M1-L2-M1, and L2-M2-L2 (L2 = chemical bond, C1-C4 alkylene, C2-C4 alkenylene, and C2-C4 alkynylene, provided that L2 is not a chemical bond when X1 is M1-L2-M1; M1 = -O-, -N(R7)-, -S-, -S(O)-, S(O)₂-, -S(O)₂N(R7)-, -N(R7)S(O)₂-, -C(O)-, -C(O)NH-, -NHC(O)-, -NHC(O)-O- and -OC(O)NH- (R7 = H, alkyl, aryl, aralkyl, acyl, heterocyclyl, and heteroaryl); and M2 = M1, heteroarylene, and heterocyclylene, either of which rings is optionally substituted). Ar2 = arylene or heteroarylene, each of which is optionally substituted; R5 and R6 = H, alkyl, aryl, and aralkyl; q is 0 or 1; and Ay2 is a 5-6 membered cycloalkyl, heterocyclyl, or heteroaryl substituted with an amino or hydroxy moiety (preferably these groups are ortho to the amide N to which Ay2 is attached) and further optionally substituted; provided that when Cy2 is naphthyl, X1 is -CH₂-, Ar2 is Ph, R5 and R6 are H, and q is 0 or 1, Ay2 is not Ph or o-hydroxyphenyl. Although the methods of preparation are not claimed, hundreds of example preps. are included.


IT 503043-79-6P, N-(2-Aminophenyl)-4-(((4-chloro-6-(3,4-dimethoxyphenyl)pyrimidin-2-yl)amino)methyl)benzamide 503043-80-9P, N-(2-Aminophenyl)-4-(((4-(3,4-dimethoxyphenyl)pyrimidin-2-yl)amino)methyl)benzamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of triazinyl and other carboxamides as inhibitors of histone deacetylase for treating cell proliferative disorders)

RN 503043-79-6 CAPLUS


CN Benzamide, N-(2-aminophenyl)-4-[[[4-chloro-6-(3,4-dimethoxyphenyl)-2-pyrimidinyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 503043-80-9 CAPLUS

CN Benzamide, N-(2-aminophenyl)-4-[[[4-(3,4-dimethoxyphenyl)-2-pyrimidinyl]amino]methyl]- (9CI) (CA INDEX NAME)

10/671,070



L10 ANSWER 54 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:133247 CAPLUS
 DN 138:187783
 TI Pyrimidin-2-amines as selective inhibitors of COX-2
 IN Carter, Malcolm Clive; Naylor, Alan; Payne, Jeremy John; Pegg, Neil
 Anthony
 PA Glaxo Group Limited, UK
 SO PCT Int. Appl., 27 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003014091	A1	20030220	WO 2002-GB3601	20020805
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP	1414807	A1	20040506	EP 2002-747620	20020805
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP	2005501086	T2	20050113	JP 2003-519041	20020805
US	2004248916	A1	20041209	US 2004-486001	20040729
US	7056928	B2	20060606		
PRAI	GB 2001-19477	A	20010809		
	WO 2002-GB3601	W	20020805		

OS MARPAT 138:187783

AB The title compds. I [R1, R2 = H, alkyl; R3 = alkyl, NH2, R6CONH; R4 = H, alkyl; R5 = CH2F, CHF2, CF3CH2, CF3CHF, CF3CF2; A = (un)substituted 5-6 membered aryl; R6 = H, alkyl, alkoxy, etc.; n = 0-4] which are potent and selective inhibitors of COX-2, and are of use in the treatment of the pain, fever, inflammation of a variety of conditions and diseases, were prepared E.g., a general procedure for synthesis of II which showed IC50 of 22 nM against COX-2 vs. IC50 of 17,700 nM against COX-1, was given.


IT **497943-83-6P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidin-2-amines as selective inhibitors of COX-2 for treating inflammatory disorders)

RN 497943-83-6 CAPLUS

CN 2-Pyrimidinamine, 4-(fluoromethyl)-6-[4-(methylsulfonyl)phenyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



(Handwritten mark resembling a stylized 'X' or '8')

RE.CNT 3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 55 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:98255 CAPLUS

DN 138:287627

TI Suzuki Cross-Coupling of Solid-Supported Chloropyrimidines with Arylboronic Acids

AU Wade, Janice V.; Krueger, Clinton A.

CS ChemRx Division, Discovery Partners International Inc., South San Francisco, CA, 94080, USA

SO Journal of Combinatorial Chemistry (2003), 5(3), 267-272

CODEN: JCCHFF; ISSN: 1520-4766

PB American Chemical Society

DT Journal

LA English

OS CASREACT 138:287627

AB The utility of the Suzuki cross-coupling to synthesize biaryl compds. is expanded herein to include reactions of resin-supported chloropyrimidines with boronic acids. In particular, an efficient method is described for the synthesis of a library of biaryl compds. from solid-supported chloropyrimidines. The Suzuki reaction was performed in an inert atmosphere using Pd2(dba)3/P(t-Bu)3 as catalyst, spray-dried KF as base, and THF as solvent. The reaction was allowed to proceed overnight at 50 °C. Upon cleavage with acid, a library of 4-(substituted amino)-6-arylpymidines, e.g. I, was obtained in moderate yield and high purity.


IT **503610-78-4DP**, resin-supported **503610-80-8DP**, resin-supported

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(Suzuki cross-coupling of solid-supported chloropyrimidines with arylboronic acids)


RN 503610-78-4 CAPLUS

CN 4-Pyrimidinamine, 6-(4-ethylphenyl)-N-[2-(3-fluorophenyl)ethyl]-2-(methylthio)- (9CI) (CA INDEX NAME)



RN 503610-80-8 CAPLUS

CN Ethanone, 1-[3-[6-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)




IT **503610-78-4P 503610-80-8P**

RL: SPN (Synthetic preparation); PREP (Preparation)

(Suzuki cross-coupling of solid-supported chloropyrimidines with arylboronic acids)


RN 503610-78-4 CAPLUS

CN 4-Pyrimidinamine, 6-(4-ethylphenyl)-N-[2-(3-fluorophenyl)ethyl]-2-(methylthio)- (9CI) (CA INDEX NAME)



RN 503610-80-8 CAPLUS

CN Ethanone, 1-[3-[6-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-4-pyrimidinyl]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 56 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:977601 CAPLUS

DN 138:55972

TI Preparation of pyrimidine inhibitors of phosphodiesterase (PDE) 7

IN Guo, Junqing; Barbosa, Joseph; Pitts, William John; Carlsen, Marianne; Quesnelle, Claude; Dodier, Marco

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 165 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 7


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002102313	A2	20021227	WO 2002-US19097	20020617
	WO 2002102313	A3	20030403		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2450934	AA	20021227	CA 2002-2450934	20020617
	US 2003162802	A1	20030828	US 2002-173442	20020617
	EP 1397142	A2	20040317	EP 2002-744381	20020617
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2005500294	T2	20050106	JP 2003-504902	20020617
	US 2006116516	A1	20060601	US 2005-281246	20051117
PRAI	US 2001-299287P	P	20010619		
	US 2002-355141P	P	20020208		
	US 2002-368752P	P	20020329		
	US 2002-173322	A3	20020617		
	WO 2002-US19097	W	20020617		
OS	MARPAT 138:55972				
AB	The title compds. [I; R1 = H, alkyl; R2 = (un)substituted heteroaryl, heterocyclyl, aryl, aryl fused to heteroaryl or heterocyclyl; Z = halo, alkyl, aryl, etc.; J = H, halo, alkyl, etc.; L = H, halo, haloalkyl, etc.], phosphodiesterase 7 (PDE 7) inhibitors (including both selective inhibitors of PDE 7, and dual inhibitors of PDE 7 and phosphodiesterase 4) which are useful in treating T-cell mediated diseases, were prepared E.g., a multi-step synthesis of II, starting from 2-imino-4-thiobiuret and Et 2-chloroacetoacetate, was given.				
IT	479230-18-7P 479230-36-9P 479230-49-4P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of pyrimidine inhibitors of phosphodiesterase (PDE) 7)				
RN	479230-18-7 CAPLUS				
CN	5-Thiazolecarboxylic acid, 4-methyl-2-[[4-[[[4-(methylsulfonyl)phenyl]methyl]amino]-6-(3,4,5-trimethoxyphenyl)-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)				



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 479230-36-9 CAPLUS


CN 5-Thiazolecarboxylic acid, 2-[[[4-(4-cyanophenyl)-6-[[[4-(methylsulfonyl)phenyl]methyl]amino]-2-pyrimidinyl]amino]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 479230-49-4 CAPLUS

CN 5-Thiazolecarboxylic acid, 2-[[[4-[[[4-(aminosulfonyl)phenyl]methyl]amino]-6-(4-carboxyphenyl)-2-pyrimidinyl]amino]-4-methyl-, 5-ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L10 ANSWER 57 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:927411 CAPLUS

DN 138:14068

TI Preparation of methylsulfonylphenylpyrimidines as cyclooxygenase-2 inhibitors.

IN Green, Richard Howard; Bravi, Gianpaolo; Carter, Malcolm; Hartley, Charles David; Naylor, Alan; Pass, Martin; Payne, Jeremy John; Pegg, Neil Anthony

PA Glaxo Group Limited, UK; Green, Jennifer Margaret

SO PCT Int. Appl., 35 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002096886	A1	20021205	WO 2002-GB2408	20020523
	WO 2002096886	C1	20040722		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1390352	A1	20040225	EP 2002-738325	20020523
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2004532264	T2	20041021	JP 2003-500065	20020523
PRAI	GB 2001-12803	A	20010525		
	WO 2002-GB2408	W	20020523		

OS MARPAT 138:14068

AB Title compds. [I; R1, R2 = H, A, fluoroalkyl, alkenyl, alkynyl, cycloalkylalkyl, bridged cycloalkyl, X(CR7R8)n, B(CR7R8)n; R3 = A, NH2, R10CONH; R4 = fluoroalkyl; R5 = H, A, fluoroalkyl, halo, cycloalkylalkyl; when R6 = H, then R5 ≠ H; R6 = H, A, fluoroalkyl, halo, alkoxy, CN, NO2, AOCO, NH2CO, ANHCO, NH2, ANH, A2N, A2NCO, ACONH, NH2SO2, ANHSO2, A2NSO2, ASO2NH, ArSO2NH, ASO2, ArSO2, alkenyl, alkynyl; when R5 = H then R6 ≠ H; R7, R8 = H, A; X = unsubstituted 5- or 6-membered heteroaryl, unsubstituted 6-membered aryl, 5- or 6-membered heteroaryl, 6-membered aryl substituted by ≥1 R9; R9 = OH, halo, A, fluoroalkyl, alkoxy, fluoroalkoxy, NH2SO2, ASO2; B = oxetanyl, tetrahydrofuryl, tetrahydropyranyl, etc.; R10 = H, A, alkoxy, AOA, Ph, HO2CA, AOCOA, AOCO, H2NA, AOCONHA, ACONHA; A = alkyl], were prepared Thus, 5-methyl-2-(methylsulfonyl)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidine (preparation given) was stirred with PhCH2NH2 in 1-methyl-2-pyrrolidinone overnight at room temperature to give N-benzyl-5-methyl-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidin-2-amine. This at 10 μM gave 61% inhibition of human cyclooxygenase-2.

IT **477770-88-0P**, N-Benzyl-5-methyl-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidin-2-amine **477770-90-4P**


477770-92-6P 477771-01-0P 477771-02-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of methylsulfonylphenylpyrimidines as cyclooxygenase-2 inhibitors)


RN 477770-88-0 CAPLUS

CN 2-Pyrimidinamine, 5-methyl-4-[4-(methylsulfonyl)phenyl]-N-(phenylmethyl)-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 477770-90-4 CAPLUS

CN Phenol, 2-[[[5-methyl-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 477770-92-6 CAPLUS

CN 2-Pyrimidinamine, 5-methyl-N-[(4-methylphenyl)methyl]-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 477771-01-0 CAPLUS

CN 2-Pyrimidinamine, N-[(4-methoxyphenyl)methyl]-5-methyl-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 477771-02-1 CAPLUS

CN 2-Pyrimidinamine, N-[(4-fluorophenyl)methyl]-5-methyl-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 58 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:927396 CAPLUS

DN 138:13955

TI Preparation of phenol and hydroxynaphthalene based inhibitors of protein kinase for the treatment of disease

IN Cao, Sheldon Xiaodong; Bounaud, Pierre-Yves; Chen, Xiaohua; Chung, Hyun-Ho; Dumas, David Paul; Kc, Sunil Kumar; Min, Changhee; Yang, Jae Young; Long, Mellissa C.

PA LG Biomedical Institute, USA

SO PCT Int. Appl., 286 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002096867	A2	20021205	WO 2002-US16920	20020528
	WO 2002096867	A3	20040304		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002310187	A1	20021209	AU 2002-310187	20020528
	US 2003187007	A1	20031002	US 2002-158030	20020528
	US 2003208067	A1	20031106	US 2002-158103	20020528
	EP 1412327	A2	20040428	EP 2002-737248	20020528
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004534779	T2	20041118	JP 2003-500047	20020528
PRAI	US 2001-294792P	P	20010530		
	WO 2002-US16920	W	20020528		

OS MARPAT 138:13955

AB Phenol and hydroxynaphthalene derivs. I [X = O, S, amine, alkylamine, alkynylamine, arylamine, and heteroarylamine; R1 = (un)substituted 5- or 6-membered aromatic or heteroarom. ring, -(X1)mCOX2-, wherein X1 = alkylene, alkenylene, alkynylene, aryl and heteroaryl, X2 = H, alkyl, aryl, heteroaryl, OH, alkoxy, amino, substituted amine, m = 0 or 1, or R1 = -C(X3)=N-NX4-C(=E)-NX5X6 wherein X3 = H, alkyl, aryl, alkylaryl, heteroaryl, and amino and E = O, S, and substituted amine with X4, X5, and X6 independently equal to H, alkyl, aryl, and heteroaryl; R2, R3, and R4 = H, alkyl, alkylene, halo, alkoxy, etc.; or R2 and R3 or R3 and R4 may be taken together to form an (un)substituted aromatic or heteroarom. ring; R5 = H, (un)substituted-alkyl, -aryl, -heterocycle, etc.; R6 = H, alkyl, alkene, alkyne, aryl, and heteroaryl] are prepared and disclosed as inhibitors of protein kinase. Thus, II was prepared by cyclocondensation of 5'-bromo-2'-methoxyacetophenone with N,N-dimethylformamide di-Et acetal with subsequent Suzuki coupling with 4-methoxyphenylboronic acid. In assays to determine cyclin dependent kinase activity, specifically against CDK2 and CDK5, II possessed IC50 values of 0-0.5 μ M. II proved highly specific for CDK2 and CDK5 and was further evaluated by in vitro tumor cell efficacy tests against numerous cancers. The present invention is directed in part towards methods of modulating the function of protein

kinases with phenol- and hydroxynaphthalene-based compds. The methods incorporate cells that express a protein kinase. In addition, the invention describes methods of preventing and treating protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to phenol- and hydroxynaphthalene-based compds. and pharmaceutical compns. comprising these compds.

IT 477727-17-6P 477727-24-5P 477727-25-6P


477727-26-7P 477727-27-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of phenol and hydroxynaphthalene based inhibitors of protein kinase)


RN 477727-17-6 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[[[1,1'-biphenyl]-2-ylmethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 477727-24-5 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[[[3-fluorophenyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 477727-25-6 CAPLUS


CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[[[2-fluorophenyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 477727-26-7 CAPLUS


CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[[[3-methoxyphenyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 477727-27-8 CAPLUS

CN [1,1'-Biphenyl]-4,4'-diol, 3-[2-amino-6-[[4-methoxyphenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 59 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:864729 CAPLUS
 DN 138:238120
 TI Synthesis of 2-amino- and 2-hydrazino-substituted 5-nitro-4,6-diphenylpyrimidines
 AU Sedova, V. F.; Shkurko, O. P.; Nekhoroshev, S. A.
 CS Novosibirsk N. N. Vorozhtsov Institute of Organic Chemistry, Siberian Branch, Russian Academy of Sciences, Novosibirsk, 630090, Russia
 SO Chemistry of Heterocyclic Compounds (New York, NY, United States) (Translation of Khimiya Geterotsiklicheskikh Soedinenii) (2002), 38(5), 564-570
 CODEN: CHCCAL; ISSN: 0009-3122
 PB Kluwer Academic/Consultants Bureau
 DT Journal
 LA English
 OS CASREACT 138:238120
 AB Nitrogen-containing derivs. of 5-nitro-4,6-diphenylpyrimidine have been synthesized by the reaction of 2-chloro-5-nitro-4,6-diphenylpyrimidine with amines or of 2-hydrazino-5-nitro-4,6-diphenylpyrimidine with carbonyl or β -dicarbonyl compds. Their structures were confirmed by IR spectroscopy and mass spectrometry.
 IT **502159-40-2P**
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (preparation and spectra of amino- and hydrazino-substituted nitrodiphenylpyrimidines from reaction of pyrimidine derivs. with amine and (di)carbonyl compds.)
 RN 502159-40-2 CAPLUS
 CN 2-Pyrimidinamine, 5-nitro-4,6-diphenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 60 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:814853 CAPLUS

DN 137:325431

TI Preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors

IN Nuss, John M.; Harrison, Stephen D.; Ring, David B.; Boyce, Rustum S.; Johnson, Kirk; Pfister, Keith B.; Ramurthy, Savithri; Seely, Lynn; Wagman, Allan S.; Desai, Manjo; Levine, Barry H.

PA USA

SO U.S. Pat. Appl. Publ., 134 pp., Cont.-in-part of U.S. 6,417,185.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002156087	A1	20021024	US 2001-949035	20010906
	US 7045519	B2	20060516		
	US 6417185	B1	20020709	US 1999-336038	19990618
	US 2003130289	A1	20030710	US 2002-309535	20021203
	US 7037918	B2	20060502		
	US 2006089369	A1	20060427	US 2005-220400	20050906
PRAI	US 1998-89978P	P	19980619		
	US 1999-336038	A2	19990618		
	US 2000-230480P	P	20000906		
	US 1999-336098	A3	19990618		
	US 2001-949035	A3	20010906		


OS MARPAT 137:325431

AB Title compds. I [wherein W = (un)substituted C or N; X and Y = independently N, O, or (un)substituted C; A = (un)substituted (hetero)aryl; R1, R1a, R2, R2a, R3, R3a, R4, and R4a = independently H, OH, alkoxy, acyl, (hetero)aryl, or (un)substituted (cyclo)alkyl, amino(alkyl), etc. ; R5 and R7 = independently H, halo, alkoxy, guanidiny, (bi)aryl, hetero(bi)aryl, heterocycloalkyl, arylsulfonamido, or (un)substituted (cyclo)alkyl, amino(alkoxy), or amidino; R6 = H, halo, carboxyl, NO2, (cyclo)amido, (cyclo)amidino, (cyclo)imido, CN, alkoxy, acyl(oxy), guanidiny, (hetero)aryl, heterocyclo(alkyl), arylsulfonyl, arylsulfonamido, or (un)substituted alkyl, amino, etc.] were prepared as glycogen synthase kinase 3 (GSK3) inhibitors. For example, 2-chloro-5-nitropyridine was aminated by H₂N(CH₂)₃NH₂ and the product N-acylated by benzotriazolecarboxamidinium tosylate to give the alkylguanidine. The latter was cyclocondensed with resin-bound 4-(MeCO)C₆H₄CONHCH₂C₆H₄Br-3 and Cs₂CO₃ to afford, after resin cleavage, the pyrimidinamine II. The most preferred compds. of the invention exhibited inhibitory activity against human GSK3 β in a cell free assay with IC₅₀ values of < 1 μ M. Thus, I and compns. containing I may be employed alone or in combination with other pharmacol. active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency, or cancer (no data).

IT 252904-40-8P, Benzonitrile, 4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-5-[(phenylmethyl)amino]-4-pyrimidinyl]-RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminopyrimidines and -pyridines as glycogen synthase kinase

3 inhibitors)
 RN 252904-40-8 CAPLUS
 CN Benzonitrile, 4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-5-
 [(phenylmethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



IT 403806-74-6, 4-[2-[[(3-Methylphenyl)methyl]amino]pyrimidin-4-yl]benzamide 403806-75-7, 4-[2-[[(4-Aminophenyl)methyl]amino]pyrimidin-4-yl]benzamide 403806-80-4, 4-[2-[[(4-Cyanophenyl)methyl]amino]pyrimidin-4-yl]benzamide 403806-81-5, 4-[2-[[(3-Methoxyphenyl)methyl]amino]pyrimidin-4-yl]benzamide 403806-82-6, 4-[2-[[(4-Methoxyphenyl)methyl]amino]pyrimidin-4-yl]benzamide 403806-83-7, 4-[2-[[2- (4-Fluorophenyl)ethyl]amino]pyrimidin-4-yl]benzamide 403806-87-1, 4-[2-[[(3-Chlorophenyl)methyl]amino]pyrimidin-4-yl]benzamide 403806-92-8, 4-[2-[[(4-Phenylbutyl)amino]pyrimidin-4-yl]benzamide 403806-94-0, 4-[2-[[2- (3-Methoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzamide 403806-98-4, 4-[2-[[(3-Nitrophenyl)methyl]amino]pyrimidin-4-yl]benzamide 403807-02-3, 4-[2-[[2- (3-Chlorophenyl)ethyl]amino]pyrimidin-4-yl]benzamide 403807-03-4, 4-[2-[[(Naphthylmethyl)amino]pyrimidin-4-yl]benzamide 403807-07-8, 4-[2-[[2- (2,5-Dimethoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzenecarbonitrile 403807-11-4, 4-[2-[[2- (2H-Benzo[3,4-d]-1,3-dioxolan-5-yl)ethyl]amino]pyrimidin-4-yl]benzamide 403807-12-5, 4-[2-[[2- (4-Nitrophenyl)ethyl]amino]pyrimidin-4-yl]benzamide 403807-13-6, 4-[2-[[(2,6-Dimethoxyphenyl)methyl]amino]pyrimidin-4-yl]benzamide 403807-14-7, 4-[2-[[(3,4-Dimethoxyphenyl)methyl]amino]pyrimidin-4-yl]benzamide 403807-19-2, 4-[2-[[(3-(Trifluoromethyl)phenyl)methyl]amino]pyrimidin-4-yl]benzamide 403807-20-5, 4-[2-[[(4-(Trifluoromethyl)phenyl)methyl]amino]pyrimidin-4-yl]benzamide 403807-21-6, 4-[2-[[(3,5-Dichlorophenyl)methyl]amino]pyrimidin-4-yl]benzamide 403807-23-8, 4-[2-[[(2,4-Dichlorophenyl)methyl]amino]pyrimidin-4-yl]benzamide 403807-37-4, 4-[2-[[(4-Bromophenyl)methyl]amino]pyrimidin-4-yl]benzamide 403807-38-5, 4-[2-[[(4-(4-


Fluorophenyl)phenyl)methyl]amino]pyrimidin-4-yl]benzamide
403807-39-6, 4-[2-[[[3-Bromophenyl)methyl]amino]pyrimidin-4-yl]benzamide **403807-47-6**, 4-[2-[[[3,4,5-Trimethoxyphenyl)methyl]amino]pyrimidin-4-yl]benzamide **403807-49-8**, 4-[2-[[[3-(3-Aminophenyl)phenyl)methyl]amino]pyrimidin-4-yl]benzamide **403807-50-1**, 4-[2-[[[4-(3-Aminophenyl)phenyl)methyl]amino]pyrimidin-4-yl]benzamide **403807-53-4**, Ethyl 4-(4-cyanophenyl)-2-[[2-(3-methoxyphenyl)ethyl]amino]pyrimidine-5-carboxylate **403807-60-3**, 4-[2-[[[3-(3-Methoxyphenyl)phenyl)methyl]amino]pyrimidin-4-yl]benzamide **403807-65-8**, 4-[2-[[[3-[3-(Methylamino)methyl]phenyl]phenyl)methyl]amino]pyrimidin-4-yl]benzamide **403807-78-3**, 4-[2-[[[3-[3-(Acetylamino)phenyl]phenyl)methyl]amino]pyrimidin-4-yl]benzamide **403807-79-4**, 4-[2-[[[3,5-Bis(trifluoromethyl)phenyl)methyl]amino]pyrimidin-4-yl]benzamide **403807-83-0**, 4-[2-[[[3-[3-(Trifluoromethyl)phenyl]phenyl)methyl]amino]pyrimidin-4-yl]benzamide **403808-16-2**, [4-[2-[[[3-Bromophenyl)methyl]amino]pyrimidin-4-yl]phenyl]-N-[(3-methylphenyl)methyl]carboxamide **403808-32-2**, N-[(3-Bromophenyl)methyl]-4-[2-[[2-(3-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403808-46-8** **403809-22-3**, 4-[2-[[2-(2,5-Dimethoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzamide **403809-23-4**, 4-[2-[[2-(2,3-Dimethoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzamide **403810-50-4**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors)


RN 403806-74-6 CAPLUS

CN Benzamide, 4-[2-[[[3-methylphenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-75-7 CAPLUS

CN Benzamide, 4-[2-[[[4-aminophenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-80-4 CAPLUS


CN Benzamide, 4-[2-[[[4-cyanophenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-81-5 CAPLUS

CN Benzamide, 4-[2-[[(3-methoxyphenyl)methyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)

RN 403806-82-6 CAPLUS


CN Benzamide, 4-[2-[[(4-methoxyphenyl)methyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)

RN 403806-83-7 CAPLUS

CN Benzamide, 4-[2-[[2-(4-fluorophenyl)ethyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)


RN 403806-87-1 CAPLUS

CN Benzamide, 4-[2-[[(3-chlorophenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA
INDEX NAME)




RN 403806-92-8 CAPLUS

CN Benzamide, 4-[2-[(4-phenylbutyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-94-0 CAPLUS

CN Benzamide, 4-[2-[[2-(3-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-98-4 CAPLUS

CN Benzamide, 4-[2-[[2-(3-nitrophenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-02-3 CAPLUS

CN Benzamide, 4-[2-[[2-(3-chlorophenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-03-4 CAPLUS

CN Benzamide, 4-[2-[(1-naphthalenylmethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-07-8 CAPLUS

CN Benzonitrile, 4-[2-[[2-(2,5-dimethoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-11-4 CAPLUS

CN Benzamide, 4-[2-[[2-(1,3-benzodioxol-5-yl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-12-5 CAPLUS

CN Benzamide, 4-[2-[[2-(4-nitrophenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-13-6 CAPLUS

CN Benzamide, 4-[2-[[2-(2,6-dimethoxyphenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-14-7 CAPLUS

CN Benzamide, 4-[2-[[2-(3,4-dimethoxyphenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-19-2 CAPLUS

CN Benzamide, 4-[2-[[2-(3-(trifluoromethyl)phenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-20-5 CAPLUS


CN Benzamide, 4-[2-[[2-(4-(trifluoromethyl)phenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-21-6 CAPLUS

CN Benzamide, 4-[2-[[(3,5-dichlorophenyl)methyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)

RN 403807-23-8 CAPLUS


CN Benzamide, 4-[2-[[(2,4-dichlorophenyl)methyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)

RN 403807-37-4 CAPLUS

CN Benzamide, 4-[2-[[(4-bromophenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA
INDEX NAME)


RN 403807-38-5 CAPLUS

CN Benzamide, 4-[2-[[(4'-fluoro[1,1'-biphenyl]-4-yl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-39-6 CAPLUS

CN Benzamide, 4-[2-[[3-(4-bromophenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-47-6 CAPLUS

CN Benzamide, 4-[2-[[3,4,5-trimethoxyphenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-49-8 CAPLUS

CN Benzamide, 4-[2-[[3'-(4-aminobiphenyl-3-yl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-50-1 CAPLUS

CN Benzamide, 4-[2-[[3'-(4-aminobiphenyl-4-yl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-53-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-2-[[2-(3-methoxyphenyl)ethyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 403807-60-3 CAPLUS

CN Benzamide, 4-[2-[[3'-(4-methoxy[1,1'-biphenyl]-3-yl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-65-8 CAPLUS

CN Benzamide, 4-[2-[[[3'-[(methylamino)methyl][1,1'-biphenyl]-3-yl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-78-3 CAPLUS

CN Benzamide, 4-[2-[[[3'-(acetamino)[1,1'-biphenyl]-3-yl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-79-4 CAPLUS

CN Benzamide, 4-[2-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-83-0 CAPLUS

CN Benzamide, 4-[2-[[[3'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403808-16-2 CAPLUS

CN Benzamide, 4-[2-[[[3-bromophenyl]methyl]amino]-4-pyrimidinyl]-N-[(3-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 403808-32-2 CAPLUS

CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-(3-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403808-46-8 CAPLUS

CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-(2,5-dimethoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-22-3 CAPLUS

CN Benzamide, 4-[2-[[2-(2,5-dimethoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-23-4 CAPLUS

CN Benzamide, 4-[2-[[2-(2,3-dimethoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 403810-50-4 CAPLUS

CN Benzamide, 4-[2-[[2-(2-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)



RE.CNT 306 THERE ARE 306 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 61 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:777933 CAPLUS

DN 137:294969

TI 4-Aryl-substituted 2-pyrimidinamines and 2-pyridinamines, useful as inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
 IN Bethiel, Randy; Cochran, John; Moon, Young-Choon; Nanthakumar, Susanthini
 PA Vertex Pharmaceuticals Incorporated, USA
 SO PCT Int. Appl., 115 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002079197	A1	20021010	WO 2002-US9554	20020328
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2441733	AA	20021010	CA 2002-2441733	20020328
	US 2003087922	A1	20030508	US 2002-109070	20020328
	US 6949544	B2	20050927		
	EP 1373257	A1	20040102	EP 2002-725391	20020328
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004529140	T2	20040924	JP 2002-577822	20020328
PRAI	US 2001-279961P	P	20010329		
	WO 2002-US9554	W	20020328		

OS MARPAT 137:294969

AB The invention provides compds. of formula I and II, and their pharmaceutically acceptable derivs. [wherein: W = N, CH; R1, R2, R3 = halo, QR, QnCN, QnNO2, QnAr2; or R1R2, R2R3 = 4- to 8-membered (un)saturated ring with 0-3 N/O/S atoms; n = 0 or 1; Q = C1-4 alkylidene with one CH2 optionally replaced by O, S, NR, NRCO, CO, CO2, CONR, SO2, SO2NR, NRSO2NR, etc.; R = H, (un)substituted aliphatic; or NRR = 3- to 7-membered (un)saturated ring with 1-2 addnl. N/O/S atoms; R4 = Ar1, TAR2, TnAr3; T = C1-2 alkylidene with optional replacement of a CH2 as above; Ar1 = (un)substituted 5- to 6-membered mono- or bicyclic (un)saturated ring system; Ar2 = (un)substituted 5- to 6-membered (un)saturated monocyclic ring with 0-3 N/O/S atoms, or (un)substituted 8- to 10-membered (un)saturated bicyclic ring with 0-5 N/O/S atoms; Ar3 = 6-membered aryl with 0-2 N atoms and substituted with certain groups; with provisos and exclusions]. The compds. are inhibitors of protein kinases, particularly JNK, a mammalian protein kinase involved in cell proliferation, cell death and response to extracellular stimuli. Furthermore, they are inhibitors of Src-family kinases, especially Src and Lck kinases. The compds. are also inhibitors of GSK3 and CDK2 kinases. The invention also relates to methods for producing the compds. Also provided are pharmaceutical compns. comprising I or II, and methods of utilizing those compns. in the treatment and prevention of various disorders. Three tables of approx. 240 compds. were prepared and claimed., and most were tested against at least one of the five mentioned kinases. For instance, 3,4-dihydroxy-5-methoxybenzaldehyde was

cyclized with 1,2-dibromoethane to give a benzodioxane derivative, followed by elaboration of the formyl group to Me₂NCH:CH:CO- in 3 steps. Cyclization of the resultant enaminone with 3-chlorophenylguanidine gave title compound III. This compound inhibited cloned human JNK3 protein in vitro with K_i < 0.1 μM.


IT **468084-56-2P**, 4-(3,4,5-Trimethoxyphenyl)-N-(phenylmethyl)-2-pyrimidinamine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of phenyl-substituted pyridinamines and pyrimidinamines as inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases)


RN 468084-56-2 CAPLUS

CN 2-Pyrimidinamine, N-(phenylmethyl)-4-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L10 ANSWER 62 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:565745 CAPLUS
DN 138:39247
TI Microwave-assisted synthesis of aminopyrimidines
AU Luo, Guanglin; Chen, Ling; Poindexter, Graham S.
CS Department of Chemistry, Bristol-Myers Squibb Pharmaceutical Research
Institute, Wallingford, CT, USA
SO Tetrahedron Letters (2002), 43(33), 5739-5742
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 138:39247
AB Series of mono- or di-substituted aminopyrimidine derivs. were synthesized
through microwave-assisted aromatic nucleophilic substitution or Suzuki
coupling.
IT **266303-86-0P**, 4-Benzylamino-6-phenylpyrimidine
RL: SPN (Synthetic preparation); PREP (Preparation)
(microwave-assisted aromatic nucleophilic substitution or Suzuki coupling
preparation of aminopyrimidines)
RN 266303-86-0 CAPLUS
CN 4-Pyrimidinamine, 6-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

Same as #80

L10 ANSWER 63 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:546802 CAPLUS
 DN 138:221538
 TI Reactions with 6-phenyl-2-thiouracil and preparation of substituted and fused pyrimidine derivatives
 AU Al-Haiza, Mohammed A.
 CS Chemistry Department, College of Science, King Khalid University, Abha, Saudi Arabia
 SO Journal of Saudi Chemical Society (2002), 6(1), 71-81
 CODEN: JSCSFO; ISSN: 1319-6103
 PB Saudi Chemical Society
 DT Journal
 LA English
 OS CASREACT 138:221538
 AB Alkylation of 6-phenyl-2-thiouracil (1) gave the S-alkyl derivs. 2a,b. Compound 2a could also be prepared by a different method via the reaction of S-methylisothiurea with Et benzoylacetate. Desulphurization of 2a with hydrazine yielded the 2-hydrazino derivative 3, which condensed with aromatic aldehydes to produce the Schiff's bases 4a-c. The reaction of 3 with each of carbon disulfide and nitrous acid resulted in the formation of s-triazolo[4,3-a]- and tetrazolo[1,5-a]pyrimidine derivs. 5 and 7, resp. Treatment of 2a,b with phosphorus oxychloride formed the 4-chloropyrimidine derivs. 11a,b. Compds. 11a,b reacted the thiophenol, benzylamine, hydrazine, anthranilic acid and Et anthranilate to give the trisubstituted pyrimidine derivs. 12a-e. Compound 12d was obtained by the hydrolysis of its ester derivative 12e, since the reaction of anthranilic acid with 11a produced directly the pyrido[6,1-b]quinazoline 13. The latter compound could also be synthesized via an alternative route by cyclization of compound 12d. Similarly, the reaction of glycine with 11a afforded directly imidazo[1,2-c]pyrimidine 14. Moreover, the reaction of the dihydrazinopyrimidine derivative 12c with each of carbon disulfide and nitrous acid formed the ditriazolo[4,3-a:4,3 -c]- and the ditetrazolo[1,5-:1,5 -c]pyrimidines 15 and 16, resp. Compound 1 reacted with 1,3-dichloroacetone to give compound 17. Oxidation of 1 afforded the expected disulfide product 18.
 IT **501030-18-8P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (in preparation of substituted and fused pyrimidine derivs. from 6-phenylthiouracil)
 RN 501030-18-8 CAPLUS
 CN 4-Pyrimidinamine, 6-phenyl-N-(phenylmethyl)-2-[(phenylmethyl)thio]- (9CI)
 (CA INDEX NAME)



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 64 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:220583 CAPLUS
 DN 136:247583
 TI Preparation of pyrazolamines and analogs as protein kinase inhibitors for
 treatment of cancer, diabetes, and Alzheimer's disease
 IN Davies, Robert; Bebbington, David; Knegt, Ronald; Wannamaker, Marion;
 Li, Pan; Forester, Cornelia; Pierce, Albert; Kay, David
 PA Vertex Pharmaceuticals Incorporated, USA
 SO PCT Int. Appl., 373 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 14

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002022607	A1	20020321	WO 2001-US28940	20010914
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2422379	AA	20020321	CA 2001-2422379	20010914
AU 2001091013	A5	20020326	AU 2001-91013	20010914
US 2003055044	A1	20030320	US 2001-953505	20010914
US 6638926	B2	20031028		
US 2003064981	A1	20030403	US 2001-952836	20010914
US 6613776	B2	20030902		
US 2003064982	A1	20030403	US 2001-952875	20010914
US 2003073687	A1	20030417	US 2001-952671	20010914
US 6660731	B2	20031209		
US 2003078166	A1	20030424	US 2001-955601	20010914
US 6696452	B2	20040224		
US 2003083327	A1	20030501	US 2001-952833	20010914
US 6610677	B2	20030826		
BR 2001014088	A	20030617	BR 2001-14088	20010914
EP 1318997	A1	20030618	EP 2001-971082	20010914
EP 1318997	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001701	A	20040301	ZA 2003-1701	20010914
ZA 2003001703	A	20040302	ZA 2003-1703	20010914
JP 2004509117	T2	20040325	JP 2002-526860	20010914
US 2004097501	A1	20040520	US 2001-953471	20010914
NZ 525008	A	20041224	NZ 2001-525008	20010914
US 2005004110	A1	20050106	US 2001-952878	20010914
ES 2242771	T3	20051116	ES 2001-1971006	20010914
CA 2432303	AA	20020829	CA 2001-2432303	20011219
CA 2432223	AA	20020906	CA 2001-2432223	20011219
EP 1345922	A1	20030924	EP 2001-271061	20011219
EP 1345922	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1355905	A1	20031029	EP 2001-273861	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
NZ 526472	A	20040430	NZ 2001-526472	20011219
JP 2004518743	T2	20040624	JP 2002-565976	20011219
JP 2004519479	T2	20040702	JP 2002-567928	20011219
NZ 526473	A	20050624	NZ 2001-526473	20011219
ZA 2003001697	A	20040301	ZA 2003-1697	20030228
ZA 2003001699	A	20040301	ZA 2003-1699	20030228
ZA 2003001700	A	20040301	ZA 2003-1700	20030228
ZA 2003001702	A	20040301	ZA 2003-1702	20030228
ZA 2003001704	A	20040301	ZA 2003-1704	20030228
ZA 2003001698	A	20040302	ZA 2003-1698	20030228
NO 2003001191	A	20030513	NO 2003-1191	20030314
ZA 2003004468	A	20040624	ZA 2003-4468	20030609
ZA 2003004469	A	20040624	ZA 2003-4469	20030609
ZA 2003004470	A	20040624	ZA 2003-4470	20030609
ZA 2003004471	A	20040624	ZA 2003-4471	20030609
ZA 2003004473	A	20040624	ZA 2003-4473	20030609
ZA 2003004475	A	20040624	ZA 2003-4475	20030609
ZA 2003004472	A	20040625	ZA 2003-4472	20030609
ZA 2003004474	A	20040625	ZA 2003-4474	20030609
NO 2003002704	A	20030821	NO 2003-2704	20030613
US 2004224944	A1	20041111	US 2003-624800	20030722
US 7008948	B2	20060307		
US 2004116454	A1	20040617	US 2003-692355	20031023
US 2004157893	A1	20040812	US 2003-722374	20031125
US 2004132781	A1	20040708	US 2003-736426	20031215
US 2004167141	A1	20040826	US 2004-775699	20040210
JP 2005097322	A2	20050414	JP 2004-366925	20041217
AU 2006201228	A1	20060413	AU 2006-201228	20060321
AU 2006201229	A1	20060413	AU 2006-201229	20060321
AU 2006201230	A1	20060413	AU 2006-201230	20060321
AU 2006201262	A1	20060427	AU 2006-201262	20060321
AU 2006201263	A1	20060427	AU 2006-201263	20060321
AU 2006201264	A1	20060427	AU 2006-201264	20060321
AU 2006201265	A1	20060427	AU 2006-201265	20060321
AU 2006201391	A1	20060427	AU 2006-201391	20060404
AU 2006201396	A1	20060504	AU 2006-201396	20060404
PRAI US 2000-232795P	P	20000915		
US 2000-257887P	P	20001221		
US 2001-286949P	P	20010427		
AU 2001-90944	A3	20010914		
AU 2001-91013	A3	20010914		
AU 2001-94558	A3	20010914		
AU 2001-96871	A3	20010914		
AU 2001-96875	A3	20010914		
US 2001-952671	A3	20010914		
US 2001-955601	A3	20010914		
WO 2001-US28940	W	20010914		
EP 2001-273861	A	20011219		
JP 2002-557938	A3	20011219		
US 2001-26966	A1	20011219		
WO 2001-US49139	W	20011219		
WO 2001-US50312	W	20011219		
US 2001-34019	A3	20011220		
US 2001-34683	A1	20011220		
OS MARPAT 136:247583				
AB Title compds. I [wherein G = Ring C or Ring D; Ring C = (un)substituted Ph, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl;				

Ring D = (un)substituted monocyclic or bicyclic ring selected from aryl, heteroaryl, heterocyclyl, or carbocyclyl; Z1 = N or CR9; Z2 = N or CH; Z3 = N or CRx; Z4 = N or CRy; Rx and Ry = independently TR3, or taken together with their intervening atoms form an (un)saturated fused ring having 1-3 ring heteroatoms; R2 and R2a = independently R, TWR6; or C2R2R2a = (un)substituted fused ring containing 0-3 heteroatoms; T = a bond or alkylidene chain; W = C(R6)2O, C(R6)2S0-2, C(R6)2NR6, CO, CO2, CR6OCO, CR6OCONR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6:NNR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, C(R6)2NR6CONR6, or CONR6; R = H or (un)substituted aliphatic, (hetero)aryl, or heterocyclyl ring; R3 = R, halo, O, OR, COR, CO2R, COCOR, COCH2COR, NO2, CN, SO0-2R, N(R4)2, CON(R4)2, SO2N(R4)2, OCOR, NR4COR, NR4CO2(aliphatic), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2; R4 = R7, COR7, CO2(aliphatic), CON(R7)2, or SO2R7; or N(R4)2 = heterocyclyl or heteroaryl; R6 and R7 = independently H or (un)substituted aliphatic group; or N(R6)2 = heterocyclyl or heteroaryl; or N(R7)2 = heterocyclyl or heteroaryl; R9 = R, halo, OR, COR, CO2R, COCOR, etc.] were prepared as protein kinase inhibitors, especially

as

inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes, and Alzheimer's disease. Claims cover (pyrimidinyl)pyrazolamines and indazolamines I [wherein Z1 and Z2 = N; Z3 = CRx; Z4 = CRy; G = Ring C]. Examples include data for approx. 300 invention compds. prepared by a variety of synthetic methods and bioassay results for the inhibition of GSK-β3, Aurora-2, ERK, and Src. For instance, the N-(4-pyrimidinyl)-3-pyrazolamine II was prepared and exhibited Ki values of < 0.1 μM for glycogen synthetase kinase 3β (GSK-3β) and 0.1-1.0 μM for Aurora-2.


IT 404873-33-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404873-33-2 CAPLUS

CN 4,6-Pyrimidinediamine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 65 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:220578 CAPLUS

DN 136:263164

TI Preparation of triazolamines as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease

IN Bebbington, David; Knegetel, Ronald; Binch, Haley; Golec, Julian M. C.; Li, Pan; Charrier, Jean-Damien

PA Vertex Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 377 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 14

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002022602	A2	20020321	WO 2001-US42162	20010914
	WO 2002022602	A3	20020627		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2422299	AA	20020321	CA 2001-2422299	20010914
	AU 2001096875	A5	20020326	AU 2001-96875	20010914
	US 2003055044	A1	20030320	US 2001-953505	20010914
	US 6638926	B2	20031028		
	US 2003064981	A1	20030403	US 2001-952836	20010914
	US 6613776	B2	20030902		
	US 2003064982	A1	20030403	US 2001-952875	20010914
	US 2003073687	A1	20030417	US 2001-952671	20010914
	US 6660731	B2	20031209		
	US 2003078166	A1	20030424	US 2001-955601	20010914
	US 6696452	B2	20040224		
	US 2003083327	A1	20030501	US 2001-952833	20010914
	US 6610677	B2	20030826		
	EP 1318814	A2	20030618	EP 2001-977783	20010914
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	ZA 2003001701	A	20040301	ZA 2003-1701	20010914
	ZA 2003001703	A	20040302	ZA 2003-1703	20010914
	JP 2004509114	T2	20040325	JP 2002-526855	20010914
	US 2004097501	A1	20040520	US 2001-953471	20010914
	US 2005004110	A1	20050106	US 2001-952878	20010914
	ES 2242771	T3	20051116	ES 2001-1971006	20010914
	CA 2432303	AA	20020829	CA 2001-2432303	20011219
	CA 2432223	AA	20020906	CA 2001-2432223	20011219
	EP 1345922	A1	20030924	EP 2001-271061	20011219
	EP 1345922	B1	20060531		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	EP 1355905	A1	20031029	EP 2001-273861	20011219
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	NZ 526472	A	20040430	NZ 2001-526472	20011219

JP	2004518743	T2	20040624	JP	2002-565976	20011219
JP	2004519479	T2	20040702	JP	2002-567928	20011219
NZ	526473	A	20050624	NZ	2001-526473	20011219
ZA	2003001697	A	20040301	ZA	2003-1697	20030228
ZA	2003001699	A	20040301	ZA	2003-1699	20030228
ZA	2003001700	A	20040301	ZA	2003-1700	20030228
ZA	2003001702	A	20040301	ZA	2003-1702	20030228
ZA	2003001704	A	20040301	ZA	2003-1704	20030228
ZA	2003001698	A	20040302	ZA	2003-1698	20030228
ZA	2003004468	A	20040624	ZA	2003-4468	20030609
ZA	2003004469	A	20040624	ZA	2003-4469	20030609
ZA	2003004470	A	20040624	ZA	2003-4470	20030609
ZA	2003004471	A	20040624	ZA	2003-4471	20030609
ZA	2003004473	A	20040624	ZA	2003-4473	20030609
ZA	2003004475	A	20040624	ZA	2003-4475	20030609
ZA	2003004472	A	20040625	ZA	2003-4472	20030609
ZA	2003004474	A	20040625	ZA	2003-4474	20030609
NO	2003002704	A	20030821	NO	2003-2704	20030613
US	2004224944	A1	20041111	US	2003-624800	20030722
US	7008948	B2	20060307			
US	2004116454	A1	20040617	US	2003-692355	20031023
US	2004157893	A1	20040812	US	2003-722374	20031125
US	2004132781	A1	20040708	US	2003-736426	20031215
US	2004167141	A1	20040826	US	2004-775699	20040210
JP	2005097322	A2	20050414	JP	2004-366925	20041217
AU	2006201228	A1	20060413	AU	2006-201228	20060321
AU	2006201229	A1	20060413	AU	2006-201229	20060321
AU	2006201230	A1	20060413	AU	2006-201230	20060321
AU	2006201262	A1	20060427	AU	2006-201262	20060321
AU	2006201263	A1	20060427	AU	2006-201263	20060321
AU	2006201264	A1	20060427	AU	2006-201264	20060321
AU	2006201265	A1	20060427	AU	2006-201265	20060321
AU	2006201391	A1	20060427	AU	2006-201391	20060404
AU	2006201396	A1	20060504	AU	2006-201396	20060404
PRAI	US 2000-232795P	P	20000915			
	US 2000-257887P	P	20001221			
	US 2001-286949P	P	20010427			
	AU 2001-90944	A3	20010914			
	AU 2001-91013	A3	20010914			
	AU 2001-94558	A3	20010914			
	AU 2001-96871	A3	20010914			
	AU 2001-96875	A3	20010914			
	US 2001-952671	A3	20010914			
	US 2001-955601	A3	20010914			
	WO 2001-US42162	W	20010914			
	EP 2001-273861	A	20011219			
	JP 2002-557938	A3	20011219			
	US 2001-26966	A1	20011219			
	WO 2001-US49139	W	20011219			
	WO 2001-US50312	W	20011219			
	US 2001-34019	A3	20011220			
	US 2001-34683	A1	20011220			
OS	MARPAT 136:263164					
AB	Triazolamines I and pyrazolamines II [wherein G = Ring C or Ring D; Ring C = (un)substituted Ph, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl; Ring D = (un)substituted monocyclic or bicyclic ring selected from aryl, heteroaryl, heterocyclyl, or carbocyclyl; Z1 = N or CR9; Z2 = N or CH; Z3 = N or CRx; Z4 = N or CRY; Rx and Ry = independently					

TR3, or taken together with their intervening atoms form an (un)saturated fused ring having 1-3 ring heteroatoms; R2 and R2a = independently R, TWR6; or C2R2R2a = (un)substituted fused ring containing 0-3 heteroatoms; T = a bond or alkylidene chain; W = C(R6)2O, C(R6)2S0-2, C(R6)2NR6, CO, CO2, CR6OCO, CR6OCONR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6:NNR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, C(R6)2NR6CONR6, or CONR6; R = H or (un)substituted aliphatic, (hetero)aryl, or heterocyclyl ring; R3 = R, halo, O, OR, COR, CO2R, COCOR, COCH2COR, NO2, CN, SO0-2R, N(R4)2, CON(R4)2, SO2N(R4)2, OCOR, NR4COR, NR4CO2(aliphatic), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2; R4 = R7, COR7, CO2(aliphatic), CON(R7)2, or SO2R7; or N(R4)2 = heterocyclyl or heteroaryl; R6 and R7 = independently H or (un)substituted aliphatic group; or N(R6)2 = heterocyclyl or heteroaryl; or N(R7)2 = heterocyclyl or heteroaryl; R9 = R, halo, OR, COR, CO2R, COCOR, etc.] were prepared as protein kinase inhibitors, especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes, and Alzheimer's disease. Claims cover (heterocyclyl)triazolamines I [wherein Z1 = N or CR9; Z2 = N or CH; R9 is defined above]. Examples include data for approx. 300 invention compds. prepared by a variety of synthetic methods and bioassay results for the inhibition of GSK-3 β , Aurora-2, ERK, and Src. For instance, the N-(4-quinazolinyl)-1H-1,2,4-triazol-3-amine III was prepared and exhibited Ki values of < 0.1 μ M for glycogen synthetase kinase 3 β (GSK-3 β) and 1.0-20 μ M for Aurora-2.


IT **404890-77-3P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of triazolamines, pyrazolamines, and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404890-77-3 CAPLUS

CN 4,6-Pyrimidinediamine, 2-(2-chlorophenyl)-N-(5-methyl-1H-1,2,4-triazol-3-yl)-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L10 ANSWER 66 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:185092 CAPLUS
 DN 136:247598
 TI Preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors
 IN Nuss, John M.; Harrison, Stephen D.; Ring, David B.; Boyce, Rustum S.; Johnson, Kirk; Pfister, Keith B.; Ramurthy, Savithri; Seely, Lynn; Wagman, Allan S.; Desai, Manoj; Levine, Barry H.
 PA Chiron Corporation, USA
 SO PCT Int. Appl., 268 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002020495	A2	20020314	WO 2001-US42081	20010906
	WO 2002020495	A3	20020620		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001095026	A5	20020322	AU 2001-95026	20010906
	EP 1317433	A2	20030611	EP 2001-975734	20010906
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004514656	T2	20040520	JP 2002-525117	20010906
	CN 1592743	A	20050309	CN 2001-818425	20010906
PRAI	US 2000-230480P	P	20000906		
	WO 2001-US42081	W	20010906		

OS MARPAT 136:247598

AB Title compds. I [wherein W = (un)substituted C or N; X and Y = independently N, O, or (un)substituted C; A = (un)substituted (hetero)aryl; R1, R1a, R2, R2a, R3, R3a, R4, and R4a = independently H, OH, alkoxy, acyl, (hetero)aryl, or (un)substituted (cyclo)alkyl, amino(alkyl), etc. ; R5 and R7 = independently H, halo, alkoxy, guanidiny, (bi)aryl, hetero(bi)aryl, heterocycloalkyl, arylsulfonamido, or (un)substituted (cyclo)alkyl, amino(alkoxy), or amidino; R6 = H, halo, carboxyl, NO2, (cyclo)amido, (cyclo)amidino, (cyclo)imido, CN, alkoxy, acyl(oxy), guanidiny, (hetero)aryl, heterocyclo(alkyl), arylsulfonyl, arylsulfonamido, or (un)substituted alkyl, amino, etc.] were prepared as glycogen synthase kinase 3 (GSK3) inhibitors. For example, 2-chloro-5-nitropyridine was aminated by H2N(CH2)3NH2 and the product N-acylated by benzotriazolecarboxamidinium tosylate to give the alkylguanidine. The latter was cyclocondensed with resin-bound 4-(MeCO)C6H4CONHCH2C6H4Br-3 and Cs2CO3 to afford, after resin cleavage, the pyrimidinamine II. The most preferred compds. of the invention exhibited inhibitory activity against human GSK3 β in a cell free assay with IC50 values of < 1 μ M. Thus, I and compns. containing I may be employed alone or in combination with other pharmacol. active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic

ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency, or cancer (no data).

- IT **252904-40-8P**, Benzonitrile, 4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-5-[(phenylmethyl)amino]-4-pyrimidinyl]-
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors)
 RN 252904-40-8 CAPLUS
 CN Benzonitrile, 4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-5-[(phenylmethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




- IT **403806-74-6**, 4-[2-[[[(3-Methylphenyl)methyl]amino]pyrimidin-4-yl]benzamide **403806-75-7**, 4-[2-[[[(4-Aminophenyl)methyl]amino]pyrimidin-4-yl]benzamide **403806-80-4**, 4-[2-[[[(4-Cyanophenyl)methyl]amino]pyrimidin-4-yl]benzamide **403806-81-5**, 4-[2-[[[(3-Methoxyphenyl)methyl]amino]pyrimidin-4-yl]benzamide **403806-82-6**, 4-[2-[[[(4-Methoxyphenyl)methyl]amino]pyrimidin-4-yl]benzamide **403806-83-7**, 4-[2-[[2-(4-Fluorophenyl)ethyl]amino]pyrimidin-4-yl]benzamide **403806-87-1**, 4-[2-[[[(3-Chlorophenyl)methyl]amino]pyrimidin-4-yl]benzamide **403806-92-8**, 4-[2-[[[(4-Phenylbutyl)amino]pyrimidin-4-yl]benzamide **403806-94-0**, 4-[2-[[2-(3-Methoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzamide **403806-98-4**, 4-[2-[[[(3-Nitrophenyl)methyl]amino]pyrimidin-4-yl]benzamide **403807-02-3**, 4-[2-[[2-(3-Chlorophenyl)ethyl]amino]pyrimidin-4-yl]benzamide **403807-03-4**, 4-[2-[[Naphthylmethyl]amino]pyrimidin-4-yl]benzamide **403807-07-8**, 4-[2-[[2-(2,5-Dimethoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzenecarbonitrile **403807-11-4**, 4-[2-[[2-(2H-Benzo[3,4-d]-1,3-dioxolan-5-yl)ethyl]amino]pyrimidin-4-yl]benzamide **403807-12-5**, 4-[2-[[2-(4-Nitrophenyl)ethyl]amino]pyrimidin-4-yl]benzamide **403807-13-6**, 4-[2-[[[(2,6-Dimethoxyphenyl)methyl]amino]pyrimidin-4-yl]benzamide **403807-14-7**, 4-[2-[[[(3,4-

Dimethoxyphenyl)methyl]amino]pyrimidin-4-yl]benzamide **403807-19-2**, 4-[2-[[[3-(Trifluoromethyl)phenyl)methyl]amino]pyrimidin-4-yl]benzamide **403807-20-5**, 4-[2-[[[4-(Trifluoromethyl)phenyl)methyl]amino]pyrimidin-4-yl]benzamide **403807-21-6**, 4-[2-[[[3,5-Dichlorophenyl)methyl]amino]pyrimidin-4-yl]benzamide **403807-23-8**, 4-[2-[[[2,4-Dichlorophenyl)methyl]amino]pyrimidin-4-yl]benzamide **403807-37-4**, 4-[2-[[[4-Bromophenyl)methyl]amino]pyrimidin-4-yl]benzamide **403807-38-5**, 4-[2-[[[4-(4-Fluorophenyl)phenyl)methyl]amino]pyrimidin-4-yl]benzamide **403807-39-6**, 4-[2-[[[3-Bromophenyl)methyl]amino]pyrimidin-4-yl]benzamide **403807-47-6**, 4-[2-[[[3,4,5-Trimethoxyphenyl)methyl]amino]pyrimidin-4-yl]benzamide **403807-49-8**, 4-[2-[[[3-(3-Aminophenyl)phenyl)methyl]amino]pyrimidin-4-yl]benzamide **403807-50-1**, 4-[2-[[[4-(3-Aminophenyl)phenyl)methyl]amino]pyrimidin-4-yl]benzamide **403807-53-4**, Ethyl 4-(4-cyanophenyl)-2-[[2-(3-methoxyphenyl)ethyl]amino]pyrimidine-5-carboxylate **403807-60-3**, 4-[2-[[[3-(3-Methoxyphenyl)phenyl)methyl]amino]pyrimidin-4-yl]benzamide **403807-65-8**, 4-[2-[[[3-[3-(Methylamino)methyl]phenyl]phenyl]methyl]amino]pyrimidin-4-yl]benzamide **403807-78-3**, 4-[2-[[[3-[3-(Acetylamino)phenyl]phenyl]methyl]amino]pyrimidin-4-yl]benzamide **403807-79-4**, 4-[2-[[[3,5-Bis(trifluoromethyl)phenyl)methyl]amino]pyrimidin-4-yl]benzamide **403807-83-0**, 4-[2-[[[3-[3-(Trifluoromethyl)phenyl]phenyl]methyl]amino]pyrimidin-4-yl]benzamide **403808-16-2**, [4-[2-[[[3-Bromophenyl)methyl]amino]pyrimidin-4-yl]phenyl]-N-[(3-methylphenyl)methyl]carboxamide **403808-32-2**, N-[(3-Bromophenyl)methyl]-4-[2-[[2-(3-methoxyphenyl)ethyl]amino]pyrimidin-4-yl]phenylcarboxamide **403808-46-8** **403809-22-3**, 4-[2-[[2-(2,5-Dimethoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzamide **403809-23-4**, 4-[2-[[2-(2,3-Dimethoxyphenyl)ethyl]amino]pyrimidin-4-yl]benzamide **403810-50-4**
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors)


RN 403806-74-6 CAPLUS

CN Benzamide, 4-[2-[[[3-methylphenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-75-7 CAPLUS

CN Benzamide, 4-[2-[[[4-aminophenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-80-4 CAPLUS

CN Benzamide, 4-[2-[[4-(aminomethyl)phenyl]methylamino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-81-5 CAPLUS

CN Benzamide, 4-[2-[[3-(methoxymethyl)phenyl]methylamino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-82-6 CAPLUS

CN Benzamide, 4-[2-[[4-(methoxymethyl)phenyl]methylamino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-83-7 CAPLUS

CN Benzamide, 4-[2-[[2-(4-fluorophenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-87-1 CAPLUS

CN Benzamide, 4-[2-[[3-(4-aminobenzoyl)phenyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-92-8 CAPLUS

CN Benzamide, 4-[2-[[4-(4-aminobenzoyl)phenyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-94-0 CAPLUS

CN Benzamide, 4-[2-[[2-[(3-aminobenzoyl)amino]phenyl]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403806-98-4 CAPLUS

CN Benzamide, 4-[2-[[2-[(3-methoxybenzoyl)amino]phenyl]ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-02-3 CAPLUS

CN Benzamide, 4-[2-[[2-(3-chlorophenyl)ethyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 403807-03-4 CAPLUS

CN Benzamide, 4-[2-[[2-(1-naphthalenylmethyl)amino]-4-pyrimidinyl]- (9CI) (CA
INDEX NAME)



RN 403807-07-8 CAPLUS


CN Benzonitrile, 4-[2-[[2-(2,5-dimethoxyphenyl)ethyl]amino]-4-pyrimidinyl]-
(9CI) (CA INDEX NAME)



RN 403807-11-4 CAPLUS


CN Benzamide, 4-[2-[[2-(1,3-benzodioxol-5-yl)ethyl]amino]-4-pyrimidinyl]-

(9CI) (CA INDEX NAME)




RN 403807-12-5 CAPLUS

CN Benzamide, 4-[2-[[2-(4-nitrophenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-13-6 CAPLUS

CN Benzamide, 4-[2-[[2-(4-nitrophenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-14-7 CAPLUS

CN Benzamide, 4-[2-[[2-(4-nitrophenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-19-2 CAPLUS

CN Benzamide, 4-[2-[[2-(4-nitrophenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-20-5 CAPLUS

CN Benzamide, 4-[2-[[4-(trifluoromethyl)phenyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-21-6 CAPLUS

CN Benzamide, 4-[2-[[3,5-dichlorophenyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-23-8 CAPLUS

CN Benzamide, 4-[2-[[2,4-dichlorophenyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-37-4 CAPLUS

CN Benzamide, 4-[2-[[4-bromophenyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-38-5 CAPLUS

CN Benzamide, 4-[2-[[4'-fluoro[1,1'-biphenyl]-4-yl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-39-6 CAPLUS

CN Benzamide, 4-[2-[[3-bromophenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-47-6 CAPLUS

CN Benzamide, 4-[2-[[3,4,5-trimethoxyphenyl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-49-8 CAPLUS

CN Benzamide, 4-[2-[[3'-amino[1,1'-biphenyl]-3-yl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-50-1 CAPLUS

CN Benzamide, 4-[2-[[3'-amino[1,1'-biphenyl]-4-yl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-53-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(4-cyanophenyl)-2-[[2-(3-methoxyphenyl)ethyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 403807-60-3 CAPLUS

CN Benzamide, 4-[2-[[3'-methoxy[1,1'-biphenyl]-3-yl)methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-65-8 CAPLUS

CN Benzamide, 4-[2-[[[3'-(methylanino)methyl][1,1'-biphenyl]-3-yl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-78-3 CAPLUS

CN Benzamide, 4-[2-[[[3'-(acetylanino)methyl][1,1'-biphenyl]-3-yl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-79-4 CAPLUS

CN Benzamide, 4-[2-[[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403807-83-0 CAPLUS

CN Benzamide, 4-[2-[[[3'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403808-16-2 CAPLUS

CN Benzamide, 4-[2-[[3-(bromophenyl)methyl]amino]-4-pyrimidinyl]-N-[(3-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 403808-32-2 CAPLUS

CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-(3-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403808-46-8 CAPLUS

CN Benzamide, N-[(3-bromophenyl)methyl]-4-[2-[[2-(2,5-dimethoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-22-3 CAPLUS

CN Benzamide, 4-[2-[[2-(2,5-dimethoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 403809-23-4 CAPLUS

CN Benzamide, 4-[2-[[2-(2,3-dimethoxyphenyl)ethyl]amino]-4-pyrimidinyl]-
(9CI) (CA INDEX NAME)



RN 403810-50-4 CAPLUS

CN Benzamide, 4-[2-[[2-(2-methoxyphenyl)ethyl]amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)



L10 ANSWER 67 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:171866 CAPLUS
 DN 136:232313
 TI Preparation of pyrimidine derivatives as G protein-coupled receptor kinase (GRK) inhibitors
 IN Fukumoto, Shoji; Watanabe, Toshifumi; Ikeda, Shota
 PA Takeda Chemical Industries, Ltd., Japan
 SO PCT Int. Appl., 322 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2002018350	A1	20020307	WO 2001-JP7397	20010829	
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	AU 2001082520	A5	20020313	AU 2001-82520	20010829	
	JP 2002145778	A2	20020522	JP 2001-259683	20010829	
PRAI	JP 2000-264499	A	20000829			
	WO 2001-JP7397	W	20010829			

OS MARPAT 136:232313

AB Disclosed are novel GRK inhibitors which contains compds. represented by the formula (I), a salt thereof, or a prodrug comprising either of these (wherein ring A represents optionally further substituted nitrogen-containing heterocycle; R1 and R2 each represents optionally substituted amino; and X represents a spacer comprising a linear part constituted of one to four atoms, provided that R1 may be bonded to R2 or/and X to form a ring). They are useful as preventives/remedies for cardiac failure. Thus, 5.48 g K2CO3 and 7.52 g 2-aminophenyl 2-nitrophenyl sulfide were added to a suspension of 5.61 g 4-amino-5-bromomethyl-2-methylpyrimidine hydrobromide in 40 mL acetone at room temperature and stirred at 65° for 64 h to give 2.36 g N-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-N-[2-[(2-nitrophenyl)thio]phenyl]amine (II). All 10 compds. tested including II at 30 µM inhibited 30% human GRK2 expressed by human GRK2 gene in COS-7 cells. A capsule and a tablet formulation containing II were also prepared

IT 403514-78-3P 403514-79-4P 403516-08-5P
 403516-29-0P 403516-31-4P 403516-36-9P
 403516-40-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine derivs. as G protein-coupled receptor kinase (GRK) inhibitors for prevention and/or treatment for cardiac failure)

RN 403514-78-3 CAPLUS



CN Benzoic acid, 2-[[[(4-amino-2-phenyl-5-pyrimidinyl)methyl]amino]-, (2E)-3-phenyl-2-propenyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 403514-79-4 CAPLUS

CN Formamide, N-[(4-amino-2-phenyl-5-pyrimidinyl)methyl]-N-[2-[(2-ethoxyethyl)thio]phenyl]- (9CI) (CA INDEX NAME)




RN 403516-08-5 CAPLUS

CN Formamide, N-[(4-amino-2-phenyl-5-pyrimidinyl)methyl]-N-[2-[[[(phenylmethyl)thio]methyl]thio]phenyl]- (9CI) (CA INDEX NAME)




RN 403516-29-0 CAPLUS

CN 5-Pyrimidinemethanamine, 4-amino-N-[2-[(4-methoxyphenyl)thio]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 403516-31-4 CAPLUS

CN Formamide, N-[(4-amino-2-phenyl-5-pyrimidinyl)methyl]-N-[2-[(4-methoxyphenyl)thio]phenyl]- (9CI) (CA INDEX NAME)




RN 403516-36-9 CAPLUS

CN 5-Pyrimidinemethanamine, 4-amino-N-[2-[(2-nitrophenyl)thio]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)



RN 403516-40-5 CAPLUS

CN Formamide, N-[(4-amino-2-phenyl-5-pyrimidinyl)methyl]-N-[2-[(2-nitrophenyl)thio]phenyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 68 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:122770 CAPLUS

DN 136:178015

TI Drugs for incontinence - salified and nonsalified nitric oxide-donors and phosphodiesterase inhibitors

IN Del Soldato, Piero; Benedini, Francesca

PA Nicox S.A., Fr.

SO PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002011707	A2	20020214	WO 2001-EP8734	20010727
	WO 2002011707	A3	20021205		
	W:				
	AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ,				
	EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT,				
	LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA,				
	US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	IT 1318674	B1	20030827	IT 2000-MI1848	20000808
	AU 2001091691	A5	20020218	AU 2001-91691	20010727
	EP 1307184	A2	20030507	EP 2001-971798	20010727
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004511436	T2	20040415	JP 2002-517044	20010727
	US 2003203899	A1	20031030	US 2003-343330	20030206
PRAI	IT 2000-MI1848	A	20000808		
	WO 2001-EP8734	W	20010727		

OS MARPAT 136:178015

AB Use in the incontinence of one or more of the following classes of drugs selected from the following: (B) salified and nonsalified nitric oxide-donor drugs, of formula: A - X1 - N(O)z, (B') nitrate salts of drugs used for the incontinence, and which do not contain in the mol. a nitric oxide donor group; (C) organic or inorg. salts of compds. inhibiting phosphodiesterases.


IT 398454-66-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(salified and nonsalified nitric oxide-donors and phosphodiesterase inhibitors for treatment of incontinence)

RN 398454-66-5 CAPLUS

CN 4-Pyrimidinamine, N-(1,3-benzodioxol-5-ylmethyl)-2-(1H-imidazol-1-yl)-5-phenyl- (9CI) (CA INDEX NAME)



L10 ANSWER 69 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:122769 CAPLUS
 DN 136:189342
 TI Drugs for treatment of sexual dysfunction
 IN Del Soldato, Piero
 PA Nicox S.A., Fr.
 SO PCT Int. Appl., 40 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002011706	A2	20020214	WO 2001-EP8733	20010727
	WO 2002011706	A3	20030918		
	W:	AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	IT 1318673	B1	20030827	IT 2000-MI1847	20000808
	AU 2001091690	A5	20020218	AU 2001-91690	20010727
	EP 1363628	A2	20031126	EP 2001-971797	20010727
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR			
	JP 2004506619	T2	20040304	JP 2002-517043	20010727
	US 2003171393	A1	20030911	US 2003-333927	20030204
PRAI	IT 2000-MI1847	A	20000808		
	WO 2001-EP8733	W	20010727		

OS MARPAT 136:189342

AB Pharmaceuticals containing nitric oxide-donor drugs or inorg. salts of compds. inhibiting phosphodiesterases are useful for the treatment of sexual dysfunction. Thus, a formulation contained 2-(acetyloxy)benzoic acid 6-(nitroxy-methyl)-2-methylpyridyl ester-HCl (NCX 4050) 4.2, white petrolatum 24, Polysorbate-60 4.8, glycerin 9.5, and water 48 g. NCX 4050 showed vasorelaxing activity on the aortas.

IT **398460-38-3**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (drugs for treatment of sexual dysfunction)


RN 398460-38-3 CAPLUS

CN 4-Pyrimidinamine, N-(1,3-benzodioxol-5-ylmethyl)-2-(1H-imidazol-1-yl)-5-phenyl-, nitrate (9CI) (CA INDEX NAME)

CM 1

CRN 398454-66-5

CMF C21 H17 N5 O2




10/671,070


CM 2

CRN 7697-37-2


CMF H N O3




L10 ANSWER 70 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:96165 CAPLUS
 DN 136:294745
 TI A Combinatorial Scaffold Approach toward Kinase-Directed Heterocycle Libraries
 AU Ding, Sheng; Gray, Nathanael S.; Wu, Xu; Ding, Qiang; Schultz, Peter G.
 CS Department of Chemistry and the Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA
 SO Journal of the American Chemical Society (2002), 124(8), 1594-1596
 CODEN: JACSAT; ISSN: 0002-7863
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 136:294745
 AB A novel strategy for efficient synthesis of various substituted nitrogen-heterocycles, e.g., I, as kinase-directed combinatorial libraries is described. The general scheme involves capture of various dichloroheterocycles onto solid support and further elaborations by aromatic substitution with amines at elevated temperature or by anilines, boronic acids, and phenols via palladium-catalyzed cross-coupling reactions, thus the scaffold itself is transformed into a diversity element within the combinatorial scheme. Libraries consisting of discrete and highly diverse heterocyclic small mols. constructed with these chemistries are currently being evaluated in a variety of cell and protein-based assays.
 IT **406932-41-0P 406932-42-1P 406932-43-2P 406932-44-3P 406932-45-4P**
 RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)
 (derivatization of resin bound chloroheterocyclic scaffolds via Suzuki coupling reaction with aryl boronic acid and subsequent cleavage of substituted heterocyclic product)
 RN 406932-41-0 CAPLUS
 CN 4-Pyrimidinamine, 2-(3-methoxyphenyl)-N-[(4-methoxyphenyl)methyl]- (9CI)
 (CA INDEX NAME)




RN 406932-42-1 CAPLUS
 CN 4-Pyrimidinamine, 2-(3-methoxyphenyl)-N-[(4-methoxyphenyl)methyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 406932-43-2 CAPLUS

CN 4-Pyrimidinamine, 2-(3-methoxyphenyl)-N-[(4-methoxyphenyl)methyl]-6-methyl-
(9CI) (CA INDEX NAME)

RN 406932-44-3 CAPLUS

CN 4-Pyrimidinamine, 6-(3-methoxyphenyl)-N-[(4-methoxyphenyl)methyl]- (9CI)
(CA INDEX NAME)


RN 406932-45-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(3-methoxyphenyl)-N4-[(4-methoxyphenyl)methyl]-
(9CI) (CA INDEX NAME)

RE.CNT 15

THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 71 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:54948 CAPLUS
 DN 136:363251
 TI Bioisosterism, enantioselectivity, and molecular modeling of new effective
 N6- and/or N(9)-substituted 2-phenyladenines and 8-aza analogs: different
 binding modes to A1 adenosine receptors
 AU Bianucci, A. Maria; Biagi, Giuliana; Coi, Alessio; Giorgi, Irene; Oreste,
 Livi; Pacchini, Federica; Scartoni, Valerio; Lucacchini, Antonio; Costa,
 Barbara
 CS Department of Pharmaceutical Sciences, University of Pisa, Pisa, 56126,
 Italy
 SO Drug Development Research (2001), 54(2), 52-65
 CODEN: DDREDK; ISSN: 0272-4391
 PB Wiley-Liss, Inc.
 DT Journal
 LA English
 OS CASREACT 136:363251
 AB Bioisosterism of the adenine and 8-azaadenine nuclei was demonstrated by
 comparison of A1 adenosine receptor binding affinity of 2-Ph
 N6-substituted adenines and the corresponding 8-azaadenines. Some of
 these new compds. are very potent A1 adenosine receptor antagonists. This
 work also describes the synthesis and A1 adenosine receptor binding of the
 enantiomers of some 2-phenyladenines substituted with a 1-phenylethyl
 chiral group in N6 and N(9) positions. Biol. results, showing the same
 stereoselectivity for all the couples of enantiomers, may supply proof for
 the hypothesis of a possible double arrangement of 2-phenylsubstituted
 adenines inside A1 adenosine receptors. Theor. studies, based on an
 improved A1 adenosine receptor model and consisting of evaluation and
 comparison of interaction energies in complexes involving some selected
 chiral ligands, support the above hypothesis.
 IT **424830-65-9P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (bioisosterism, enantioselectivity, and mol. modeling of new effective
 phenyladenines and aza analogs and different binding modes to A1
 adenosine receptors)
 RN 424830-65-9 CAPLUS
 CN 4,5-Pyrimidinediamine, 6-chloro-2-phenyl-N4-(phenylmethyl)- (9CI) (CA
 INDEX NAME)



RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 72 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2001:816647 CAPLUS
 DN 135:357948
 TI Preparation of heterocyclic compounds as phosphodiesterase V (PDE V) inhibitors
 IN Yamada, Koichiro; Matsuki, Kenji; Omori, Kenji; Kikkawa, Kohei
 PA Tanabe Seiyaku Co., Ltd., Japan
 SO PCT Int. Appl., 207 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001083460	A1	20011108	WO 2001-JP2034	20010315
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001041142	A5	20011112	AU 2001-41142	20010315
	CA 2407231	AA	20021023	CA 2001-2407231	20010315
	EP 1277741	A1	20030122	EP 2001-912373	20010315
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	NZ 522217	A	20040430	NZ 2001-522217	20010315
	CN 1657523	A	20050824	CN 2004-10098098	20010315
	US 2003229089	A1	20031211	US 2002-258545	20021025
	US 2004142930	A1	20040722	US 2003-699804	20031104
	AU 2005203687	A1	20050908	AU 2005-203687	20050817
PRAI	JP 2000-130371	A	20000428		
	JP 2000-277652	A	20000913		
	AU 2001-41142	A3	20010315		
	WO 2001-JP2034	W	20010315		
	US 2002-258545	A2	20021025		

OS MARPAT 135:357948

AB Compds. of the general formula (I) or pharmacol. acceptable salts thereof [wherein X is :CH or N; Y is NH, NR₄, S, O, CH:N, N:CH, N:N, CH:CH, or the like; R₁ is lower alkoxy, amino, a nitrogenous heterocyclic group, or a hydroxyl group substituted with a heterocyclic group (wherein each group may be substituted); R₂ is either a lower alkylamino or lower alkoxy group which may be substituted with aryl, or a lower alkoxy group substituted with a nitrogenous aromatic heterocyclic group; and R₃ is aryl, a nitrogenous heterocyclic group, lower alkyl, lower alkoxy, lower cycloalkoxy, a hydroxyl group substituted with a nitrogenous heterocyclic group, or amino (wherein each group may be substituted), or alternatively, R₃ and the substituent of Y may be united to form a lactone ring] or pharmacol. acceptable salts thereof are prepared These compds. exhibit excellent PDE V inhibitory activity and are useful as preventive or therapeutic agents for various diseases due to dysfunction of the signal transduction through cGMP, in particular impotence, pulmonary hypertension, and diabetic renal failure paralysis (no data). Thus, 2-(hydroxymethyl)pyridine was treated with NaH in THF at room temperature for 30 min and then condensed with 2-chloro-5-(3,4,5-trimethoxyphenylcarbonyl)-4-(3-chloro-4-

methoxybenzylamino)pyrimidine (preparation given) in THF at room temperature for 1 h

to give 2-(2-pyridylmethoxy)-5-(3,4,5-trimethoxyphenylcarbonyl)-4-(3-chloro-4-methoxybenzylamino)pyrimidine.


IT 372117-36-7P 372117-37-8P 372117-38-9P
372117-39-0P 372117-40-3P 372117-41-4P
372117-44-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic compds. as phosphodiesterase V inhibitors preventive or therapeutic agents for various diseases due to dysfunction of signal transduction through cGMP)


RN 372117-36-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[[[3-chloro-4-methoxyphenyl)methyl]amino]-2-(2-pyridinylmethoxy)-6-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 372117-37-8 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[[[3-chloro-4-methoxyphenyl)methyl]amino]-2-(4-hydroxy-1-piperidinyl)-6-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 372117-38-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[[[3-chloro-4-methoxyphenyl)methyl]amino]-2-[2-(hydroxymethyl)-4-morpholinyl]-6-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 372117-39-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[[[3-chloro-4-methoxyphenyl)methyl]amino]-2-[2-methoxyethyl)methylamino]-6-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 372117-40-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[[[3-chloro-4-methoxyphenyl)methyl]amino]-2-[2-(dimethylamino)ethoxy]-6-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 372117-41-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(1-piperazinyl)-6-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 372117-44-7 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-[bis(2-hydroxyethyl)amino]-4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-6-(3,4,5-trimethoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 16

THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 73 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:635876 CAPLUS

DN 135:211049

TI Preparation of pyrimidinamines and pyridinamines as adenosine receptor modulators for treatment of CNS disorders

IN Borroni, Edilio Maurizio; Huber-Trottman, Gerda; Kilpatrick, Gavin John; Norcross, Roger David

PA F. Hoffmann La Roche A.-G., Switz.

SO PCT Int. Appl., 256 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001062233	A2	20010830	WO 2001-EP1679	20010215
	WO 2001062233	A3	20020103		
	W:				
	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2398274	AA	20010830	CA 2001-2398274	20010215
	EP 1261327	A2	20021204	EP 2001-927670	20010215
	EP 1261327	B1	20050427		
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001008611	A	20030506	BR 2001-8611	20010215
	JP 2003523380	T2	20030805	JP 2001-561300	20010215
	NZ 520241	A	20040528	NZ 2001-520241	20010215
	AU 780527	B2	20050324	AU 2001-54643	20010215
	AT 293962	E	20050515	AT 2001-927670	20010215
	ES 2240449	T3	20051016	ES 2001-1927670	20010215
	US 2001027196	A1	20011004	US 2001-788956	20010220
	US 6586441	B2	20030701		
	ZA 2002006077	A	20031030	ZA 2002-6077	20020730
	NO 2002004006	A	20020822	NO 2002-4006	20020822
PRAI	EP 2000-103432	A	20000225		
	WO 2001-EP1679	W	20010215		

OS MARPAT 135:211049

AB The title compds. (I) [wherein A = a bond, S, N(R), (CH₂)₂, CH:CH, C.tplbond.C, or O; X and Y = independently N:, :N, :CH, C(CN):, :C(CN), C(CSNH₂):, or :C(CSNH₂), wherein at least 1 of X or Y is N; R₁ = H, (cyclo)alkyl, alkenyl, alkynyl, halo, CN, (alkyl)carboxylates, (alkyl)carbamates, alkoxy(alkyl), phenoxy(alkyl), phenylamino(alkyl), (un)substituted phenyl(alkyl) or amino(alkyl), morpholinyl(alkyl), piperidinyl(alkyl), pyridinyl(alkyl), piperazinyl(alkyl), etc.; R₂ = H, halo, CN, NO₂, acyl, carboxylate, (un)substituted alkyl, alkenyl, alkynyl, or Ph; R₃ = alkyl or thienyl, (dihydro)furanlyl, benzodioxolyl, isoxazolyl, pyridinyl, dihydropyranyl, pyrazinyl, aryl(alkyl)oxy, pyrazolyl, (un)substituted Ph, etc.; R₄ and R₅ = independently H, benzoyl, or (un)substituted phenacyl; or A and R₂ taken together the with the C atoms to which they are attached may form a substituted thienyl group] were prepared as adenosine receptor modulators. For example, treating 3,4,5-trimethoxybenzoylacetonitrile with to NaH in DMSO, followed by addition


of CS2 and MeI, gave the bis(methylthio) intermediate. Cycloaddn. with guanidine nitrate in the presence of TEA in DMF afforded the pyrimidinenitrile (II), which exhibited high selectivity toward the A1 and A3 adenosine receptors compared to the A2 receptor with pKi values of 5.88, 5.71 and 7.24, resp. I are useful for the treatment of Alzheimer's disease, Parkinson's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, asthma, allergic responses, hypoxia, ischemia, seizure, substance abuse, and sedation, and they may be active as muscle relaxants, antipsychotics, antiepileptics, anticonvulsants, and cardioprotective agents (no data). The most preferred indications for I are those which include disorders of the central nervous system, such as certain depressive disorders, neuroprotection, and Parkinson's disease.

IT 357285-14-4P 357285-22-4P 357285-25-7P
357285-37-1P 357288-80-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidinamines and pyridinamines as adenosine receptor modulators for treatment of CNS disorders and other diseases)


RN 357285-14-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-amino-4-phenyl-6-[(phenylmethyl)amino]- (9CI)
(CA INDEX NAME)




RN 357285-22-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-amino-4-phenyl-6-[(3-phenylpropyl)amino]- (9CI)
(CA INDEX NAME)




RN 357285-25-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-amino-4-phenyl-6-[(2-phenylethyl)amino]- (9CI)
(CA INDEX NAME)




RN 357285-37-1 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-amino-4-[[2-(4-hydroxyphenyl)ethyl]amino]-6-phenyl- (9CI) (CA INDEX NAME)



RN 357288-80-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-amino-4-(2-methoxyphenyl)-6-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



L10 ANSWER 74 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2001:597969 CAPLUS
 DN 135:180777
 TI Preparation of 2-pyrimidinamines as selective inhibitors of COX-2
 IN Carter, Malcolm Clive; Naylor, Alan; Payne, Jeremy John; Pegg, Neil
 Anthony
 PA Glaxo Group Ltd., UK
 SO PCT Int. Appl., 38 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001058881	A1	20010816	WO 2001-GB511	20010208
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001032036	A5	20010820	AU 2001-32036	20010208
	EP 1254119	A1	20021106	EP 2001-904117	20010208
	EP 1254119	B1	20060412		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003522761	T2	20030729	JP 2001-558432	20010208
	AT 323072	E	20060415	AT 2001-904117	20010208
	TW 230705	B1	20050411	TW 2001-90104533	20010227
	US 2003109538	A1	20030612	US 2002-182788	20020731
	US 6780870	B2	20040824		
PRAI	GB 2000-3224	A	20000211		
	WO 2001-GB511	W	20010208		

OS MARPAT 135:180777


AB The title compds. [I; R1, R2 = H, alkyl; R3 = alkyl, NH2; R4 = H, alkyl; A = 5-6 membered aryl, 5-6 membered aryl substituted by one or more R5; R5 = halo, alkyl, alkoxy, etc.; n = 1-4] which are potent and selective inhibitors of COX-2 and are of use in the treatment of the pain, fever, inflammation of a variety of conditions and diseases, were prepared and formulated. E.g., a multi-step synthesis of the pyrimidinamine I [R1, R2 = H; R3 = Me; R4 = H; A = 4-pyridyl; n = 1] which showed IC50 of 1.3 nM against COX-2, was given.

IT 354806-68-1P 354806-72-7P 354806-73-8P
 354806-74-9P 354806-75-0P 354806-76-1P
 354806-77-2P 354806-78-3P 354806-79-4P
 354806-80-7P 354806-81-8P 354806-82-9P
 354806-83-0P 354806-84-1P 354806-85-2P
 354806-86-3P 354806-89-6P 354806-90-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 2-pyrimidinamines as selective inhibitors of COX-2)


RN 354806-68-1 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(methylsulfonyl)phenyl]-N-(phenylmethyl)-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 354806-72-7 CAPLUS

CN 2-Pyrimidinamine, N-[(4-methoxyphenyl)methyl]-4-[4-(methanesulfonyl)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 354806-73-8 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(methanesulfonyl)phenyl]-N-[[4-(trifluoromethoxy)phenyl]methyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 354806-74-9 CAPLUS

CN 2-Pyrimidinamine, N-[(3,4-difluorophenyl)methyl]-4-[4-(methanesulfonyl)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 354806-75-0 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(methanesulfonyl)phenyl]-6-(trifluoromethyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 354806-76-1 CAPLUS

CN 2-Pyrimidinamine, N-[(4-methylphenyl)methyl]-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 354806-77-2 CAPLUS

CN 2-Pyrimidinamine, N-[(3-fluorophenyl)methyl]-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 354806-78-3 CAPLUS

CN 2-Pyrimidinamine, N-[(4-fluorophenyl)methyl]-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 354806-79-4 CAPLUS

CN 2-Pyrimidinamine, N-[(3,5-difluorophenyl)methyl]-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 354806-80-7 CAPLUS

CN 2-Pyrimidinamine, N-[(2,5-difluorophenyl)methyl]-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 354806-81-8 CAPLUS

CN 2-Pyrimidinamine, N-[(2,6-difluorophenyl)methyl]-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 354806-82-9 CAPLUS

CN 2-Pyrimidinamine, N-[(2,4-difluorophenyl)methyl]-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 354806-83-0 CAPLUS

CN 2-Pyrimidinamine, N-[[4-(difluoromethoxy)phenyl]methyl]-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 354806-84-1 CAPLUS

CN 2-Pyrimidinamine, N-[(3-methylphenyl)methyl]-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 354806-85-2 CAPLUS

CN 2-Pyrimidinamine, N-[(2-fluorophenyl)methyl]-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 354806-86-3 CAPLUS

CN 2-Pyrimidinamine, N-[(3-chlorophenyl)methyl]-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 354806-89-6 CAPLUS

CN 2-Pyrimidinamine, N-methyl-4-[4-(methylsulfonyl)phenyl]-N-(phenylmethyl)-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 354806-90-9 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(methylsulfonyl)phenyl]-N-(3-phenylpropyl)-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 75 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2001:235559 CAPLUS
 DN 134:266319
 TI CD40 function inhibitors containing (hetero)aryl compounds and their preparation
 IN Saito, Shoichi; Akane, Katsura; Fujimoto, Katsumi; Shiraishi, Akio; Kurakata, Shinichi; Maeda, Hiroaki; Tatsuta, Toru
 PA Sankyo Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 139 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001089452	A2	20010403	JP 1999-267909	19990922
PRAI	JP 1999-267909		19990922		
OS	MARPAT 134:266319				


AB Title inhibitors, useful for prevention and treatment of allergy, rheumatoid, autoimmune disease, and arteriosclerosis, contain aromatic compds. I [R1, R3, R4 = H, OH, halo, C1-15 alkyl(oxy), C1-15 alkylthio, (un)substituted (hetero)aryl, etc.; R2 = NO2, nitrile, CO2H, C2-6 alkoxy carbonyl; R1CCR2 may form (un)substituted (hetero)aryl; X, Y = N, CH] or their salts as active ingredients. Thus, MeOCPh:C(CO2Et)2 was refluxed with benzamidine HCl salt and NaH in EtOH for 5 h, evaporated, neutralized, extracted with AcOEt, the organic phase concentrated, and treated with POCl3 and morpholine to give 52% I (R1 = R4 = Ph, R2 = CO2Et, R3 = 4-morpholino, X = Y = N), which at 25 μ M inhibited 88% formation of IL-12.

IT **332071-66-6P**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of (hetero)aryl compds. as CD40 function inhibitors)
 RN 332071-66-6 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-chloro-2-phenyl-6-[(phenylmethyl)amino]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

IT **332072-06-7**
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of (hetero)aryl compds. as CD40 function inhibitors)
 RN 332072-06-7 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-chloro-2-phenyl-6-[(phenylmethyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



L10 ANSWER 76 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2000:861658 CAPLUS
 DN 134:29425
 TI Novel 4-phenyl-pyrimidine derivatives as NK-1 receptor antagonists
 IN Boes, Michael; Galley, Guido; Godel, Thierry; Hoffmann, Torsten; Hunkeler, Walter; Schnider, Patrick; Stadler, Heinz
 PA F. Hoffmann-La Roche A.-G., Switz.
 SO PCT Int. Appl., 64 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000073279	A1	20001207	WO 2000-EP4701	20000524
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6274588	B1	20010814	US 2000-575382	20000522
	TW 550258	B	20030901	TW 2000-89109829	20000522
	CA 2375671	AA	20001207	CA 2000-2375671	20000524
	BR 2000011127	A	20020219	BR 2000-11127	20000524
	EP 1187815	A1	20020320	EP 2000-927234	20000524
	EP 1187815	B1	20060208		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
	TR 200103457	T2	20020422	TR 2001-3457	20000524
	JP 2003500478	T2	20030107	JP 2000-621345	20000524
	JP 3590592	B2	20041117		
	AU 770786	B2	20040304	AU 2000-45677	20000524
	NZ 515407	A	20040326	NZ 2000-515407	20000524
	RU 2243221	C2	20041227	RU 2001-133458	20000524
	AT 317389	E	20060215	AT 2000-927234	20000524
	ZA 2001009163	A	20030206	ZA 2001-9163	20011106
	NO 2001005700	A	20011122	NO 2001-5700	20011122
	NO 321354	B1	20060502		
	HR 2001000871	A1	20030430	HR 2001-871	20011122
	HK 1046528	A1	20050225	HK 2002-107643	20021022
PRAI	EP 1999-110483	A	19990531		
	WO 2000-EP4701	W	20000524		
OS	MARPAT 134:29425				

AB The invention discloses pyrimidine derivs. I [R1 = H or halo; R2 = H, halo, lower alkyl or lower alkoxy; R1 and R2 may be together with the two carbon atoms -CH=CH-CH=CH-; R3 = halo, CF3, lower alkyl or lower alkoxy; R4, R6 = (independently) H or lower alkyl; R5 = lower alkyl, lower alkoxy, amino, Ph, hydroxy-lower alkyl, cyano-lower alkyl, carbamoyl-lower alkyl, pyridyl, pyrimidyl, (un)substituted -(CH2)n-piperazinyl, which is optionally substituted by one or two lower alkyl groups or by hydroxy-lower alkyl, -(CH2)n-morpholinyl, -(CH2)n-piperidinyl, -(CH2)n+1-imidazolyl, lower alkyl-sulfanyl, lower alkyl-sulfonyl, benzylamino, -NH-(CH2)n+1N(R7)2, -(CH2)n+1N(R7)2, -O-(CH2)n+1-morpholinyl, -O-(CH2)n+1-piperidinyl or -O-(CH2)n+1N(R7)2, wherein R7 = H or lower alkyl; n = 0-2; X = -C(O)N(R7)- or -N(R7)C(O)-] and their pharmaceutically


acceptable acid addition salts as NK-1 receptor antagonists. The preferred compds. exhibited pKi values for NK-1 receptor affinity in the range of 8.00-9.20, e.g., the pKi of II was 8.45. With demonstrated affinity to the NK-1 receptor, these compds. may prove useful for the treatment of medical conditions related to this receptor, e.g., inflammatory conditions such as arthritis, migraine, asthma, etc., and in particular CNS disorders such as depression or emesis.

IT **311339-73-8P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn and biol. activity of phenylpyrimidine derivs. as NK-1 antagonists)

RN 311339-73-8 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-phenyl-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 77 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:217698 CAPLUS

DN 133:2300

TI Identification of *Cryptosporidium parvum* dihydrofolate reductase inhibitors by complementation in *Saccharomyces cerevisiae*

AU Brophy, Victoria Hertle; Vasouez, John; Nelson, Richard G.; Forney, John R.; Rosowsky, Andre; Sibley, Carol Hopkins

CS Department of Genetics, University of Washington, Seattle, WA, 98195-7360, USA

SO Antimicrobial Agents and Chemotherapy (2000), 44(4), 1019-1028

CODEN: AMACCQ; ISSN: 0066-4804

PB American Society for Microbiology

DT Journal

LA English

AB There is a pressing need for drugs effective against the opportunistic protozoan pathogen *Cryptosporidium parvum*. Folate metabolic enzymes and enzymes of the thymidylate cycle, particularly dihydrofolate reductase (DHFR), have been widely exploited as chemotherapeutic targets. Although many DHFR inhibitors have been synthesized, only a few have been tested against *C. parvum*. To expedite and facilitate the discovery of effective anti-*Cryptosporidium* antifolates, the authors have developed a rapid and facile method to screen potential inhibitors of *C. parvum* DHFR using the model eukaryote, *Saccharomyces cerevisiae*. They expressed the DHFR genes of *C. parvum*, *Plasmodium falciparum*, *Toxoplasma gondii*, *Pneumocystis carinii*, and humans in the same DHFR-deficient yeast strain and observed that each heterologous enzyme complemented the yeast DHFR deficiency. In this work, the authors describe their use of the complementation system to screen known DHFR inhibitors and their discovery of several compds. that inhibited the growth of yeast reliant on the *C. parvum* enzyme. These same compds. were also potent or selective inhibitors of the purified recombinant *C. parvum* DHFR enzyme. Six novel lipophilic DHFR inhibitors potently inhibited the growth of yeast expressing *C. parvum* DHFR. However, the inhibition was nonselective, as these compds. also strongly inhibited the growth of yeast dependent on the human enzyme. Conversely, the antibacterial DHFR inhibitor trimethoprim and two close structural analogs were highly selective, but weak, inhibitors of yeast complemented by the *C. parvum* enzyme. Future chemical refinement of the potent and selective lead compds. identified in this study may allow the design of an efficacious antifolate drug for the treatment of cryptosporidiosis.

IT 35960-68-0


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(identification of *Cryptosporidium parvum* dihydrofolate reductase inhibitors by complementation in *Saccharomyces cerevisiae*)

RN 35960-68-0 CAPLUS

CN L-Glutamic acid, N-[4-[[3-(2-amino-1,4-dihydro-4-oxo-6-phenyl-5-pyrimidinyl)propyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 66

THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 78 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:115763 CAPLUS

DN 132:151833

TI Preparation of 4-amino-2-arylpyrimidines as modulators of cyclic guanosine monophosphate production.

IN Schindler, Ursula; Schoenafinger, Karl; Strobel, Hartmut

PA Hoechst Marion Roussel Deutschland G.m.b.H., Germany

SO Ger. Offen., 22 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19836697	A1	20000217	DE 1998-19836697	19980813
	CA 2340405	AA	20000224	CA 1999-2340405	19990804
	WO 2000009496	A1	20000224	WO 1999-EP5636	19990804
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9957307	A1	20000306	AU 1999-57307	19990804
	AU 760988	B2	20030529		
	BR 9913003	A	20010508	BR 1999-13003	19990804
	EP 1112266	A1	20010704	EP 1999-944330	19990804
	EP 1112266	B1	20030514		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002522536	T2	20020723	JP 2000-564948	19990804
	AT 240315	E	20030515	AT 1999-944330	19990804
	PT 1112266	T	20030930	PT 1999-944330	19990804
	ES 2196849	T3	20031216	ES 1999-944330	19990804
	US 6844347	B1	20050118	US 2001-762893	20010213
PRAI	DE 1998-19836697	A	19980813		
	WO 1999-EP5636	W	19990804		

OS MARPAT 132:151833

AB Title compds. [I; R1 = (substituted) alkyl, cycloalkyl, 5-7 membered heterocyclyl; R2 = H, (substituted) alkyl, cycloalkyl, 5-7 membered heterocyclyl; R1R2N = (substituted) 5-7 membered heterocyclyl; R3 = aryl; R4 = alkyl, CF3, aryl], were prepared Thus, 4-chloro-2-(4-chlorophenyl)-6-isopropylpyrimidine (preparation given) and 4-amino-2,2,6,6,-tetramethylpiperidine were stirred at 150° for 2 h to give 2-(4-chlorophenyl)-6-isopropyl-4-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]pyrimidine dihydrochloride. Tested I at 50 µM stimulated guanylate cyclase by >4 to 28-fold.

IT 257948-67-7P 257948-73-5P 257948-92-8P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-amino-2-arylpyrimidines as modulators of cyclic guanosine monophosphate production)

RN 257948-67-7 CAPLUS


CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-N-[2-(3-methoxyphenyl)ethyl]-6-(1-

methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 257948-73-5 CAPLUS

CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-6-(1-methylethyl)-N-(phenylmethyl)-
(9CI) (CA INDEX NAME)

RN 257948-92-8 CAPLUS

CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-N-[2-(3-methoxyphenyl)ethyl]-6-phenyl-
, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

IT 257949-74-9


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of 4-amino-2-arylpyrimidines as modulators of cyclic guanosine

monophosphate production)

RN 257949-74-9 CAPLUS

CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-N-ethyl-6-(1-methylethyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 79 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1999:811233 CAPLUS
 DN 132:64265
 TI Preparation of aminopyrimidines and -pyridines as glycogen synthase kinase
 3 inhibitors
 IN Nuss, John M.; Harrison, Stephen D.; Ring, David B.; Boyce, Rustum S.;
 Brown, Sean P.; Goff, Dane; Johnson, Kirk; Pfister, Keith B.; Ramurthy,
 Savithry; Renhowe, Paul A.; Seely, Lynn; Subramanian, Sharadha; Wagman,
 Allan S.; Zhou, Xiaohui A.
 PA Chiron Corporation, USA
 SO PCT Int. Appl., 262 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9965897	A1	19991223	WO 1999-US13809	19990618
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9949566	A1	20000105	AU 1999-49566	19990618
	EP 1087963	A1	20010404	EP 1999-933522	19990618
	EP 1087963	B1	20040825		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6489344	B1	20021203	US 1999-336098	19990618
	JP 2003527303	T2	20030916	JP 2000-554722	19990618
	AT 274510	E	20040915	AT 1999-933522	19990618
	US 2003130289	A1	20030710	US 2002-309535	20021203
	US 7037918	B2	20060502		
PRAI	US 1998-89978P	P	19980619		
	US 1999-336098	A3	19990618		
	WO 1999-US13809	W	19990618		

OS MARPAT 132:64265


AB RZCR2R12CR3R13Z1R5 [I; R = (un)substituted (hetero)aryl; Z = O, NR1,
 CR1R11; Z1 = O, NR4, CR4R14; R1-R4 = H, OH, NH2, alkyl, alkoxy, etc.; R5 =
 (un)substituted 2-pyridyl or -pyrimidyl; R11-R14 = H or alkyl] were prepared
 Thus, 2-chloro-5-nitropyridine was aminated by H2N(CH2)3NH2 and the
 product N-acylated by benzotriazolecarboxamidinium tosylate to give the
 alkylguanidine which was cyclocondensed with resin-bound
 4-(MeCO)C6H4CONHCH2C6H4Br-3 and Cs2CO3 to give, after resin cleavage,
 title compound II. Data for biol. activity of I were given.

IT 252904-40-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of aminopyrimidines and -pyridines as glycogen synthase kinase
 3 inhibitors)


RN 252904-40-8 CAPLUS

CN Benzonitrile, 4-[2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-5-
 [(phenylmethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 80 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1999:729784 CAPLUS
DN 132:308303
TI Synthesis and preliminary study of anticonvulsive activity of
4-substituted amino-6-phenylpyrimidines
AU Zhang, Xiaohui; Wang, Donghui; Chen, Naiyong; Tao, Cheng
CS Institute of Applied Pharmacy Science, Beijing Medical Univ., Beijing,
100083, Peop. Rep. China
SO Zhongguo Yaowu Huaxue Zazhi (1999), 9(3), 192-195
CODEN: ZYHZEJ; ISSN: 1005-0108
PB Zhongguo Yaowu Huaxue Zazhi Bianjibu
DT Journal
LA Chinese
AB Seven 4-substituted amino-6-phenylpyrimidines were designed and
synthesized, and their anticonvulsive activities were studied. All the
synthetic compds. showed some anticonvulsive activity,
4-benzylamino-6-phenylpyrimidine showed strong effects, even stronger than
dilatant sodium. Structure-activity relationship was discussed.
IT **266303-86-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); BIOL (Biological
study); PREP (Preparation)
(synthesis and anticonvulsant activity of 4-substituted
amino-6-phenylpyrimidines)
RN 266303-86-0 CAPLUS
CN 4-Pyrimidinamine, 6-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 81 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1999:583185 CAPLUS

DN 131:199710

TI Preparation of nitrogen containing aromatic compounds as herbicides

IN Kuboyama, Nobuhiro; Koizumi, Kazuya; Yamashita, Osamu; Wakabayashi, Osamu; Tomono, Kotaro; Hattori, Takashi

PA Tomono Agrica K. K., Japan

SO Jpn. Kokai Tokkyo Koho, 42 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 11246528	A2	19990914	JP 1998-345843	19981204
PRAI	JP 1997-335223	A	19971205		

OS MARPAT 131:199710

AB Title compds. [I; X, Y, Z are independently N, CH; R = CF₃; R₁ = CH₃, H, CH₂CH₃, (CH₃)₂CH, C₆H₅; A = NH, NCHO, NCOCH₃, NCOCH₂CH₃, NCOCH₂CH₂CH₃, NCOCH(CH₃)₂, NCOC(CH₃)₃, O, NCH₂CCH, S; B = CH₂, (S)-CH₃CH, (R)-CH₃CH, CH₃CH, CH₃CHCH₂CH₂, (CH₃)₂CCH₂, (CH₂)₄, (CH₂)₂, (CH₂)₃; R₂ = 4-ClC₆H₄, 2-ClC₆H₄, 3-ClC₆H₄, 4-BrC₆H₄, 3-F₃CC₆H₄, 4-F₃CC₆H₄, 2-BrC₆H₄, 3-BrC₆H₄, 3-Br-4-FC₆H₃, 2-CH₃C₆H₄, 3-O₂NC₆H₄, 2-HOC₆H₄, C₆H₅, 2-pyridyl, 3-pyridyl, cyclohexyl; BR₂ = (CH₂)₇CH₃, (CH₂)₂CH(C₆H₅)₂; etc.], and salts are prepared as herbicides and tested on rice paddies. Thus, the title compound I (R = CF₃; R₁ = CH₃; A = NH; B = CH₂; R₂ = 4-ClC₆H₄; X = N; Y = N; Z = CH) was prepared

IT 241162-08-3P 241163-03-1P 241163-09-7P


241163-10-0P 241163-11-1P 241163-12-2P

241163-13-3P 241163-68-8P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of nitrogen containing aromatic compds. as herbicides)


RN 241162-08-3 CAPLUS

CN 4-Pyrimidinamine, N-[(4-chlorophenyl)methyl]-2-phenyl-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 241163-03-1 CAPLUS

CN Formamide, N-[(4-chlorophenyl)methyl]-N-[2-phenyl-6-(trifluoromethyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 241163-09-7 CAPLUS

CN Formamide, N-[(2-chlorophenyl)methyl]-N-[2-phenyl-6-(trifluoromethyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 241163-10-0 CAPLUS

CN Formamide, N-[(3-chlorophenyl)methyl]-N-[2-phenyl-6-(trifluoromethyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 241163-11-1 CAPLUS

CN Formamide, N-[(2-methylphenyl)methyl]-N-[2-phenyl-6-(trifluoromethyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 241163-12-2 CAPLUS

CN Formamide, N-[(3-methylphenyl)methyl]-N-[2-phenyl-6-(trifluoromethyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 241163-13-3 CAPLUS

CN Formamide, N-[(4-methylphenyl)methyl]-N-[2-phenyl-6-(trifluoromethyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 241163-68-8 CAPLUS

CN 4-Pyrimidinamine, 2-phenyl-N-(4-phenylbutyl)-6-(trifluoromethyl)- (9CI)
(CA INDEX NAME)



L10 ANSWER 82 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1999:387716 CAPLUS

DN 131:78466

TI Adenosine A3 antagonists

IN Sugiura, Yoshihiro; Miwatari, Seiji; Kimura, Hiroyuki; Knzaki, Naoyuki

PA Takeda Chemical Industries, Ltd., Japan

SO Jpn. Kokai Tokyo Koho, 30 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 11158073	A2	19990615	JP 1998-270755	19980925
PRAI	JP 1997-262525	A	19970926		

OS MARPAT 131:78466

AB Adenosine A3 receptor antagonists contain (un)substituted amino-substituted N2-3-containing heterocyclic [5-8 ring-containing] compds. such

as 2-chloro-4-ethylamino-6-phenylamino-1,3,5-triazine and 2,4-bis[phenylamino]-6-cyclohexylamino-1,3,5-triazine. Of 6 compds. tested, the IC50 values of adenosine A3 receptor antagonist activities ranged from 0.7 to 285.9 nM as determined in human adenosine A3 receptor-expressing plasmid-transformed CHO (dhfr-) cell cultures. Tablets were formulated containing 2,4-bis[phenylamino]-6-cyclohexylamino-1,3,5-triazine 50, lactose 34, corn starch 10.6, corn starch paste 5, magnesium stearate 0.4 and calcium CM-cellulose 20 mg. The drugs are useful for treating e.g. brain ischemic disease.


IT 228575-16-4

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(adenosine A3 receptor antagonists and pharmaceutical compns.)

RN 228575-16-4 CAPLUS

CN 4,6-Pyrimidinediamine, N,2-diphenyl-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 83 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:788746 CAPLUS

DN 130:52406

TI Substituted biphenyl isoxazole sulfonamides useful as endothelin antagonists

IN Murugesan, Natesan; Barrish, Joel C.; Spergel, Steven H.

PA Bristol-Myers Squibb Co., USA

SO U.S., 107 pp., Cont.-in-part of U.S. Ser. No. 754,715, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5846990	A	19981208	US 1997-799616	19970213
	TW 517057	B	20030111	TW 1997-86101898	19970218
	ZA 9701423	A	19980819	ZA 1997-1423	19970219
	CA 2240043	AA	19970821	CA 1997-2240043	19970220
	WO 9729748	A1	19970821	WO 1997-US3956	19970220
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9722098	A1	19970902	AU 1997-22098	19970220
	AU 720458	B2	20000601		
	EP 921800	A1	19990616	EP 1997-915055	19970220
	EP 921800	B1	20040414		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002500619	T2	20020108	JP 1997-529620	19970220
	AT 264324	E	20040415	AT 1997-915055	19970220
	ES 2219762	T3	20041201	ES 1997-915055	19970220
PRAI	US 1995-493331	B2	19950724		
	US 1996-603975	B1	19960220		
	US 1996-754715	B2	19961121		
	US 1997-799616	A	19970213		
	WO 1997-US3956	W	19970220		

OS MARPAT 130:52406

AB Title compds. I inhibit the activity of endothelin (no data), and are useful as antihypertensives, etc. The symbols in I are defined as follows [one of X and Y = N, other = O; J = O, S, N, (un)substituted NH; K, L = N or C, provided that at least one is C; p = 0-2; R1-R4 (bound to ring C atoms) = H, (un)substituted alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl, aralkoxy, halo, OH, cyano, NO₂, CHO, etc.; or R3R4 = (un)substituted alkylene or alkenylene; R5-R8 = groups similar to R1-R4, plus heterocyclyl, heterocyclyloxy, and others]. Over 280 synthetic examples are given. For instance, the MEM-protected, isoxazole-containing bromide II [R = Br] was lithiated, treated with B(OPr-iso)₃, and hydrolyzed to give 82% II [R = B(OH)₂]. The latter was coupled with 2-(4-bromophenyl)oxazole using Pd(PPh₃)₄ catalyst (70%), followed by acidic deprotection of the MEM group (52%), to give title compound III.

IT 195446-58-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of substituted biphenyl isoxazole sulfonamides as endothelin
 antagonists)


RN 195446-58-3 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'-[[[4-(4-chlorophenyl)-6-ethoxy-2-
 pyrimidinyl]amino]methyl]-N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)-
 (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RE.CNT 43

THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 84 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1998:197493 CAPLUS
 DN 128:217383
 TI Preparation of pyrimidine compounds as pesticides
 IN Hamamoto, Isami; Ishimitsu, Keiichi; Ihori, Yoichi; Takahashi, Hidemitsu;
 Nakamura, Takehiko; Iwasa, Takao
 PA Nippon Soda Co., Ltd., Japan
 SO PCT Int. Appl., 55 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9812184	A1	19980326	WO 1997-JP3292	19970918
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9742217	A1	19980414	AU 1997-42217	19970918
PRAI	JP 1996-269309	A	19960919		
	JP 1996-356867	A	19961226		
	WO 1997-JP3292	W	19970918		

OS MARPAT 128:217383


AB The title compds. (I; R1-R5, R8-R12 = H, halo, C1-6 alkyl, haloalkyl, alkoxy, alkylthio, or haloalkoxy, etc.; R6, R7 = H, halo, C1-6 alkyl or haloalkyl; R13 = H, optionally substituted C1-6 alkyl, C2-6 alkenyl, or alkynyl, optionally substituted carbamoyl, etc.) are prepared I are useful as pesticides. Thus, 4-chloro-6-(4-fluoro-3-trifluoromethylphenoxy)pyrimidine (preparation given) was reacted with 4-fluoro-3-trifluoromethylaniline in the presence of Et3N to give 67% the title compound (II). II at 125 ppm showed 100% insecticidal effect for Pseudaletia separata after 6 days.

IT **204121-40-4P**

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of pyrimidine compds. as pesticides)

RN 204121-40-4 CAPLUS

CN 4-Pyrimidinamine, N-[(4-chlorophenyl)methyl]-N,6-bis[4-fluoro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 85 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:136037 CAPLUS

DN 128:244022

TI Synthesis and transformations of methyl (E)-2-(acetylamino)-3-cyanoprop-2-enoate and methyl (E)-2-(benzoylamino)-3-cyanoprop-2-enoate, versatile reagents for the preparation of polyfunctional heterocyclic systems

AU Pizzioli, Lucija; Ornik, Brina; Svete, Jurij; Stanovnik, Branko

CS Fac. Chem. Chem. Technol., Univ. Ljubljana, Ljubljana, 1000, Slovenia

SO Helvetica Chimica Acta (1998), 81(2), 231-235

CODEN: HCACAV; ISSN: 0018-019X

PB Verlag Helvetica Chimica Acta AG

DT Journal

LA English

OS CASREACT 128:244022


AB The title compds. were prepared from the corresponding (Z)-2-(acylamino)-3-(dimethylamino)propenoates. The compds. proved to be versatile synthons for the synthesis of polysubstituted heterocyclic systems such as pyrroles, pyrimidines, pyridazines, pyrazoles, and isoxazoles.

IT 204767-43-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of polyfunctional heterocyclic compds. from
(acylamino)cyanopropenoates)

RN 204767-43-1 CAPLUS

CN 4-Pyrimidinecarboxamide, 2-phenyl-N-(phenylmethyl)-6-[(phenylmethyl)amino]-
(9CI) (CA INDEX NAME)



L10 ANSWER 86 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1997:557640 CAPLUS
 DN 127:248103
 TI Substituted biphenyl isoxazole sulfonamides useful as endothelin antagonists
 IN Murugesan, Natesan; Barrish, Joel C.; Spergel, Steven H.
 PA Bristol-Myers Squibb Company, USA
 SO PCT Int. Appl., 325 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9729748	A1	19970821	WO 1997-US3956	19970220
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5846990	A	19981208	US 1997-799616	19970213
	TW 517057	B	20030111	TW 1997-86101898	19970218
	ZA 9701423	A	19980819	ZA 1997-1423	19970219
	AU 9722098	A1	19970902	AU 1997-22098	19970220
	AU 720458	B2	20000601		
	EP 921800	A1	19990616	EP 1997-915055	19970220
	EP 921800	B1	20040414		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002500619	T2	20020108	JP 1997-529620	19970220
	AT 264324	E	20040415	AT 1997-915055	19970220
PRAI	US 1996-603975	A	19960220		
	US 1996-754715	A	19961121		
	US 1997-799616	A	19970213		
	US 1995-493331	B2	19950724		
	WO 1997-US3956	W	19970220		

OS MARPAT 127:248103

AB Title compds. I inhibit the activity of endothelin (no data), and are useful as antihypertensives, etc. The symbols in I are defined as follows [one of X and Y = N, other = O; J = O, S, N, (un)substituted NH; K, L = N or C, provided that at least one is C; p = 0-2; R1-R4 (bound to ring C atoms) = H, (un)substituted alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl, aralkoxy, halo, OH, cyano, NO2, CHO, etc.; or R3R4 = (un)substituted alkylene or alkenylene; R5-R8 = groups similar to R1-R4, plus heterocyclyl, heterocyclyloxy, and others]. Over 280 synthetic examples are given. For instance, the MEM-protected, isoxazole-containing bromide II [R = Br] was lithiated, treated with B(OPr-iso)₃, and hydrolyzed to give 82% II [R = B(OH)₂]. The latter was coupled with 2-(4-bromophenyl)oxazole using Pd(PPh₃)₄ catalyst (70%), followed by acidic deprotection of the MEM group (52%), to give title compound III.

IT 195446-58-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted biphenyl isoxazole sulfonamides as endothelin antagonists)


RN 195446-58-3 CAPLUS

CN [1,1'-Biphenyl]-2-sulfonamide, 2'-[[[4-(4-chlorophenyl)-6-ethoxy-2-pyrimidinyl]amino]methyl]-N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L10 ANSWER 87 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1997:407610 CAPLUS

DN 127:121691

TI Synthesis of 4,6-disubstituted and 4,5,6-trisubstituted

2-phenylpyrimidines and their affinity towards A1 adenosine receptors

AU Biagi, Giuliana; Giorgi, Irene; Livi, Oreste; Scartoni, Valerio;

Lucacchini, Antonio

CS Dip. Scienze Farmaceutiche, Univ. Pisa, Pisa, 56126, Italy

SO Farmaco (1997), 52(1), 61-65

CODEN: FRMCE8; ISSN: 0014-827X

PB Societa Chimica Italiana

DT Journal

LA English

AB The preparation and assay of the title compds., e.g., I (R = cyclohexyl, pentyl), are reported. The results support our hypothesis about the possibility that mols. characterized by great flexibility, such as 2-phenyl-4,5,6-triaminopyrimidines, can better interact with the receptor sites than rigid mols. such as 2,6,9-trisubstituted 8-azaadenines. The relatively low activity shown by pyrimidine derivs. demonstrated the importance of the bicyclic aromatic system in 8-azaadenines and adenines for a favorable interaction with the A1 adenosine receptors.

IT 192631-72-4P 192631-73-5P 192631-74-6P

192631-75-7P 192631-86-0P 192631-87-1P


192631-88-2P 192631-89-3P 192631-94-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of 4,6-disubstituted and 4,5,6-trisubstituted 2-phenylpyrimidines and their A1 adenosine receptor affinity)


RN 192631-72-4 CAPLUS

CN 4,6-Pyrimidinediamine, N-cyclopentyl-2-phenyl-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 192631-73-5 CAPLUS

CN 4,6-Pyrimidinediamine, N-cyclohexyl-2-phenyl-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 192631-74-6 CAPLUS


CN 4,6-Pyrimidinediamine, N-butyl-2-phenyl-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 192631-75-7 CAPLUS
 CN 4,6-Pyrimidinediamine, N-pentyl-2-phenyl-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 192631-86-0 CAPLUS
 CN 4,5,6-Pyrimidinetriamine, N4-cyclopentyl-2-phenyl-N6-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 192631-87-1 CAPLUS
 CN 4,5,6-Pyrimidinetriamine, N4-cyclohexyl-2-phenyl-N6-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 192631-88-2 CAPLUS
 CN 4,5,6-Pyrimidinetriamine, N4-butyl-2-phenyl-N6-(phenylmethyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 192631-89-3 CAPLUS
 CN 4,5,6-Pyrimidinetriamine, N4-pentyl-2-phenyl-N6-(phenylmethyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 192631-94-0 CAPLUS
 CN 4,5,6-Pyrimidinetriamine, 2-phenyl-N4,N6-bis(phenylmethyl)-,
 monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 192631-70-2P 192631-77-9P 192631-78-0P


192631-79-1P 192631-80-4P 192631-81-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 4,6-disubstituted and 4,5,6-trisubstituted 2-phenylpyrimidines and their A1 adenosine receptor affinity)


RN 192631-70-2 CAPLUS

CN 4-Pyrimidinamine, 6-chloro-2-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 192631-77-9 CAPLUS

CN 4,6-Pyrimidinediamine, 5-nitro-2-phenyl-N,N'-bis(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 192631-78-0 CAPLUS

CN 4,6-Pyrimidinediamine, N-cyclopentyl-5-nitro-2-phenyl-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 192631-79-1 CAPLUS

CN 4,6-Pyrimidinediamine, N-cyclohexyl-5-nitro-2-phenyl-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 192631-80-4 CAPLUS

CN 4,6-Pyrimidinediamine, N-butyl-5-nitro-2-phenyl-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 192631-81-5 CAPLUS

CN 4,6-Pyrimidinediamine, 5-nitro-N-pentyl-2-phenyl-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)



IT 192631-76-8P


RL: SPN (Synthetic preparation); PREP (Preparation)

10/671,070

(preparation of 4,6-disubstituted and 4,5,6-trisubstituted
2-phenylpyrimidines and their A1 adenosine receptor affinity)

RN 192631-76-8 CAPLUS

CN 4-Pyrimidinamine, 6-chloro-5-nitro-2-phenyl-N-(phenylmethyl)- (9CI) (CA
INDEX NAME)



L10 ANSWER 88 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1997:151137 CAPLUS

DN 126:251130

TI A novel and efficient approach for the combinatorial synthesis of structurally diverse pyrimidines on solid support

AU Obrecht, Daniel; Abrecht, Christine; Grieder, Alfred; Villalgordo, Jose M.

CS Hoffmann-La Roche A.-G., Basel, CH-4070, Switz.

SO Helvetica Chimica Acta (1997), 80(1), 65-72

CODEN: HCACAV; ISSN: 0018-019X

PB Verlag Helvetica Chimica Acta

DT Journal

LA English

OS CASREACT 126:251130


AB A versatile approach for the synthesis of 2,4,6-trisubstituted pyrimidines on solid support is described. Thus, polymer-bound thiouronium chloride reacted in high yield in a cyclocondensation reaction with $\text{RCOC.tplbond.CCO}_2\text{CMe}_3$ ($\text{R} = \text{Ph}$, 2-furyl, 5-benzo[1,3]dioxolyl) to form, after ester cleavage, polymer-bound pyrimidinecarboxylates which were cleaved by oxidation with MCPBA and pyrrolidine to give 85-90% pyrrolidinylpyrimidinecarboxylates I ($\text{R}_1 = \text{OH}$) in 96-99% purities. Alternatively, Ugi 4-component condensation gave Ugi products such as I [$\text{R} = \text{Ph}$; $\text{R}_1 = \text{NR}_2\text{C}(\text{CHMe}_2)\text{CONHR}_3$; $\text{R}_2 = 4\text{-MeOC}_6\text{H}_4$, Pr , cyclohexyl; $\text{R}_3 = \text{cyclohexyl}$] in 65-87% yields. Multi-directional cleavage reaction of polymer-bound sulfone II with different nucleophiles resulted in the clean formation of pyrimidine-4-carboxamides. This strategy combines efficiently solid-phase chemical which a multicomponent reaction and a multi-directional cleavage step to form highly diverse pyrimidines in a parallel array.

IT 188633-61-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(combinatorial synthesis of pyrimidines on solid support)

RN 188633-61-6 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[1-[(cyclohexylamino)carbonyl]-3-methylbutyl]-N-(4-methoxyphenyl)-6-phenyl-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



L10 ANSWER 89 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1997:26297 CAPLUS
 DN 126:89387
 TI Preparation of 5-[phenyl(methyl)- and pyridyl(methyl)]pyrimidine
 derivatives as pesticides
 IN Kasahara, Isamu; Oooka, Hirohito; Murahashi, Kazuhiko; Matsuda, Mitsuhiko;
 Sano, Chikaaki
 PA Nippon Soda Co, Japan
 SO Jpn. Kokai Tokkyo Koho, 42 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 08283246	A2	19961029	JP 1995-153806	19950529
PRAI	JP 1994-142513	A	19940601		
	JP 1995-51827	A	19950216		

OS MARPAT 126:89387


AB The title compds. [I; Ar = (un)substituted Ph or pyridyl; n = 0.1; n = 0,1; R1 = H, halo, lower alkyl; R2 = H, lower alkyl or alkylthio; X = NR4, O, S; R3 = (CHR5)m-A1, (CHR6)k-O-A2, C1-12 alkyl, C2-12 alkenyl; m, k, = 1,2; wherein A1, A2 = (un)substituted Ph or pyridyl; R4 = H, lower alkyl or alkoxy; R5, R6 = H, lower alkyl], which are useful as agrochem. fungicides, insecticides, and aphicides, are prepared Thus, 0.4 g 4-chloro-5-phenylpyrimidine was dissolved in DMSO, treated with 0.42 g 2-(2,4-dimethylphenoxy)ethylamine and 0.3 g Et3N, and the resulting mixture was stirred at room temperature at 70° for 5 h to give 0.55 g of the title compound (II). II killed ≥80% Aphis gossypii on cucumber seedlings and Nilaparvata lugens on rice seedlings at 125 ppm and ≥80% Erysiphe graminis f.sp. tritici on wheat seedlings at 200 ppm.

IT 185052-66-8P 185052-68-0P 185052-71-5P
 185052-72-6P 185052-74-8P 185052-75-9P
 185052-76-0P 185052-78-2P 185052-79-3P
 185052-80-6P 185052-81-7P 185052-83-9P
 185052-87-3P 185052-91-9P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of [phenyl(methyl)- and pyridyl(methyl)]pyrimidine derivs. as pesticides)


RN 185052-66-8 CAPLUS

CN 4-Pyrimidinamine, 5-phenyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 185052-68-0 CAPLUS


CN 4-Pyrimidinamine, 5-phenyl-N-[2-[2-(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 185052-71-5 CAPLUS
 CN 4-Pyrimidinamine, 5-(2,4-dichlorophenyl)-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 185052-72-6 CAPLUS
 CN 4-Pyrimidinamine, 5-(2,4-dichlorophenyl)-N-[2-[2-(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 185052-74-8 CAPLUS
 CN 4-Pyrimidinamine, 5-phenyl-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 185052-75-9 CAPLUS
 CN 4-Pyrimidinamine, 5-(2,4-dichlorophenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 185052-76-0 CAPLUS

CN 4-Pyrimidinamine, 5-(2,4-dichlorophenyl)-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 185052-78-2 CAPLUS

CN 4-Pyrimidinamine, 5-(4-methoxyphenyl)-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 185052-79-3 CAPLUS

CN 4-Pyrimidinamine, 5-(4-methoxyphenyl)-N-[2-[2-(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 185052-80-6 CAPLUS

CN 4-Pyrimidinamine, 5-(4-methoxyphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 185052-81-7 CAPLUS

CN 4-Pyrimidinamine, 5-(4-methoxyphenyl)-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 185052-83-9 CAPLUS


CN 4-Pyrimidinamine, 6-chloro-5-phenyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 185052-87-3 CAPLUS


CN 4-Pyrimidinamine, N-[(4-chlorophenyl)methyl]-N-ethoxy-5-phenyl- (9CI) (CA

INDEX NAME)




RN 185052-91-9 CAPLUS

CN 4-Pyrimidinamine, N-ethoxy-5-phenyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




L10 ANSWER 90 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1996:488269 CAPLUS
 DN 125:211838
 TI Electron-topological study of structure-activity relationship in the series of dihydrofolate reductase inhibitors
 AU Vlasenko, S. P.; Dimoglo, A. S.
 CS Inst. Chem., Acad. Sci. Moldova, Chisinau, Moldova
 SO Khimiko-Farmatsevticheskii Zhurnal (1996), 30(6), 25-28
 CODEN: KHFZAN; ISSN: 0023-1134
 PB Izdatel'stvo Folium
 DT Journal
 LA Russian
 AB An electron-topol. method for forecasting the inhibitory activity of 2-aminopyrimidine derivs. toward dihydrofolate reductase was developed. The parts of the mol. structure responsible for the binding to dihydrofolate reductase active site and hence for the inhibitory activity of the compds. were established.
 IT **2211-01-0**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (electron-topol. modeling of MSBAR of aminopyrimidines as dihydrofolate reductase inhibitors)
 RN 2211-01-0 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-phenyl-5-[3-(phenylamino)propyl]- (9CI) (CA INDEX NAME)



Handwritten signature or mark.

L10 ANSWER 91 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1996:411057 CAPLUS
 DN 125:114708
 TI 4-Aminopyrimidine derivatives
 IN Lee, Sung J.; Konishi, Yoshitaka; Macina, Orest T.; Kondo, Kigen; Yu, Dingwei T.; Miskowski, Tamara A.
 PA Ono Pharmaceutical Co., Ltd., Japan
 SO U.S., 28 pp., Cont.-in-part of U.S. Ser. No. 111,906, abandoned.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5525604	A	19960611	US 1994-295377	19940824
	AT 163647	E	19980315	AT 1994-305973	19940812
	ES 2114662	T3	19980601	ES 1994-305973	19940812
	JP 07089958	A2	19950404	JP 1994-222654	19940824
	CA 2130878	AA	19950227	CA 1994-2130878	19940825
	CA 2130878	C	19990323		
	CN 1109055	A	19950927	CN 1994-109363	19940825
	KR 204433	B1	19990615	KR 1994-21017	19940825
PRAI	US 1993-111906	B2	19930826		
OS	MARPAT 125:114708				
AB	4-Aminopyrimidines I [A = bond, alkylene, oxyalkylene; Y = bond, alkylene, alkyleneoxy, alkoxyphenylene, phenylalkylene; Z = bond, CH:CH; R1 = heterocyclic containing 1 or 2 N atom; R2 = heterocyclic containing 1 or 2 N, 1 or 2 O or 1 S atom, carbocyclic, alkoxy, hydroxy alkoxy, OH; R3 = heterocyclic containing 1 or 2 N, 1 O, 1 S, or 1 N and 1 S atom, carbocyclic, halovinyl, H; n = 1, 2] with some exceptions, and acid addition salts thereof, inhibit cGMP-PDE, or TXA2 synthetase. Thus, 5-(3-methoxybenzyl)tetrahydro-2,4-pyrimidinedione was chlorinated, treated with H2NCH2CH2OCH2CH2OH and then imidazole to give the pyrimidine II, which had an IC50 against cGMP-PDE of 21.0 μ M.				
IT	163345-82-2P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of 4-aminopyrimidine derivs. as cGMP phosphodiesterase and TXA2 synthase inhibitors)				
RN	163345-82-2 CAPLUS				
CN	4-Pyrimidinamine, N-(1,3-benzodioxol-5-ylmethyl)-2-(1H-imidazol-1-yl)-5-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)				




● HCl

IT 163345-83-3P 163345-84-4P 163345-89-9P
 163345-92-4P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 4-aminopyrimidine derivs. as cGMP phosphodiesterase and TXA2 synthase inhibitors)

RN 163345-83-3 CAPLUS


CN 4-Pyrimidinamine, N-(1,3-benzodioxol-5-ylmethyl)-2-(1H-imidazol-1-yl)-5-(4-methylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 163345-84-4 CAPLUS


CN 4-Pyrimidinamine, N-(1,3-benzodioxol-5-ylmethyl)-2-(1H-imidazol-1-yl)-5-(4-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 163345-89-9 CAPLUS


CN 4-Pyrimidinamine, N-(1,3-benzodioxol-5-ylmethyl)-5-(4-chlorophenyl)-2-(1H-imidazol-1-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 163345-92-4 CAPLUS

CN 4-Pyrimidinamine, N-(1,3-benzodioxol-5-ylmethyl)-2-(1H-imidazol-1-yl)-5-(2-naphthalenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L10 ANSWER 92 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1996:184015 CAPLUS
 DN 124:232480
 TI Preparation and formulation of pyrimidine derivatives for treatment of kidney diseases
 IN Yanaka, Mikiro; Nishijima, Fuyuhiko; Enari, Hiroyuki; Ise, Michihito
 PA Kureha Chemical Industry Co., Ltd., Japan
 SO Eur. Pat. Appl., 24 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 686631	A1	19951213	EP 1995-108380	19950601
	EP 686631	B1	20010117		
	R: AT, BE, CH, DE, DK, FR, GB, IT, LI, NL				
	CA 2150609	AA	19951202	CA 1995-2150609	19950531
	CA 2150609	C	19981208		
	US 5585381	A	19961217	US 1995-454629	19950531
	AU 9520427	A1	19960104	AU 1995-20427	19950601
	AU 679361	B2	19970626		
	JP 08048672	A2	19960220	JP 1995-158658	19950601
	JP 2996609	B2	20000111		
	AT 198746	E	20010215	AT 1995-108380	19950601
PRAI	JP 1994-142274	A	19940601		

OS MARPAT 124:232480


AB The title compds. I [R1 = H, alkyl, etc.; R2 = H, halo, etc.; R3 = CO₂H, etc.] are claimed. In rats (with exptl. kidney disease) dosed with I [R1 = butyl; R2 = 6-Cl; R3 = 4-CO₂Me] (preparation given) at 20 mg/kg/day, the survival time was 6.9 wk, vs. 5 wk in untreated controls, and 6.9 wk in rats treated with DuP753. The title compds. do not show angiotensin II receptor antagonism.

IT **174697-58-6P 174697-83-7P 174697-86-0P 174697-87-1P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrimidine derivs. for treatment of kidney diseases)


RN 174697-58-6 CAPLUS

CN Benzoic acid, 4-[[[5-[(1-oxopentyl)amino]-6-phenyl-4-pyrimidinyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 174697-83-7 CAPLUS

CN Pentanamide, N-[4-[[[4-(4-hydroxyphenyl)methyl]amino]-6-phenyl-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 174697-86-0 CAPLUS

CN Pentanamide, N-[4-[[[4-(methylanino)phenyl]methyl]amino]-6-phenyl-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 174697-87-1 CAPLUS

CN Pentanamide, N-[4-[[[4-(dimethylamino)phenyl]methyl]amino]-6-phenyl-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 93 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1995:573846 CAPLUS

DN 122:314567

TI Preparation of 4-aminopyrimidine cyclic-guanosine monophosphate-phosphodiesterase and thromboxane A2 synthetase inhibitors

IN Lee, Sung Jai; Konishi, Yoshitaka; Macina, Orest Taras; Kondo, Kigen; Yu, Dingwei Tim; Miskowski, Tamara Ann

PA Ono Pharmaceutical Co., Ltd., Japan

SO Eur. Pat. Appl., 56 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 640599	A1	19950301	EP 1994-305973	19940812
	EP 640599	B1	19980304		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	AT 163647	E	19980315	AT 1994-305973	19940812
	ES 2114662	T3	19980601	ES 1994-305973	19940812
	JP 07089958	A2	19950404	JP 1994-222654	19940824
	CA 2130878	AA	19950227	CA 1994-2130878	19940825
	CA 2130878	C	19990323		
	CN 1109055	A	19950927	CN 1994-109363	19940825
	KR 204433	B1	19990615	KR 1994-21017	19940825
PRAI	US 1993-111906	A	19930826		

OS MARPAT 122:314567

AB The title compds. [I; A = direct bond, C1-4 alkylene or oxyalkylene; R1 = 4-15-membered (un)substituted heterocyclyl; R2= 4-15-membered (un)substituted heterocyclyl, C4-15 carbocyclyl, C1-4 alkoxy, hydroxyalkoxy, OH; R3 = 4-15-membered (un)substituted heterocyclyl, C4-15 carbocyclyl, SONR7R8, H, etc.; R7, R8 = H, alkyl; Y = direct bond, C1-4 alkylene, alkyleneoxy, alkoxyphenylene, phenylalkylene; Z = direct bond, vinylene; l = 1, 2], which are inhibitors of cGMP-PDE and TXA2 synthetase, useful for the treatment of hypertension (no data), peptic ulcer (no data), etc., are prepared and a I-containing formulation presented. Thus, aminopyrimidine II (m.p. 153.0-156.0°) was prepared and demonstrated 100% inhibition of TXA2 synthetase at 10 μ M.

IT 163345-40-2P 163345-41-3P 163345-47-9P


163345-50-4P

RL: PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of 4-aminopyrimidine cyclic-guanosine monophosphate-phosphodiesterase and thromboxane A2 synthetase inhibitors)


RN 163345-40-2 CAPLUS

CN 4-Pyrimidinamine, N-(1,3-benzodioxol-5-ylmethyl)-2-(1H-imidazol-1-yl)-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 163345-41-3 CAPLUS

CN 4-Pyrimidinamine, N-(1,3-benzodioxol-5-ylmethyl)-2-(1H-imidazol-1-yl)-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 163345-47-9 CAPLUS

CN 4-Pyrimidinamine, N-(1,3-benzodioxol-5-ylmethyl)-5-(4-chlorophenyl)-2-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



RN 163345-50-4 CAPLUS

CN 4-Pyrimidinamine, N-(1,3-benzodioxol-5-ylmethyl)-2-(1H-imidazol-1-yl)-5-(2-naphthalenyl)- (9CI) (CA INDEX NAME)




IT 163345-82-2P 163345-83-3P 163345-84-4P
163345-89-9P 163345-92-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-aminopyrimidine cyclic-guanosine monophosphate-phosphodiesterase and thromboxane A2 synthetase inhibitors)

RN 163345-82-2 CAPLUS


CN 4-Pyrimidinamine, N-(1,3-benzodioxol-5-ylmethyl)-2-(1H-imidazol-1-yl)-5-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 163345-83-3 CAPLUS


CN 4-Pyrimidinamine, N-(1,3-benzodioxol-5-ylmethyl)-2-(1H-imidazol-1-yl)-5-(4-methylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 163345-84-4 CAPLUS


CN 4-Pyrimidinamine, N-(1,3-benzodioxol-5-ylmethyl)-2-(1H-imidazol-1-yl)-5-(4-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 163345-89-9 CAPLUS


CN 4-Pyrimidinamine, N-(1,3-benzodioxol-5-ylmethyl)-5-(4-chlorophenyl)-2-(1H-imidazol-1-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 163345-92-4 CAPLUS

CN 4-Pyrimidinamine, N-(1,3-benzodioxol-5-ylmethyl)-2-(1H-imidazol-1-yl)-5-(2-naphthalenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


L10 ANSWER 94 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1995:542200 CAPLUS
 DN 123:83308
 TI Synthesis of functionalized pyrimidine-4-thiones and pyrido[2,3-d]pyrimidin-5-one derivatives from amins of monoacylketenes
 AU Dorokhov, V. A.; Komkov, A. V.; Shashkova, E. M.; Bogdanov, V. S.; Bochkareva, M. N.
 CS N. D. Zelinsky Inst. Org. Chem., Russian Acad. Sci., Moscow, 117913, Russia
 SO Izvestiya Akademii Nauk, Seriya Khimicheskaya (1993), (11), 1932-7
 CODEN: IASKEA
 PB Institut Organicheskoi Khimii im. N. D. Zelinskogo Rossiiskoi Akademii Nauk
 DT Journal
 LA Russian
 AB Monoacylketene amins containing an unsubstituted NH₂ group react with benzoyl isothiocyanate as C-nucleophiles yielding the corresponding thioamides, which are cyclized by sodium methoxide in methanol to 6-amino-5-acetyl-2-phenyl-4(3H)-pyrimidinethiones, e.g., I.. Reaction of the thiones with DMF di-Me acetal leads to 4-(methylthio)pyrido[2,3-d]pyrimidin-5(8H)-ones, e.g., II (R = H, R₁ = Ph). Cyclization of 5-acetyl-6-benzamido-4-(methylthio)-2-phenylpyrimidine by sodium methoxide yields II (R = Ph, R₁ = H).
 IT **165401-59-2P 165401-65-0P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (functionalized pyrimidinethiones and pyridopyrimidinones from acylketene amins)
 RN 165401-59-2 CAPLUS
 CN Ethanone, 1-[1,4-dihydro-2-phenyl-6-[(phenylmethyl)amino]-4-thioxo-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 165401-65-0 CAPLUS
 CN 2-Propen-1-one, 3-(dimethylamino)-1-[4-(methylthio)-2-phenyl-6-[(phenylmethyl)amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




L10 ANSWER 95 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1995:484203 CAPLUS
 DN 123:55795
 TI Synthesis and immunomodulatory activity of 6-methyl-2-phenyl-5-substituted pyrimidines
 AU Cieplik, Jerzy; Machon, Zdzislaw; Zimecki, Michal; Wieczorek, Zbigniew
 CS Dep. Org. Chemistry, Medical Academy, Wroclaw, 50-137, Pol.
 SO Farmaco (1995), 50(2), 131-6
 CODEN: FRMCE8
 PB Societa Chimica Italiana
 DT Journal
 LA English
 AB Various new 4-arylamino-6-methyl-2-phenyl-5-methylamino- and 5-alkoxymethylpyrimidines were synthesized in two chemical series from 4-arylamino-6-methyl-2-phenyl-5-hydroxymethylpyrimidines. Some of these products display immunomodulatory activities comparable to that of levamisole.
 IT 164927-01-9P 164927-02-0P 164927-06-4P
 164927-07-5P 164927-08-6P 164927-09-7P
 164927-10-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (synthesis and immunomodulatory activity of substituted pyrimidines)
 RN 164927-01-9 CAPLUS
 CN 5-Pyrimidinemethanamine, 4-[(4-chlorophenyl)amino]-N-(4-ethoxyphenyl)-6-methyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 164927-02-0 CAPLUS
 CN 5-Pyrimidinemethanamine, N-(4-chlorophenyl)-4-[(4-chlorophenyl)amino]-6-methyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 164927-06-4 CAPLUS
 CN 5-Pyrimidinemethanamine, 4-[(4-chlorophenyl)amino]-N-(2,6-dichlorophenyl)-6-methyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 164927-07-5 CAPLUS

CN 5-Pyrimidinemethanamine, N-(4-ethoxyphenyl)-4-methyl-2-phenyl-6-(phenylamino)- (9CI) (CA INDEX NAME)




RN 164927-08-6 CAPLUS

CN 5-Pyrimidinemethanamine, N-(4-chlorophenyl)-4-methyl-2-phenyl-6-(phenylamino)- (9CI) (CA INDEX NAME)




RN 164927-09-7 CAPLUS

CN 5-Pyrimidinemethanamine, N-(4-chlorophenyl)-4-[(4-ethoxyphenyl)amino]-6-methyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 164927-10-0 CAPLUS

CN 5-Pyrimidinemethanamine, N-(4-ethoxyphenyl)-4-[(4-ethoxyphenyl)amino]-6-methyl-2-phenyl- (9CI) (CA INDEX NAME)



L10 ANSWER 96 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1994:605382 CAPLUS

DN 121:205382

TI Aminopyrimidine derivatives and their production and use.

IN Ohtsuka, Toshikazu; Masui, Moriyasu; Takeda, Takami; Masuko, Michio; Ohba, Katsuaki

PA Shionogi and Co., Ltd., Japan

SO Eur. Pat. Appl., 85 pp.


CODEN: EPXXDW

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 606011	A1	19940713	EP 1993-310556	19931224
	EP 606011	B1	19970305		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	US 5439911	A	19950808	US 1993-168217	19931217
	AT 149491	E	19970315	AT 1993-310556	19931224
	ES 2101254	T3	19970701	ES 1993-310556	19931224
	JP 06279417	A2	19941004	JP 1993-353743	19931227
	JP 3366715	B2	20030114		
	US 5519139	A	19960521	US 1995-448193	19950523
PRAI	JP 1992-348535	A	19921228		
	JP 1993-14980	A	19930201		
	US 1993-168217	A3	19931217		
OS	MARPAT 121:205382				
AB	The title compds., i.e. 4-amino-5-pyrimidinecarboxylates I (R1 = H, halo, alkyl, etc.; R2 = alkyl; R3 = H, alkyl, alkenyl, etc.; R4 = H, alkyl; R5, R6, R11 = H, halo, alkyl, alkoxy, etc.; X = alkanediyl, alkyleneoxy) were disclosed. I were claimed as fungicides, insecticides and miticides. A specifically claimed example compound is Et 4-[[2-[4-(difluoromethoxy)phenyl]ethyl]amino]-6-ethyl-5-pyrimidinecarboxylate (II).				
IT	157980-55-7P 157981-15-2P RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as insecticide, fungicide or miticide)				
RN	157980-55-7 CAPLUS				
CN	5-Pyrimidinecarboxylic acid, 4-[[2-[4-(1,1-dimethylethyl)phenyl]ethyl]amino]-6-ethyl-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)				




RN 157981-15-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-6-ethyl-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



L10 ANSWER 97 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1994:217513 CAPLUS
 DN 120:217513
 TI Synthesis of [1,5-a]pyrimidinone ring derivatives
 AU Rashed, N.; Mousaad, A.; Saleh, A.
 CS Fac. Sci., Alexandria Univ., Alexandria, Egypt
 SO Journal of the Chinese Chemical Society (Taipei, Taiwan) (1993), 40(4),
 393-7
 CODEN: JCCTAC; ISSN: 0009-4536
 DT Journal
 LA English
 AB Cyclodehydrogenation of the benzalhydrazino derivs. I (Ar = 4-MeOC₆H₄, R =
 H, Me) gave 6-cyano-7-(4-methoxyphenyl)-2-phenyl-5-oxo-1,2,4-triazolo[1,5-
 a]pyrimidine (II) and 6-cyano-7-(4-methoxyphenyl)-4-methyl-2-phenyl-5-oxo-
 1,2,4-triazolo[1,5-a]pyrimidine (III), resp. Methylation, acetylation and
 benzylation of I (R = H) gave the corresponding N-Me, acetyl and benzyl
 derivs. Acetylation of I (R = H) with boiling acetic anhydride afforded
 the diacetyl derivative IV; its benzylation gave the mono-N-benzyl derivative
 IT **153896-60-7P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 153896-60-7 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 1,4-dihydro-6-(4-methoxyphenyl)-4-oxo-2-
 [(phenylmethyl)(phenylmethylene)hydrazino]- (9CI) (CA INDEX NAME)



L10 ANSWER 98 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1994:4377 CAPLUS

DN 120:4377

TI Identification of highly potent and selective inhibitors of *Toxoplasma gondii* dihydrofolate reductase

AU Chio, Li Chun; Queener, Sherry F.

CS Sch. Med., Indiana Univ., Indianapolis, IN, 46202-5120, USA

SO Antimicrobial Agents and Chemotherapy (1993), 37(9), 1914-23

CODEN: AMACCQ; ISSN: 0066-4804

DT Journal

LA English

AB *Toxoplasma gondii* RH was obtained in high yield from culture in RPMI medium on a line of Chinese hamster ovary cells lacking dihydrofolate reductase activity (ATCC 3952 dhfr-). Dihydrofolate reductase preps. from harvested organisms had sp. activities of 22.9 nmol/min/mg. The 50% inhibitory concns. against reference compds. were 0.014 μ M for methotrexate, 0.25 μ M for pyrimethamine, 2.7 μ M for trimethoprim, and 0.010 μ M for trimetrexate. The K_m value for NADPH was 11 μ M and followed Michaelis-Menten kinetics; the K_m for dihydrofolate was .apprx.11 μ M, but substrate inhibition appeared to occur at high substrate concns. Dihydrofolate reductase from *T. gondii* was used to screen 130 compds. from the National Cancer Institute repository. Thirteen compds. were >100-fold more potent than pyrimethamine toward *T. gondii* dihydrofolate reductase; 6 compds. with various potencies were 8-46 times as selective as pyrimethamine for the protozoal form of the enzyme over the mammalian form. Four trimetrexate analogs were more potent than trimetrexate, and 2 were significantly more selective. Representative compds. were also tested in a culture model of *T. gondii* employing uracil incorporation as an index of growth. One pyrimethamine analog was as effective as pyrimethamine in inhibiting *T. gondii* in culture (50% inhibitory concentration, 0.45 μ M). Three other compds. were also effective at micromolar concns.


IT 136242-86-9

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(dihydrofolate reductase of *Toxoplasma gondii* inhibition by, structure in relation to)

RN 136242-86-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-(4-chlorophenyl)-6-[(4-nitrophenyl)amino]methyl)-(9CI) (CA INDEX NAME)



L10 ANSWER 99 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1993:671185 CAPLUS
 DN 119:271185
 TI Heterocyclic 4-pyrimidinamine derivatives
 IN Edwards, Martin Paul; Ratcliffe, Arnold Harry
 PA Imperial Chemical Industries PLC, UK
 SO Ger. Offen., 29 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4239440	A1	19930609	DE 1992-4239440	19921124
	CA 2082668	AA	19930605	CA 1992-2082668	19921112
	ZA 9208742	A	19930609	ZA 1992-8742	19921112
	FR 2684672	A1	19930611	FR 1992-14376	19921130
	NL 9202091	A	19930701	NL 1992-2091	19921202
	GB 2262096	A1	19930609	GB 1992-25283	19921203
	BE 1005473	A3	19930803	BE 1992-1065	19921203
	JP 05255327	A2	19931005	JP 1992-325478	19921204
PRAI	GB 1991-25842	A	19911204		

OS MARPAT 119:271185


AB The title compds., 4-pyrimidinamine derivs. are claimed. These compds. are potentially useful for as antihypertensives and the treatment of congestive heart failure. Thus, 2,6-dimethyl-N-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-pyrimidinamine hydrochloride (I) was prepared in several steps. I had activity as angiotensin II antagonist.

IT 150358-31-9P


RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 150358-31-9 CAPLUS


CN 4-Pyrimidinamine, 2,6-diethyl-5-(4-methylphenyl)-N-[[2'-[2-(triphenylmethyl)-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]- (9CI)
 (CA INDEX NAME)



L10 ANSWER 100 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1992:633688 CAPLUS
 DN 117:233688
 TI Autorecycling oxidation of alcohols catalyzed by pyridodipyrimidines as an NAD(P)+ model
 AU Nagamatsu, Tomohisa; Yamato, Hirotake; Ono, Masami; Takarada, Shigeki; Yoneda, Fumio
 CS Fac. Pharm. Sci., Okayama Univ., Okayama, 700, Japan
 SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1992), (16), 2101-9
 CODEN: JCPRB4; ISSN: 0300-922X
 DT Journal
 LA English
 AB Pyridodipyrimidinetetrone I (R = H, Me, Ph; R1 = alkyl, Ph) have been synthesized by the condensation of 6-aminouracils with 6-chloro-5-formyluracils in DMF. Pyridodipyrimidinetrione II (R1 = alkyl, Ph; R2 = H, alkyl) have been synthesized by the condensation of 6-amino-2-phenylpyrimidin-4(3H)-ones with 2,4,6-trichloropyrimidine-5-carboxaldehyde in AcOH. I and II catalyze the oxidation of alcs. under neutral conditions (in the absence of base) to yield carbonyl compds., with a remarkably high turnover number. The oxidation yields were markedly dependent upon the presence of lipophilic substituents, particularly of a longer alkyl group at the 10-position. These catalysts are so stable that the oxidation reaction proceeds until the substrate is exhausted.
 IT **144486-32-8P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reaction of, with formylpyridines)
 RN 144486-32-8 CAPLUS
 CN 4(1H)-Pyrimidinone, 2-phenyl-6-[(2-phenylethyl)amino]- (9CI) (CA INDEX NAME)



L10 ANSWER 101 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1992:448462 CAPLUS
DN 117:48462
TI Reactivity of 6-anisyl-5-cyano-4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidine
towards some electrophiles and nucleophiles
AU Hassan, M. F. Madkour; Mahamed, A. E. Sayed; Ashraf, A. Hamed; Adel, M.
Gaber; Abd El-Khalik, A. Hataba
CS Fac. Sci., Ain Shams Univ., Cairo, Egypt
SO Chinese Journal of Chemistry (1991), 9(3), 262-9
CODEN: CJOCEV; ISSN: 1001-604X
DT Journal
LA English
AB The title compound I was subjected to reaction with some electrophiles and
nucleophiles, such as alkyl halides, Et chloroacetate, or amines,
hydrazines etc. The resulting compds. were used in further syntheses for
the purpose of obtaining some new types of heterocycles with possible
biol. and pharmaceutical activities.
IT **138609-06-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 138609-06-0 CAPLUS
CN 5-Pyrimidinecarbonitrile, 1,4-dihydro-6-(4-methoxyphenyl)-4-oxo-2-
[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



A handwritten signature or mark, possibly a stylized 'S' or 'Z', located to the right of the chemical structure.

L10 ANSWER 102 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1991:647448 CAPLUS

DN 115:247448

TI Pneumocystis carinii dihydrofolate reductase used to screen potential antipneumocystis drugs

AU Broughton, M. Christine; Queener, Sherry F.

CS Sch. Med., Indiana Univ., Indianapolis, IN, 46202-5120, USA

SO Antimicrobial Agents and Chemotherapy (1991), 35(7), 1348-55

CODEN: AMACQ; ISSN: 0066-4804

DT Journal

LA English

AB P. carinii was obtained in high yield from the lungs of immunosuppressed rats by rupturing mammalian host cells, washing away the soluble mammalian dihydrofolate reductase, and harvesting intact organisms in association with the mammalian plasma membranes. P. carinii dihydrofolate reductase, measured in the 100,000 + g supernatant from sonicated organisms, was obtained in yields ranging up to 62 IU per rat. The enzyme prepared in the presence of protease inhibitors was stable when frozen in liquid nitrogen. P. carinii dihydrofolate reductase differed from the mammalian enzyme in that the former was slightly inhibited by 150 mM KCl, whereas the latter was stimulated over twofold by 150 mM KCl. The standard assay for P. carinii dihydrofolate reductase contained 0.12 mM NADPH and 92 μ M dihydrofolic acid. Under these conditions, the 50% inhibitory concns. of the known inhibitors trimethoprim, trimetrexate, and pyrimethamine were 12 μ M, 42 nM, and 3.8 μ M, resp. These standard compds. were also tested against dihydrofolate reductase from rat liver to allow an assessment of the selectivity of the drugs. Although it was the least potent, trimethoprim was the most selective. Pyrimethamine was more potent but was nonselective. Trimetrexate was extremely potent but was selective for mammalian dihydrofolate reductase. A series of exptl. compds. was obtained from the National Cancer Institute and other sources through the Developmental Therapeutics Branch of the Division of AIDS at the National Institute of Allergy and Infectious Diseases. Among the first 87 compds. tested, 11 had 50% inhibitory concns. below that of trimetrexate and 3 were more selective than trimethoprim. The most promising compds. in this original group were chemical related to methotrexate.


IT 136242-86-9

RL: BIOL (Biological study)

(dihydrofolate reductase from liver vs. Pneumocystis carinii inhibition by, AIDS therapy and mol. structure in relation to)

RN 136242-86-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-(4-chlorophenyl)-6-[[4-(4-nitrophenyl)amino]methyl]-
(9CI) (CA INDEX NAME)



L10 ANSWER 103 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1991:57530 CAPLUS
 DN 114:57530
 TI 2-Iodopropargyloxypyrimidines and agrochemical microbicides containing them
 IN Masuda, Katsumi; Ito, Shigehisa; Maeno, Shinichiro; Eguchi, Katsumi; Hasegawa, Keisuke
 PA Kumiai Chemical Industry Co., Ltd., Japan; Ihara Chemical Industry Co., Ltd.
 SO Jpn. Kokai Tokkyo Koho, 12 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 02200678	A2	19900808	JP 1989-18778	19890128
PRAI	JP 1989-18778		19890128		
OS	MARPAT 114:57530				


AB Agrochem. microbicides contain the title compds. I [R1 = H, halo, (halo)alkyl, alkoxy; R2 = H, halo, alkyl, alkoxy, alkylthio, Ph; R3 = H, alkyl; R4 = (alkoxy, cyclo, or alkoxy carbonyl)alkyl, alkenyl alkynyl, CR5R6C6H4X; R5, R6 = H, alkyl; X = H, halo, alkyl, alkoxy; R3R4 may form 5- or 6-membered heterocycle] as active ingredients. NaH in benzene was stirred with propargyl alc. at room temperature for 2.5 h and treated with 4-chloro-6-diethylamino-2-methylsulfonylpyrimidine at 6-15° for 1.5 h to give 99.2% 4-chloro-6-diethylamino-2-propargyloxypyrimidine, which was iodinated with NaOH and iodine in MeOH at room temperature for 2.5 h to afford 81.0% I (R1 = Cl, R2 = H, R3 = R4 = Et) (II). II was applied to cucumber at 50 ppm to show ≥90% control of *Pseudoperonospora cubensis* after 7 days, vs. <40% control, for a conventional fungicide.

IT 130718-37-5P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as agrochem. microbicide)

RN 130718-37-5 CAPLUS

CN 4-Pyrimidinamine, 6-chloro-2-[(3-iodo-2-propynyl)oxy]-5-phenyl-N-(phenylmethyl)--(9CI) (CA INDEX NAME)



L10 ANSWER 104 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1989:515128 CAPLUS

DN 111:115128

TI Azolopyrimidines and pyrimidoquinazolines from 4-chloropyrimidines

AU El-Reedy, A. M.; Ali, A. S.; Ayyad, A. O.

CS Fac. Sci., Univ. Cairo, Giza, Egypt

SO Journal of Heterocyclic Chemistry (1989), 26(2), 313-16

CODEN: JHTCAD; ISSN: 0022-152X

DT Journal

LA English

OS CASREACT 111:115128

AB 5-Cyano-3,4-dihydro-6-phenyl-2-substituted pyrimidinones reacted with phosphorus oxychloride to give the corresponding 4-chloropyrimidine derivs. I (R = Ph, NHPH, NHCH₂Ph, R₁ = Cl). Compds. I (R₁ = Cl) reacted with aniline and hydrazine to yield I (R = Ph, NHPH, NHCH₂Ph; R₁ = NHPH, NHNH₂). The hydrazino derivs. could be converted into the triazolo- and tetrazolopyrimidines II (R₂ = Ph, NHCH₂Ph) and III by the action of CS₂ and nitrous acid, resp. The reaction of I (R = NHPH, NHCH₂Ph; R₁ = Cl) with phenylhydrazine afforded directly the 5-amino-4,6-diphenyl-6H-2-substituted pyrazolopyrimidines IV (same R₂). The 4-chloro derivative I (R = Ph, R₁ = Cl) reacted with anthranilic acid to form the 5-cyano-2,4-diphenyl-6-(o-carboxyphenylamino)pyrimidine, which could be cyclized into the 4-cyano-1,3-diphenyl-10H-pyrimido[6,1-b]quinazolin-10-one by heating with acetic anhydride.


IT 122379-68-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and cyclocondensation reaction of, with carbon disulfide)

RN 122379-68-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-hydrazino-6-phenyl-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




IT 122379-67-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and cyclocondensation reaction of, with phenylhydrazine, aminopyrazolopyrimidine from)


RN 122379-67-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-chloro-6-phenyl-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




IT **122379-65-1P**RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)(preparation and reaction of, with phosphorus oxychloride, chloropyrimidine
derivative from)

RN 122379-65-1 CAPLUS

CN 5-Pyrimidinecarbonitrile, 1,4-dihydro-4-oxo-6-phenyl-2-
[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)

L10 ANSWER 105 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1989:95143 CAPLUS
 DN 110:95143
 TI Synthesis of pyrimidine derivatives by the reaction of ketene dithioacetals with amides
 AU Kohra, Shinya; Tominaga, Yoshinori; Hosomi, Akira
 CS Fac. Pharm. Sci., Nagasaki Univ., Nagasaki, 852, Japan
 SO Journal of Heterocyclic Chemistry (1988), 25(3), 959-68
 CODEN: JHTCAD; ISSN: 0022-152X
 DT Journal
 LA English
 OS CASREACT 110:95143
 AB Reactions of Me 2-cyano-3,3-bis(methylthio)acrylate (MeS)₂C:CRN (I, R = CO₂Me) with carboxamides R₁CONH₂(II, R₁ = 4-R₂C₆H₄, ClCH₂, Me, PhCH₂CH; R₂ = H, NO₂, Me, MeO) in the presence of NaH gave the resp. Me 3-N-acylamino-2-cyano-3-(methylthio)acrylates R₁CONaC(SMe):C(CO₂Me)CN, which were readily converted to the resp. pyrimidine derivs. III (R = CO₂Me) at reflux in methanol in good yields. Reactions of 2-cyano-3,3-bis(methylthio)acrylonitrile I (R = CN) with the carboxamides II gave directly pyrimidine-5-carbonitrile derivs. III (R = CN). Ketene dithioacetals smoothly reacted with thioacetamide or ureas to give the expected pyrimidine derivs. Polyfunctionalized pyrimidines, thus obtained, were also used for the synthesis of fused pyrimidine derivs.
 IT **87694-01-7P**
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 87694-01-7 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 1,4-dihydro-4-oxo-2-phenyl-6-[(phenylmethyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



L10 ANSWER 106 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1989:77445 CAPLUS
 DN 110:77445
 TI Light stabilizers for dyed polyester fibers
 IN Reinert, Gerhard; Burdeska, Kurt
 PA Ciba-Geigy A.-G., Switz.
 SO Eur. Pat. Appl., 13 pp.
 CODEN: EPXXDW
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 280654	A1	19880831	EP 1988-810106	19880222
	EP 280654	B1	19920513		
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, SE				
	AT 76131	E	19920515	AT 1988-810106	19880222
	ES 2032594	T3	19930216	ES 1988-810106	19880222
	AU 8812325	A1	19880901	AU 1988-12325	19880226
	AU 607188	B2	19910228		
	JP 63227879	A2	19880922	JP 1988-42448	19880226
	BR 8800824	A	19881004	BR 1988-824	19880226
	ZA 8801376	A	19881026	ZA 1988-1376	19880226
	US 4895981	A	19900123	US 1989-331071	19890324
PRAI	CH 1987-751	A	19870227		
	CH 1987-3820	A	19871001		
	US 1988-156771	A1	19880217		
	EP 1988-810106	A	19880222		

OS MARPAT 110:77445

AB The pyrimidines I [R = alkyl, alkoxy, halogen, OH; R1 = alkyl; R2 = H, halogen, amino, alkoxy, alkenyl, Ph (optionally substituted); m = 0 or 1; n = 0-2] are light stabilizers for dyed polyester fibers which need not be incorporated in the fibers. A polyester fabric was dyed with a disperse dye in a dyebath containing 1.65% 6-(4-ethoxy-2-hydroxyphenyl-4-methyl-2-phenylpyrimidine (II), giving dyeings with Ford lightfastness 3-4, 3-4, and 3-4 after 0 and 1 h at 180° or 1 h at 200°, resp.; vs. 1-2, 1-2, and 1-2, resp., without II, and 3-4, 3-4, and 2-3, resp., with a benzotriazole in place of II.


IT **118823-24-8**

RL: USES (Uses)

(light stabilizers, for dyed polyester fibers)

RN 118823-24-8 CAPLUS

CN Phenol, 5-ethoxy-2-[2-phenyl-6-[(2-phenylethyl)amino]-4-pyrimidinyl]-
 (9CI) (CA INDEX NAME)



L10 ANSWER 107 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1988:406537 CAPLUS

DN 109:6537

TI New 2-substituted amino-6-(2-hydroxyphenyl)pyrimidine derivatives as blood platelet aggregation inhibitors and a process for preparing them

IN Murakami, Yukitoshi; Takagi, Kaname

PA Zeria Pharmaceutical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 10 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 62255487	A2	19871107	JP 1986-97991	19860430
PRAI	JP 1986-97991		19860430		

OS CASREACT 109:6537

AB The title compds. (I; R1 = lower alkylamino, lower dialkylamino, cyclic amino, aralkylamino; R2 = O2N, NH2) (II), useful as blood platelet aggregation inhibitors, were prepared A solution of 5 mmol I (R1 = SMe, R2 = O2N) and 50% aqueous cyclohexylamine was refluxed 2 h to give 98.5% I (R1 = cyclohexylamino, R2 = O2N) which was hydrogenated over 5% Pd/C to give, after acidification with 2N aqueous HCl, I (R1 = cyclohexylamino, R2 = NH2).HCl (III). III inhibited collagen-induced blood platelet aggregation with a IC50 of 39.8 μ M in platelet rich plasma of a dog.


IT 114798-05-9P 114798-06-0P 114798-21-9P

114798-22-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as blood platelet aggregation inhibitor)


RN 114798-05-9 CAPLUS

CN Phenol, 2-[6-methyl-5-nitro-2-[(phenylmethyl)amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)




RN 114798-06-0 CAPLUS

CN Phenol, 2-[6-methyl-5-nitro-2-[(2-phenylethyl)amino]-4-pyrimidinyl]- (9CI)
(CA INDEX NAME)



RN 114798-21-9 CAPLUS


CN Phenol, 2-[5-amino-6-methyl-2-[(phenylmethyl)amino]-4-pyrimidinyl]-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 114798-22-0 CAPLUS

CN Phenol, 2-[5-amino-6-methyl-2-[(2-phenylethyl)amino]-4-pyrimidinyl]-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L10 ANSWER 108 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1988:150408 CAPLUS

DN 108:150408

TI Syntheses of 2,3-dihydro-5H-thiazolo[3,2-a]pyrimidines and tetrasubstituted dihydropyrimidine derivatives as possible anthelmintic agents

AU Akhtar, M. Shamim; Seth, M.; Bhaduri, A. P.

CS Div. Med. Chem., Cent. Drug Res. Inst., Lucknow, 226 001, India

SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1987), 26B(6), 556-61

CODEN: IJSBDB; ISSN: 0376-4699

DT Journal

LA English

OS CASREACT 108:150408

AB The hitherto unreported ring closure reaction of dihydropyrimidinethiones I [R = Ph, 3,4-(MeO)2C6H3, 4-MeOC6H4, 3-MeC6H4] with ClCH2CO2H in the presence of BF3·OEt2 gave dihydrothiazolo[3,2-a]pyrimidines II in 45-60% yields. Synthesis of a number of tetrasubstituted dihydropyrimidines is also reported. None of the compds. exhibit any anthelmintic activity.


IT 113697-50-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and anthelmintic activity of)

RN 113697-50-0 CAPLUS

CN Carbamic acid, [5-[[[4-methyl-2-(methylthio)-6-phenyl-5-pyrimidinyl]methyl]amino]-1H-benzimidazol-2-yl]-, methyl ester (9CI) (CA INDEX NAME)




IT 113697-49-7P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation, catalytic reduction, and cyclocondensation reaction of, with thiourea derivative)

RN 113697-49-7 CAPLUS

CN 1,4-Benzenediamine, N4-[[[4-methyl-2-(methylthio)-6-phenyl-5-pyrimidinyl]methyl]-2-nitro- (9CI) (CA INDEX NAME)



L10 ANSWER 109 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1987:138466 CAPLUS
 DN 106:138466
 TI Preparation of hydroxy- and alkoxyprymidines as antiallergics and
 antiinflammatories.
 IN Lamattina, John Lawrence; Walker, Frederick J.
 PA Pfizer Inc., USA
 SO Eur. Pat. Appl., 32 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 210044	A2	19870128	EP 1986-305466	19860716
	EP 210044	A3	19871021		
	EP 210044	B1	19900829		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	US 4711888	A	19871208	US 1985-758199	19850724
	AT 55995	E	19900915	AT 1986-305466	19860716
	IL 79471	A1	19910816	IL 1986-79471	19860721
	CA 1265519	A1	19900206	CA 1986-514336	19860722
	CN 86104539	A	19870121	CN 1986-104539	19860723
	CN 1006792	B	19900214		
	DK 8603494	A	19870125	DK 1986-3494	19860723
	DK 162986	B	19920106		
	DK 162986	C	19920601		
	FI 8603029	A	19870125	FI 1986-3029	19860723
	FI 89911	B	19930831		
	FI 89911	C	19931210		
	NO 8602956	A	19870126	NO 1986-2956	19860723
	NO 173442	B	19930906		
	NO 173442	C	19931215		
	AU 8660447	A1	19870430	AU 1986-60447	19860723
	AU 569194	B2	19880121		
	HU 41745	A2	19870528	HU 1986-3000	19860723
	HU 196764	B	19890130		
	DD 248588	A5	19870812	DD 1986-292804	19860723
	ES 2000734	A6	19880316	ES 1986-529	19860723
	ZA 8605489	A	19880330	ZA 1986-5489	19860723
	SU 1574171	A3	19900623	SU 1986-4027808	19860723
	JP 62026276	A2	19870204	JP 1986-174704	19860724
	JP 06047579	B4	19940622		
	PL 150617	B1	19900630	PL 1986-260784	19860724
	PL 151571	B1	19900928	PL 1986-271856	19860724
PRAI	US 1985-758199	A	19850724		
	EP 1986-305466	A	19860716		

AB Pyrimidines I [R1 = H, alkyl; R2 = H, alkyl, cyclopentyl or -hexyl, alkenyl, Ph, (un)substituted phenylalkyl; NR1R2 = (un)substituted pyrrolidino, piperidino; R3 = alkyl, Ph, (un)substituted phenylalkyl, furyl, thienyl; R4, R5 = H, alkyl, Ph, (un)substituted phenylalkyl; some restrictions apply to R1, R2, and R3] are prepared as pharmaceuticals for the title conditions (no data). Reduction of I (R1 = H, R2 = 4-ClC6H4CH2CH2CO, R3 = R4 = Me, R5 = Ac) with Dibal in THF at -23° gave 37% I [R1 = R5 = H, R2 = 4-ClC6H4(CH2)3, R3 = R4 = Me].

IT **107361-59-1P 107361-65-9P 107361-83-1P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as antiallergic and antiinflammatory agent)


RN 107361-59-1 CAPLUS

CN 5-Pyrimidinol, 2-[[3-(4-chlorophenyl)propyl]amino]-4-phenyl- (9CI) (CA INDEX NAME)




RN 107361-65-9 CAPLUS

CN 5-Pyrimidinol, 4-(2-fluorophenyl)-2-[(6-phenylhexyl)amino]- (9CI) (CA INDEX NAME)




RN 107361-83-1 CAPLUS


CN 5-Pyrimidinol, 4-phenyl-2-[(6-phenylhexyl)amino]- (9CI) (CA INDEX NAME)



L10 ANSWER 110 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1986:406471 CAPLUS
 DN 105:6471
 TI Reactions of polarized ketene S,N-acetals with guanidine: a facile general route to novel 5,6-substituted 2-amino-4-N-alkyl/aryl/N-azacycloalkylaminopyrimidines. Part XLIV
 AU Vishwakarma, J. N.; Apparao, S.; Ila, H.; Junjappa, H.
 CS Dep. Chem., North-Eastern Hill Univ., Shillong, 793 003, India
 SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1985), 24B(5), 466-71
 CODEN: IJSBDB; ISSN: 0376-4699
 DT Journal
 LA English
 OS CASREACT 105:6471
 AB Cyclization of polarized ketene S,N-acetals, e.g., I (R = substituted Ph; R1 = Et, Pr, PhCH2), with guanidine nitrate in Me3COH/NaOCMe3 gave the title pyrimidines, e.g., II.
 IT **101476-59-9P**
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation and failed ring closure of)
 RN 101476-59-9 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(4-chlorophenyl)-5-nitroso-N4-(phenylmethyl)- (9CI) (CA INDEX NAME)




IT **101460-10-0P 101460-11-1P**
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 101460-10-0 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-phenyl-N4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 101460-11-1 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-(4-chlorophenyl)-N4-(phenylmethyl)- (9CI) (CA INDEX NAME)

10/671,070



L10 ANSWER 111 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1986:188149 CAPLUS
 DN 104:188149
 TI Azo dyes for polyamide fibers and leather
 IN Lamm, Gunther
 PA BASF A.-G. , Fed. Rep. Ger.
 SO Ger. Offen., 34 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3405859	A1	19850822	DE 1984-3405859	19840218
	EP 154816	A2	19850918	EP 1985-101428	19850211
	EP 154816	A3	19860827		
	EP 154816	B1	19881214		
	R: CH, DE, FR, GB, IT, LI				
	US 4652633	A	19870324	US 1985-702067	19850215
	JP 60188469	A2	19850925	JP 1985-28503	19850218
PRAI	DE 1984-3405859	A	19840218		

OS MARPAT 104:188149

AB Azo dyes of general structure I are prepared, where R = F, Br, Cl, Me, CF₃, Cl-4 alkylsulfonyl, arylsulfonyl, Ac, or Bz; R₁ = H, F, Cl, Br, Cl-4 alkylsulfonyl, Me, or CF₃; R₂ = H, Me, or Cl; and Q is the residue of a hydroxypyridone, diaminocyanopyridine, or diaminopyrimidine type coupler. I are fast, level dyes for nylon fiber and wool, and are especially suitable

for


trichromatic dyeing; some also can be used as leather dyes. Thus, diazotization of 2,4,6-Cl₂(HO₃S)C₆H₂NH₂ and coupling with 2,6-bis(3-hydroxypropylamino)-3-cyano-4-methylpyridine gave I (R = R₁ = Cl, R₂ = H, Q = Q₁) (II), a lightfast, deep golden yellow dye for nylon 6 and wool. II also shows high migration and good dyeing properties in combination with red and blue dyes on nylon 6. I (R = R₁ = Cl, R₂ = H, Q = Q₂) (Li salt; lemon yellow on leather), I (R = R₁ = Cl, R₂ = H, Q = Q₃) (Na salt; golden yellow on nylon and wool), and numerous other yellow to orange dyes were prepared

IT 101045-17-4 101045-26-5 101045-27-6

RL: TEM (Technical or engineered material use); USES (Uses)
 (dye, for polyamides)


RN 101045-17-4 CAPLUS

CN Benzenesulfonic acid, 3,5-dichloro-2-[[4-[(2-hydroxyethyl)amino]-2-(3-methylphenyl)-6-[[2-(4-sulfophenyl)ethyl]amino]-5-pyrimidinyl]azo]- (9CI)
 (CA INDEX NAME)




RN 101045-26-5 CAPLUS

CN Benzenesulfonic acid, 5-chloro-2-[[4-[(2-hydroxyethyl)amino]-2-(3-methylphenyl)-6-[[[4-sulfophenyl)methyl]amino]-5-pyrimidinyl]azo]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 101045-27-6 CAPLUS


CN Benzenesulfonic acid, 3,5-dichloro-2-[[4-[(2-methoxy-1-methylethyl)amino]-2-phenyl-6-[[2-(4-sulfophenyl)ethyl]amino]-5-pyrimidinyl]azo]- (9CI) (CA INDEX NAME)



L10 ANSWER 112 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1986:68809 CAPLUS
 DN 104:68809
 TI Regiospecific synthesis of N-1 and N-2 substituted pyrimidinones employing
 a novel 1,3-oxazine preparation
 AU Skulnick, Harvey I.; Wierenga, Wendell
 CS Cancer Viral Dis. Res., Upjohn Co., Kalamazoo, MI, 49001, USA
 SO Heterocycles (1985), 23(7), 1685-9
 CODEN: HTCYAM; ISSN: 0385-5414
 DT Journal
 LA English
 OS CASREACT 104:68809
 AB Pyrimidinones I (R = Me, PhCH₂, OH) and II (R₁ = Me, HOCH₂CH₂CH₂, Ph) were
 prepared from PhCOCH₂CO₂Et and MeSC(:NH)NH₂·H₂SO₄ via oxazinone III.
 III was treated with RNH₂ to give I. Hydrolysis of III with 10% HCl gave
 the oxazinedione IV which was treated with R₁NH₂ to give II (R₁ = Me,
 HOCH₂CH₂CH₂). Treatment of IV with PhNH₂ afforded PhNHCONHCOCH₂COPh which
 was cyclized with polyphosphoric acid to give II.
 IT **100008-31-9P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 100008-31-9 CAPLUS
 CN 4(1H)-Pyrimidinone, 6-phenyl-2-[(phenylmethyl)amino]- (9CI) (CA INDEX
 NAME)




L10 ANSWER 113 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1984:591821 CAPLUS
 DN 101:191821
 TI Dihydropyrimidines and related structures. I. N2-Substituted
 2-pyrimidinamines and dihydro-2-pyrimidinamines by reaction of
 phenylbutenones and monosubstituted guanidines
 AU Wendelin, Winfried; Schermanz, Karl
 CS Inst. Pharm. Chem., Univ. Graz, Graz, A-8010, Austria
 SO Journal of Heterocyclic Chemistry (1984), 21(1), 65-9
 CODEN: JHTCAD; ISSN: 0022-152X
 DT Journal
 LA English
 OS CASREACT 101:191821
 AB H2NC(:NH)NHR (R = Me, PhCH2) reacted with PhCH:CHCOMe and H2NC(:NH)NHCH2Ph
 with PhCOCH:CHMe under atmospheric O to give pyrimidine I (R = Me, PhCH2).
 Dihydropyrimidines II, probable intermediates in the reaction, could not
 be isolated. Heating H2NC(:NH)NHR (R = Ph, p-MeOC6H4) with PhCH:CHCOMe
 gave II. II (R = Ph) reacted with MeOH to give pyrimidinamine III. I (R
 = Ph) was heated to give I (R = Ph). The low stability of II is
 attributed to their strong basicity.
 IT **89242-69-3P 89242-70-6P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 89242-69-3 CAPLUS
 CN 2-Pyrimidinamine, 4-methyl-6-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX
 NAME)



RN 89242-70-6 CAPLUS
 CN 2-Pyrimidinamine, 4-methyl-6-phenyl-N-(phenylmethyl)-, compd. with
 2,4,6-trinitrophenol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 89242-69-3
 CMF C18 H17 N3




CM 2


CRN 88-89-1

10/671,070

CMF C6 H3 N3 O7



L10 ANSWER 114 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1984:121009 CAPLUS
 DN 100:121009
 TI Heterocycles. 76. Reactions of monosubstituted guanidines with
 1-phenyl-1,3-butanedione
 AU Wendelin, Winfried; Schermanz, Karl; Schweiger, Klaus; Fuchsgruber, Alfred
 CS Inst. Pharm. Chem., Univ. Graz, Graz, A-8010, Austria
 SO Monatshefte fuer Chemie (1983), 114(12), 1371-9
 CODEN: MOCMB7; ISSN: 0026-9247
 DT Journal
 LA German
 OS CASREACT 100:121009
 AB $\text{H}_2\text{NC}(\text{:NH})\text{NHR}$ ($\text{R} = \text{Me}, \text{CH}_2\text{Ph}, \text{Ph}$) react with $\text{PhCOCH}_2\text{COMe}$ to yield
 exclusively pyrimidinamines I. The formation of pyrimidinimines was observed
 The structure of I ($\text{R} = \text{Ph}$) was determined by comparison with an authentic
 sample prepared from the pyrimidinethione II via the methylthiopyrimidine.
 Boiling II with $\text{PhNH}_2\text{-BuOH}$ yields the thiodipyrimidine III.
 IT **89242-69-3P 89242-70-6P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 89242-69-3 CAPLUS
 CN 2-Pyrimidinamine, 4-methyl-6-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX
 NAME)




Same ^m #113

RN 89242-70-6 CAPLUS
 CN 2-Pyrimidinamine, 4-methyl-6-phenyl-N-(phenylmethyl)-, compd. with
 2,4,6-trinitrophenol (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 89242-69-3
 CMF C18 H17 N3




CM 2

CRN 88-89-1
 CMF C6 H3 N3 O7

10/671,070



L10 ANSWER 115 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1983:594921 CAPLUS
 DN 99:194921
 TI Reaction of ketenethioacetals with carboxamides
 AU Kohra, Shinya; Tominaga, Yoshinori; Matsuda, Yoshiro; Kobayashi, Goro
 CS Fac. Pharm. Sci., Nagasaki Univ., Nagasaki, 852, Japan
 SO Heterocycles (1983), 20(9), 1745-50
 CODEN: HTCYAM; ISSN: 0385-5414
 DT Journal
 LA English
 OS CASREACT 99:194921
 AB (MeS)2C:C(CN)CO2Me reacted with RCONH2 [I; R = Me, ClCH2, Ph, 4-R1C6H4, PhCH:CH2 (R1 = Me, OMe, Cl, NO2)] in the presence of NaH to give RCONHC(SMe):C(CN)CO2Me (II), which cyclized on refluxing in MeOH to give III (R2 = CO2Me). (MeS)2C:C(CN)2 underwent direct cyclocondensed with I to give III (R2 = CN). II (R = Ph) underwent cyclocondensed with HNR3R4 (R3 = H, R4 = Ph, PhCH2, cyclohexyl; NR3R4 = morpholino) to give IV. IV (R3 = H, R4 = Ph) cyclyzed in refluxing Ph2O to give V.
 IT **87694-01-7P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 87694-01-7 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 1,4-dihydro-4-oxo-2-phenyl-6-[(phenylmethyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



L10 ANSWER 116 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1982:423815 CAPLUS
 DN 97:23815
 TI 7,8-Dihydro-2,5,8-trisubstituted-7-oxopyrido[2,3-d]pyrimidine-6-carboxamides
 IN Scotese, Anthony C.; Morris, Robert L.; Santilli, Arthur A.
 PA American Home Products Corp., USA
 SO U.S., 14 pp. Cont.-in-part of U.S. 4,215,216.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4301281	A	19811117	US 1980-125620	19800228
	US 4215216	A	19800729	US 1979-31256	19790418
	JP 55141485	A2	19801105	JP 1980-50214	19800415
	CA 1120475	A1	19820323	CA 1980-350056	19800417
PRAI	US 1979-31256	A2	19790418		
	US 1980-116123	A	19800128		
	US 1980-125620	A	19800228		

OS CASREACT 97:23815

AB Carboxamides I [R = H, OH, C1-6 alkyl, alkylthio, Ph, 4-MeOC6H4, 4-ClC6H4, 1-pyrrolidinyl, MePhN; R1 = OH, (di) C1-6 alkylamino, HOCH2CH2NH, C3-8 2-alkoxyethylamino, 4-methyl-1-piperazinyl, 4-morpholinyl, 1-pyrrolidinyl, NH2; R2 = (di) (C1-6 alkyl) amino; R3 = H, C1-6 alkyl, C3-6 alkoxyethyl, allyl, propargyl, Ph, 4-MeOC6H4, 4-ClC6H4, PhCH2, 4-MeOC6H4CH2, 4-ClC6H4CH2, 4-(4-morpholinyl)phenyl, piperonyl], useful as gastric antisecretory agents and in suppression of allergic manifestations in warm-blooded animals, were prepared. Also prepared were esters I (R2 = C1-6 alkoxy). Aminating chloropyrimidinecarboxylate II (R4 = Cl) with EtNH2 in EtOH containing Na2CO3 overnight at room temperature, then 1 h at reflux gave amine


derivative II (R4 = EtNH) which was cyclized with EtO2CCH2COCl in Et2O in 3 h at room temperature, then treated with Na in EtOH to give pyridopyrimidinecarboxylate I (R = Ph, R1 = OH, R2 = OEt, R3 = Et) (III). At 32 mg/kg (rat) intraduodenal, III gave 45% inhibition of gastric total acid output; at 50 mg/kg i.p. or orally, III inhibited 99% allergy response in sensitized rats.

IT 76360-73-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and cyclization of, with Et chloroformate, pyrimidooxazinedione derivative by)

RN 76360-73-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[[[4-methoxyphenyl)methyl]amino]-2-phenyl- (9CI) (CA INDEX NAME)




IT 76360-67-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(preparation and cyclization of, with Et malonyl chloride,
pyridopyrimidinecarboxylate derivative by)


RN 76360-67-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-phenyl-4-[(phenylmethyl)amino]-, ethyl
ester (9CI) (CA INDEX NAME)


IT 76360-72-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and saponification of)


RN 76360-72-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[[[4-methoxyphenyl)methyl]amino]-2-phenyl-,
ethyl ester (9CI) (CA INDEX NAME)

L10 ANSWER 117 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1982:85504 CAPLUS
DN 96:85504
TI Alkylation and acylation of 2-aminopyrimidine N-oxides
AU Sedova, V. F.; Mustafina, T. Yu.; Mamaev, V. P.
CS Novosib. Inst. Org. Khim., Novosibirsk, 630090, USSR
SO Khimiya Geterotsiklicheskikh Soedinenii (1981), (11), 1515-22
CODEN: KGSSAQ; ISSN: 0453-8234
DT Journal
LA Russian
OS CASREACT 96:85504
AB Acylation of 2-aminopyrimidines, e.g., I (R1 = R2 = H, Me; R1 = Ph, R2 = H) gave the products of O- and N-acylation; with alkylating agents only the products of O-alkylation were obtained. Reaction of 2-aminopyrimidine N-oxides with aldehydes gave only the products of amino group reaction. The structure of the obtained products depended on the reactivity of the carbonyl component.
IT **80830-66-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 80830-66-6 CAPLUS
CN 2-Pyrimidinamine, 4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 118 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1981:139730 CAPLUS
 DN 94:139730
 TI Syntheses with nitriles. 60. Preparation of 4-amino-5-cyano-6-phenylpyrimidines from 2-amino-1,1-dicyano-2-phenylethene
 AU Mittelbach, Martin; Junek, Hans
 CS Inst. Org. Chem., Univ. Graz, Graz, A-8010, Austria
 SO Journal of Heterocyclic Chemistry (1980), 17(7), 1385-7
 CODEN: JHTCAD; ISSN: 0022-152X
 DT Journal
 LA English
 OS CASREACT 94:139730
 AB The reaction of 2-amino-1,1-dicyanobut-1-ene and 2-amino-1,1-dicyano-2-phenylethene, resp., with DMF dimethylacetal provided the corresponding (N,N-dimethylaminomethylene)amino derivs. 2-[(N,N-Dimethylaminomethylene)amino]-1,1-dicyano-2-phenylethene was converted into 4-amino-5-cyano-6-phenylpyrimidines, e.g. I, by treatment with primary aliphatic and aromatic amines. The structure of the reaction products was confirmed by ^{13}C NMR spectroscopy.
 IT **76990-15-3P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 76990-15-3 CAPLUS
 CN 5-Pyrimidinecarbonitrile, 4-phenyl-6-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



L10 ANSWER 119 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1981:65719 CAPLUS
 DN 94:65719
 TI 7,8-Dihydro-2,5,8-trisubstituted-7-oxo-pyrido[2,3-d]pyrimidine-6-carboxylic acid derivatives
 IN Morris, Robert L.; Santilli, Arthur A.; Scotese, Anthony C.
 PA American Home Products Corp., USA
 SO U.S., 14 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4215216	A	19800729	US 1979-31256	19790418
	US 4233446	A	19801111	US 1979-89065	19791029
	US 4236004	A	19801125	US 1979-89013	19791029
	US 4255568	A	19810310	US 1979-89652	19791029
	US 4301281	A	19811117	US 1980-125620	19800228
	EP 18139	A2	19801029	EP 1980-301075	19800403
	EP 18139	A3	19810107		
	EP 18139	B1	19830504		
	R: AT, BE, CH, DE, FR, IT, LU, NL, SE				
	GB 2048859	A	19801217	GB 1980-11250	19800403
	GB 2048859	B2	19830427		
	AT 3208	E	19830515	AT 1980-301075	19800403
	ZA 8002047	A	19811125	ZA 1980-2047	19800408
	JP 55141485	A2	19801105	JP 1980-50214	19800415
	CA 1120475	A1	19820323	CA 1980-350056	19800417
PRAI	US 1979-31256	A3	19790418		
	US 1980-116123	A	19800128		
	US 1980-125620	A	19800228		
	EP 1980-301075	A	19800403		

OS MARPAT 94:65719

AB Pyrido[2,3-d]pyrimidines I [R = H, OH, C1-6 alkyl, C1-6 alkylthio, Ph, 4-MeOC6H4, 4-ClC6H4, 1-pyrrolidinyl, MePhNH; R1 = HO, C1-6 alkylamino, 2-HOCH2CH2NH, C3-8 2-alkoxyethylamino, C1-6 dialkylamino, heterocyclyl; R2 = C1-6 alkoxy, 2-HOCH2CH2NH2, 2-alkoxy- and 2-(dialkylamino)ethylamino; R3 = H, C1-6 alkyl, C3-6 2-alkoxyethyl, allyl, propargyl, Ph, 4-tolyl, 4-ClC6H4, PhCH2, 4-MeOC6H4CH2, 4-ClC6H4CH2, 4-morpholinophenyl, piperonyl] were prepared by several methods, e.g., successive aminolysis of pyrimidinecarboxylate II (R4 = Cl), cyclocondensation with ClCOCH2COR2, chlorination, and further aminolysis. Thus, treating II (R = Ph, R4 = Cl) with EtNH2 (g) gave II (R4 = EtNH), whose cyclocondensation with ClCH2CO2Et gave I (R = Ph, R1 = OH, R2 = OEt, R3 = Et) (III). Treating III with POCl3 and then with pyrrolidine gave I (R1 = 1-pyrrolidinyl). At 32 mg/kg id. IV had 45% antigastric secretory activity and at 50 mg/kg p.o. had 99% antiallergy activity.


IT 76360-73-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and cyclocondensation of, with Et chloroformate, pyrimidooxazinedione derivative by)

RN 76360-73-1 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-[[[(4-methoxyphenyl)methyl]amino]-2-phenyl-(9CI) (CA INDEX NAME)

IT **76360-67-3P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclocondensation of, with Et malonyl chloride)

RN 76360-67-3 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 2-phenyl-4-[(phenylmethyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)

IT **76360-72-0P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deesterification of)

RN 76360-72-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[[4-(4-methoxyphenyl)methyl]amino]-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



L10 ANSWER 120 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1980:408129 CAPLUS

DN 93:8129

TI 2,6-disubstituted 4-(benzylamino)-5-cyanopyrimidines - a new series of pyrimidine derivatives

AU Robev, S.

CS Dep. Pharmacol. Phythother., Fac. Med., Sofia, 1431, Bulg.

SO Doklady Bolgarskoi Akademii Nauk (1979), 32(9), 1235-8

CODEN: DBANAD; ISSN: 0366-8681

DT Journal

LA English


AB Pyrimidines I (R = Ph, 4-MeC₆H₄, 2-naphthyl, R₁ = H, Cl) were obtained in 48-70% yield by cycloaddn. of 4-R₁C₆H₄CH₂N:CPhNH₂ with RCH:C(CN)₂, oxidation, and Dimroth rearrangement. I (R = Ph, R₁ = H) was hydrolyzed by H₃PO₄ to 2,6-diphenyl-4(3H)-pyrimidinone.

IT **73885-40-2P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)

RN 73885-40-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2,4-diphenyl-6-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




IT **73885-41-3P 73885-42-4P 73885-43-5P**

73885-45-7P 73885-46-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 73885-41-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(4-methylphenyl)-2-phenyl-6-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 73885-42-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(2-naphthalenyl)-2-phenyl-6-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 73885-43-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[4-(benzo[d][1,3]dioxol-5-yl)methyl]amino]-2,6-diphenyl- (9CI) (CA INDEX NAME)




RN 73885-45-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[4-(4-chlorophenyl)methyl]amino]-6-(4-methylphenyl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 73885-46-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[4-(4-chlorophenyl)methyl]amino]-6-(2-naphthalenyl)-2-phenyl- (9CI) (CA INDEX NAME)



L10 ANSWER 121 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1980:34952 CAPLUS

DN 92:34952

TI Correlation analysis of pyrimidine folic acid antagonists as antibacterial agents. II. Classification by mode of action using discriminant analysis

AU Smith, Carl C.; Genther, Clara S.; Coats, Eugene A.

CS Dep. Environ. Health, Univ. Cincinnati, Cincinnati, OH, 45267, USA

SO European Journal of Medicinal Chemistry (1979), 14(3), 271-6

CODEN: EJMCA5; ISSN: 0009-4374

DT Journal

LA English

AB The ability of folic acid [59-30-3] or folinic acid [58-05-9] to reverse the inhibitory effect of pyrimidines against *Streptococcus faecium*, *Lactobacillus casei*, and *Pediococcus cerevisiae* was studied. an amino group at the 2-position of the pyrimidine nucleus was related to reversible antifolate action in all 3 organisms Ph or anilino substituents at the 6-position resulted in irreversible antibacterial activity against *L. casei* and *P. cerevisiae*, but was not significant against *S. faecium*. Discriminant anal. as an adjunct to regression anal. in characterization of structure-activity relations of pyrimidines in quant. terms is discussed.


IT 71525-22-9

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(bactericidal activity of, folate reversal of, structure in relation to)

RN 71525-22-9 CAPLUS

CN Benzenesulfonamide, 4-amino-N-[3-(2,4-diamino-6-phenyl-5-pyrimidinyl)propyl]-N-phenyl- (9CI) (CA INDEX NAME)



L10 ANSWER 122 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1980:34951 CAPLUS

DN 92:34951

TI Correlation analysis of pyrimidine folic acid antagonists as antibacterial agents. I

AU Coats, Eugene A.; Genther, Clara S.; Smith, Carl C.

CS Coll. Pharm., Univ. Cincinnati, Cincinnati, OH, 45267, USA

SO European Journal of Medicinal Chemistry (1979), 14(3), 261-70

CODEN: EJMCA5; ISSN: 0009-4374

DT Journal

LA English

AB The activities of 175 pyrimidines as inhibitors of *Streptococcus faecium*, *Lactobacillus casei*, and *Pediococcus cerevisiae* are reported. In addition, the mode of action according to the ability of folic acid [59-30-3] or folinic acid [58-05-9] to reverse the inhibitory effect of the pyrimidines was determined. The 2,4-diamino substituent pattern appeared to be the dominant but not the sole factor controlling mode of action. Quant. structure-activity relations using regression anal., substituent consts., and indicator variables were developed in an effort to delineate influences on potency and to quant. differences between the test systems. Although aromatic and(or) lipophilic substituents at the 5 position of 2,4-diaminopyrimidines enhanced folate reversible inhibition against all 3 systems the derived equations quant. establish differences in and limitations on the extent of this effect.


IT 71525-22-9

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)



(bactericidal activity of, structure in relation to)

RN 71525-22-9 CAPLUS

CN Benzenesulfonamide, 4-amino-N-[3-(2,4-diamino-6-phenyl-5-pyrimidinyl)propyl]-N-phenyl- (9CI) (CA INDEX NAME)





L10 ANSWER 123 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1978:190753 CAPLUS
 DN 88:190753
 TI Synthesis of purines by cyclization of the Michael-type adducts from
 6-aminopyrimidines and 4-phenyl-1,2,4-triazoline-3,5-dione
 AU Yoneda, Fumio; Kawamura, Mitsuko; Matsumoto, Shigeru; Higuchi, Masatsugu
 CS Fac. Pharm. Sci., Kumamoto Univ., Kumamoto, Japan
 SO Journal of the Chemical Society, Perkin Transactions 1: Organic and
 Bio-Organic Chemistry (1972-1999) (1977), (20), 2285-8
 CODEN: JCPRB4; ISSN: 0300-922X
 DT Journal
 LA English
 OS CASREACT 88:190753
 AB The Michael-type adducts I (R = H, Me, R1 = Me, R2 = H, CH2Ph; R = Me, R1
 = H, R2 = Me, Pr, Bu) and II [R = Me, R1 = Pr, Bu, CH2Ph, (CH2)2Ph; R =
 Ph, R1 = CH2Ph] were prepared by treatment of the corresponding uracils with
 4-phenyl-1,2,4-triazoline-3,5-dione. Oxidative cyclization of I (R = H,
 Me, R1 = Me, R2 = CH2Ph) with PhNO2 gave the corresponding xanthines III
 (R3 = Ph), which were also obtained, together with III (R = R1 = Me, R3 =
 3,4-Cl2C6H3, 4-ClC6H4, 4-MeOC6H4, 4-Me2NC6H4; R = H, R1 = Me, R3 =
 4-ClC6H4, 3,4-Cl2C6H3), by condensation of I (R = H, Me, R1 = Me, R2 = H)
 with R3CHO. Direct cyclization of the Michael-type adducts II [R = Me, R1
 = CH2Ph, (CH2)2Ph; R = Ph, R1 = CH2Ph] with PhNO2 gave the corresponding
 purines IV.
 IT **66487-67-0P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and Michael addition reaction of, with phenyltriazolinedione)
 RN 66487-67-0 CAPLUS
 CN 4(1H)-Pyrimidinone, 2-phenyl-6-[(phenylmethyl)amino]- (9CI) (CA INDEX
 NAME)




IT **66487-61-4P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and oxidative cyclization of)
 RN 66487-61-4 CAPLUS
 CN 1,2,4-Triazolidine-3,5-dione, 1-[1,4-dihydro-4-oxo-2-phenyl-6-
 [(phenylmethyl)amino]-5-pyrimidinyl]-4-phenyl- (9CI) (CA INDEX NAME)


10/671,070




L10 ANSWER 124 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1978:105255 CAPLUS
 DN 88:105255
 TI Displacement reactions of 2-alkylsulfonyl-4-chloropyrimidine derivatives with nucleophiles
 AU Sawayama, Tadahiro; Yamamoto, Ryuichi; Kinugasa, Hiroaki; Nishimura, Haruki
 CS Res. Lab., Dainippon Pharm. Co., Ltd., Suita, Japan
 SO Heterocycles (1977), 8, 299-305
 CODEN: HTCYAM; ISSN: 0385-5414
 DT Journal
 LA English
 OS CASREACT 88:105255
 AB Aminolysis of chloropyrimidines I [R = Ph, H, R1 = Et, R2 = Cl; R = R1 = Me, R2 = Cl] gave I (R2 = NH2, NHCH2Ph, NHMe, NHPh, morpholino, piperidino, 4-methylpiperazino, 4-(2-hydroxyethyl)piperazino] and II (R = same; R3 = SO2R1, Cl; R4 = H, CH2Ph, Me, Ph). 4-Chloro-2-ethoxy-6-phenylpyrimidine was obtained as a by-product of the ammonolysis of I (R = Ph, R1 = Et, R2 = Cl) in EtOH.
 IT **65766-20-3P 65766-22-5P 65766-26-9P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 65766-20-3 CAPLUS
 CN 2-Pyrimidinamine, 4-chloro-6-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 65766-22-5 CAPLUS
 CN 4-Pyrimidinamine, 2-(ethylsulfonyl)-6-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 65766-26-9 CAPLUS
 CN 2-Pyrimidinamine, 4-(ethylsulfonyl)-6-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 125 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1977:171488 CAPLUS
 DN 86:171488
 TI Substituted-2-(pyrimidinylthio)acetamidoximes and acetonitriles
 IN Santilli, Arthur A.; Scotese, Anthony C.
 PA American Home Products Corp., USA
 SO U.S., 5 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3950339	A	19760413	US 1975-570546	19750422
PRAI	US 1974-514676	A2	19741015		


AB Six acetamidoximes I (R = p-ClC₆H₄CH₂, 1,3-benzodioxol-5-ylmethyl, p-MeOC₆H₄; R₁ = Me, Pr, Ph), with antiarrhythmic activity in dogs, were prepared by reaction of acetonitriles II (R₁ as before; R₂ = RNH; R as before) with NH₂OH.HCl in DMF in the presence of Na₂CO₃ at elevated temperature II (R₂ = RNH) were prepared by reaction of RNH₂ with II (R₂ = Cl), which were obtained by condensing 6-substituted 2-thiouracil Na salts with ClCH₂CONH₂ and treating the resultant (pyrimidinylthio)acetamides with POCl₃.

IT **56605-25-5P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reaction of, with hydroxylamine hydrochloride)

RN 56605-25-5 CAPLUS

CN Acetonitrile, [[4-[(1,3-benzodioxol-5-ylmethyl)amino]-6-phenyl-2-pyrimidinyl]thio]- (9CI) (CA INDEX NAME)




IT **56605-34-6P**


RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, for use as antiarrhythmic agent)

RN 56605-34-6 CAPLUS


CN Ethanimidamide, 2-[[4-[(1,3-benzodioxol-5-ylmethyl)amino]-6-phenyl-2-pyrimidinyl]thio]-N-hydroxy- (9CI) (CA INDEX NAME)



L10 ANSWER 126 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1976:478077 CAPLUS
 DN 85:78077
 TI Methylation of 4-amino-5-phenylpyrimidine and proof of the structure of its derivatives
 AU Tsatsaronis, G.; Soulis, T.
 CS Lab. Org. Chem. Technol. Food Chem., Univ. Thessaloniki, Salonika, Greece
 SO Prakt. Panelleniou Chem. Synedriou, 4th (1972), Meeting Date 1970, Volume 1, 64-8 Publisher: Chem. Chron., Athens, Greece.
 CODEN: 32PRAD
 DT Conference
 LA Greek
 AB Alkylation of 4-amino-5-phenylpyrimidine with R_2SO_4 ($R = Me, Et$) afforded products alkylated in the 1-position, which gave the corresponding imines I when treated with NaOH. II was obtained by treatment of I ($R = Me$) with hot or cold alkali. Reaction of $MeNHCHO$ with $PhCH(CN)CH:NH$ gave 4-methylamino-5-phenylpyrimidine. Reaction of 4-chloro-5-phenyl (or p-nitrophenyl)pyrimidine with R_1NH_2 ($R_1 = Et, Pr, Bu, cyclohexyl, PhCH_2$) gave 21-63% III (same R_1 ; $R_2 = H, NO_2$).
 IT **60122-84-1P 60122-87-4P**
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 60122-84-1 CAPLUS
 CN 4-Pyrimidinamine, 5-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 60122-87-4 CAPLUS
 CN 4-Pyrimidinamine, 5-(4-nitrophenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 127 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1976:38578 CAPLUS

DN 84:38578

TI Correlation analysis of Baker's studies on enzyme inhibition. 2. Chymotrypsin, trypsin, thymidine phosphorylase, uridine phosphorylase, thymidilate synthetase, cytosine nucleoside deaminase, dihydrofolate reductase, malate, glutamate, lactate, and glyceraldehyde-phosphate dehydrogenase

AU Yoshimoto, Masafumi; Hansch, Corwin

CS Dep. Chem., Pomona Coll., Claremont, CA, USA

SO Journal of Medicinal Chemistry (1976), 19(1), 71-98
CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

AB The inhibitory activity of .apprx.1000 inhibitors of the title enzymes, α -chymotrypsin [9004-07-3], trypsin [9002-07-7], thymidine phosphorylase [9030-23-3], uridine phosphorylase [9030-22-2], thymidylate synthetase [9031-61-2], cytosine nucleoside deaminase [9025-06-3], dihydrofolate reductase [9002-03-3], malate dehydrogenase [9001-64-3], glutamate dehydrogenase [9001-46-1], glyceraldehyde-phosphate dehydrogenase [9001-50-7], and lactate dehydrogenase [9001-60-9], were formulated in 13 equations correlating chemical structure with inhibiting potency. Two types of regions in enzymes were defined by means of π and molar refractive consts. The correlation equations showed that substituent effects are additive to a 1st approximation. Examples are given of use of the equations in comparing structural features of different systems.


IT 2211-01-0

RL: BIOL (Biological study)

(dihydrofolate reductase inhibition by, correlation anal. in relation to)

RN 2211-01-0 CAPLUS

CN 2,4-Pyrimidinediamine, 6-phenyl-5-[3-(phenylamino)propyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 128 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1975:578969 CAPLUS

DN 83:178969

TI Synthesis of 5,6,7,8-tetrahydro-5-oxopyrido[2,3-d]pyrimidine-6-carbonitriles and -6-carboxylic acid esters

AU Santilli, Arthur A.; Wanser, Stephen V.; Kim, Dong H.; Scotese, Anthony C.

CS Res. Dev. Div., Wyeth Lab. Inc., Radnor, PA, USA

SO Journal of Heterocyclic Chemistry (1975), 12(2), 311-16

CODEN: JHTCAD; ISSN: 0022-152X

DT Journal

LA English

OS CASREACT 83:178969

AB 5-Carbethoxy-4-chloro-2-phenylpyrimidine was treated with $\text{RNHCH}_2\text{CH}_2\text{CN}$ ($\text{R} = \text{Me}$, PhCH_2CH_2 , morpholinoethyl, etc.) to give I, which underwent ring closure to give II ($\text{R}_1 = \text{H}$). II ($\text{R} = \text{Me}$, $\text{R}_1 = \text{H}$) was methylated to give II ($\text{R} = \text{R}_1 = \text{Me}$). II ($\text{R} = \text{Me}$, $\text{R}_1 = \text{H}$) and $p\text{-MeC}_6\text{H}_4\text{SO}_2\text{Cl}$ gave III. II ($\text{R} = \text{Me}$, $\text{R}_1 = \text{H}$) and SOCl_2 gave IV. Several similar pyridopyrimidines were also prepared


IT 35855-41-5P 35855-45-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and cyclization of, pyridopyrimidinecarbonitriles from)



RN 35855-41-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[(2-cyanoethyl)(2-phenylethyl)amino]-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 35855-45-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[[[(4-chlorophenyl)methyl](2-cyanoethyl)amino]-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



L10 ANSWER 129 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1975:557714 CAPLUS

DN 83:157714

TI Synthesis and antiarrhythmic activity of substituted (2-pyrimidinylthio)acetamidoximes

AU Scotese, Anthony C.; Santilli, Arthur A.; Nelson, George L.

CS Res. Dev. Div., Wyeth Lab., Inc., Radnor, PA, USA

SO Journal of Medicinal Chemistry (1975), 18(8), 852-4

CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

OS CASREACT 83:157714

AB Of 17 title acetamidoximes and acetonitrile intermediates, prepared by S-alkylation of the 6-substituted thiouracil with 2-chloroacetamide [79-07-2], dehydration to the nitrile and replacement of the 4-OH group by Cl by treatment with POCl₃, amination and treatment with hydroxylamine, 5 compds. had significant activity in the antiarrhythmic screen in dogs. 2-[4-Methyl-6-(p-chlorobenzylamino)-2-pyrimidinylthio]acetamidoxime-2HCl (I-2HCl) [56605-29-9] was the most potent antiarrhythmic agent. Structure-activity relations are discussed.


IT 56605-25-5P 56605-32-4P 56605-34-6P

56641-09-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antiarrhythmic activity of)


RN 56605-25-5 CAPLUS

CN Acetonitrile, [[4-[(1,3-benzodioxol-5-ylmethyl)amino]-6-phenyl-2-pyrimidinyl]thio]- (9CI) (CA INDEX NAME)




RN 56605-32-4 CAPLUS

CN Ethanimidamide, 2-[[4-[[4-(4-chlorophenyl)methyl]amino]-6-phenyl-2-pyrimidinyl]thio]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 56605-34-6 CAPLUS

CN Ethanimidamide, 2-[[4-[(1,3-benzodioxol-5-ylmethyl)amino]-6-phenyl-2-pyrimidinyl]thio]-N-hydroxy- (9CI) (CA INDEX NAME)




RN 56641-09-9 CAPLUS

CN Acetonitrile, [[4-[[[(4-chlorophenyl)methyl]amino]-6-phenyl-2-pyrimidinyl]thio]- (9CI) (CA INDEX NAME)





L10 ANSWER 130 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1975:43455 CAPLUS
 DN 82:43455
 TI 5,6,7,8-Tetrahydro-5-oxo-pyrido(2,3-d)pyrimidine-6-carbonitriles and related compounds
 IN Santilli, Arthur A.; Kim, Dong H.
 PA American Home Products Corp.
 SO U.S., 6 pp. Division of U.S. 3,726,869 (CA 78: 159653x).
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3843645	A	19741022	US 1972-310311	19721129
	US 3726869	A	19730410	US 1971-136997	19710423
PRAI	US 1971-136997	A3	19710423		
	US 1968-752485	A3	19680814		
AB	The pyridopyrimidines I (R = Me, CH ₂ CH ₂ Ph, morpholinoethyl, CH ₂ CH ₂ OMe, CH ₂ C ₆ H ₄ Cl-p) were prepared by treating the chloropyrimidine II with RNHCH ₂ CH ₂ CN and cyclizing with NaOEt. I were central nervous system depressants in mice at 12.7-40 mg/kg i.p.				
IT	35855-41-5P 35855-45-9P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and cyclization of)				
RN	35855-41-5 CAPLUS				
CN	5-Pyrimidinecarboxylic acid, 4-[(2-cyanoethyl) (2-phenylethyl) amino]-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)				



RN 35855-45-9 CAPLUS
 CN 5-Pyrimidinecarboxylic acid, 4-[[[4-chlorophenyl)methyl] (2-cyanoethyl) amino]-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



L10 ANSWER 131 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1973:432081 CAPLUS

DN 79:32081

TI 4-[(2-Cyanoethyl)amino]-2-phenyl-5-pyrimidinecarboxylic acid esters

IN Santilli, Arthur A.; Kim, Dong H.

PA American Home Products Corp.

SO U.S., 5 pp. Division of U.S. 3,641,027 (CA 76:127008h).

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3732226	A	19730508	US 1971-136670	19710423
	US 3641027	A	19720208	US 1968-752485	19680814
PRAI	US 1968-752485	A3	19680814		


AB The pyrido[2,3-d]pyrimidinecarbonitriles I (R = Me, PhCH₂CH₂, morpholinoethyl, MeOCH₂CH₂, p-ClC₆H₄CH₂) were prepared by cyclization of the pyrimidinecarboxylates II. Thus, 5-carbethoxy-4-chloro-2-phenylpyrimidine was treated with MeNHCH₂CH₂CN to give II (R = Me) which was heated in EtOH containing EtONa to give I (R = Me). I were depressants at 12.7-40 mg/kg.

IT 35855-41-5P 35855-45-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)



RN 35855-41-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[(2-cyanoethyl) (2-phenylethyl) amino]-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 35855-45-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[[[4-chlorophenyl)methyl] (2-cyanoethyl)amino]-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



L10 ANSWER 132 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1972:127008 CAPLUS
 DN 76:127008
 TI 5,6,7,8-Tetrahydro-5-oxopyrido[2,3-d]pyrimidine-6-carbonitriles and related compounds
 IN Santilli, Arthur A.; Kim, Dong H.
 PA American Home Products Corp.
 SO U.S., 5 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3641027	A	19720208	US 1968-752485	19680814
	US 3726869	A	19730410	US 1971-136997	19710423
	US 3732226	A	19730508	US 1971-136670	19710423
PRAI	US 1968-752485	A3	19680814		


AB 5-Carbethoxy-4-chloro-2-phenylpyrimidine was treated with $\text{MeNH}(\text{CH}_2)_2\text{CN}$ and Na_2CO_3 to give I (R = Me) (II). Five similar I (R = $\text{Ph}(\text{CH}_2)_2$, 2-morpholinoethyl, $\text{MeO}(\text{CH}_2)_2$, $\text{Et}_2\text{N}(\text{CH}_2)_2$, p- $\text{ClC}_6\text{H}_4\text{CH}_2$) were prepared II was treated with NaOEt to give the pyrido[2,3-d]pyrimidine (III, R = Me). Four similar III (R = $\text{Ph}(\text{CH}_2)_2$, 2-morpholinoethyl, $\text{MeO}(\text{CH}_2)_2$, p- $\text{ClC}_6\text{H}_4\text{CH}_2$) were prepared I and III were depressants.

IT **35855-41-5P 35855-45-9P**

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)



RN 35855-41-5 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[(2-cyanoethyl)(2-phenylethyl)amino]-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 35855-45-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[[[4-chlorophenyl)methyl](2-cyanoethyl)amino]-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



L10 ANSWER 133 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1972:82480 CAPLUS
 DN 76:82480
 TI Role of folate coenzymes in the initiation of protein synthesis
 AU Dickerman, Herbert W.
 CS Sch. Med., Johns Hopkins Univ., Baltimore, MD, USA
 SO Annals of the New York Academy of Sciences (1971), 186, 70-81
 CODEN: ANYAA9; ISSN: 0077-8923
 DT Journal
 LA English
 AB Methionyl tRNA^fMet was characterized by its activity as a substrate in the formylation reaction; its participation, as the N-formyl derivative, in the formation of the initiation complex; and its exclusion from participation in the transfer complex. Methionyl tRNA^fMet transformylase, approx. 90% pure, had a slightly acidic isoelec. point, a mol. weight of approx. 25,000 daltons, and was not a cationic protein like the histones. 44 references.
 IT **35960-68-0**
 RL: BIOL (Biological study)
 (methionyl ribonucleic acid formylation by transformylase inhibition by)
 RN 35960-68-0 CAPLUS
 CN L-Glutamic acid, N-[4-[[3-(2-amino-1,4-dihydro-4-oxo-6-phenyl-5-pyrimidinyl)propyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 134 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1972:34229 CAPLUS

DN 76:34229

TI Syntheses of N-heterocyclic compounds. II. Pyrimido[4,5-e]-, pyridazino[3,4-e]-, and pyrido[4,3-e]-1,2,3,5-tetrahydro[1,4]oxazepin-5-one

AU Yurugi, Shojiro; Hieda, Masaru; Fushimi, Tomiyoshi; Tomimoto, Mitsumi

CS Res. Dev. Div., Takeda Chem. Ind., Ltd., Osaka, Japan

SO Chemical & Pharmaceutical Bulletin (1971), 19(11), 2354-64

CODEN: CPBTAL; ISSN: 0009-2363

DT Journal

LA English


AB Pyrimido[4,5-e][1,4]oxazepines were synthesized by the reaction of 2-substituted-4-chloro-5-ethoxycarbonylpyrimidines with N-substituted ethanolamines. The reaction was applied to the syntheses of the pyridazo[3,4-e]-[1,4]oxazepines and pyrido[4,3-e][1,4]oxazepines. In the course of this study a N-O rearrangement at the 4-position of 2-phenyl-4-(N-phenyl-2-hydroxyethylamino)-5-ethoxycarbonylpyrimidine was observed

IT **34750-69-1P 34753-26-9P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 34750-69-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-[(2-hydroxyethyl)(phenylmethyl)amino]-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 34753-26-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-phenyl-N-(phenylmethyl)-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



L10 ANSWER 135 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1970:79077 CAPLUS

DN 72:79077

TI Coccidiostatic N-[(2-substituted-4-aminopyrimidinyl)methyl]-3-ethoxy-4-alkoxycarbonylanilinium bromide hydrobromides

PA Chimetron S.a r.l.

SO Fr., 4 pp.

CODEN: FRXXAK

DT Patent

LA French

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 1566160		19690509	FR	19660527

AB The title compds. (I), useful as coccidiostats, are prepared by treating 4-amino-5-(halomethyl)pyrimidines with 4-amino-2-ethoxybenzoic acids. Thus, 0.1 mole 2-propyl-4-amino-5-(bromomethyl)-pyrimidine was treated with 0.1 mole of Me 4-amino-2-ethoxybenzoate in 250 ml iso-PrOH and 50 ml 2M HBr added to give I (R = Pr, R1 = Me, X = Br).HBr. 2-Ethyl-4-amino-5-(bromomethyl)pyrimidine (0.1 mole) in 300 ml MeCN was treated with 27.6 g Me 4-amino-2-ethoxybenzoate-HBr and the mixture refluxed 1 hr to give I (R = R1 = Et, X = Br).HBr.

IT **26667-80-1P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 26667-80-1 CAPLUS

CN Benzoic acid, 4-[[[(4-amino-2-phenyl-5-pyrimidinyl)methyl]amino]-2-ethoxy-, methyl ester, dihydrobromide (8CI) (CA INDEX NAME)



●2 HBr

L10 ANSWER 136 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1968:400301 CAPLUS

DN 69:301

TI Irreversible enzyme inhibitors. CXIX. Active-site-directed irreversible inhibitors of dihydrofolic reductase with tissue specificity derived from 2,4,6-triaminopyrimidine with a terminal sulfonyl fluoride at the 5 position

AU Baker, Bernard Randall; Meyer, Rich B., Jr.

CS Univ. of California Santa Barbara, Santa Barbara, CA, USA

SO Journal of Medicinal Chemistry (1968), 11(3), 489-94

CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

AB Four derivs. of 5-phenoxypropyl-2,4,6-triaminopyrimidine with the following substituents on the para position were synthesized as candidate active-site-directed irreversible inhibitors of dihydrofolic reductase: m-fluorosulfonylbenzamido (I), p-fluorosulfonylbenzamido (II), m-fluorosulfonylphenylureido (III), and p-fluorosulfonyl-phenylureido (IV). At a concentration near 1 μ M, I could rapidly inactivate the dihydrofolic reductase from Walker 256 rat tumor and L1210/FR8 mouse leukemia, but showed little irreversible inhibition of the enzyme from rat liver, mouse liver, or L1210/0. This specificity for rat tumor enzyme over rat liver enzyme was considerably decreased when the carboxamido group of I was lengthened to ureido (III), the tumor enzyme being inactivated about four-fold faster than the rat liver enzyme; however, specificity of inactivation of the L1210/FR8 enzyme by III with no irreversible inhibition of the mouse liver enzyme was maintained. Movement of the sulfonyl fluoride from the meta position of I and III to give II and IV resulted in considerably slower irreversible inhibitors; since the enzyme could apparently catalyze hydrolysis of the sulfonyl fluoride of II and IV to the irreversibly ineffective sulfonic acid more rapidly, the amount of irreversible inhibition was also decreased. 25 references.

IT 20768-17-6P 20768-18-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 20768-17-6 CAPLUS

CN m-Acetotoluidide, 2-bromo- α -[(2,4-diamino-6-phenyl-5-pyrimidinyl)amino]-, monopicrate (8CI) (CA INDEX NAME)

CM 1

CRN 47539-37-7


CMF C19 H19 Br N6 O



CM 2

CRN 88-89-1

CMF C6 H3 N3 O7




RN 20768-18-7 CAPLUS

CN p-Acetotoluidide, 2-bromo- α -[(2,4-diamino-6-phenyl-5-pyrimidinyl)amino]-, monopicrate (8CI) (CA INDEX NAME)

CM 1

CRN 47539-38-8


CMF C19 H19 Br N6 O



CM 2

CRN 88-89-1

CMF C6 H3 N3 O7



L10 ANSWER 137 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1968:400299 CAPLUS

DN 69:299

TI Irreversible enzyme inhibitors. CXVI. Active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 6-substituted 2,4-diamino-5-phenylpyrimidines. 3

AU Baker, Bernard Randall; Huang, Ping Cheong; Meyer, Rich B., Jr.

CS Univ. of California, Santa Barbara, CA, USA

SO Journal of Medicinal Chemistry (1968), 11(3), 475-82

CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English



AB Ten candidate irreversible inhibitors derived from 5-(p-chlorophenyl)-2,4-diaminopyrimidine bearing a leaving group on a chain at the 6 position were evaluated on dihydrofolic reductase from Walker 256 rat tumor and L1210/FR8 mouse leukemia; three had a chloromethyl, 4 had a sulfonyl fluoride, and 3 had a bromoacetamido leaving group. Strong evidence was obtained that the diaminopyrimidine could complex as one of 2 rotomers depending upon the hydrophobicity of the group at the 6 position; 6-phenoxyethyl- and 6-phenethylpyrimidines were bound in a conformation giving a hydrophobic interaction of the 6 group with the enzyme, but the more polar 6-anilinomethyl-pyrimidines were bound in a flipped-over conformation. Three of the sulfonyl fluorides, 6-[m-(m-fluorosulfonylphenylureido)-phenoxyethyl]-2,4-diamino-5-(p-chlorophenyl)pyrimidine (I), the 5-(3,4-dichlorophenyl) analog of I, and the phenethyl analog of I, were good active-site-directed irreversible inhibitors of dihydrofolic reductase. 22 references.

IT 20535-55-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 20535-55-1 CAPLUS

CN Pyrimidine, 2,4-diamino-6-[[p-[2-(chloromethyl)-1,3-dioxolan-2-yl]anilino]methyl]-5-(3,4-dichlorophenyl)- (8CI) (CA INDEX NAME)




IT 20535-88-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of and tetrahydrofolic acid dehydrogenase inhibition by)

RN 20535-88-0 CAPLUS

CN Acetophenone, 2-chloro-4'-[[[2,6-diamino-5-(3,4-dichlorophenyl)-4-pyrimidinyl]methyl]amino]-, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

L10 ANSWER 138 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1968:27157 CAPLUS

DN 68:27157

TI Irreversible enzyme inhibitors. CVIII. 6-(p-Chloroacetylanilinomethyl)-5-(p-chlorophenyl)-2,4-diaminopyrimidine, an active-site-directed irreversible inhibitor of dihydrofolic reductase

AU Baker, Bernard Randall; Huang, Ping Cheong; Pogolotti, Alfonso L., Jr.

CS Univ. of California, Santa Barbara, CA, USA

SO Journal of Medicinal Chemistry (1967), 10(6), 1134-8

CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

AB The title compound (I) was synthesized by reductive condensation of 5-(p-chlorophenyl)-2,4-diaminopyrimidine-6-carboxaldehyde with 2-(p-aminophenyl)-2-chloromethyl-1,3-dioxolane followed by hydrolysis of the ketal blocking group. Three higher homologs were also synthesized from the appropriate 2-(p-aminophenylalkyl)-2-chloromethyl-1,3-dioxolane. I rapidly inactivated the dihydrofolic reductase from Walker 256 rat tumor, rat liver, and mouse leukemia L1210/FR8; the enzyme from pigeon liver was inactivated perceptibly slower. That reversible complex formation between the enzyme and the inhibitor was a necessary prerequisite for inactivation was shown by the failure of p-amino- α -chloroacetophenone to inactivate dihydrofolic reductase under conditions that led to rapid inactivation with I. 22 references.


IT 18861-36-4P 18861-37-5P 18861-38-6P

18861-39-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 18861-36-4 CAPLUS

CN Pyrimidine, 2,4-diamino-6-[p-[2-(chloromethyl)-1,3-dioxolan-2-yl]anilino]methyl]-5-(p-chlorophenyl)- (8CI) (CA INDEX NAME)




RN 18861-37-5 CAPLUS

CN Pyrimidine, 2,4-diamino-6-[p-[2-[2-(chloromethyl)-1,3-dioxolan-2-yl]vinyl]anilino]methyl]-5-(p-chlorophenyl)- (8CI) (CA INDEX NAME)




RN 18861-38-6 CAPLUS

CN Pyrimidine, 2,4-diamino-6-[[p-[2-[2-(chloromethyl)-1,3-dioxolan-2-yl]ethyl]anilino]methyl]-5-(p-chlorophenyl)- (8CI) (CA INDEX NAME)



RN 18861-39-7 CAPLUS

CN Pyrimidine, 2,4-diamino-6-[[p-[4-[2-(chloromethyl)-1,3-dioxolan-2-yl]butyl]anilino]methyl]-5-(p-chlorophenyl)- (8CI) (CA INDEX NAME)



IT 15422-30-7P 15422-31-8P 15422-32-9P



15422-33-0P

RL: SPN (Synthetic preparation); PREP (Preparation)



(preparation of and tetrahydrofolate dehydrogenase inhibition by)

RN 15422-30-7 CAPLUS



CN Ethanone, 2-chloro-1-[4-[[[2,6-diamino-5-(4-chlorophenyl)-4-pyrimidinyl]methyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 15422-31-8 CAPLUS
 CN 2-Butanone, 1-chloro-4-[[[2,6-diamino-5-(4-chlorophenyl)-4-pyrimidinyl]methyl]amino]phenyl]- (9CI) (CA INDEX NAME)





RN 15422-32-9 CAPLUS
 CN 2-Hexanone, 1-chloro-6-[4-[[[2,6-diamino-5-(4-chlorophenyl)-4-pyrimidinyl]methyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 15422-33-0 CAPLUS
 CN 3-Buten-2-one, 1-chloro-4-[[[2,6-diamino-5-(4-chlorophenyl)-4-pyrimidinyl]methyl]amino]phenyl]- (9CI) (CA INDEX NAME)

10/671,070


pyrimidinyl)methyl]amino]phenyl]~ (9CI) (CA INDEX NAME)




L10 ANSWER 139 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1967:418079 CAPLUS
 DN 67:18079
 TI Irreversible enzyme inhibitors. LXXXV. On the mode of pyrimidine binding of 5-alkyl and 5-arylpyrimidines to dihydrofolic reductase
 AU Baker, Bernard Randall; Lourens, Gerhardus J.; Jordaan, Johannes H.
 CS Univ. of California, Santa Barbara, CA, USA
 SO Journal of Heterocyclic Chemistry (1967), 4(1), 39-48
 CODEN: JHTCAD; ISSN: 0022-152X
 DT Journal
 LA English
 AB cf. preceding abstract A series of 5-isoamyl- and 5-(p-chlorophenyl)pyrimidines substituted with amino, alkylamino, mercapto, benzyloxy, hydroxy, or hydrogen at the 2- and 4-positions and with amino or methyl at the 6-position have been synthesized for evaluation of the mode of pyrimidine binding to dihydrofolic reductase. The studies were performed in order to determine where a bulky group could be placed on the pyrimidine ring that would still allow good binding; such studies are essential to find a suitable position for placement of a covalent forming group for design of active-site-directed irreversible inhibitors. Two classes of candidate compds. have emerged for further study as irreversible inhibitors, namely, 2-amino-4-mercapto-6-(p-bromoacetamidophenylalkyl)pyrimidines (I) and 2,4-diamino-6-(p-bromoacetamidophenylalkyl)aminopyrimidines having a group such as phenyl, phenylbutyl or isoamyl at the 5-position that can give strong hydrophobic bonding to the enzyme. 27 references.
 IT **17005-50-4P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of and tetrahydrofolate dehydrogenase inhibition by)
 RN 17005-50-4 CAPLUS
 CN Pyrimidine, 2-amino-5-(p-chlorophenyl)-4-methyl-6-[(3-phenylpropyl)amino]-
 (8CI) (CA INDEX NAME)



L10 ANSWER 140 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1967:418076 CAPLUS
 DN 67:18076
 TI Irreversible enzyme inhibitors. LXXXII. Candidate active-site-directed irreversible inhibitors of dihydrofolic reductase. 7. Derivatives of 2,4-diaminopyrimidine I
 AU Baker, Bernard Randall; Jackson, Graham D. F.; Meyers, Rich B., Jr.
 CS Univ. of California, Santa Barbara, CA, USA
 SO Journal of Pharmaceutical Sciences (1967), 56(5), 566-70
 CODEN: JPMSAE; ISSN: 0022-3549
 DT Journal
 LA English
 AB cf. preceding abstract Fusion of α -benzoyl- α -(phenylazo)acetonitrile with guanidine carbonate gave 2,4-diamino-6-phenyl-5-phenylazopyrimidine (I) in 52% yield; catalytic reduction of I to 6-phenyl-2,4,5-triaminopyrimidine (II) proceeded smoothly. Condensation of the triaminopyrimidine (II) with p-nitrocinnamaldehyde to an anil, followed by a 2-stage reduction, afforded 5-(p-aminophenylpropylamino)-2,4-diamino-6-phenylpyrimidine; selective bromoacetylation on the p-amino group gave the candidate irreversible inhibitor, 5-(p-bromoacetamidophenylpropylamino)-2,4 - diamino - 6 - phenylpyrimidine (III). When III was incubated with dihydrofolic reductase in the presence or absence of TPNH, no inactivation occurred; the possible conformational differences in binding to dihydrofolic reductase between III and other successful activesite-directed irreversible inhibitors are discussed.
 IT 13491-73-1P 17005-17-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of and tetrahydrofolate dehydrogenase inhibition by)
 RN 13491-73-1 CAPLUS
 CN 2,4,5-Pyrimidinetriamine, N5-[3-(4-aminophenyl)propyl]-6-phenyl- (9CI)
 (CA INDEX NAME)




RN 17005-17-3 CAPLUS
 CN Acetanilide, 2-bromo-4'-[3-[(2,4-diamino-6-phenyl-5-pyrimidinyl)amino]propyl]-, monopicrate (8CI) (CA INDEX NAME)
 CM 1
 CRN 13491-74-2
 CMF C21 H23 Br N6 O




CM 2

CRN 88-89-1

CMF C6 H3 N3 O7



L10 ANSWER 141 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1967:62159 CAPLUS
DN 66:62159
TI Structure-activity analysis of tetrahydrofolate analogs using substituent constants and regression analysis
AU Miller, Elinor; Hansch, Corwin
CS Pomona Coll., Claremont, CA, USA
SO Journal of Pharmaceutical Sciences (1967), 56(1), 92-7
CODEN: JPMSAE; ISSN: 0022-3549
DT Journal
LA English
AB The binding to dihydrofolate reductase of a series of substituted pyrimidines and triazines is dependent on the electron-contributing and lipophilic character of the substituents. The configuration of binding is variable, and is determined by the necessity of placing the most lipophilic substituent in a hydrophobic region of the enzyme. When two or more lipophilic substituents are present, competition between them for the hydrophobic site is dominated by the more lipophilic group, while the less lipophilic group contributes to hydrophobic bonding to a slight extent. Suggestions are made for the design of a new tetrahydrofolate analog with possible application as a nonclassical antimetabolite. 24 references.
IT 2211-01-0
RL: PROC (Process)
(structure-activity anal. of)
RN 2211-01-0 CAPLUS
CN 2,4-Pyrimidinediamine, 6-phenyl-5-[3-(phenylamino)propyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 142 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1967:62157 CAPLUS

DN 66:62157

TI Irreversible enzyme inhibitors LXXI. Candidate active-site-directed irreversible inhibitors of dihydrofolic reductase. 5. Derivatives of 6-phenylpyrimidine

AU Baker, Bernard Randall; Shapiro, Howard S.

CS Univ. of California, Santa Barbara, CA, USA

SO Journal of Pharmaceutical Sciences (1967), 56(1), 33-8

CODEN: JPMSAE; ISSN: 0022-3549

DT Journal

LA English


AB cf. preceding abstract A series of 2-amino-5-(anilinopropyl)-6-phenyl-4-pyrimidinols bearing p-chloroacetyl, p-(4-chloro-3-butanon-1-yl) (I), p-(4-chloro-1-buten-3-on-1-yl) (II), and p-bromoacetamidoethyl (III) groups on the anilino moiety were synthesized as candidate active-site-directed irreversible inhibitors of dihydrofolic reductase. Only I inactivated dihydrofolic reductase when they were incubated together at 37°; the half-life was about 60 min. when sufficient I was utilized to convert 45% of the enzyme to a reversible complex. That this inactivation by I proceeded through a reversible enzyme-inhibitor complex and not by a random bimol. mechanism was indicated by the lack of inactivation of dihydrofolic reductase by chloroacetone at 2.5 times the concentration of I. The failure of II and III to inactivate the enzyme at a concentration sufficient to convert 50-60% of the enzyme to the respective reversible complexes indicated that the alkylating function of II and III could not bridge to a nucleophilic site on the enzyme within the enzyme-inhibitor complex. 34 references.

IT 15473-88-8P 15946-59-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 15473-88-8 CAPLUS

CN Acetamide, N-[p-[[3-(2-amino-4-hydroxy-6-phenyl-5-pyrimidinyl)propyl]amino]phenethyl]- (8CI) (CA INDEX NAME)



RN 15946-59-5 CAPLUS

CN 4-Pyrimidinol, 2-amino-5-[3-[p-(2-aminoethyl)anilino]propyl]-6-phenyl-, monohydrochloride (8CI) (CA INDEX NAME)



● HCl


IT 15473-84-4 15473-85-5 15473-86-6
15473-87-7

RL: BIOL (Biological study)

(tetrahydrofolate dehydrogenase inhibition by, active-site-directed irreversible inhibition in relation to)


RN 15473-84-4 CAPLUS

CN Acetamide, N-[2-[4-[[3-(2-amino-1,4-dihydro-4-oxo-6-phenyl-5-pyrimidinyl)propyl]amino]phenyl]ethyl]-2-bromo- (9CI) (CA INDEX NAME)




RN 15473-85-5 CAPLUS

CN 4(1H)-Pyrimidinone, 2-amino-5-[3-[[4-(chloroacetyl)phenyl]amino]propyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 15473-86-6 CAPLUS

CN 4(1H)-Pyrimidinone, 2-amino-5-[3-[[4-(4-chloro-3-oxo-1-butenyl)phenyl]amino]propyl]-6-phenyl- (9CI) (CA INDEX NAME)



RN 15473-87-7 CAPLUS

CN 4(3H)-Pyrimidinone, 2-amino-5-[3-[p-(4-chloro-3-oxobutyl)anilino]propyl]-6-phenyl- (8CI) (CA INDEX NAME)



L10 ANSWER 143 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1967:37878 CAPLUS

DN 66:37878

TI Analogs of tetrahydrofolic acid. XXXIX. Selective bromoacylation of polyfunctional molecules for synthesis of active-site-directed irreversible enzyme inhibitors

AU Baker, Bernard Randall; Santi, Daniel V.; Coward, James K.; Shapiro, Howard S.; Jordaan, Johannes H.

CS Univ. of California, Santa Barbara, CA, USA

SO Journal of Heterocyclic Chemistry (1966), 3(4), 425-34

CODEN: JHTCAD; ISSN: 0022-152X

DT Journal

LA English

AB cf. CA 65, 2558b, 18581e. A number of methods for selective bromoacylation of side-chain amino groups on 2-amino-4-pyrimidinols (I) or 2,4,6-triaminopyrimidines were developed for these extremely sensitive products. The choice of method depends upon whether (a) the aminopyrimidine is a stronger base than the amine to be bromoacylated, (b) as weak a base as the amine to be bromoacylated but the amine is more reactive, (c) the amine group to be bromoacylated is a strong aliphatic amine. In case (a) the aminopyrimidine can be protonated to protect it from acylation with an anhydride; in case (b), the reaction with an anhydride is controlled by temperature, stoichiometry, and time of reaction; in case (c), the reaction is selectively controlled by use of the less reactive p-nitrophenyl esters. Other difficulties were solved such as (a) proper characterization of the products when combustion analyses were unsatisfactory due to polymerization; in these cases a combination of

thin-layer


chromatography, color reactions, and derivatization were employed; and (b) insolubility leading to overreaction on the aminopyrimidine which was solved with partial aqueous systems. 38 references.

IT **13480-67-6P 15473-84-4P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 13480-67-6 CAPLUS

CN 1-Piperidineacetamide, N-[p-[[3-(2-amino-4-hydroxy-6-phenyl-5-pyrimidinyl)propyl]amino]phenethyl]- (8CI) (CA INDEX NAME)



RN 15473-84-4 CAPLUS

CN Acetamide, N-[2-[4-[[3-(2-amino-1,4-dihydro-4-oxo-6-phenyl-5-pyrimidinyl)propyl]amino]phenyl]ethyl]-2-bromo- (9CI) (CA INDEX NAME)



L10 ANSWER 144 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1966:106358 CAPLUS

DN 64:106358

OREF 64:20106b-c

TI Analogs of tetrahydrofolic acid. XXXIV. Hydrophobic bonding to dihydrofolic reductase. 6. Mode of phenyl binding of some 6-arylpyrimidines

AU Baker, B. R.; Shapiro, Howard S.

CS State Univ. of New York, Buffalo

SO Journal of Pharmaceutical Sciences (1966), 55(3), 308-17

CODEN: JPMSAE; ISSN: 0022-3549

DT Journal


LA English

AB cf. preceding abstrs. New data are presented which strongly support the concept that the increment in better binding observed by substituting a phenyl group on the 6-position of 4-pyrimidinol is due to hydrophobic bonding of the phenyl group. Furthermore, 11 6-phenylpyrimidines with various substituents at the 2, 4, and 5-positions were compared with 18 5-aryl- and 5-arylalkylpyrimidines as inhibitors of dihydrofolic reductase. The results cannot be explained by a single conformation of the pyrimidine being complexed to the enzyme; therefore, a number of rotational conformers for the pyrimidine ring are proposed where the strong hydrophobic bonding by the phenyl or phenylalkyl substituent is the determining factor for the particular preferred conformation of a given inhibitor. Such a hypothesis has previously been invoked to explain the inhibitor and substrate binding to chymotrypsin by Niemann, et al. (cf. Jones, et al., CA 63, 10254f).

IT 4455-56-5, Pyrimidine, 2-amino-5-(3-anilinopropyl)-4-phenyl-
(preparation of and tetrahydrofolic dehydrogenase inhibition by)

RN 4455-56-5 CAPLUS


CN 5-Pyrimidinepropanamine, 2-amino-N,4-diphenyl- (9CI) (CA INDEX NAME)



IT 853-66-7, 4-Pyrimidinol, 2-amino-5-(3-anilinopropyl)-6-phenyl-
2211-01-0, Pyrimidine, 2,4-diamino-5-(3-anilinopropyl)-6-phenyl-
2360-67-0, 4-Pyrimidinethiol, 2-amino-5-(3-anilinopropyl)-6-phenyl-
4455-56-5, Pyrimidine, 2-amino-5-(3-anilinopropyl)-4-phenyl-
(tetrahydrofolic dehydrogenase inhibition by)


RN 853-66-7 CAPLUS

CN 4(1H)-Pyrimidinone, 2-amino-6-phenyl-5-[3-(phenylamino)propyl]- (9CI) (CA INDEX NAME)




RN 2211-01-0 CAPLUS

CN 2,4-Pyrimidinediamine, 6-phenyl-5-[3-(phenylamino)propyl]- (9CI) (CA INDEX NAME)




RN 2360-67-0 CAPLUS

CN 4(1H)-Pyrimidinethione, 2-amino-6-phenyl-5-[3-(phenylamino)propyl]- (9CI) (CA INDEX NAME)




RN 4455-56-5 CAPLUS

CN 5-Pyrimidinepropanamine, 2-amino-N,4-diphenyl- (9CI) (CA INDEX NAME)




L10 ANSWER 145 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1965:404573 CAPLUS
 DN 63:4573
 OREF 63:861e-f
 TI Analogs of tetrahydrofolic acid. XVIII. On the mode of binding of some
 6-aryl- and 6-alkylpyrimidines to folic reductase
 AU Baker, B. R.; Shapiro, Howard S.; Werkheiser, William C.
 CS State Univ. of New York, Buffalo
 SO Journal of Medicinal Chemistry (1965), 8(3), 283-7
 CODEN: JMCMAR; ISSN: 0022-2623
 DT Journal
 LA English
 AB cf. CA 62, 8048a, 14667a. A series of 2-amino-5-anilinopropyl-4-
 pyrimidinols bearing a p-nitrophenyl, p-tolyl, or 2-furyl group at the
 6-position were synthesized. In addition, a series of 2,4-diaminopyrimidines
 with a phenylbutyl or anilinopropyl group at the 5-position and bearing
 either a 6-phenyl or 6-benzyl group were prepared. Enzymic evaluation of the
 effects of these and related compds. on folic reductase showed that the
 increase in binding of 2-amino-5-(3-anilinopropyl)-6-methyl-4-pyrimidinol
 previously observed by single replacement of (a) the anilino group by
 benzyl, (b) the 6-methyl by 6-phenyl or 6-benzyl, (c) the 4-hydroxyl by
 4-amino, or (d) the 4-hydroxyl by 4-mercapto were not necessarily additive
 if 2 or more of these changes were made in the same mol.; some cases of
 additivity in binding were observed with 2 structural changes.
 IT **853-66-7**, 4-Pyrimidinol, 2-amino-5-(3-anilinopropyl)-6-phenyl-,
 complex with folic reductase **2211-01-0**, Pyrimidine,
 2,4-diamino-5-(3-anilinopropyl)-6-phenyl-, complex with folic reductase
2257-74-1, p-Toluenesulfonanilide, N-[3-(2-amino-4-chloro-6-phenyl-
 5-pyrimidinyl)propyl]-, complex with folic reductase **2257-80-9**,
 p-Toluenesulfonanilide, N-[3-(2-amino-4-hydroxy-6-p-tolyl-5-
 pyrimidinyl)propyl]-, complex with folic reductase **2360-67-0**,
 4-Pyrimidinethiol, 2-amino-5-(3-anilinopropyl)-6-phenyl-, complex with
 folic reductase
 (preparation of)
 RN 853-66-7 CAPLUS
 CN 4(1H)-Pyrimidinone, 2-amino-6-phenyl-5-[3-(phenylamino)propyl]- (9CI) (CA
 INDEX NAME)




Handwritten signature or mark.

RN 2211-01-0 CAPLUS
 CN 2,4-Pyrimidinediamine, 6-phenyl-5-[3-(phenylamino)propyl]- (9CI) (CA
 INDEX NAME)





RN 2257-74-1 CAPLUS

CN p-Toluenesulfonanilide, N-[3-(2-amino-4-chloro-6-phenyl-5-pyrimidinyl)propyl]- (8CI) (CA INDEX NAME)




RN 2257-80-9 CAPLUS

CN p-Toluenesulfonanilide, N-[3-(2-amino-4-hydroxy-6-p-tolyl-5-pyrimidinyl)propyl]- (8CI) (CA INDEX NAME)



RN 2360-67-0 CAPLUS

CN 4(1H)-Pyrimidinethione, 2-amino-6-phenyl-5-[3-(phenylamino)propyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 146 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1965:43892 CAPLUS

DN 62:43892

OREF 62:7750g-h,7751a-h,7752a-e

TI Analogs of tetrahydrofolic acid. XIV. Facile synthetic route to the 2-amino-5-(3-anilinopropyl)-6-methyl-4-pyrimidinol-type of folic reductase and thymidylate synthetase inhibitor

AU Baker, B. R.; Santi, Daniel V.; Shapiro, Howard S.

CS State Univ. of New York, Buffalo

SO Journal of Pharmaceutical Sciences (1964), 53(11), 1317-25

CODEN: JPMSAE; ISSN: 0022-3549

DT Journal

LA English

AB cf. CA 61, 4346d. Tosylation of p-O₂NC₆H₄NH₂ with 21 g. tosyl chloride in 50 ml. pyridine gave 27.7 g. N-(p-nitrophenyl)-p-toluenesulfonamide (I), m. 193°. Similarly p-H₂NC₆H₄.CO₂Et gave N-(p-carbethoxyphenyl)-p-toluenesulfonamide (II), m. 206-7°. A solution of 2.47 g. p-toluenesulfonanilide in 10 ml. Me₂SO was treated with 1.38 g. K₂CO₃ and 8.07 g. 1,3-dibromopropane, the mixture stirred at room temperature 3 days, added

to 75 ml. H₂O, and extracted with C₆H₆, the benzene solution washed with NaOH, and the solvents distilled to give 2.72 g. N-(3-bromopropyl)-p-toluenesulfonanilide (III), m. 64-5°. Similarly I gave N-(3-bromopropyl)-N-(p-nitrophenyl)-p-toluenesulfonamide (IV), m. 119-20° and II gave N-(3-bromopropyl)-N-(p-carbethoxyphenyl)-p-toluenesulfonamide (V), m. 77-9°. Reaction of III with AcCH₂CO₂Et in EtOH proceeded poorly. Hence a mixture of 73 ml. tert-BuOH, 3.9 g. AcCH₂CO₂Et, and 1.43 g. NaH was warmed till the NaH dissolved completely. To this was then added 7.37 g. III and the mixture refluxed 20 hrs. to give 8.32 g. Et 2-acetyl-5-anilino-N-(p-tolylsulfonyl)valerate (VI) as a glass, 84% pure based on uv analysis. Similarly, IV gave Et 2-acetyl-5-(p-nitroanilino)-N-(p-tolylsulfonyl)valerate (VII), m. 107-8°. Since VI seemed to be labile to EtOH, its use as a solvent in the next stage was avoided and tert-BuOH substituted. A mixture of 8.32 g. VI, 2 g. guanidine carbonate, and 50 ml. tert-BuOH was refluxed 48 hrs. and filtered, the precipitate dissolved in 50 ml. H₂O, and the solution acidified to neutrality

with

HOAc and filtered to give 5.54 g. 2-amino-6-methyl-5-[N-(p-tolylsulfonylanilino)propyl]-4-pyrimidinol (VIII), m. 226-8°. Similarly, VII gave 2-amino-6-methyl-5-[N-(p-tolylsulfonyl-p-nitroanilino)-propyl]-4-pyrimidinol (IX), m. 125-55° (decomposition), and V gave 2-amino-5-[N-(p-tolylsulfonyl-p-carbethoxyanilino)propyl]-4-pyrimidinol (X) as a glass, which showed several spots in thin layer chromatography and could not be purified further. The tosyl group of VIII could not be removed by hydrolysis with 96% H₂SO₄ at room temperature or with boiling

concentrated

HCl; the material was recovered. Hence a solution of 1.03 g. VIII in 50 ml. liquid NH₃ was treated with 340 mg. Na in small pieces when the blue color failed to fade. The mixture was then treated with 1 g. NH₄Cl, NH₃ removed, the residue dissolved in 25 ml. H₂O, the solution acidified with HCl to pH 1 and filtered, and the filtrate treated with NaOH to pH 8 to give 0.34 g. 2-amino-6-methyl-5-(3-anilinopropyl)-4-pyrimidinol (XI), m. 219°. Alternatively, a mixture of 2.19 g. VIII, 1 g. PhOH, and 11.5 g. 30% HBr in HOAc was stirred 16 hrs. and diluted with Et₂O, HBr salt filtered off and dissolved in 20 ml. 3N HCl, and the solution made slightly alkaline with NH₃ to give 0.965 g. XI, m. 219-20°, identical with the above sample. Similarly IX gave 2-amino-6-methyl-5-(p-nitroanilinopropyl)-4-pyrimidinol (XII), m. 260-1°, and X gave 2-amino-6-methyl-5-(p-


carbethoxyanilinopropyl)-4-pyrimidinol (XIII), m. 194-6°. Hydrolysis of 150 mg. XIII with 5% NaOH on a steam bath 30 min. gave 104 mg. 2-amino-6-methyl-5-(p-carboxyanilinopropyl)-4-pyrimidinol, identical with a sample prepared by an earlier method (Baker et al., J. Med. Chemical, 1964, 7, 24). VIII was used to synthesize pyrimidines with a blocked anilino group, e.g., synthesis of 2,4-diamino-5-(3-anilinopropyl)-6-methylpyrimidine (results to be published). Syntheses of some other blocked anilinopyrimidines were investigated. A solution of 0.294 g. Na and 1.94 g. BzCH₂CO₂Et in 25 ml. tert-BuOH was refluxed with III 20 hrs. and worked up as above to give 3.27 g. BzCH(CO₂Et)(CH₂)₃N(O₂SC₆H₄Me-p)Ph (XIV) as an oil. A solution of 3.26 g. crude XIV in 15 ml. tert-BuOH was refluxed with 0.61 g. guanidine carbonate 51 hrs. to give 0.804 g. 2-amino-6-phenyl-[N-(p-tolylsulfonyl)anilinopropyl]-4-pyrimidinol (XV), m. 222-4°. A solution of 500 mg. XV and 200 mg. PhOH in 2.3 g. 30% HBr in HOAc was kept 20 hrs. and worked up to give 300 mg. 2-amino-5-(3-anilinopropyl)-6-phenyl-4-pyrimidinol (XVI), m. 235-41° (decomposition). XVI was also obtained from known XVII (CA 59, 13979e). A solution of 2 g. XVII and 6 g. PhNH₂ in 40 ml. HCONMe₂ (DMF) was stirred 30 min., 300 ml. MeOH added, and the mixture treated with 4 g. NaBH₄ portionwise. After stirring 18 hrs. the reaction was worked up to give 1.52 g. XVI identical with the above. Reduction of 0.5 g. XVII in 10 ml. DMF and 50 ml. MeOH with NaBH₄ gave 0.349 g. 2-amino-4-hydroxy-6-phenyl-5-pyrimidylpropanol, m. 265-8°. Reduction of XV with Na in liquid NH₃ removed the tosyl group but the product appeared to be the 5,6-dihydro derivative of XVI since it no longer had an absorption peak at 280 mμ characteristic of the 6-phenylpyrimidines. Apparently the 6-Ph substituent activated the 5,6-double bond for reduction. Similar marked differences due to 6-Ph group were noticed in other compds. of this type. A homolog of XVI was also synthesized. Reaction of PhCH₂COCl with Et ethoxymagnesiummalonate gave Et phenylacetylmalonate which on refluxing with H₂O gave Et γ-phenylacetoacetate (XVIII), b_{0.05} 80-107°, n_D²⁰ 1.054-1.059. Refluxing 4 g. XVIII with 1.75 g. guanidine carbonate in 40 ml. MeOH gave 1.64 g. 2-amino-6-benzyl-4-pyrimidinol, m. 278-80°. Condensation of XVIII with acrolein under base-catalyzed conditions did not give the expected product, PhCH₂COCH(CO₂Et)CH₂CH₂CHO (XIX). A further aldol condensation occurred to give XX since the product showed absence of aldehyde CH absorption at 2600 cm.⁻¹. Milder conditions gave unchanged XVIII or mixts. of XIX and XX and hence this approach was abandoned. In a second route PhCH₂COCl was condensed with the Na derivative of XXI (R = Me, R₁ = H) (XXII) to give XXI (R = PhCH₂, R₁ = Ac) XXIII). Cleavage of XXIII with NaOMe did not give the expected product XXI (R = PhCH₂, R₁ = H) by cleavage of the Ac group but mainly XXII by cleavage of PhCH₂CO group. XXII was characterized by conversion to the 6-methylpyrimidine (XXIV). Hence the method used above for the synthesis of the title compound was used. Alkylation of 20.3 g. XVIII with 12.5 g. III followed by condensation of the product with guanidine 67 hrs. gave 7.4g. 2-amino-6-benzyl-5-(N-tosylanilinopropyl)-4-pyrimidinol (XXV), m. 133-5°. Reduction of 450 mg. XXV as described above gave 133 mg. 2-amino-5-(anilinopropyl)-6-benzyl-4-pyrimidinol (XXVI), m. 181°. Before the successful attempt to insert a 1,3-dihalopropane between an oxo ester and an aniline as outlined above, 4 other routes were investigated. The dianion of α benzoylacetanilide was prepared by heating 2 g. with 0.728 g. NaH in DMF and then treated with 1,3-dibromopropane 48 hrs. to give 0.586 g. 3-benzoyl-1-phenyl-2-piperidone (XXVII), m. 160-2°, existing probably as a stable chelate. That it was fully enolized was confirmed by its ir and N.M.R., spectra. XXVII did not react with guanidine carbonate under normal conditions and when conditions were forced, C-benzoyl cleavage took place. With guanidine hydrochloride in

polyphosphoric acid there was decomposition XXVII did not form an enol ether with Et orthoformate or Et orthoacetate. No enamine or O-mesitylate could be prepared Possibility of O-methylation with CH₂N₂ was not investigated. Alkylation of AcCH₂CO₂Et with 1-bromo-3-chloropropane in EtOH-MeONa gave only 5% yield of AcCH(CO₂Et)(CH₂)₃Cl (XXVIII), the rest being converted to XXIX and this method was not further investigated. Reaction of the anion of PhNHAc with 1,3-dibromopropane did not give a clear cut product and the separation of desired N-(3-bromopropyl)acetanilide was not of preparative value. Reaction of PhNHMe with excess 1,3-dibromopropane gave distillable but unstable Br(CH₂)₃NMePh (XXX) which on redistn. or standing gave crystals of putative XXXI bromide. Reaction of XXX with Et sodioacetoacetate to prepare AcCH(CO₂Et)(CH₂)₃NMePh failed. The ir spectra of all the compds. were described. The biol. properties were described and discussed.

IT **853-66-7**, 4-Pyrimidinol, 2-amino-5-(3-anilinopropyl)-6-phenyl-
863-89-8, p-Toluenesulfonanilide, N-[3-(2-amino-4-hydroxy-6-phenyl-5-pyrimidinyl)propyl]-
 (preparation of)


RN 853-66-7 CAPLUS

CN 4(1H)-Pyrimidinone, 2-amino-6-phenyl-5-[3-(phenylamino)propyl]- (9CI) (CA INDEX NAME)




RN 863-89-8 CAPLUS

CN p-Toluenesulfonanilide, N-[3-(2-amino-4-hydroxy-6-phenyl-5-pyrimidinyl)propyl]- (7CI, 8CI) (CA INDEX NAME)



L10 ANSWER 147 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1956:28390 CAPLUS
 DN 50:28390
 OREF 50:5779c-e
 TI Pyridine compds.
 PA Societe des usines chimiques de Rhone-Poulenc
 DT Patent
 LA Unavailable
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 731956 DE 1082267		19550615	GB DE	
AB	<p>Compds. having antimalarial properties are obtained from 2-amino-4-chloro-5-(4-chlorophenyl)-6-ethylpyrimidine (I) or its 2-AcNH analog and an amine, RNH₂, or its salt, where R is a saturated or unsatd. aliphatic radical with 1-6 C atoms, cycloalkyl, or arylalkyl. I is prepared from guanidine and p-ClC₆H₄CH(COEt)CO₂Et in 15-40% oleum, followed by treatment with POCl₃. E.g., 5 g. I, 10 ml. MeNH₂, and 10 ml. EtOH heated in an autoclave 7.5 hrs. at 160-5°, taken up in 100 ml. H₂O, filtered, and the product washed with H₂O and dried yielded 4.1 g. 2-amino-4-methylamino-5-(4-chlorophenyl)-6-ethylpyrimidine (II), m. 212-13°; II.HCl.H₂O, m. 160° and 245-50°. II is formed also from the acyl derivative of I. The following 4-RNH analogs of II were prepared by this procedure (R and m.p. given); Et, 182-3° (HCl salt-H₂O, 150° and 232°); Pr, 140 and 157°; iso-Pr, 210° (HCl salt-H₂O, 150 and 210°); Bu, 133° (HCl salt, 200-5°); n-pentyl, 114-15°; n-hexyl, 109-10 and 118°; "2'-butyl," 166°; "3'-butyl," 164°; isopentyl, 143°; cyclohexyl, 202° (HCl salt, 240°); allyl, 150-1°; benzyl, 140°. These compds. are also prepared from I and an amine HCl salt heated at 200° without a solvent.</p>				
IT	<p>856972-58-2, Pyrimidine, 2-amino-4-benzylamino-5-(p-chlorophenyl)-6-ethyl- (preparation of)</p>				
RN	856972-58-2 CAPLUS				
CN	Pyrimidine, 2-amino-4-benzylamino-5-(p-chlorophenyl)-6-ethyl- (5CI) (CA INDEX NAME)				



L10 ANSWER 148 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1955:60839 CAPLUS

DN 49:60839

OREF 49:11726h-i,11727a-b

TI 2-Amino-4-substituted amino-6-arylpyrimidines

IN Hitchings, Geo. H.; Russell, Peter B.

PA Burroughs Wellcome and Co. (U.S.A.) Inc.

DT Patent

LA Unavailable

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2691655		19541012	US 1952-289907	19520524
AB	2-Amino-4-substituted amino-6-arylpyrimidines, useful as growth inhibitors for rapidly growing virus are prepared from the corresponding 4-hydroxypyrimidine by conversion to the 4-chloropyrimidine and subsequent reaction with the appropriate amine. Thus, 47 g. BzCHPrCO ₂ Et, refluxed 6 hrs. with 12 g. guanidine carbonate in 200 ml. EtOH, gives 2-amino-4-hydroxy-5-propyl-6-phenylpyrimidine (I), m. 311-13°, obtained by dilution of the reaction mixture with 500 ml. H ₂ O and recrystn. of the precipitate from EtOH; the 5-benzyl analog (II), m. 340°, was prepared similarly from BzCH(CH ₂ Ph)CO ₂ Et. Refluxing 10 g. I with 50 ml. POCl ₃ until solution was achieved, removing the excess POCl ₃ , and suspending the residue in iced aqueous NH ₄ OH gave 2-amino-4-chloro-5-propyl-6-phenylpyrimidine (III). Similarly, II yields the 5-benzyl analog (IV) of III; heating 5 g. III with 100 ml. of a saturated solution of MeNH ₂ in EtOH in				

a


bomb for 16 hrs. at 150° gives 4.2 g. 4-MeNH analog of III, m. 198°, and IV gives the 4-MeNH analog of IV, m. 177°.

Refluxing 5 g. III with 25 ml. of PhNH₂ 5 hrs., cooling, and recrystg. the precipitate from EtOH, gives needles of the 4-PhNH analog of III, m. 171°; 4-PhNH analog of IV, m. 211°. The following compds. are obtained by analogous procedures: 2-amino-4-methylamino-6-(2-naphthyl)pyrimidine, m. 238-9°; 2-amino-4-methylamino-6-phenylpyrimidine, m. 195-6°, and its 4-PhNH, m. 305-6° (decomposition), 4-(p-ClC₆H₄NH), m. 304-5°, and 4-(p-MeOC₆H₄NH) analogs, m. 259-63°.

IT **856972-54-8**, Pyrimidine, 2-amino-4-benzylamino-5-ethyl-6-(p-nitrophenyl)- (preparation of)

RN 856972-54-8 CAPLUS

CN Pyrimidine, 2-amino-4-benzylamino-5-ethyl-6-(p-nitrophenyl)- (5CI) (CA INDEX NAME)




L10 ANSWER 149 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1955:16281 CAPLUS
 DN 49:16281
 OREF 49:3270d-h
 TI 2-Mercapto-4-(secondary-amino)pyrimidines
 IN Hitchings, Geo. H.; Russell, Peter B.
 PA Burroughs Wellcome & Co. (U.S.A.) Inc.
 DT Patent
 LA Unavailable
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2671087		19540302	US 1951-261394	19511212
AB	2,4-Dimercaptopyrimidine (I) (1 mole) treated with 3 moles of primary amine at approx. 100° gives 80-90% corresponding N:C(SH).N:C(NHR).CR1:CR2 (II), where R consists of alkyl, monocyclic aryl, or aralkyl radicals, R1 consists of alkyl groups and H, and R2 consists of alkyl, monocyclic aryl and aralkyl radicals and H. II are useful pharmaceutical products. 5-Methyldithiouracil 1.3 g. and 10 cc. of a 33% aqueous MeNH ₂ solution are heated in a bomb at 100° for 3.5 hrs., the contents of the tube evaporated to dryness, and the residue crystallized several				

times from hot aqueous solution giving 60% 2-mercapto-5-methyl-4-methylaminopyrimidine. Similarly prepared are the following 2-mercapto-4-aminopyrimidine derivs.: 5-amyl-N4-methyl, m. 198°; 5-amyl-6-methyl-N4-methyl; 5-methyl-6-amyl-N4-methyl; 5-methyl-6-propyl-N4-methyl; 5-ethyl-6-phenyl-N4-methyl; 5-methyl-N4-tetradecyl; 5-hexyl-N4-tetradecyl; N4,5-ditetradecyl-6-methyl; 5-methyl-6-propyl-N4-amyl; 5-methyl-N4-benzyl; 5-ethyl-6-phenyl-N4-benzyl; 5-propyl-N4-β-hydroxyethyl; 5-methyl-6-phenyl-N4-β-hydroxyethyl; 5-propyl-6-methyl-N4-phenyl; 5-methyl-6-phenyl-N4-phenyl; N4-methyl, m. 236-7°; N4-tetradecyl, m. 148-9°; N4-amyl, m. 218°; N4-benzyl, m. 248-9°; N4-β-methylhexyl; 6-ethyl-N4-propyl; 6-phenyl-N4-hexyl; N4-β-diethylaminoethyl, m. 114-15°; N4-β-hydroxyethyl, m. 226-8°; 6-methyl-N4-phenyl, m. 230°; 6-amyl-N4-phenyl, m. 227-8°; 6-phenyl-N4-phenyl, 6-phenyl-N4-tetradecyl; N4-phenyl, m. 285°; N4-p-chlorophenyl, m. 299°; 6-methyl-N4-amyl, m. 221; 6-phenyl-N4-amyl, m. 227-8°; and 6-phenyl-N4-p-methoxyphenyl, m. 264-5° (from 6-phenyldithiouracil and p-methoxyaniline).

IT **857412-78-3**, 2-Pyrimidinethiol, 4-benzylamino-5-ethyl-6-phenyl- (preparation of)
 RN 857412-78-3 CAPLUS
 CN 2-Pyrimidinethiol, 4-benzylamino-5-ethyl-6-phenyl- (5CI) (CA INDEX NAME)



L10 ANSWER 150 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1953:28894 CAPLUS

DN 47:28894

OREF 47:4921d-i,4922a-b

TI 4-Amino-5-arylpyrimidines

IN Hitchings, Geo. H.; Russell, Peter B.; Falco, Elvira A.

PA Burroughs Wellcome & Co. (U.S.A.) Inc.

DT Patent


LA Unavailable

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2602794		19520708	US	
AB	<p>4-Amino-5-arylpyrimidines (I) are prepared by condensing an α-aryl-β-alkoxyacrylonitrile with a suitable urea derivative, such as a guanidine or amidine. I are useful antimalarials and bactericides. 2,4-Diamino-5-phenylpyrimidine is prepared in 60% yield from guanidine (II) and PhCH(CHO)CN in refluxing CH₂N₂ (III) or HC(OEt)₃. The following are similarly prepared: 6-Methyl-2,4-diamino-5-(p-chlorophenyl)-pyrimidines, m. 264-5° (from aqueous alc.) [60% from p-ClC₆H₄CHAcCN, II, and III, or 70% from II and p-ClC₆H₄C(CN):C(OEt)Me], 6-Et, needles from alc., m. 218-20°, from p-ClC₆H₄CH(COEt)CN, m. 108-12° (from Et₂O-petr. ether), obtained from p-ClC₆H₄CH₂CN, EtCO₂Et, and NaOEt, and II + III; 6-Pr, m. 171-4° (from alc.), 56% from p-ClC₆H₄C(CN):C(OMe)Pr and II; 6-iso-Bu, colorless prisms from C₆H₆, m. 147-8°, from p-ClC₆H₄C(CN):C(OMe)CH₂CHMe₂, and II; 6-α-Et₂CH, colorless prisms from C₆H₆-petr. ether, m. 225-8°, from the corresponding oxonitrile and II; 6-Am, m. 188-90° (from alc.), 70% yield from p-ClC₆H₄C(CN):C(OMe)Am and II; 6-Cl₁₁H₂₃, m. 139-40° (from MeOH-C₆H₆), more than 60% from p-ClC₆H₄CH(COC₁₁H₂₁)CN, II and III; 6-PhCH₂CH₂, m. 150-4° (from MeOH), from p-ClC₆H₄C(CN):C(OMe)CH₂CH₂Ph. 2,4-Diamino-5-phenyl-6-methylpyrimidine (IV), m. 249-51° (from alc.), is prepared from Me(MeO)C:CPhCN (obtained from III and α-acetyl-PhCHMeCN) and II, or from Me(PhCH₂O)C:CPhCN and II; 5-p-nitrophenyl analog, decompose above 350°, from IV and KNO₃-H₂SO₄ at -5°. 2,4-Diamino-5-phenyl-6-(N-methylanilinomethyl)-pyrimidine, m. 150-2° (from C₆H₆-petr. ether), 50% from the condensation product of PhCH₂CN and PhNMeCH₂CO₂Et on treatment with II and III. 2,4-Diamino-5-(o-chlorophenyl)pyrimidine, m. 129-31°, is prepared from o-ClC₆H₄CH(CHO)CN, II, and III; 2,4-diamino-5-(1-naphthyl)-6-methylpyrimidine, m. 159-60° (from C₆H₆), from 1-Cl₁₀H₇C(CN):C(OMe)Me; 2,4-diamino-5-(1-naphthyl)pyrimidine, needles from C₆H₆-petr. ether, m. 179-80°, is prepared in very high yield from 1-Cl₁₀H₇CH(CHO)CN, II, and III; 2,4-diamino-5-(p-chlorophenyl)-6-phenylpyrimidine, m. 268-70° (from alc.), is prepared from p-ClC₆H₄CHBzCN (obtained from BzOEt and p-ClC₆H₄CH₂CN), II, and III; 2,4-diamino-5,6-diphenylpyrimidine, m. 241-2° (from alc.), absorption maximum at 292.5 μ, is prepared from PhCHBzCN, II, and III; 4-amino-5-phenylpyrimidine, m. 152-5° (from C₆H₆), from MeOCH₂:CPhCN and HC(:NH)NH₂ (V); 4-amino-6-methyl-5-phenylpyrimidine (from C₆H₆), from MeC(OMe):CPhCN and V; 4-amino-5-(p-chlorophenyl)-6-phenylpyrimidine (from C₆H₆) from p-ClC₆H₄C(CN):C(OMe)Ph (obtained from p-ClC₆H₄CHBzCN and III) and V; 4-amino-2-methyl-5-(p-chlorophenyl)pyrimidine, m. 177-9° (from aqueous alc.), from p-ClC₆H₄C(CN):CHOMe and MeC(:NH)NH₂ (VI); 4-amino-5-(p-chlorophenyl)-2,6-dimethylpyrimidine, m. 201-2° (from C₆H₆-petr. ether), from p-ClC₆H₄C(CN):C(OMe)Me and VI; 4-amino-5-p-chlorophenyl-2-methyl-6-phenylpyrimidine (from C₆H₆-alc.), from p-ClC₆H₄CHBzCN and VI;</p>				

4-amino-5-(p-chlorophenyl)-2-p-tolylpyrimidine, m. 87° (yellow prisms), from p-ClC₆H₄C(CN):CHOMe and p-MeC₆H₄C(:NH)NH₂ (VII); 4-amino-5-(p-chlorophenyl)-6-methyl-2-phenylpyrimidine (from C₆H₆), from p-ClC₆H₄CHAcCN, III, and PhC(:NH)NH₂; and 4-amino-5-(p-chlorophenyl)-6-phenyl-2-p-tolylpyrimidine (from C₆H₆), from p-ClC₆H₄CHBzCN, III, and VII.

IT **874494-81-2**, Pyrimidine, 2,4-diamino-6-(N-methylanilinomethyl)-5-phenyl-
 (preparation of)
 RN 874494-81-2 CAPLUS
 CN Pyrimidine, 2,4-diamino-6-(N-methylanilinomethyl)-5-phenyl- (5CI) (CA INDEX NAME)



L10 ANSWER 151 OF 151 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1952:11515 CAPLUS

DN 46:11515

OREF 46:2075c-i,2076a-i,2077a-d

TI 2,4-Diaminopyrimidines as antimalarials. III. 5-Aryl derivatives

AU Russell, Peter B.; Hitchings, George H.

CS Wellcome Research Labs., Tuckahoe, NY

SO Journal of the American Chemical Society (1951), 73, 3763-70

CODEN: JACSAT; ISSN: 0002-7863

DT Journal


LA Unavailable

AB The attempted condensation of guanidine (I) with α -aryl- α -formyl or β -keto esters to give 2-amino-4-hydroxy-pyrimidines was limited in its application to the few α -formyl- α -Ph derivs. unsubstituted or bearing halogen in the meta or para position in the C₆H₆ ring. A new general synthesis of 4-amino-5-aryl pyrimidines was found in the condensation of amidines or I with β -alkoxy- α -arylacrylonitriles. With I this leads directly to the 2,4-diaminopyrimidines desired for antimalarial testing. The maximum activity is found with a 5-Ph group substituted with an electron-attractive group in the para position and an alkyl radical in the pyrimidine 6-position. The (p-chloro- and 3,4-dichlorophenyl)pyrimidines are significantly more active than the p-NO₂ derivs., and the optimal 6-alkyl radical is Et. In contrast to the PhO and PhCH₂ series, the higher homologs in the (p-chlorophenyl)-6-alkyl series have high activities, reaching values above 1000 times the activity of quinine. Condensation of an Et α -formylarylacacetate with I yielded 2-amino-4-hydroxy-5-arylpyrimidines (Ar, m.p., and % yield given): Ph, 244-5°, 20; p-ClC₆H₄, 323° (decomposition), 10; m-ClC₆H₄, 255-8°, 15; 3,4-Cl₂C₆H₃, 330° (decomposition), 16; p-BrC₆H₄, 313° (decomposition), 23. 2,4-Diamino-5-arylpyrimidines from the 4-HO compds. Method A: The OH compds. were chlorinated with POCl₃ and aminated with EtOH-NH₃. HCO₂Et (20 cc.) and 54 g. 3,4-Cl₂C₆H₃-CH₂CO₂Et added to 5.75 g. Na in dry Et₂O, 19 g. CS(NH₂)₂ and 100 cc. EtOH added, and the mixture refluxed 6 h., poured into 700 cc. water, filtered with C, and acidified with AcOH yielded 2.05 g. disulfide of 5-(3,4-dichlorophenyl)-4-hydroxy-2-mercaptopyrimidine [5-(3,4-dichlorophenyl)-2-thiouracil] (II), deep yellow plates from EtOH, m. 305-9° (decomposition); p-ClC₆H₄CH₂CO₂Et yielded 5-(p-chlorophenyl)-2-thiouracil, yellow plates m. 335-7° (decomposition). NaHSO₃ (0.3 g.) added to 0.54 g. II in a slight excess of 0.5 N NaOH, the colorless solution acidified with 0.5 N H₂SO₄, filtered, and the precipitate in 0.5 N NaOH filtered with C and precipitated with 0.5 N H₂SO₄ yielded 5-(3,4-dichlorophenyl)-2-thiouracil (III), pale yellow needles from aqueous EtOH, m. 308-11° (decomposition). II (2.0 g.), 2.0 g. ClCH₂CO₂H, 10 cc. water, and 1 cc. concentrated HCl refluxed 8 h., cooled, filtered, and the solid treated with 2 N NaOH and filtered with C yielded on addition of hot AcOH 5-(3-4-dichlorophenyl)uracil, m. 358° (after darkening at 290°). Formylguanidine (9.1 g.) and 11.7 g. PhCH₂CN heated with 25 cc. EtOH in a bomb, the EtOH evaporated, and the solution diluted with water and made strongly alkaline with NH₄OH yielded colorless needles, C₇H₆N₃(?), m. 139° (from C₆H₆). KCN and benzyl halides by the method of Kharasch and Brown (C.A. 33, 7728.8) yielded arylacetoneitriles; for (substituted-phenyl)acetoneitriles the m. ps. (or b.p./mm.) are: 2,4-di-Cl, 57-9°; 3,4-di-Cl, 41-2° (160-70°/10); 3,4-di-Br, 68-9°; 2,5-di-Br, 112-13°; m-F, 124-6°/10; o-F, 122-6°/10. The appropriate Et esters and nitriles condensed

with NaOEt yielded ArCH(COR)CN (IV). EtOAc (44 g.) and 76 g. p-ClC₆H₄CH₂CN added to 11.5 g. Na in 250 cc. EtOH, the solution refluxed 5 h., cooled, poured into water 2.5 l., the oil extracted with Et₂O, the aqueous solution acidified with N H₂SO₄, the oil extracted with Et₂O, the Et₂O washed and dried, and the Et₂O removed yielded 56 g. α-(p-chlorophenyl)acetoacetonitrile, m. 124° (from Et₂O-petr. ether). IV (m.p. given). For Ar = p-ClC₆H₄: R = H, 164-5°; Me, 124-5°; Et, 50-2°; Pr, 86-7°; Bu, 69-70°; Am, 65-7°; C₆H₁₃, 48-50°; C₇H₁₅, oil; C₁₁H₂₃, 60-1°; Me₂CHCH₂, 84-5°; MeOCH₂, 107°. For Ar = m-ClC₆H₄: R = H, 176-7°; Me, 84-6°. For Ar = o-ClC₆H₄: R = H, 118-20°; Me, oil. Ar = p-BrC₆H₄, R = Et, 60-3°; Ar = m-BrC₆H₄, R = Me, 95°; Ar = o-BrC₆H₄, R = H, 120-1°. For Ar = p-FC₆H₄: R = H, 146-8°; Me, 89-90°; Et, oil. Ar = m-FC₆H₄, R = Me, 117-18°; Ar = o-FC₆H₄, R = H, 125°; Ar = 2,4-Cl₂C₆H₃, R = H, 158-60°. For Ar = 3,4-Cl₂C₆H₃: R = Me, 161-3°; Et, 105-6°; Pr, 101°; Bu, oil. Ar = 3,4-Br₂C₆H₃, R = Et, 108°; Ar = p-MeOC₆H₄, R = H, 100-2°; Ar = p-MeC₆H₄, R = H, 152-3°; Ar = p-PhC₆H₄, R = H, 210°; Ar = 3,4-(MeO)₂C₆H₃, R = Me, 98°; Ar = 1-Cl₁₀H₇, R = Me, oil. IV treated with CH₂N₂ in Et₂O and the crude product condensed with I yielded the pyrimidine. Several of the α-aryl-β-methoxyacrylonitriles were isolated and characterized. 2,4-Cl₂C₆H₃CH(CHO)CN (8.0 g.) treated with excess CH₂N₂ in 200 cc. Et₂O and the solution allowed to stand overnight yielded 5.0 g. α-(2,4-dichlorophenyl)-β-methoxyacrylonitrile, m. 105-7° (from EtOH). p-FC₆H₄CH(CHO)CN (8 g.) with CH₂N₂ in 150 cc. Et₂O yielded α-(p-fluorophenyl)-β-methoxyacrylonitrile, colorless silky needles from EtOH, m. 197-8°; the o-F isomer, m. 156-7°. 3,4-Cl₂C₆H₃CH₂AcCN (8.0 g.) treated with CH₂N₂ and allowed to stand 5 h. yielded α-(3,4-dichlorophenyl)-β-methoxy-β-methylacrylonitrile, plates from EtOH, m. 71-3°. Methylation and condensation of IV with I yielded the following 2,4-diamino-5-arylpurimidines, N: C(NH₂).N.C-(NH₂).CAr:CR (m.p. given). For Ar = Ph: R = H, 162-4°; Me, 249-50°; Et, 237-40°; Ph, 241-2°. For Ar = p-ClC₆H₄: R = H, 194-5°; Me, 264-5°; Et, 232-4°; Pr, 171-4°; Bu, 208-10°; iso-Bu, 147-9°; Am, 188-90°; hexyl, 172-3°; heptyl, 156°; C₁₁H₂₃, 139-40°; MeOCH₂, 218-19°; Ph, 268-70°. For Ar = m-ClC₆H₄: R = H, 204-6°; Me, 219-20°. For Ar = o-ClC₆H₄: R = H, 125-8°; Me, 225°. For Ar = p-BrC₆H₄: R = H, 205-7°; Me, 263-5°; Et, 213-16°. Ar = m-BrC₆H₄: R = Me, 236°; Ar = o-BrC₆H₄, R = H, 140-1°. For Ar = p-FC₆H₄: R = H, 207°; Me, 295°; Et, 269°; Ar = m-FC₆H₄, R = Me, 237°; Ar = 2,4-Cl₂C₆H₃, R = H, 178°. For Ar = 3,4-Cl₂C₆H₃: R = H, 208-10°; Me, 275-6°; Et, 230°; Pr, 174-6°; Bu, 192°. Ar = 2,5-Br₂C₆H₃, R = H, 220°; Ar = 3,4-Br₂C₆H₃, R = Et, 225°; Ar = p-MeOC₆H₄, R = H, 202-3°. For Ar = p-MeC₆H₄: R = H, 200°; Me, 241°. Ar = p-PhC₆H₄, R = H, 204-5°; Ar = 3,4-(MeO)₂C₆H₃, R = Me, about 300°. For Ar = 1-Cl₁₀H₇: R = H, 179-80°; Me, 160°. CH₂N₂ in 100 cc. Et₂O and 7.25 g. PhCH(CHO)CN allowed to stand overnight, the Et₂O evaporated, I from 4.75 g. HCl salt in 50 cc. EtOH added to the residue in 25 cc. EtOH, the solution heated on the steam bath 3 h., the EtOH removed, concentrated NaOH added to the residue, the insol. material filtered off, dissolved in 10 cc. AcOH, 30 cc. water added, the solution filtered with C, and the filtrate made alkaline with 2 N NaOH yielded 2,4-diamino-5-phenylpyrimidine (V), colorless plates

from water, m. 162-4°. PhCHAcCN and CH₂N₂ treated with I and 1.3 g. Na in 150 cc. EtOH yielded the 6-Me derivative (VI) of V, m. 249-50°. Nitration of VI and the 6-Et analog yielded microcryst. powders m. above 350°. The 5-(p-O₂NC₆H₄) analog of V (1.25 g.) in 150 cc. 50% EtOH containing 3 equivs. of 2 N HCl shaken in H with Adams catalyst yielded 2,4-diamino-5-(p-aminophenyl)pyrimidine (VI), colorless plates from 2 N NaOH m. 233°. VI refluxed 0.5 h. with Ac₂O and anhydrous NaOAc, and the mixture poured into 50 cc. ice-cold dilute NH₄OH yielded the Ac derivative; AcOH salt, C₁₄H₁₇N₅O₃ (VII), colorless needles, m. 241-2°. Water (10 cc.) added to 0.3 g. VII and 0.5 cc. 2.25 N NaOH, and the solution warmed on the steam bath 3 h. and cooled yielded 5-p-acetamido-2,4-diaminopyrimidine, yellowish needles, m. 237°. The crude nitrile from 17.9 g. p-ClC₆H₄CH(CHO)CN and CH₂N₂ treated with ethylguanidine (from 16.9 g. HBr salt) and 2.3 g. Na in 100 cc. EtOH and the solution heated 8 h. yielded 12 g. plates, m. 200-2° (from C₆H₆-petr. ether) (position of the Et group not determined), inactive as an antimalarial. Condensation of methylated IV and amidines as with I yielded 4-amino-5-arylpyrimidines, N:CR.N:C(NH₂).CA: CR', for which R, R', Ar, and m.p. are: H, H, Ph, 152-3°; Me, H, p-ClC₆H₄, 178°; Me, Me, p-ClC₆H₄, 201-2°; p-MeC₆H₄, H, p-ClC₆H₄, 186°; Me, Ph, p-ClC₆H₄, 201-2°; p-MeC₆H₄, H, o-ClC₆H₄, 180°; Ph, Ph, Ph, 161°; Ph, Me, p-ClC₆H₄, 154-5°; Me, H, 2,4-Cl₂C₆H₃, 230°. PhCH(CHO)CN (3.6 g.) treated with CH₂N₂, the mixture let stand overnight, the Et₂O removed, formamidine (from 2 g. HCl salt) in 30 cc. EtOH added to the residue in 10 cc. EtOH, the mixture heated on the steam bath 3 h., the alc. evaporated, and the product made strongly alkaline yielded 4-amino-5-phenylpyrimidine, plates from C₆H₆, m. 152-4°. p-ClC₆H₄CH(CHO)-CN (8.5 g.) treated with CH₂N₂, then with p-toluamidine (from 9.0 g. HCl salt), yielded 4-amino-2-p-tolyl-5-(p-chlorophenyl)pyrimidine. PhCH₂CN (23.4 g.) and 38.6 g. CH₂N(PhMe)CO₂Et added to the NaOEt from 4.6 g. Na and 200 cc. EtOH, the mixture refluxed 24 h., cooled, poured into 1 l. water, the insol. material removed with Et₂O, and the solution neutralized with 2 N H₂SO₄ yielded (N-methyl-anilinoacetyl)phenylacetonitrile (VIII), colorless needles from EtOH, m. 111°. VIII (6.6 g.) in 200 cc. 1:1 EtOH-Et₂O and CH₂N₂ allowed to stand overnight, the solvents evaporated, the residue in 50 cc. EtOH treated with I in alc. and 0.6 g. Na in 100 cc. EtOH, the mixture heated 4 h., the alc. evaporated, and the residue made alkaline with strong NaOH and dissolved in Et₂O yielded 2,4-diamino-5-phenyl-6-(N-methylanilinomethyl)pyrimidine, yellow prisms from petr. ether-C₆H₆, m. 150-1°. Me₂NCH₂CO₂Et (26 g.) and 30 g. p-ClC₆H₄CH₂CN (IX) added to 4.6 g. Na in 150 cc. EtOH, the solution heated 5 h. on the steam bath, cooled, poured into water, and the insol. material removed with Et₂O yielded a compound m. 225-31° (effervescence) and remelts sharply at 240° (decomposition); by the same procedure PhCH₂CN yielded colorless plates, m. 239°. PhNHCH₂CO₂Et (17.9 g.) and 15.1 g. IX yielded a crystalline product, m. 225° (decomposition) (from EtOH).

IT 874494-81-2, Pyrimidine, 2,4-diamino-6-(N-methylanilinomethyl)-5-phenyl-
 (preparation of)
 RN 874494-81-2 CAPLUS
 CN Pyrimidine, 2,4-diamino-6-(N-methylanilinomethyl)-5-phenyl- (5CI) (CA INDEX NAME)



=> => d his

(FILE 'HOME' ENTERED AT 13:08:53 ON 15 JUN 2006)

FILE 'REGISTRY' ENTERED AT 13:09:01 ON 15 JUN 2006

L1 STRUCTURE UPLOADED
L2 1 S L1 SSS SAM
L3 STRUCTURE UPLOADED
L4 50 S L3 SSS SAM

FILE 'STNGUIDE' ENTERED AT 13:25:02 ON 15 JUN 2006

FILE 'REGISTRY' ENTERED AT 13:27:58 ON 15 JUN 2006

L5 STRUCTURE UPLOADED
L6 50 S L5 SSS SAM
L7 STRUCTURE UPLOADED
L8 23 S L7 SSS SAM
L9 1779 S L7 SSS FUL

FILE 'CAPLUS' ENTERED AT 13:44:56 ON 15 JUN 2006

L10 151 S L9

FILE 'CAOLD' ENTERED AT 13:48:03 ON 15 JUN 2006

=> s 19

L11 4 L9

=> d l11 1-4 bib,hitstr

L11 ANSWER 1 OF 4 CAOLD COPYRIGHT 2006 ACS on STN

AN CA64:20106b CAOLD


TI analogs of tetrahydrofolic acid - (XXXIV) hydrophobic bonding of dihydrofolic reductase (6) mode of phenyl binding of some 6-arylpurimidines

AU Baker, Bernard R.; Shapiro, H. S.

IT 853-66-7 2211-01-0 2360-67-0
4455-56-5


RN 853-66-7 CAOLD

CN 4(1H)-Pyrimidinone, 2-amino-6-phenyl-5-[3-(phenylamino)propyl]- (9CI) (CA INDEX NAME)



RN 2211-01-0 CAOLD


CN 2,4-Pyrimidinediamine, 6-phenyl-5-[3-(phenylamino)propyl]- (9CI) (CA INDEX NAME)



Isomer


RN 2360-67-0 CAOLD

CN 4(1H)-Pyrimidinethione, 2-amino-6-phenyl-5-[3-(phenylamino)propyl]- (9CI) (CA INDEX NAME)



RN 4455-56-5 CAOLD

CN 5-Pyrimidinepropanamine, 2-amino-N,4-diphenyl- (9CI) (CA INDEX NAME)



Isomer

L11 ANSWER 2 OF 4 CAOLD COPYRIGHT 2006 ACS on STN

AN CA63:861e CAOLD

TI analogs of tetrahydrofolic acid - (XVIII) mode of binding of some 6-aryl-and 6-aralkylpyrimidines to folic reductase


AU Baker, Bernard R.; Shapiro, H. S.; Werkheiser, W. C.

IT 2211-06-5 2211-07-6 2257-73-0

2257-74-1 2257-80-9 2520-04-9


RN 2211-06-5 CAOLD

CN 4(1H)-Pyrimidinone, 2-amino-6-(4-methylphenyl)-5-[3-(phenylamino)propyl]-
(9CI) (CA INDEX NAME)




RN 2211-07-6 CAOLD

CN 4(1H)-Pyrimidinone, 2-amino-6-(4-nitrophenyl)-5-[3-(phenylamino)propyl]-
(9CI) (CA INDEX NAME)




RN 2257-73-0 CAOLD

CN p-Toluenesulfonamide, N-[3-(2-amino-4-mercapto-6-phenyl-5-pyrimidinyl)propyl]-N-phenyl- (8CI) (CA INDEX NAME)





RN 2257-74-1 CAOLD

CN p-Toluenesulfonamide, N-[3-(2-amino-4-chloro-6-phenyl-5-pyrimidinyl)propyl]- (8CI) (CA INDEX NAME)




RN 2257-80-9 CAOLD

CN p-Toluenesulfonamide, N-[3-(2-amino-4-chloro-6-phenyl-5-pyrimidinyl)propyl]- (8CI) (CA INDEX NAME)




RN 2520-04-9 CAOLD

CN Benzenesulfonamide, N-[3-(2,4-diamino-6-phenyl-5-pyrimidinyl)propyl]-4-methyl-N-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L11 ANSWER 3 OF 4 CAOLD COPYRIGHT 2006 ACS on STN
 AN CA62:7750h CAOLD
 TI analogs of tetrahydrofolic acid - (XIV) facile synthetic route to the
 2-amino-5-(3-anilinopropyl)-6-methyl-4-pyrimidinol-type of folic reductase
 and thymidylate synthetase inhibitor
 AU Baker, Bernard R.; Santi, D. V.; Shapiro, H. S.
 IT 853-66-7 863-89-8
 RN 853-66-7 CAOLD
 CN 4(1H)-Pyrimidinone, 2-amino-6-phenyl-5-[3-(phenylamino)propyl]- (9CI) (CA
 INDEX NAME)




RN 863-89-8 CAOLD
 CN p-Toluenesulfonanilide, N-[3-(2-amino-4-hydroxy-6-phenyl-5-pyrimidinyl)propyl]- (7CI, 8CI) (CA INDEX NAME)



L11 ANSWER 4 OF 4 CAOLD COPYRIGHT 2006 ACS on STN
AN CA59:13979e CAOLD
TI analogs of tetrahydrofolic acid - (IX) synthesis of N-[1-(2-amino-4-hydroxy-6-phenyl-5-pyrimidyl)-3-propyl]-p-aminobenzoyl-L-glutamic acid, a nonclassical inhibitor of some folic cofactor area enzymes
AU Baker, Bernard R.; Shapiro, H. S.
IT 35960-68-0
RN 35960-68-0 CAOLD
CN L-Glutamic acid, N-[4-[[3-(2-amino-1,4-dihydro-4-oxo-6-phenyl-5-pyrimidinyl)propyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/671,070

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

12.16

977.28

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-113.25

STN INTERNATIONAL LOGOFF AT 13:48:33 ON 15 JUN 2006